Patent Publication Number: US-2023137844-A1

Title: Prostate cancer detection kit or device, and detection method

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     This application is a Divisional of application Ser. No. 16/808,095 filed Mar. 3, 2020, which is a Divisional of application Ser. No. 15/317,882, filed on Dec. 9, 2016 (now U.S. Pat. No. 10,619,213), which was filed as a national phase application of PCT International Application No. PCT/JP2015/066964 on Jun. 12, 2015, which claims the benefit under 35 U.S.C. § 119(a) to Patent Application No. 2014-121377, filed in Japan on Jun. 12, 2014 and Patent Application No. 2015-071756, filed in Japan on Mar. 31, 2015, all of which are hereby expressly incorporated by reference into the present application. 
    
    
     REFERENCE TO ELECTRONIC SEQUENCE LISTING 
     The application contains a Sequence Listing which has been submitted electronically in .XML format and is hereby incorporated by reference in its entirety. Said .XML copy, created on Oct. 25, 2022, is named “PH-6233-PCT-US-DIV1-DIV1.xml” and is 615,824 bytes in size. The sequence listing contained in this .XML file is part of the specification and is hereby incorporated by reference herein in its entirety. 
     TECHNICAL FIELD 
     The present invention relates to a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a particular miRNA, which is used for examining the presence or absence of prostate cancer in a subject, and a method for detecting prostate cancer, comprising measuring an expression level of the miRNA using the nucleic acid. 
     BACKGROUND ART 
     The prostate is an organ that produces a component of the semen in males, and is positioned underneath the urinary bladder and in front of the rectum. Prostate cancer is a 
     The prostate is an organ that produces a component of the semen in males, and is positioned underneath the urinary bladder and in front of the rectum. Prostate cancer is a disease caused by the disorganized and repeated proliferation of cells of this prostate. According to the 2011 statistics of cancer type specific mortality in Japan disclosed by the Center for Cancer Control and Information Services, National Cancer Center, the number of individuals affected by prostate cancer was 51,534 people. Namely, it is estimated that one out of 14 Japanese males will experience prostate cancer. The number of incidences of this cancer in males takes the 4th place by cancer type. Also, the number of prostate cancer deaths climbed to 10,823 people and takes the 6th place by cancer type in males. It is estimated that one out of 7 American males will experience prostate cancer. Prostate cancer is particularly common in elderly people, and 6 out of 10 men aged 65 or older are diagnosed with prostate cancer (Non-Patent Literature 1). The estimated number of American individuals affected by prostate cancer climbed to 233,000 people in 2014, among which approximately 29,480 people reportedly died (Non-Patent Literature 1). 
     The progression stages of prostate cancer are specified in Non-Patent Literature 2 and classified into stage I (T1 to T2a/N0/M0), stage II (T2b to T2c/N0/M0), stage III (T3/N0/M0), and stage IV (T4/N0/M0 and N1 and cM1) according to tumor spread (T1a to T1c, T2a to T2c, T3a to T3b, and T4), lymph node metastasis (N0 and N1), distant metastasis (M0 and M1a to M1c), etc. 
     Since prostate cancer progresses relatively slowly in most cases, its 5-year relative survival rate is almost 100%, indicating one of cancers having the best prognosis (Non-Patent Literature 1). Some of prostate cancer cases, however, progress relatively fast and cause various disorders or symptoms. Prostate cancer found to have distant metastasis at stage 4 exhibits a 5-year relative survival rate as significantly low as 28% (Non-Patent Literature 1). 
     The treatment of prostate cancer in regular protocols includes surgical treatment, radiotherapy, endocrine therapy (hormone therapy), and palliative treatment which continues follow-up while monitoring a tumor marker PSA without special treatment. Particularly, the treatment of early prostate cancer has some options such as external beam radiotherapy, internal radiotherapy (brachytherapy), radical prostatectomy, and cryosurgery, in addition to palliative treatment (Non-Patent Literature 1). 
     As described in Non-Patent Literature 1, a test of PSA, a tumor marker in blood, is widely used as a primary test for prostate cancer. Rectal examination or transrectal ultrasonography of the prostate is carried out when the PSA measurement value is high. Biopsy is further carried out as definite diagnosis when a subject is suspected of having prostate cancer. An imaging test such as CT scan, MRI scan, or bone scintigraphy is also conducted when a subject is suspected of having distant metastasis. 
     The prostate-specific antigen (PSA) is produced by the prostate and contained in the semen, but is also present in blood, albeit slightly. The PSA concentration in blood of ordinary males is usually 4 ng/mL or lower, and a subject is suspected of having prostate cancer when the measurement value exceeds this reference value (Non-Patent Literature 1). The PSA concentration in blood is reportedly useful and widely implemented, for example, because this concentration elevates even in asymptomatic early prostate cancer and correlates with the stages of cancer progression. The American Cancer Society promotes the early detection of prostate cancer and recommends that subjects who desire screening of prostate cancer should undergo the PSA test (Non-Patent Literature 1). 
     As shown in Patent Literatures 1 to 3, there are reports, albeit at a research stage, on the detection of prostate cancer using the expression levels of microRNAs (miRNAs) or combinations of the expression levels of miRNAs and the expression levels of additional markers in biological samples including blood. 
     Patent Literature 1 discloses a method for detecting prostate cancer as well as Wilms tumor and COPD using hsa-miR-760, hsa-miR-920, has-miR-887-3p, hsa-miR-486-3p, hsa-miR-663b, hsa-miR-187-5p, hsa-miR-1231, hsa-miR-371a-5p, has-miR-575, hsa-miR-615-5p, hsa-miR-711, hsa-miR-939-5p, hsa-miR-1203, hsa-miR-1225-3p, hsa-miR-1225-5p, hsa-miR-1915-5p and the like in blood. 
     Patent Literature 2 discloses a method for detecting prostate cancer, etc., comprising isolating a vesicle from blood using EpCam and using a miRNA such as hsa-miR-92b-5p contained in the vesicle, for the detection. 
     Patent Literature 3 has reported that prostate cancer is determined by combining the expression level of PCA3 gene with the expression level of miR-141. 
     CITATION LIST 
     Patent Literature 
     
         
         Patent Literature 1: European Patent Application Publication No. 2341145 
         Patent Literature 2: International Publication No. WO 2013/022995 
         Patent Literature 3: International Publication No. WO 2010/062706 
       
    
     Non-Patent Literature 
     
         
         Non-Patent Literature 1: American Cancer Society “Prostate Cancer”, 2013, p. 5, 14 to 26, 32 to 54, and 68 to 70 
         Non-Patent Literature 2: Sobin, L. et al., “TNM Classification of Malignant Tumours, the 7th edition”, 2010, p. 230 to 234 
         Non-Patent Literature 3: Wolf, A M. et al., 2010, A Cancer Journal for Clinicians, Vol. 60 (2), p. 70-98 
         Non-Patent Literature 4: Mitchell P S. et al., 2008, Proceedings of the National Academy of Sciences of the United States of America, Vol. 105 (30), p. 10513-10518 
       
    
     SUMMARY OF INVENTION 
     Technical Problem 
     An object of the present invention is to find a novel tumor marker for prostate cancer and to provide a method that can effectively detect prostate cancer using a nucleic acid capable of specifically binding to the marker. The PSA test is widely used as a tumor marker test for prostate cancer. The PSA test is, however, known that 15% of males having a PSA concentration in blood corresponding to the reference value 4 ng/mL or lower are confirmed to be prostate cancer-positive as a result of biopsy. On the other hand, it is also known that the PSA concentration in blood elevates in males having benign prostatic hyperplasia or prostatitis and in ordinary elderly men, leading to a high probability of false positives even in the absence of cancer (Non-Patent Literature 1). Furthermore, the false detection of a cancer other than prostate cancer also leads to false positives. Such a high probability of false positives in the PSA test leads to overdiagnosis and overtreatment, and various aftereffects ascribable to the unnecessary treatment of prostate cancer has been viewed as problems in recent years (Non-Patent Literature 3). According to the large-scale research using 5000 or more recruited subjects (Non-Patent Literature 3), the specific performance of the PSA test showed the sensitivity as low as 20.5% for the overall prostate cancer cases and the sensitivity of merely 51% even limited for highly malignant prostate cancer cases, suggesting that the tumor marker measurement is less significant as a preoperative test. 
     As described below, there are reports, albeit at a research stage, on the determination of prostate cancer using the expression levels of microRNAs (miRNAs) in biological samples including blood, none of which, however, have yet been brought into practical use. 
     Patent Literature 1 discloses a method for detecting prostate cancer as well as Wilms tumor and COPD using hsa-miR-760, hsa-miR-920, has-miR-887-3p, hsa-miR-486-3p, hsa-miR-663b, hsa-miR-187-5p, hsa-miR-1231, hsa-miR-371a-5p, has-miR-575, hsa-miR-615-5p, hsa-miR-711, hsa-miR-939-5p, hsa-miR-1203, hsa-miR-1225-3p, hsa-miR-1225-5p, hsa-miR-1915-5p and the like in blood. Patent Literature 1 describes many miRNAs, whereas this literature lacks a direct statement showing that these miRNA markers are markers for prostate cancer, and includes insufficient evidence for the usefulness of the miRNA markers as prostate cancer markers. 
     Patent Literature 2 discloses a method for detecting prostate cancer, etc., comprising isolating a vesicle from blood using EpCam and using a miRNA such as hsa-miR-92b-5p contained in the vesicle, for the detection. This literature, however, is less reliable because the miRNA marker was not reproducibly validated in an independent sample group and the literature has no mention about a threshold for detecting prostate cancer. 
     Patent Literature 3 specifically states that prostate cancer can be determined with 100% sensitivity and specificity by combining the expression levels of miR-141 and PCA3. This literature, however, does not state that prostate cancer can be determined conveniently and highly accurately using a single marker. In fact, Non-Patent Literature 4 is cited in Patent Literature 3. Non-Patent Literature 4 has reported the determination of prostate cancer using miR-141 in serum and states that the accuracy of the determination is 60% sensitivity when the specificity is 100%. In addition, a sample that is subjected to the PCA3 test currently used generally is urine, particularly, urine after digital rectal examination. On the other hand, the sample that is subjected to the determination of prostate cancer using miR-141 is blood (serum) as mentioned above. Thus, for obtaining highly sensitive and specific results by combining them, it is necessary to collect two samples. 
     Solution to Problem 
     The present inventors have conducted diligent studies to attain the object and consequently completed the present invention by finding several genes usable as markers for the detection of prostate cancer from blood, which can be collected with limited invasiveness, and finding that prostate cancer can be significantly detected by using nucleic acids capable of specifically binding to any of these markers. 
     SUMMARY OF INVENTION 
     Specifically, the present invention has the following features: 
     (1) A kit for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to at least one or more polynucleotide(s) selected from the group consisting of prostate cancer markers miR-4443, miR-1908-5p, miR-4257, miR-3197, miR-3188, miR-4649-5p, miR-1343-3p, miR-6861-5p, miR-1343-5p, miR-642b-3p, miR-6741-5p, miR-4745-5p, miR-6826-5p, miR-3663-3p, miR-3131, miR-92a-2-5p, miR-4258, miR-4448, miR-6125, miR-6880-5p, miR-6132, miR-4467, miR-6749-5p, miR-2392, miR-1273g-3p, miR-4746-3p, miR-1914-3p, miR-7845-5p, miR-6726-5p, miR-128-2-5p, miR-4651, miR-6765-3p, miR-3185, miR-4792, miR-6887-5p, miR-5572, miR-3619-3p, miR-6780b-5p, miR-4707-5p, miR-8063, miR-4454, miR-4525, miR-7975, miR-744-5p, miR-3135b, miR-4648, miR-6816-5p, miR-4741, miR-7150, miR-6791-5p, miR-1247-3p, miR-7977, miR-4497, miR-6090, miR-6781-5p, miR-6870-5p, miR-6729-5p, miR-4530, miR-7847-3p, miR-6825-5p, miR-4674, miR-3917, miR-4707-3p, miR-6885-5p, miR-6722-3p, miR-4516, miR-6757-5p, miR-6840-3p, miR-5195-3p, miR-6756-5p, miR-6800-5p, miR-6727-5p, miR-6126, miR-6872-3p, miR-4446-3p, miR-1268a, miR-1908-3p, miR-3679-5p, miR-4534, miR-4675, miR-7108-5p, miR-6799-5p, miR-4695-5p, miR-3178, miR-5090, miR-3180, miR-1237-5p, miR-4758-5p, miR-3184-5p, miR-4286, miR-6784-5p, miR-6768-5p, miR-6785-5p, miR-4706, miR-711, miR-1260a, miR-6746-5p, miR-6089, miR-6821-5p, miR-4667-5p, miR-8069, miR-4726-5p, miR-6124, miR-4532, miR-4486, miR-4728-5p, miR-4508, miR-128-1-5p, miR-4513, miR-6795-5p, miR-4689, miR-6763-5p, miR-8072, miR-6765-5p, miR-4419b, miR-7641, miR-3928-3p, miR-1227-5p, miR-4492, miR-296-3p, miR-6769a-5p, miR-6889-5p, miR-4632-5p, miR-4505, miR-3154, miR-3648, miR-4442, miR-3141, miR-7113-3p, miR-6819-5p, miR-3195, miR-1199-5p, miR-6738-5p, miR-4656, miR-6820-5p, miR-204-3p, miR-642a-3p, miR-762, miR-1202, miR-3162-5p, miR-3196, miR-3622a-5p, miR-3665, miR-3940-5p, miR-4294, miR-4466, miR-4476, miR-4723-5p, miR-4725-3p, miR-4730, miR-4739, miR-4787-5p, miR-5787, miR-6085, miR-6717-5p, miR-6724-5p, miR-6777-5p, miR-6778-5p, miR-6787-5p, miR-6789-5p, miR-6845-5p and miR-6893-5p. 
     (2) The kit according to (1), wherein miR-4443 is hsa-miR-4443, miR-1908-5p is hsa-miR-1908-5p, miR-4257 is hsa-miR-4257, miR-3197 is hsa-miR-3197, miR-3188 is hsa-miR-3188, miR-4649-5p is hsa-miR-4649-5p, miR-1343-3p is hsa-miR-1343-3p, miR-6861-5p is hsa-miR-6861-5p, miR-1343-5p is hsa-miR-1343-5p, miR-642b-3p is hsa-miR-642b-3p, miR-6741-5p is hsa-miR-6741-5p, miR-4745-5p is hsa-miR-4745-5p, miR-6826-5p is hsa-miR-6826-5p, miR-3663-3p is hsa-miR-3663-3p, miR-3131 is hsa-miR-3131, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-4258 is hsa-miR-4258, miR-4448 is hsa-miR-4448, miR-6125 is hsa-miR-6125, miR-6880-5p is hsa-miR-6880-5p, miR-6132 is hsa-miR-6132, miR-4467 is hsa-miR-4467, miR-6749-5p is hsa-miR-6749-5p, miR-2392 is hsa-miR-2392, miR-1273g-3p is hsa-miR-1273g-3p, miR-4746-3p is hsa-miR-4746-3p, miR-1914-3p is hsa-miR-1914-3p, miR-7845-5p is hsa-miR-7845-5p, miR-6726-5p is hsa-miR-6726-5p, miR-128-2-5p is hsa-miR-128-2-5p, miR-4651 is hsa-miR-4651, miR-6765-3p is hsa-miR-6765-3p, miR-3185 is hsa-miR-3185, miR-4792 is hsa-miR-4792, miR-6887-5p is hsa-miR-6887-5p, miR-5572 is hsa-miR-5572, miR-3619-3p is hsa-miR-3619-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-4707-5p is hsa-miR-4707-5p, miR-8063 is hsa-miR-8063, miR-4454 is hsa-miR-4454, miR-4525 is hsa-miR-4525, miR-7975 is hsa-miR-7975, miR-744-5p is hsa-miR-744-5p, miR-3135b is hsa-miR-3135b, miR-4648 is hsa-miR-4648, miR-6816-5p is hsa-miR-6816-5p, miR-4741 is hsa-miR-4741, miR-7150 is hsa-miR-7150, miR-6791-5p is hsa-miR-6791-5p, miR-1247-3p is hsa-miR-1247-3p, miR-7977 is hsa-miR-7977, miR-4497 is hsa-miR-4497, miR-6090 is hsa-miR-6090, miR-6781-5p is hsa-miR-6781-5p, miR-6870-5p is hsa-miR-6870-5p, miR-6729-5p is hsa-miR-6729-5p, miR-4530 is hsa-miR-4530, miR-7847-3p is hsa-miR-7847-3p, miR-6825-5p is hsa-miR-6825-5p, miR-4674 is hsa-miR-4674, miR-3917 is hsa-miR-3917, miR-4707-3p is hsa-miR-4707-3p, miR-6885-5p is hsa-miR-6885-5p, miR-6722-3p is hsa-miR-6722-3p, miR-4516 is hsa-miR-4516, miR-6757-5p is hsa-miR-6757-5p, miR-6840-3p is hsa-miR-6840-3p, miR-5195-3p is hsa-miR-5195-3p, miR-6756-5p is hsa-miR-6756-5p, miR-6800-5p is hsa-miR-6800-5p, miR-6727-5p is hsa-miR-6727-5p, miR-6126 is hsa-miR-6126, miR-6872-3p is hsa-miR-6872-3p, miR-4446-3p is hsa-miR-4446-3p, miR-1268a is hsa-miR-1268a, miR-1908-3p is hsa-miR-1908-3p, miR-3679-5p is hsa-miR-3679-5p, miR-4534 is hsa-miR-4534, miR-4675 is hsa-miR-4675, miR-7108-5p is hsa-miR-7108-5p, miR-6799-5p is hsa-miR-6799-5p, miR-4695-5p is hsa-miR-4695-5p, miR-3178 is hsa-miR-3178, miR-5090 is hsa-miR-5090, miR-3180 is hsa-miR-3180, miR-1237-5p is hsa-miR-1237-5p, miR-4758-5p is hsa-miR-4758-5p, miR-3184-5p is hsa-miR-3184-5p, miR-4286 is hsa-miR-4286, miR-6784-5p is hsa-miR-6784-5p, miR-6768-5p is hsa-miR-6768-5p, miR-6785-5p is hsa-miR-6785-5p, miR-4706 is hsa-miR-4706, miR-711 is hsa-miR-711, miR-1260a is hsa-miR-1260a, miR-6746-5p is hsa-miR-6746-5p, miR-6089 is hsa-miR-6089, miR-6821-5p is hsa-miR-6821-5p, miR-4667-5p is hsa-miR-4667-5p, miR-8069 is hsa-miR-8069, miR-4726-5p is hsa-miR-4726-5p, miR-6124 is hsa-miR-6124, miR-4532 is hsa-miR-4532, miR-4486 is hsa-miR-4486, miR-4728-5p is hsa-miR-4728-5p, miR-4508 is hsa-miR-4508, miR-128-1-5p is hsa-miR-128-1-5p, miR-4513 is hsa-miR-4513, miR-6795-5p is hsa-miR-6795-5p, miR-4689 is hsa-miR-4689, miR-6763-5p is hsa-miR-6763-5p, miR-8072 is hsa-miR-8072, miR-6765-5p is hsa-miR-6765-5p, miR-4419b is hsa-miR-4419b, miR-7641 is hsa-miR-7641, miR-3928-3p is hsa-miR-3928-3p, miR-1227-5p is hsa-miR-1227-5p, miR-4492 is hsa-miR-4492, miR-296-3p is hsa-miR-296-3p, miR-6769a-5p is hsa-miR-6769a-5p, miR-6889-5p is hsa-miR-6889-5p, miR-4632-5p is hsa-miR-4632-5p, miR-4505 is hsa-miR-4505, miR-3154 is hsa-miR-3154, miR-3648 is hsa-miR-3648, miR-4442 is hsa-miR-4442, miR-3141 is hsa-miR-3141, miR-7113-3p is hsa-miR-7113-3p, miR-6819-5p is hsa-miR-6819-5p, miR-3195 is hsa-miR-3195, miR-1199-5p is hsa-miR-1199-5p, miR-6738-5p is hsa-miR-6738-5p, miR-4656 is hsa-miR-4656, miR-6820-5p is hsa-miR-6820-5p, miR-204-3p is hsa-miR-204-3p, miR-642a-3p is hsa-miR-642a-3p, miR-762 is hsa-miR-762, miR-1202 is hsa-miR-1202, miR-3162-5p is hsa-miR-3162-5p, miR-3196 is hsa-miR-3196, miR-3622a-5p is hsa-miR-3622a-5p, miR-3665 is hsa-miR-3665, miR-3940-5p is hsa-miR-3940-5p, miR-4294 is hsa-miR-4294, miR-4466 is hsa-miR-4466, miR-4476 is hsa-miR-4476, miR-4723-5p is hsa-miR-4723-5p, miR-4725-3p is hsa-miR-4725-3p, miR-4730 is hsa-miR-4730, miR-4739 is hsa-miR-4739, miR-4787-5p is hsa-miR-4787-5p, miR-5787 is hsa-miR-5787, miR-6085 is hsa-miR-6085, miR-6717-5p is hsa-miR-6717-5p, miR-6724-5p is hsa-miR-6724-5p, miR-6777-5p is hsa-miR-6777-5p, miR-6778-5p is hsa-miR-6778-5p, miR-6787-5p is hsa-miR-6787-5p, miR-6789-5p is hsa-miR-6789-5p, miR-6845-5p is hsa-miR-6845-5p, and miR-6893-5p is hsa-miR-6893-5p. 
     (3) The kit according to (1) or (2), wherein the nucleic acid is a polynucleotide selected from the group consisting of the following polynucleotides (a) to (e): 
     (a) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(b) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606,
 
(c) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(d) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(e) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (a) to (d).
 
     (4) The kit according to any of (1) to (3), wherein the kit further comprises a nucleic acid capable of specifically binding to at least one or more polynucleotide(s) selected from the group consisting of other prostate cancer markers miR-615-5p, miR-486-3p, miR-1225-3p, miR-760, miR-187-5p, miR-1203, miR-7110-5p, miR-371a-5p, miR-939-5p, miR-575, miR-92b-5p, miR-887-3p, miR-920, miR-1915-5p, miR-1231, miR-663b, miR-1225-5p, miR-16-5p, miR-423-5p, miR-451a, miR-564 and miR-671-5p. 
     (5) The kit according to (4), wherein miR-615-5p is hsa-miR-615-5p, miR-486-3p is hsa-miR-486-3p, miR-1225-3p is hsa-miR-1225-3p, miR-760 is hsa-miR-760, miR-187-5p is hsa-miR-187-5p, miR-1203 is hsa-miR-1203, miR-7110-5p is hsa-miR-7110-5p, miR-371a-5p is hsa-miR-371a-5p, miR-939-5p is hsa-miR-939-5p, miR-575 is hsa-miR-575, miR-92b-5p is hsa-miR-92b-5p, miR-887-3p is hsa-miR-887-3p, miR-920 is hsa-miR-920, miR-1915-5p is hsa-miR-1915-5p, miR-1231 is hsa-miR-1231, miR-663b is hsa-miR-663b, miR-1225-5p is hsa-miR-1225-5p, miR-16-5p is hsa-miR-16-5p, miR-423-5p is hsa-miR-423-5p, miR-451a is hsa-miR-451a, miR-564 is hsa-miR-564, and miR-671-5p is hsa-miR-671-5p. 
     (6) The kit according to (4) or (5), wherein the nucleic acid is a polynucleotide selected from the group consisting of the following polynucleotides (f) to (j): 
     (f) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, any variant thereof, any derivative thereof, or any fragment thereof comprising 15 or more consecutive nucleotides,
 
(g) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611,
 
(h) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(i) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(j) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (f) to (i).
 
     (7) The kit according to any of (1) to (6), wherein the kit further comprises a nucleic acid capable of specifically binding to at least one or more polynucleotide(s) selected from the group consisting of other prostate cancer markers miR-4763-3p, miR-3656, miR-4488, miR-125a-3p, miR-1469, miR-1228-5p, miR-6798-5p, miR-1268b, miR-6732-5p, miR-1915-3p, miR-4433b-3p, miR-1207-5p, miR-4433-3p, miR-6879-5p, miR-4417, miR-30c-1-3p, miR-4638-5p, miR-6088, miR-4270, miR-6782-5p, miR-665, miR-486-5p, miR-4655-5p, miR-1275, miR-6806-5p, miR-614, miR-3937, miR-6752-5p, miR-6771-5p, miR-4450, miR-211-3p, miR-663a, miR-6842-5p, miR-7114-5p and miR-6779-5p. 
     (8) The kit according to (7), wherein miR-4763-3p is hsa-miR-4763-3p, miR-3656 is hsa-miR-3656, miR-4488 is hsa-miR-4488, miR-125a-3p is hsa-miR-125a-3p, miR-1469 is hsa-miR-1469, miR-1228-5p is hsa-miR-1228-5p, miR-6798-5p is hsa-miR-6798-5p, miR-1268b is hsa-miR-1268b, miR-6732-5p is hsa-miR-6732-5p, miR-1915-3p is hsa-miR-1915-3p, miR-4433b-3p is hsa-miR-4433b-3p, miR-1207-5p is hsa-miR-1207-5p, miR-4433-3p is hsa-miR-4433-3p, miR-6879-5p is hsa-miR-6879-5p, miR-4417 is hsa-miR-4417, miR-30c 3p is hsa-miR-30c-1-3p, miR-4638-5p is hsa-miR-4638-5p, miR-6088 is hsa-miR-6088, miR-4270 is hsa-miR-4270, miR-6782-5p is hsa-miR-6782-5p, miR-665 is hsa-miR-665, miR 5p is hsa-miR-486-5p, miR-4655-5p is hsa-miR-4655-5p, miR-1275 is hsa-miR-1275, miR-6806-5p is hsa-miR-6806-5p, miR-614 is hsa-miR-614, miR-3937 is hsa-miR-3937, miR-6752-5p is hsa-miR-6752-5p, miR-6771-5p is hsa-miR-6771-5p, miR-4450 is hsa-miR-4450, miR-211-3p is hsa-miR-211-3p, miR-663a is hsa-miR-663a, miR-6842-5p is hsa-miR-6842-5p, miR-7114-5p is hsa-miR-7114-5p, and miR-6779-5p is hsa-miR-6779-5p. 
     (9) The kit according to (7) or (8), wherein the nucleic acid is a polynucleotide selected from the group consisting of the following polynucleotides (k) to (o): 
     (k) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(l) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187,
 
(m) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(n) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(o) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (k) to (n).
 
     (10) The kit according to any of (1) to (9), wherein the kit comprises at least two or more nucleic acids capable of specifically binding to at least two or more polynucleotides, respectively, selected from all of the prostate cancer markers according to (1) or (2). 
     (11) A device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to at least one or more polynucleotide(s) selected from the group consisting of prostate cancer markers miR-4443, miR-1908-5p, miR-4257, miR-3197, miR-3188, miR-4649-5p, miR-1343-3p, miR-6861-5p, miR-1343-5p, miR-642b-3p, miR-6741-5p, miR-4745-5p, miR-6826-5p, miR-3663-3p, miR-3131, miR-92a-2-5p, miR-4258, miR-4448, miR-6125, miR-6880-5p, miR-6132, miR-4467, miR-6749-5p, miR-2392, miR-1273g-3p, miR-4746-3p, miR-1914-3p, miR-7845-5p, miR-6726-5p, miR-128-2-5p, miR-4651, miR-6765-3p, miR-3185, miR-4792, miR-6887-5p, miR-5572, miR-3619-3p, miR-6780b-5p, miR-4707-5p, miR-8063, miR-4454, miR-4525, miR-7975, miR-744-5p, miR-3135b, miR-4648, miR-6816-5p, miR-4741, miR-7150, miR-6791-5p, miR-1247-3p, miR-7977, miR-4497, miR-6090, miR-6781-5p, miR-6870-5p, miR-6729-5p, miR-4530, miR-7847-3p, miR-6825-5p, miR-4674, miR-3917, miR-4707-3p, miR-6885-5p, miR-6722-3p, miR-4516, miR-6757-5p, miR-6840-3p, miR-5195-3p, miR-6756-5p, miR-6800-5p, miR-6727-5p, miR-6126, miR-6872-3p, miR-4446-3p, miR-1268a, miR-1908-3p, miR-3679-5p, miR-4534, miR-4675, miR-7108-5p, miR-6799-5p, miR-4695-5p, miR-3178, miR-5090, miR-3180, miR-1237-5p, miR-4758-5p, miR-3184-5p, miR-4286, miR-6784-5p, miR-6768-5p, miR-6785-5p, miR-4706, miR-711, miR-1260a, miR-6746-5p, miR-6089, miR-6821-5p, miR-4667-5p, miR-8069, miR-4726-5p, miR-6124, miR-4532, miR-4486, miR-4728-5p, miR-4508, miR-128-1-5p, miR-4513, miR-6795-5p, miR-4689, miR-6763-5p, miR-8072, miR-6765-5p, miR-4419b, miR-7641, miR-3928-3p, miR-1227-5p, miR-4492, miR-296-3p, miR-6769a-5p, miR-6889-5p, miR-4632-5p, miR-4505, miR-3154, miR-3648, miR-4442, miR-3141, miR-7113-3p, miR-6819-5p, miR-3195, miR-1199-5p, miR-6738-5p, miR-4656, miR-6820-5p, miR-204-3p, miR-642a-3p, miR-762, miR-1202, miR-3162-5p, miR-3196, miR-3622a-5p, miR-3665, miR-3940-5p, miR-4294, miR-4466, miR-4476, miR-4723-5p, miR-4725-3p, miR-4730, miR-4739, miR-4787-5p, miR-5787, miR-6085, miR-6717-5p, miR-6724-5p, miR-6777-5p, miR-6778-5p, miR-6787-5p, miR-6789-5p, miR-6845-5p and miR-6893-5p. 
     (12) The device according to (11), wherein miR-4443 is hsa-miR-4443, miR-1908-5p is hsa-miR-1908-5p, miR-4257 is hsa-miR-4257, miR-3197 is hsa-miR-3197, miR-3188 is hsa-miR-3188, miR-4649-5p is hsa-miR-4649-5p, miR-1343-3p is hsa-miR-1343-3p, miR-6861-5p is hsa-miR-6861-5p, miR-1343-5p is hsa-miR-1343-5p, miR-642b-3p is hsa-miR-642b-3p, miR-6741-5p is hsa-miR-6741-5p, miR-4745-5p is hsa-miR-4745-5p, miR-6826-5p is hsa-miR-6826-5p, miR-3663-3p is hsa-miR-3663-3p, miR-3131 is hsa-miR-3131, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-4258 is hsa-miR-4258, miR-4448 is hsa-miR-4448, miR-6125 is hsa-miR-6125, miR-6880-5p is hsa-miR-6880-5p, miR-6132 is hsa-miR-6132, miR-4467 is hsa-miR-4467, miR-6749-5p is hsa-miR-6749-5p, miR-2392 is hsa-miR-2392, miR-1273g-3p is hsa-miR-1273g-3p, miR-4746-3p is hsa-miR-4746-3p, miR-1914-3p is hsa-miR-1914-3p, miR-7845-5p is hsa-miR-7845-5p, miR-6726-5p is hsa-miR-6726-5p, miR-128-2-5p is hsa-miR-128-2-5p, miR-4651 is hsa-miR-4651, miR-6765-3p is hsa-miR-6765-3p, miR-3185 is hsa-miR-3185, miR-4792 is hsa-miR-4792, miR-6887-5p is hsa-miR-6887-5p, miR-5572 is hsa-miR-5572, miR-3619-3p is hsa-miR-3619-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-4707-5p is hsa-miR-4707-5p, miR-8063 is hsa-miR-8063, miR-4454 is hsa-miR-4454, miR-4525 is hsa-miR-4525, miR-7975 is hsa-miR-7975, miR-744-5p is hsa-miR-744-5p, miR-3135b is hsa-miR-3135b, miR-4648 is hsa-miR-4648, miR-6816-5p is hsa-miR-6816-5p, miR-4741 is hsa-miR-4741, miR-7150 is hsa-miR-7150, miR-6791-5p is hsa-miR-6791-5p, miR-1247-3p is hsa-miR-1247-3p, miR-7977 is hsa-miR-7977, miR-4497 is hsa-miR-4497, miR-6090 is hsa-miR-6090, miR-6781-5p is hsa-miR-6781-5p, miR-6870-5p is hsa-miR-6870-5p, miR-6729-5p is hsa-miR-6729-5p, miR-4530 is hsa-miR-4530, miR-7847-3p is hsa-miR-7847-3p, miR-6825-5p is hsa-miR-6825-5p, miR-4674 is hsa-miR-4674, miR-3917 is hsa-miR-3917, miR-4707-3p is hsa-miR-4707-3p, miR-6885-5p is hsa-miR-6885-5p, miR-6722-3p is hsa-miR-6722-3p, miR-4516 is hsa-miR-4516, miR-6757-5p is hsa-miR-6757-5p, miR-6840-3p is hsa-miR-6840-3p, miR-5195-3p is hsa-miR-5195-3p, miR-6756-5p is hsa-miR-6756-5p, miR-6800-5p is hsa-miR-6800-5p, miR-6727-5p is hsa-miR-6727-5p, miR-6126 is hsa-miR-6126, miR-6872-3p is hsa-miR-6872-3p, miR-4446-3p is hsa-miR-4446-3p, miR-1268a is hsa-miR-1268a, miR-1908-3p is hsa-miR-1908-3p, miR-3679-5p is hsa-miR-3679-5p, miR-4534 is hsa-miR-4534, miR-4675 is hsa-miR-4675, miR-7108-5p is hsa-miR-7108-5p, miR-6799-5p is hsa-miR-6799-5p, miR-4695-5p is hsa-miR-4695-5p, miR-3178 is hsa-miR-3178, miR-5090 is hsa-miR-5090, miR-3180 is hsa-miR-3180, miR-1237-5p is hsa-miR-1237-5p, miR-4758-5p is hsa-miR-4758-5p, miR-3184-5p is hsa-miR-3184-5p, miR-4286 is hsa-miR-4286, miR-6784-5p is hsa-miR-6784-5p, miR-6768-5p is hsa-miR-6768-5p, miR-6785-5p is hsa-miR-6785-5p, miR-4706 is hsa-miR-4706, miR-711 is hsa-miR-711, miR-1260a is hsa-miR-1260a, miR-6746-5p is hsa-miR-6746-5p, miR-6089 is hsa-miR-6089, miR-6821-5p is hsa-miR-6821-5p, miR-4667-5p is hsa-miR-4667-5p, miR-8069 is hsa-miR-8069, miR-4726-5p is hsa-miR-4726-5p, miR-6124 is hsa-miR-6124, miR-4532 is hsa-miR-4532, miR-4486 is hsa-miR-4486, miR-4728-5p is hsa-miR-4728-5p, miR-4508 is hsa-miR-4508, miR-128-1-5p is hsa-miR-128-1-5p, miR-4513 is hsa-miR-4513, miR-6795-5p is hsa-miR-6795-5p, miR-4689 is hsa-miR-4689, miR-6763-5p is hsa-miR-6763-5p, miR-8072 is hsa-miR-8072, miR-6765-5p is hsa-miR-6765-5p, miR-4419b is hsa-miR-4419b, miR-7641 is hsa-miR-7641, miR-3928-3p is hsa-miR-3928-3p, miR-1227-5p is hsa-miR-1227-5p, miR-4492 is hsa-miR-4492, miR-296-3p is hsa-miR-296-3p, miR-6769a-5p is hsa-miR-6769a-5p, miR-6889-5p is hsa-miR-6889-5p, miR-4632-5p is hsa-miR-4632-5p, miR-4505 is hsa-miR-4505, miR-3154 is hsa-miR-3154, miR-3648 is hsa-miR-3648, miR-4442 is hsa-miR-4442, miR-3141 is hsa-miR-3141, miR-7113-3p is hsa-miR-7113-3p, miR-6819-5p is hsa-miR-6819-5p, miR-3195 is hsa-miR-3195, miR-1199-5p is hsa-miR-1199-5p, miR-6738-5p is hsa-miR-6738-5p, miR-4656 is hsa-miR-4656, miR-6820-5p is hsa-miR-6820-5p, miR-204-3p is hsa-miR-204-3p, miR-642a-3p is hsa-miR-642a-3p, miR-762 is hsa-miR-762, miR-1202 is hsa-miR-1202, miR-3162-5p is hsa-miR-3162-5p, miR-3196 is hsa-miR-3196, miR-3622a-5p is hsa-miR-3622a-5p, miR-3665 is hsa-miR-3665, miR-3940-5p is hsa-miR-3940-5p, miR-4294 is hsa-miR-4294, miR-4466 is hsa-miR-4466, miR-4476 is hsa-miR-4476, miR-4723-5p is hsa-miR-4723-5p, miR-4725-3p is hsa-miR-4725-3p, miR-4730 is hsa-miR-4730, miR-4739 is hsa-miR-4739, miR-4787-5p is hsa-miR-4787-5p, miR-5787 is hsa-miR-5787, miR-6085 is hsa-miR-6085, miR-6717-5p is hsa-miR-6717-5p, miR-6724-5p is hsa-miR-6724-5p, miR-6777-5p is hsa-miR-6777-5p, miR-6778-5p is hsa-miR-6778-5p, miR-6787-5p is hsa-miR-6787-5p, miR-6789-5p is hsa-miR-6789-5p, miR-6845-5p is hsa-miR-6845-5p, and miR-6893-5p is hsa-miR-6893-5p. 
     (13) The device according to (11) or (12), wherein the nucleic acid is a polynucleotide selected from the group consisting of the following polynucleotides (a) to (e): 
     (a) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(b) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606,
 
(c) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(d) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(e) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (a) to (d).
 
     (14) The device according to any of (11) to (13), wherein the device further comprises a nucleic acid capable of specifically binding to at least one or more polynucleotide(s) selected from the group consisting of other prostate cancer markers miR-615-5p, miR-486-3p, miR-1225-3p, miR-760, miR-187-5p, miR-1203, miR-7110-5p, miR-371a-5p, miR-939-5p, miR-575, miR-92b-5p, miR-887-3p, miR-920, miR-1915-5p, miR-1231, miR-663b, miR-1225-5p, miR-16-5p, miR-423-5p, miR-451a, miR-564, and miR-671-5p. 
     (15) The device according to (14), wherein miR-615-5p is hsa-miR-615-5p, miR-486-3p is hsa-miR-486-3p, miR-1225-3p is hsa-miR-1225-3p, miR-760 is hsa-miR-760, miR-187-5p is hsa-miR-187-5p, miR-1203 is hsa-miR-1203, miR-7110-5p is hsa-miR-7110-5p, miR-371a-5p is hsa-miR-371a-5p, miR-939-5p is hsa-miR-939-5p, miR-575 is hsa-miR-575, miR-92b-5p is hsa-miR-92b-5p, miR-887-3p is hsa-miR-887-3p, miR-920 is hsa-miR-920, miR-1915-5p is hsa-miR-1915-5p, miR-1231 is hsa-miR-1231, miR-663b is hsa-miR-663b, miR-1225-5p is hsa-miR-1225-5p, miR-16-5p is hsa-miR-16-5p, miR-423-5p is hsa-miR-423-5p, miR-451a is hsa-miR-451a, miR-564 is hsa-miR-564, and miR-671-5p is hsa-miR-671-5p. 
     (16) The device according to (14) or (15), wherein the nucleic acid is a polynucleotide selected from the group consisting of the following polynucleotides (f) to (j): 
     (f) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(g) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611,
 
(h) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(i) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(j) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (f) to (i).
 
     (17) The device according to any of (11) to (16), wherein the device further comprises a nucleic acid capable of specifically binding to at least one or more polynucleotide(s) selected from the group consisting of other prostate cancer markers miR-4763-3p, miR-3656, miR-4488, miR-125a-3p, miR-1469, miR-1228-5p, miR-6798-5p, miR-1268b, miR-6732-5p, miR-1915-3p, miR-4433b-3p, miR-1207-5p, miR-4433-3p, miR-6879-5p, miR-4417, miR-30c-1-3p, miR-4638-5p, miR-6088, miR-4270, miR-6782-5p, miR-665, miR-486-5p, miR-4655-5p, miR-1275, miR-6806-5p, miR-614, miR-3937, miR-6752-5p, miR-6771-5p, miR-4450, miR-211-3p, miR-663a, miR-6842-5p, miR-7114-5p and miR-6779-5p. 
     (18) The device according to (17), wherein miR-4763-3p is hsa-miR-4763-3p, miR-3656 is hsa-miR-3656, miR-4488 is hsa-miR-4488, miR-125a-3p is hsa-miR-125a-3p, miR-1469 is hsa-miR-1469, miR-1228-5p is hsa-miR-1228-5p, miR-6798-5p is hsa-miR-6798-5p, miR-1268b is hsa-miR-1268b, miR-6732-5p is hsa-miR-6732-5p, miR-1915-3p is hsa-miR-1915-3p, miR-4433b-3p is hsa-miR-4433b-3p, miR-1207-5p is hsa-miR-1207-5p, miR-4433-3p is hsa-miR-4433-3p, miR-6879-5p is hsa-miR-6879-5p, miR-4417 is hsa-miR-4417, miR-30c-1-3p is hsa-miR-30c-1-3p, miR-4638-5p is hsa-miR-4638-5p, miR-6088 is hsa-miR-6088, miR-4270 is hsa-miR-4270, miR-6782-5p is hsa-miR-6782-5p, miR-665 is hsa-miR-665, miR-486-5p is hsa-miR-486-5p, miR-4655-5p is hsa-miR-4655-5p, miR-1275 is hsa-miR-1275, miR-6806-5p is hsa-miR-6806-5p, miR-614 is hsa-miR-614, miR-3937 is hsa-miR-3937, miR-6752-5p is hsa-miR-6752-5p, miR-6771-5p is hsa-miR-6771-5p, miR-4450 is hsa-miR-4450, miR-211-3p is hsa-miR-211-3p, miR-663a is hsa-miR-663a, miR-6842-5p is hsa-miR-6842-5p, miR-7114-5p is hsa-miR-7114-5p, and miR-6779-5p is hsa-miR-6779-5p. 
     (19) The device according to (17) or (18), wherein the nucleic acid is a polynucleotide selected from the group consisting of the following polynucleotides (k) to (o): 
     (k) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(l) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187,
 
(m) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(n) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(o) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (k) to (n).
 
     (20) The device according to any one of (11) to (19), wherein the device is a device for measurement by a hybridization technique. 
     (21) The device according to (20), wherein the hybridization technique is a nucleic acid array technique. 
     (22) The device according to any one of (11) to (21), wherein the device comprises at least two or more nucleic acids capable of specifically binding to at least two or more polynucleotides, respectively, selected from all of the prostate cancer markers according to (11) or (12). 
     (23) A method for detecting prostate cancer, comprising measuring an expression level of a target nucleic acid in a sample from a subject using a kit according to any one of (1) to (10) or a device according to any one of (11) to (22), and evaluating in vitro whether or not the subject has prostate cancer using the measured expression level and a control expression level in a sample from a healthy subject measured in the same way as above. 
     (24) The method according to (23), wherein the subject is a human. 
     (25) The method according to (23) or (24), wherein the sample is blood, serum, or plasma. 
     Definition of Term 
     The terms used in the present specification are defined as follows. 
     Abbreviations or terms such as nucleotide, polynucleotide, DNA, and RNA abide by “Guidelines for the preparation of specification which contain nucleotide and/or amino acid sequences” (edited by Japan Patent Office) and common use in the art. 
     In the present specification, the term “polynucleotide” is used for a nucleic acid including all of RNA, DNA, and RNA/DNA (chimera). The DNA includes all of cDNA, genomic DNA, and synthetic DNA. The RNA includes all of total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA and synthetic RNA. In the present specification, the “synthetic DNA” and the “synthetic RNA” refer to a DNA and an RNA artificially prepared using, for example, an automatic nucleic acid synthesizer, on the basis of predetermined nucleotide sequences (which may be any of natural and non-natural sequences). In the present specification, the “non-natural sequence” is intended to be used in a broad sense and includes, for example, a sequence containing substitution, deletion, insertion, and/or addition of one or more nucleotide(s) (i.e., a variant sequence) and a sequence containing one or more modified nucleotide(s) (i.e., a modified sequence), which are different from the natural sequence. In the present specification, the polynucleotide is used interchangeably with a nucleic acid. 
     In the present specification, the term “fragment” is a polynucleotide having a nucleotide sequence having a consecutive portion of a polynucleotide and desirably has a length of 15 or more nucleotides, preferably 17 or more nucleotides, more preferably 19 or more nucleotides. 
     In the present specification, the term “gene” is intended to include not only RNA and double-stranded DNA but also each single-stranded DNA such as a plus strand (or a sense strand) or a complementary strand (or an antisense strand) constituting the duplex. The gene is not particularly limited by its length. 
     Thus, in the present specification, the “gene” includes all of double-stranded DNA including human genomic DNA, single-stranded DNA (plus strand) including cDNA, single-stranded DNA having a sequence complementary to the plus strand (complementary strand), microRNA (miRNA), and their fragments, and their transcripts, unless otherwise specified. The “gene” includes not only a “gene” represented by a particular nucleotide sequence (or SEQ ID N0) but “nucleic acids” encoding RNAs having biological functions equivalent to an RNA encoded by the gene, for example, a congener (i.e., a homolog or an ortholog), a variant (e.g., a genetic polymorph), and a derivative. Specific examples of such a “nucleic acid” encoding a congener, a variant, or a derivative can include a “nucleic acid” having a nucleotide sequence hybridizing under stringent conditions described later to a complementary sequence of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 684 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t. The “gene” is not particularly limited by its functional region and can contain, for example, an expression control region, a coding region, an exon, or an intron. The “gene” may be contained in a cell or may exist alone after being released into the outside of a cell. Alternatively, the “gene” may be in a state enclosed in a vesicle called exosome. 
     In the present specification, the term “exosome” is a vesicle that is capsulated with a lipid bilayer and secreted from a cell. The exosome is derived from a multivesicular endosome and may incorporate a biomaterial such as a “gene” (e.g., RNA or DNA) or a protein when released into an extracellular environment. The exosome is known to be contained in a body fluid such as blood, serum, plasma, serum, or lymph. 
     In the present specification, the term “transcript” refers to an RNA synthesized with the DNA sequence of a gene as a template. RNA polymerase binds to a site called promoter located upstream of the gene and adds ribonucleotides complementary to the nucleotide sequence of the DNA to the 3′ end to synthesize an RNA. This RNA contains not only the gene itself but also the whole sequence from a transcription initiation site to the end of a poly A sequence, including an expression regulatory region, a coding region, an exon, or an intron. 
     In the present specification, the term “microRNA (miRNA)” is intended to mean a 15- to 25-nucleotide non-coding RNA that is transcribed as an RNA precursor having a hairpin-like structure, cleaved by a dsRNA-cleaving enzyme which has RNase III cleavage activity, integrated into a protein complex called RISC, and involved in the suppression of translation of mRNA, unless otherwise specified. The term “miRNA” used in the present specification includes not only a “miRNA” represented by a particular nucleotide sequence (or SEQ ID N0) but a precursor of the “miRNA” (pre-miRNA or pri-miRNA), and miRNAs having biological functions equivalent thereto, for example, a congener (i.e., a homolog or an ortholog), a variant (e.g., a genetic polymorph), and a derivative. Such a precursor, a congener, a variant, or a derivative can be specifically identified using miRBase Release 20 (http://www.mirbase.org/), and examples thereof can include a “miRNA” having a nucleotide sequence hybridizing under stringent conditions described later to a complementary sequence of any particular nucleotide sequence represented by any of SEQ ID NOs: 1 to 684. The term “miRNA” used in the present specification may be a gene product of a miR gene. Such a gene product includes a mature miRNA (e.g., a 15- to 25-nucleotide or 19- to 25-nucleotide non-coding RNA involved in the suppression of translation of mRNA as described above) or a miRNA precursor (e.g., pre-miRNA or pri-miRNA as described above). 
     In the present specification, the term “probe” includes a polynucleotide that is used for specifically detecting an RNA resulting from the expression of a gene or a polynucleotide derived from the RNA, and/or a polynucleotide complementary thereto. 
     In the present specification, the term “primer” includes a polynucleotide that specifically recognizes and amplifies an RNA resulting from the expression of a gene or a polynucleotide derived from the RNA, and/or a polynucleotide complementary thereto. 
     In this context, the complementary polynucleotide (complementary strand or reverse strand) means a polynucleotide in a complementary base relationship based on A:T (U) and G:C base pairs with the full-length sequence of a polynucleotide consisting of a nucleotide sequence defined by any of SEQ ID NOs: 1 to 684 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, or a partial sequence thereof (here, this full-length or partial sequence is referred to as a plus strand for the sake of convenience). However, such a complementary strand is not limited to a sequence completely complementary to the nucleotide sequence of the target plus strand and may have a complementary relationship to an extent that permits hybridization under stringent conditions to the target plus strand. 
     In the present specification, the term “stringent conditions” refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a larger extent (e.g., a measurement value equal to or larger than a mean of background measurement values+a standard deviation of the background measurement values×2) than that for other sequences. The stringent conditions are dependent on a sequence and differ depending on an environment where hybridization is performed. A target sequence complementary 100% to the nucleic acid probe can be identified by controlling the stringency of hybridization and/or washing conditions. Specific examples of the “stringent conditions” will be mentioned later. 
     In the present specification, the term “Tm value” means a temperature at which the double-stranded moiety of a polynucleotide is denatured into single strands so that the double strands and the single strands exist at a ratio of 1:1. 
     In the present specification, the term “variant” means, in the case of a nucleic acid, a natural variant attributed to polymorphism, mutation, or the like; a variant containing the deletion, substitution, addition, or insertion of 1, 2, or 3 or more nucleotides in a nucleotide sequence represented by any of SEQ ID NOs: 1 to 684 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, or a partial sequence thereof; a variant containing the deletion, substitution, addition, or insertion of 1 or 2 or more nucleotides in a nucleotide sequence of a premature miRNA of a sequence represented by any of SEQ ID NOs: 1 to 684 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, or a partial sequence thereof; a variant that exhibits % identity of approximately 90% or higher, approximately 95% or higher, approximately 97% or higher, approximately 98% or higher, approximately 99% or higher to each of these nucleotide sequences or the partial sequences thereof; or a nucleic acid hybridizing under the stringent conditions defined above to a polynucleotide or an oligonucleotide comprising each of these nucleotide sequences or the partial sequences thereof. 
     In the present specification, the term “several” means an integer of approximately 10, 9, 8, 7, 6, 5, 4, 3, or 2. 
     In the present specification, the variant can be prepared by use of a well-known technique such as site-directed mutagenesis or PCR-based mutagenesis. 
     In the present specification, the term “percent (%) identity” can be determined with or without an introduced gap, using a protein or gene search system based on BLAST or FASTA described above (Zheng Zhang et al., 2000, J. Comput. Biol., Vol. 7, p. 203-214; Altschul, S. F. et al., 1990, Journal of Molecular Biology, Vol. 215, p. 403-410; and Pearson, W. R. et al., 1988, Proc. Natl. Acad. Sci. U.S.A., Vol. 85, p. 2444-2448). 
     In the present specification, the term “derivative” is meant to include a modified nucleic acid, for example, a derivative labeled with a fluorophore or the like, a derivative containing a modified nucleotide (e.g., a nucleotide containing a group such as halogen, alkyl such as methyl, alkoxy such as methoxy, thio, or carboxymethyl, and a nucleotide that has undergone base rearrangement, double bond saturation, deamination, replacement of an oxygen molecule with a sulfur atom, etc.), PNA (peptide nucleic acid; Nielsen, P. E. et al., 1991, Science, Vol. 254, p. 1497-500), and LNA (locked nucleic acid; Obika, S. et al., 1998, Tetrahedron Lett., Vol. 39, p. 5401-5404) without any limitation. 
     In the present specification, the “nucleic acid” capable of specifically binding to a polynucleotide selected from the prostate cancer marker miRNAs described above is a synthesized or prepared nucleic acid and specifically includes a “nucleic acid probe” or a “primer”. The “nucleic acid” is utilized directly or indirectly for detecting the presence or absence of prostate cancer in a subject, for diagnosing the severity, the degree of amelioration, or the therapeutic sensitivity of prostate cancer, or for screening for a candidate substance useful in the prevention, amelioration, or treatment of prostate cancer. The “nucleic acid” includes a nucleotide, an oligonucleotide, and a polynucleotide capable of specifically recognizing and binding to a transcript represented by any of SEQ ID NOs: 1 to 684, or a synthetic cDNA nucleic acid thereof in vivo, particularly, in a sample such as a body fluid (e.g., blood or urine), in relation to the development of prostate cancer. The nucleotide, the oligonucleotide, and the polynucleotide can be effectively used as probes for detecting the aforementioned gene expressed in vivo, in tissues, in cells, or the like on the basis of the properties described above, or as primers for amplifying the aforementioned gene expressed in vivo. 
     The term “detection” used in the present specification is interchangeable with the term “examination”, “measurement”, or “detection or decision support”. In the present specification, the term “evaluation” is meant to include diagnosis or evaluation support on the basis of examination results or measurement results. 
     The term “subject” used in the present specification means a mammal such as a primate including a human and a chimpanzee, a pet animal including a dog and a cat, a livestock animal including cattle, a horse, sheep, and a goat, and a rodent including a mouse and a rat. The term “healthy subject” also means such a mammal without the cancer to be detected. 
     The term “P” or “P value” used in the present specification refers to a probability at which a more extreme statistic than that actually calculated from data under a null hypothesis is observed in a statistical test. Thus, smaller “P” or “P value” means more significant difference between subjects to be compared. 
     In the present specification, the term “sensitivity” means a value of (the number of true positives)/(the number of true positives+the number of false negatives). High sensitivity allows prostate cancer to be detected early, leading to the complete resection of cancer sites and reduction in the rate of recurrence. 
     In the present specification, the term “specificity” means a value of (the number of true negatives)/(the number of true negatives+the number of false positives). High specificity prevents needless extra examination for healthy subjects misjudged as being prostate cancer patients, leading to reduction in burden on patients and reduction in medical expense. 
     In the present specification, the term “accuracy” means a value of (the number of true positives+the number of true negatives)/(the total number of cases). The accuracy indicates the ratio of samples that were correctly identified to all samples and serves as a primary index to evaluate detection performance. 
     In the present specification, the “sample” that is subjected to determination, detection, or diagnosis refers to a tissue and a biological material in which the expression of the gene of the present invention varies as prostate cancer develops, prostate cancer progresses, and therapeutic effects on prostate cancer are exerted. Specifically, the “sample” refers to a prostatic tissue, a periprostatic vascular channel, lymph node, and organ, an organ suspected of having metastasis, the skin, a body fluid such as blood, urine, saliva, sweat, or tissue exudates, serum or plasma prepared from blood, feces, hair, and the like. The “sample” further refers to a biological sample extracted therefrom, specifically, a gene such as RNA or miRNA. 
     The term “hsa-miR-4443 gene” or “hsa-miR-4443” used in the present specification includes the hsa-miR-4443 gene (miRBase Accession No. MIMAT0018961) described in SEQ ID NO: 1, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4443 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4443” (miRBase Accession No. MI0016786, SEQ ID NO: 188) having a hairpin-like structure is known as a precursor of “hsa-miR-4443”. 
     The term “hsa-miR-1908-5p gene” or “hsa-miR-1908-5p” used in the present specification includes the hsa-miR-1908-5p gene (miRBase Accession No. MIMAT0007881) described in SEQ ID NO: 2, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1908-5p gene can be obtained by a method described in Bar M et al., 2008, Stem Cells, Vol. 26, p. 2496-2505. Also, “hsa-mir-1908” (miRBase Accession No. MI0008329, SEQ ID NO: 189) having a hairpin-like structure is known as a precursor of “hsa-miR-1908-5p”. 
     The term “hsa-miR-4257 gene” or “hsa-miR-4257” used in the present specification includes the hsa-miR-4257 gene (miRBase Accession No. MIMAT0016878) described in SEQ ID NO: 3, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4257 gene can be obtained by a method described in Goff L A et al., 2009, PLoS One, Vol. 4, e7192. Also, “hsa-mir-4257” (miRBase Accession No. MI0015856, SEQ ID NO: 190) having a hairpin-like structure is known as a precursor of “hsa-miR-4257”. 
     The term “hsa-miR-3197 gene” or “hsa-miR-3197” used in the present specification includes the hsa-miR-3197 gene (miRBase Accession No. MIMAT0015082) described in SEQ ID NO: 4, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3197 gene can be obtained by a method described in Stark M S et al., 2010, PLoS One, Vol. 5, e9685. Also, “hsa-mir-3197” (miRBase Accession No. MI0014245, SEQ ID NO: 191) having a hairpin-like structure is known as a precursor of “hsa-miR-3197”. 
     The term “hsa-miR-3188 gene” or “hsa-miR-3188” used in the present specification includes the hsa-miR-3188 gene (miRBase Accession No. MIMAT0015070) described in SEQ ID NO: 5, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3188 gene can be obtained by a method described in Stark M S et al., 2010, PLoS One, Vol. 5, e9685. Also, “hsa-mir-3188” (miRBase Accession No. MI0014232, SEQ ID NO: 192) having a hairpin-like structure is known as a precursor of “hsa-miR-3188”. 
     The term “hsa-miR-4649-5p gene” or “hsa-miR-4649-5p” used in the present specification includes the hsa-miR-4649-5p gene (miRBase Accession No. MIMAT0019711) described in SEQ ID NO: 6, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4649-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4649” (miRBase Accession No. MI0017276, SEQ ID NO: 193) having a hairpin-like structure is known as a precursor of “hsa-miR-4649-5p”. 
     The term “hsa-miR-1343-3p gene” or “hsa-miR-1343-3p” used in the present specification includes the hsa-miR-1343-3p gene (miRBase Accession No. MIMAT0019776) described in SEQ ID NO: 7, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1343-3p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-1343” (miRBase Accession No. MI0017320, SEQ ID NO: 194) having a hairpin-like structure is known as a precursor of “hsa-miR-1343-3p”. 
     The term “hsa-miR-6861-5p gene” or “hsa-miR-6861-5p” used in the present specification includes the hsa-miR-6861-5p gene (miRBase Accession No. MIMAT0027623) described in SEQ ID NO: 8, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6861-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6861” (miRBase Accession No. MI0022708, SEQ ID NO: 195) having a hairpin-like structure is known as a precursor of “hsa-miR-6861-5p”. 
     The term “hsa-miR-1343-5p gene” or “hsa-miR-1343-5p” used in the present specification includes the hsa-miR-1343-5p gene (miRBase Accession No. MIMAT0027038) described in SEQ ID NO: 9, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1343-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-1343” (miRBase Accession No. MI0017320, SEQ ID NO: 194) having a hairpin-like structure is known as a precursor of “hsa-miR-1343-5p”. 
     The term “hsa-miR-642b-3p gene” or “hsa-miR-642b-3p” used in the present specification includes the hsa-miR-642b-3p gene (miRBase Accession No. MIMAT0018444) described in SEQ ID NO: 10, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-642b-3p gene can be obtained by a method described in Witten D et al., 2010, BMC Biol, Vol. 8, p. 58. Also, “hsa-mir-642b” (miRBase Accession No. MI0016685, SEQ ID NO: 196) having a hairpin-like structure is known as a precursor of “hsa-miR-642b-3p”. 
     The term “hsa-miR-6741-5p gene” or “hsa-miR-6741-5p” used in the present specification includes the hsa-miR-6741-5p gene (miRBase Accession No. MIMAT0027383) described in SEQ ID NO: 11, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6741-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6741” (miRBase Accession No. M10022586, SEQ ID NO: 197) having a hairpin-like structure is known as a precursor of “hsa-miR-6741-5p”. 
     The term “hsa-miR-4745-5p gene” or “hsa-miR-4745-5p” used in the present specification includes the hsa-miR-4745-5p gene (miRBase Accession No. MIMAT0019878) described in SEQ ID NO: 12, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4745-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4745” (miRBase Accession No. MI0017384, SEQ ID NO: 198) having a hairpin-like structure is known as a precursor of “hsa-miR-4745-5p”. 
     The term “hsa-miR-6826-5p gene” or “hsa-miR-6826-5p” used in the present specification includes the hsa-miR-6826-5p gene (miRBase Accession No. MIMAT0027552) described in SEQ ID NO: 13, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6826-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6826” (miRBase Accession No. M10022671, SEQ ID NO: 199) having a hairpin-like structure is known as a precursor of “hsa-miR-6826-5p”. 
     The term “hsa-miR-3663-3p gene” or “hsa-miR-3663-3p” used in the present specification includes the hsa-miR-3663-3p gene (miRBase Accession No. MIMAT0018085) described in SEQ ID NO: 14, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3663-3p gene can be obtained by a method described in Liao J Y et al., 2010, PLoS One, Vol. 5, e10563. Also, “hsa-mir-3663” (miRBase Accession No. MI0016064, SEQ ID NO: 200) having a hairpin-like structure is known as a precursor of “hsa-miR-3663-3p”. 
     The term “hsa-miR-3131 gene” or “hsa-miR-3131” used in the present specification includes the hsa-miR-3131 gene (miRBase Accession No. MIMAT0014996) described in SEQ ID NO: 15, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3131 gene can be obtained by a method described in Stark M S et al., 2010, PLoS One, Vol. 5, e9685. Also, “hsa-mir-3131” (miRBase Accession No. MI0014151, SEQ ID NO: 201) having a hairpin-like structure is known as a precursor of “hsa-miR-3131”. 
     The term “hsa-miR-92a-2-5p gene” or “hsa-miR-92a-2-5p” used in the present specification includes the hsa-miR-92a-2-5p gene (miRBase Accession No. MIMAT0004508) described in SEQ ID NO: 16, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-92a-2-5p gene can be obtained by a method described in Mourelatos Z et al., 2002, Genes Dev, Vol. 16, p. 720-728. Also, “hsa-mir-92a-2” (miRBase Accession No. M10000094, SEQ ID NO: 202) having a hairpin-like structure is known as a precursor of “hsa-miR-92a-2-5p”. 
     The term “hsa-miR-4258 gene” or “hsa-miR-4258” used in the present specification includes the hsa-miR-4258 gene (miRBase Accession No. MIMAT0016879) described in SEQ ID NO: 17, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4258 gene can be obtained by a method described in Goff L A et al., 2009, PLoS One, Vol. 4, e7192. Also, “hsa-mir-4258” (miRBase Accession No. MI0015857, SEQ ID NO: 203) having a hairpin-like structure is known as a precursor of “hsa-miR-4258”. 
     The term “hsa-miR-4448 gene” or “hsa-miR-4448” used in the present specification includes the hsa-miR-4448 gene (miRBase Accession No. MIMAT0018967) described in SEQ ID NO: 18, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4448 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4448” (miRBase Accession No. MI0016791, SEQ ID NO: 204) having a hairpin-like structure is known as a precursor of “hsa-miR-4448”. 
     The term “hsa-miR-6125 gene” or “hsa-miR-6125” used in the present specification includes the hsa-miR-6125 gene (miRBase Accession No. MIMAT0024598) described in SEQ ID NO: 19, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6125 gene can be obtained by a method described in Smith J L et al., 2012, J Virol, Vol. 86, p. 5278-5287. Also, “hsa-mir-6125” (miRBase Accession No. MI0021259, SEQ ID NO: 205) having a hairpin-like structure is known as a precursor of “hsa-miR-6125”. 
     The term “hsa-miR-6880-5p gene” or “hsa-miR-6880-5p” used in the present specification includes the hsa-miR-6880-5p gene (miRBase Accession No. MIMAT0027660) described in SEQ ID NO: 20, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6880-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6880” (miRBase Accession No. M10022727, SEQ ID NO: 206) having a hairpin-like structure is known as a precursor of “hsa-miR-6880-5p”. 
     The term “hsa-miR-6132 gene” or “hsa-miR-6132” used in the present specification includes the hsa-miR-6132 gene (miRBase Accession No. MIMAT0024616) described in SEQ ID NO: 21, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6132 gene can be obtained by a method described in Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, p. 552-564. Also, “hsa-mir-6132” (miRBase Accession No. MI0021277, SEQ ID NO: 207) having a hairpin-like structure is known as a precursor of “hsa-miR-6132”. 
     The term “hsa-miR-4467 gene” or “hsa-miR-4467” used in the present specification includes the hsa-miR-4467 gene (miRBase Accession No. MIMAT0018994) described in SEQ ID NO: 22, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4467 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4467” (miRBase Accession No. MI0016818, SEQ ID NO: 208) having a hairpin-like structure is known as a precursor of “hsa-miR-4467”. 
     The term “hsa-miR-6749-5p gene” or “hsa-miR-6749-5p” used in the present specification includes the hsa-miR-6749-5p gene (miRBase Accession No. MIMAT0027398) described in SEQ ID NO: 23, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6749-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6749” (miRBase Accession No. M10022594, SEQ ID NO: 209) having a hairpin-like structure is known as a precursor of “hsa-miR-6749-5p”. 
     The term “hsa-miR-2392 gene” or “hsa-miR-2392” used in the present specification includes the hsa-miR-2392 gene (miRBase Accession No. MIMAT0019043) described in SEQ ID NO: 24, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-2392 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-2392” (miRBase Accession No. MI0016870, SEQ ID NO: 210) having a hairpin-like structure is known as a precursor of “hsa-miR-2392”. 
     The term “hsa-miR-1273g-3p gene” or “hsa-miR-1273g-3p” used in the present specification includes the hsa-miR-1273g-3p gene (miRBase Accession No. MIMAT0022742) described in SEQ ID NO: 25, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1273g-3p gene can be obtained by a method described in Reshmi G et al., 2011, Genomics, Vol. 97, p. 333-340. Also, “hsa-mir-1273g” (miRBase Accession No. MI0018003, SEQ ID NO: 211) having a hairpin-like structure is known as a precursor of “hsa-miR-1273g-3p”. 
     The term “hsa-miR-4746-3p gene” or “hsa-miR-4746-3p” used in the present specification includes the hsa-miR-4746-3p gene (miRBase Accession No. MIMAT0019881) described in SEQ ID NO: 26, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4746-3p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4746” (miRBase Accession No. MI0017385, SEQ ID NO: 212) having a hairpin-like structure is known as a precursor of “hsa-miR-4746-3p”. 
     The term “hsa-miR-1914-3p gene” or “hsa-miR-1914-3p” used in the present specification includes the hsa-miR-1914-3p gene (miRBase Accession No. MIMAT0007890) described in SEQ ID NO: 27, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1914-3p gene can be obtained by a method described in Bar M et al., 2008, Stem Cells, Vol. 26, p. 2496-2505. Also, “hsa-mir-1914” (miRBase Accession No. MI0008335, SEQ ID NO: 213) having a hairpin-like structure is known as a precursor of “hsa-miR-1914-3p”. 
     The term “hsa-miR-7845-5p gene” or “hsa-miR-7845-5p” used in the present specification includes the hsa-miR-7845-5p gene (miRBase Accession No. MIMAT0030420) described in SEQ ID NO: 28, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-7845-5p gene can be obtained by a method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. Also, “hsa-mir-7845” (miRBase Accession No. MI0025515, SEQ ID NO: 214) having a hairpin-like structure is known as a precursor of “hsa-miR-7845-5p”. 
     The term “hsa-miR-6726-5p gene” or “hsa-miR-6726-5p” used in the present specification includes the hsa-miR-6726-5p gene (miRBase Accession No. MIMAT0027353) described in SEQ ID NO: 29, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6726-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6726” (miRBase Accession No. MI0022571, SEQ ID NO: 215) having a hairpin-like structure is known as a precursor of “hsa-miR-6726-5p”. 
     The term “hsa-miR-128-2-5p gene” or “hsa-miR-128-2-5p” used in the present specification includes the hsa-miR-128-2-5p gene (miRBase Accession No. MIMAT0031095) described in SEQ ID NO: 30, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-128-2-5p gene can be obtained by a method described in Lagos- Quintana  M et al., 2002, Curr Biol, Vol. 12, p. 735-739. Also, “hsa-mir-128-2” (miRBase Accession No. M10000727, SEQ ID NO: 216) having a hairpin-like structure is known as a precursor of “hsa-miR-128-2-5p”. 
     The term “hsa-miR-4651 gene” or “hsa-miR-4651” used in the present specification includes the hsa-miR-4651 gene (miRBase Accession No. MIMAT0019715) described in SEQ ID NO: 31, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4651 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4651” (miRBase Accession No. MI0017279, SEQ ID NO: 217) having a hairpin-like structure is known as a precursor of “hsa-miR-4651”. 
     The term “hsa-miR-6765-3p gene” or “hsa-miR-6765-3p” used in the present specification includes the hsa-miR-6765-3p gene (miRBase Accession No. MIMAT0027431) described in SEQ ID NO: 32, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6765-3p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6765” (miRBase Accession No. MI0022610, SEQ ID NO: 218) having a hairpin-like structure is known as a precursor of “hsa-miR-6765-3p”. 
     The term “hsa-miR-3185 gene” or “hsa-miR-3185” used in the present specification includes the hsa-miR-3185 gene (miRBase Accession No. MIMAT0015065) described in SEQ ID NO: 33, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3185 gene can be obtained by a method described in Stark M S et al., 2010, PLoS One, Vol. 5, e9685. Also, “hsa-mir-3185” (miRBase Accession No. MI0014227, SEQ ID NO: 219) having a hairpin-like structure is known as a precursor of “hsa-miR-3185”. 
     The term “hsa-miR-4792 gene” or “hsa-miR-4792” used in the present specification includes the hsa-miR-4792 gene (miRBase Accession No. MIMAT0019964) described in SEQ ID NO: 34, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4792 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4792” (miRBase Accession No. MI0017439, SEQ ID NO: 220) having a hairpin-like structure is known as a precursor of “hsa-miR-4792”. 
     The term “hsa-miR-6887-5p gene” or “hsa-miR-6887-5p” used in the present specification includes the hsa-miR-6887-5p gene (miRBase Accession No. MIMAT0027674) described in SEQ ID NO: 35, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6887-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6887” (miRBase Accession No. M10022734, SEQ ID NO: 221) having a hairpin-like structure is known as a precursor of “hsa-miR-6887-5p”. 
     The term “hsa-miR-5572 gene” or “hsa-miR-5572” used in the present specification includes the hsa-miR-5572 gene (miRBase Accession No. MIMAT0022260) described in SEQ ID NO: 36, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-5572 gene can be obtained by a method described in Tandon M et al., 2012, Oral Dis, Vol. 18, p. 127-131. Also, “hsa-mir-5572” (miRBase Accession No. MI0019117, SEQ ID NO: 222) having a hairpin-like structure is known as a precursor of “hsa-miR-5572”. 
     The term “hsa-miR-3619-3p gene” or “hsa-miR-3619-3p” used in the present specification includes the hsa-miR-3619-3p gene (miRBase Accession No. MIMAT0019219) described in SEQ ID NO: 37, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3619-3p gene can be obtained by a method described in Witten D et al., 2010, BMC Biol, Vol. 8, p. 58. Also, “hsa-mir-3619” (miRBase Accession No. MI0016009, SEQ ID NO: 223) having a hairpin-like structure is known as a precursor of “hsa-miR-3619-3p”. 
     The term “hsa-miR-6780b-5p gene” or “hsa-miR-6780b-5p” used in the present specification includes the hsa-miR-6780b-5p gene (miRBase Accession No. MIMAT0027572) described in SEQ ID NO: 38, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6780b-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6780b” (miRBase Accession No. M10022681, SEQ ID NO: 224) having a hairpin-like structure is known as a precursor of “hsa-miR-6780b-5p”. 
     The term “hsa-miR-4707-5p gene” or “hsa-miR-4707-5p” used in the present specification includes the hsa-miR-4707-5p gene (miRBase Accession No. MIMAT0019807) described in SEQ ID NO: 39, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4707-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4707” (miRBase Accession No. MI0017340, SEQ ID NO: 225) having a hairpin-like structure is known as a precursor of “hsa-miR-4707-5p”. 
     The term “hsa-miR-8063 gene” or “hsa-miR-8063” used in the present specification includes the hsa-miR-8063 gene (miRBase Accession No. MIMAT0030990) described in SEQ ID NO: 40, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-8063 gene can be obtained by a method described in Wang H J et al., 2013, Shock, Vol. 39, p. 480-487. Also, “hsa-mir-8063” (miRBase Accession No. MI0025899, SEQ ID NO: 226) having a hairpin-like structure is known as a precursor of “hsa-miR-8063”. 
     The term “hsa-miR-4454 gene” or “hsa-miR-4454” used in the present specification includes the hsa-miR-4454 gene (miRBase Accession No. MIMAT0018976) described in SEQ ID NO: 41, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4454 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4454” (miRBase Accession No. MI0016800, SEQ ID NO: 227) having a hairpin-like structure is known as a precursor of “hsa-miR-4454”. 
     The term “hsa-miR-4525 gene” or “hsa-miR-4525” used in the present specification includes the hsa-miR-4525 gene (miRBase Accession No. MIMAT0019064) described in SEQ ID NO: 42, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4525 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4525” (miRBase Accession No. MI0016892, SEQ ID NO: 228) having a hairpin-like structure is known as a precursor of “hsa-miR-4525”. 
     The term “hsa-miR-7975 gene” or “hsa-miR-7975” used in the present specification includes the hsa-miR-7975 gene (miRBase Accession No. MIMAT0031178) described in SEQ ID NO: 43, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-7975 gene can be obtained by a method described in Velthut-Meikas A et al., 2013, Mol Endocrinol, online. Also, “hsa-mir-7975” (miRBase Accession No. MI0025751, SEQ ID NO: 229) having a hairpin-like structure is known as a precursor of “hsa-miR-7975”. 
     The term “hsa-miR-744-5p gene” or “hsa-miR-744-5p” used in the present specification includes the hsa-miR-744-5p gene (miRBase Accession No. MIMAT0004945) described in SEQ ID NO: 44, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-744-5p gene can be obtained by a method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p. 1289-1298. Also, “hsa-mir-744” (miRBase Accession No. MI0005559, SEQ ID NO: 230) having a hairpin-like structure is known as a precursor of “hsa-miR-744-5p”. 
     The term “hsa-miR-3135b gene” or “hsa-miR-3135b” used in the present specification includes the hsa-miR-3135b gene (miRBase Accession No. MIMAT0018985) described in SEQ ID NO: 45, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3135b gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-3135b” (miRBase Accession No. MI0016809, SEQ ID NO: 231) having a hairpin-like structure is known as a precursor of “hsa-miR-3135b”. 
     The term “hsa-miR-4648 gene” or “hsa-miR-4648” used in the present specification includes the hsa-miR-4648 gene (miRBase Accession No. MIMAT0019710) described in SEQ ID NO: 46, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4648 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4648” (miRBase Accession No. MI0017275, SEQ ID NO: 232) having a hairpin-like structure is known as a precursor of “hsa-miR-4648”. 
     The term “hsa-miR-6816-5p gene” or “hsa-miR-6816-5p” used in the present specification includes the hsa-miR-6816-5p gene (miRBase Accession No. MIMAT0027532) described in SEQ ID NO: 47, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6816-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6816” (miRBase Accession No. MI0022661, SEQ ID NO: 233) having a hairpin-like structure is known as a precursor of “hsa-miR-6816-5p”. 
     The term “hsa-miR-4741 gene” or “hsa-miR-4741” used in the present specification includes the hsa-miR-4741 gene (miRBase Accession No. MIMAT0019871) described in SEQ ID NO: 48, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4741 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4741” (miRBase Accession No. MI0017379, SEQ ID NO: 234) having a hairpin-like structure is known as a precursor of “hsa-miR-4741”. 
     The term “hsa-miR-7150 gene” or “hsa-miR-7150” used in the present specification includes the hsa-miR-7150 gene (miRBase Accession No. MIMAT0028211) described in SEQ ID NO: 49, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-7150 gene can be obtained by a method described in Oulas A et al., 2009, Nucleic Acids Res, Vol. 37, p. 3276-3287. Also, “hsa-mir-7150” (miRBase Accession No. MI0023610, SEQ ID NO: 235) having a hairpin-like structure is known as a precursor of “hsa-miR-7150”. 
     The term “hsa-miR-6791-5p gene” or “hsa-miR-6791-5p” used in the present specification includes the hsa-miR-6791-5p gene (miRBase Accession No. MIMAT0027482) described in SEQ ID NO: 50, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6791-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6791” (miRBase Accession No. MI0022636, SEQ ID NO: 236) having a hairpin-like structure is known as a precursor of “hsa-miR-6791-5p”. 
     The term “hsa-miR-1247-3p gene” or “hsa-miR-1247-3p” used in the present specification includes the hsa-miR-1247-3p gene (miRBase Accession No. MIMAT0022721) described in SEQ ID NO: 51, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1247-3p gene can be obtained by a method described in Morin R D et al., 2008, Genome Res, Vol. 18, p. 610-621. Also, “hsa-mir-1247” (miRBase Accession No. MI0006382, SEQ ID NO: 237) having a hairpin-like structure is known as a precursor of “hsa-miR-1247-3p”. 
     The term “hsa-miR-7977 gene” or “hsa-miR-7977” used in the present specification includes the hsa-miR-7977 gene (miRBase Accession No. MIMAT0031180) described in SEQ ID NO: 52, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-7977 gene can be obtained by a method described in Velthut-Meikas A et al., 2013, Mol Endocrinol, online. Also, “hsa-mir-7977” (miRBase Accession No. MI0025753, SEQ ID NO: 238) having a hairpin-like structure is known as a precursor of “hsa-miR-7977”. 
     The term “hsa-miR-4497 gene” or “hsa-miR-4497” used in the present specification includes the hsa-miR-4497 gene (miRBase Accession No. MIMAT0019032) described in SEQ ID NO: 53, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4497 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4497” (miRBase Accession No. MI0016859, SEQ ID NO: 239) having a hairpin-like structure is known as a precursor of “hsa-miR-4497”. 
     The term “hsa-miR-6090 gene” or “hsa-miR-6090” used in the present specification includes the hsa-miR-6090 gene (miRBase Accession No. MIMAT0023715) described in SEQ ID NO: 54, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6090 gene can be obtained by a method described in Yoo J K et al., 2012, Stem Cells Dev, Vol. 21, p. 2049-2057. Also, “hsa-mir-6090” (miRBase Accession No. M10020367, SEQ ID NO: 240) having a hairpin-like structure is known as a precursor of “hsa-miR-6090”. 
     The term “hsa-miR-6781-5p gene” or “hsa-miR-6781-5p” used in the present specification includes the hsa-miR-6781-5p gene (miRBase Accession No. MIMAT0027462) described in SEQ ID NO: 55, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6781-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6781” (miRBase Accession No. M10022626, SEQ ID NO: 241) having a hairpin-like structure is known as a precursor of “hsa-miR-6781-5p”. 
     The term “hsa-miR-6870-5p gene” or “hsa-miR-6870-5p” used in the present specification includes the hsa-miR-6870-5p gene (miRBase Accession No. MIMAT0027640) described in SEQ ID NO: 56, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6870-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6870” (miRBase Accession No. M10022717, SEQ ID NO: 242) having a hairpin-like structure is known as a precursor of “hsa-miR-6870-5p”. 
     The term “hsa-miR-6729-5p gene” or “hsa-miR-6729-5p” used in the present specification includes the hsa-miR-6729-5p gene (miRBase Accession No. MIMAT0027359) described in SEQ ID NO: 57, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6729-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6729” (miRBase Accession No. M10022574, SEQ ID NO: 243) having a hairpin-like structure is known as a precursor of “hsa-miR-6729-5p”. 
     The term “hsa-miR-4530 gene” or “hsa-miR-4530” used in the present specification includes the hsa-miR-4530 gene (miRBase Accession No. MIMAT0019069) described in SEQ ID NO: 58, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4530 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4530” (miRBase Accession No. MI0016897, SEQ ID NO: 244) having a hairpin-like structure is known as a precursor of “hsa-miR-4530”. 
     The term “hsa-miR-7847-3p gene” or “hsa-miR-7847-3p” used in the present specification includes the hsa-miR-7847-3p gene (miRBase Accession No. MIMAT0030422) described in SEQ ID NO: 59, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-7847-3p gene can be obtained by a method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. Also, “hsa-mir-7847” (miRBase Accession No. MI0025517, SEQ ID NO: 245) having a hairpin-like structure is known as a precursor of “hsa-miR-7847-3p”. 
     The term “hsa-miR-6825-5p gene” or “hsa-miR-6825-5p” used in the present specification includes the hsa-miR-6825-5p gene (miRBase Accession No. MIMAT0027550) described in SEQ ID NO: 60, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6825-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6825” (miRBase Accession No. M10022670, SEQ ID NO: 246) having a hairpin-like structure is known as a precursor of “hsa-miR-6825-5p”. 
     The term “hsa-miR-4674 gene” or “hsa-miR-4674” used in the present specification includes the hsa-miR-4674 gene (miRBase Accession No. MIMAT0019756) described in SEQ ID NO: 61, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4674 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4674” (miRBase Accession No. MI0017305, SEQ ID NO: 247) having a hairpin-like structure is known as a precursor of “hsa-miR-4674”. 
     The term “hsa-miR-3917 gene” or “hsa-miR-3917” used in the present specification includes the hsa-miR-3917 gene (miRBase Accession No. MIMAT0018191) described in SEQ ID NO: 62, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3917 gene can be obtained by a method described in Creighton C J et al., 2010, PLoS One, Vol. 5, e9637. Also, “hsa-mir-3917” (miRBase Accession No. MI0016423, SEQ ID NO: 248) having a hairpin-like structure is known as a precursor of “hsa-miR-3917”. 
     The term “hsa-miR-4707-3p gene” or “hsa-miR-4707-3p” used in the present specification includes the hsa-miR-4707-3p gene (miRBase Accession No. MIMAT0019808) described in SEQ ID NO: 63, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4707-3p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4707” (miRBase Accession No. MI0017340, SEQ ID NO: 225) having a hairpin-like structure is known as a precursor of “hsa-miR-4707-3p”. 
     The term “hsa-miR-6885-5p gene” or “hsa-miR-6885-5p” used in the present specification includes the hsa-miR-6885-5p gene (miRBase Accession No. MIMAT0027670) described in SEQ ID NO: 64, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6885-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6885” (miRBase Accession No. M10022732, SEQ ID NO: 249) having a hairpin-like structure is known as a precursor of “hsa-miR-6885-5p”. 
     The term “hsa-miR-6722-3p gene” or “hsa-miR-6722-3p” used in the present specification includes the hsa-miR-6722-3p gene (miRBase Accession No. MIMAT0025854) described in SEQ ID NO: 65, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6722-3p gene can be obtained by a method described in Li Y et al., 2012, Gene, Vol. 497, p. 330-335. Also, “hsa-mir-6722” (miRBase Accession No. MI0022557, SEQ ID NO: 250) having a hairpin-like structure is known as a precursor of “hsa-miR-6722-3p”. 
     The term “hsa-miR-4516 gene” or “hsa-miR-4516” used in the present specification includes the hsa-miR-4516 gene (miRBase Accession No. MIMAT0019053) described in SEQ ID NO: 66, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4516 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4516” (miRBase Accession No. MI0016882, SEQ ID NO: 251) having a hairpin-like structure is known as a precursor of “hsa-miR-4516”. 
     The term “hsa-miR-6757-5p gene” or “hsa-miR-6757-5p” used in the present specification includes the hsa-miR-6757-5p gene (miRBase Accession No. MIMAT0027414) described in SEQ ID NO: 67, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6757-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6757” (miRBase Accession No. M10022602, SEQ ID NO: 252) having a hairpin-like structure is known as a precursor of “hsa-miR-6757-5p”. 
     The term “hsa-miR-6840-3p gene” or “hsa-miR-6840-3p” used in the present specification includes the hsa-miR-6840-3p gene (miRBase Accession No. MIMAT0027583) described in SEQ ID NO: 68, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6840-3p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6840” (miRBase Accession No. MI0022686, SEQ ID NO: 253) having a hairpin-like structure is known as a precursor of “hsa-miR-6840-3p”. 
     The term “hsa-miR-5195-3p gene” or “hsa-miR-5195-3p” used in the present specification includes the hsa-miR-5195-3p gene (miRBase Accession No. MIMAT0021127) described in SEQ ID NO: 69, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-5195-3p gene can be obtained by a method described in Schotte D et al., 2011, Leukemia, Vol. 25, p. 1389-1399. Also, “hsa-mir-5195” (miRBase Accession No. MI0018174, SEQ ID NO: 254) having a hairpin-like structure is known as a precursor of “hsa-miR-5195-3p”. 
     The term “hsa-miR-6756-5p gene” or “hsa-miR-6756-5p” used in the present specification includes the hsa-miR-6756-5p gene (miRBase Accession No. MIMAT0027412) described in SEQ ID NO: 70, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6756-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6756” (miRBase Accession No. MI0022601, SEQ ID NO: 255) having a hairpin-like structure is known as a precursor of “hsa-miR-6756-5p”. 
     The term “hsa-miR-6800-5p gene” or “hsa-miR-6800-5p” used in the present specification includes the hsa-miR-6800-5p gene (miRBase Accession No. MIMAT0027500) described in SEQ ID NO: 71, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6800-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6800” (miRBase Accession No. MI0022645, SEQ ID NO: 256) having a hairpin-like structure is known as a precursor of “hsa-miR-6800-5p”. 
     The term “hsa-miR-6727-5p gene” or “hsa-miR-6727-5p” used in the present specification includes the hsa-miR-6727-5p gene (miRBase Accession No. MIMAT0027355) described in SEQ ID NO: 72, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6727-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6727” (miRBase Accession No. M10022572, SEQ ID NO: 257) having a hairpin-like structure is known as a precursor of “hsa-miR-6727-5p”. 
     The term “hsa-miR-6126 gene” or “hsa-miR-6126” used in the present specification includes the hsa-miR-6126 gene (miRBase Accession No. MIMAT0024599) described in SEQ ID NO: 73, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6126 gene can be obtained by a method described in Smith J L et al., 2012, J Virol, Vol. 86, p. 5278-5287. Also, “hsa-mir-6126” (miRBase Accession No. MI0021260, SEQ ID NO: 258) having a hairpin-like structure is known as a precursor of “hsa-miR-6126”. 
     The term “hsa-miR-6872-3p gene” or “hsa-miR-6872-3p” used in the present specification includes the hsa-miR-6872-3p gene (miRBase Accession No. MIMAT0027645) described in SEQ ID NO: 74, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6872-3p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6872” (miRBase Accession No. M10022719, SEQ ID NO: 259) having a hairpin-like structure is known as a precursor of “hsa-miR-6872-3p”. 
     The term “hsa-miR-4446-3p gene” or “hsa-miR-4446-3p” used in the present specification includes the hsa-miR-4446-3p gene (miRBase Accession No. MIMAT0018965) described in SEQ ID NO: 75, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4446-3p gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4446” (miRBase Accession No. MI0016789, SEQ ID NO: 260) having a hairpin-like structure is known as a precursor of “hsa-miR-4446-3p”. 
     The term “hsa-miR-1268a gene” or “hsa-miR-1268a” used in the present specification includes the hsa-miR-1268a gene (miRBase Accession No. MIMAT0005922) described in SEQ ID NO: 76, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1268a gene can be obtained by a method described in Morin R D et al., 2008, Genome Res, Vol. 18, p. 610-621. Also, “hsa-mir-1268a” (miRBase Accession No. MI0006405, SEQ ID NO: 261) having a hairpin-like structure is known as a precursor of “hsa-miR-1268a”. 
     The term “hsa-miR-1908-3p gene” or “hsa-miR-1908-3p” used in the present specification includes the hsa-miR-1908-3p gene (miRBase Accession No. MIMAT0026916) described in SEQ ID NO: 77, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1908-3p gene can be obtained by a method described in Bar M et al., 2008, Stem Cells, Vol. 26, p. 2496-2505. Also, “hsa-mir-1908” (miRBase Accession No. MI0008329, SEQ ID NO: 189) having a hairpin-like structure is known as a precursor of “hsa-miR-1908-3p”. 
     The term “hsa-miR-3679-5p gene” or “hsa-miR-3679-5p” used in the present specification includes the hsa-miR-3679-5p gene (miRBase Accession No. MIMAT0018104) described in SEQ ID NO: 78, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3679-5p gene can be obtained by a method described in Creighton C J et al., 2010, PLoS One, Vol. 5, e9637. Also, “hsa-mir-3679” (miRBase Accession No. MI0016080, SEQ ID NO: 262) having a hairpin-like structure is known as a precursor of “hsa-miR-3679-5p”. 
     The term “hsa-miR-4534 gene” or “hsa-miR-4534” used in the present specification includes the hsa-miR-4534 gene (miRBase Accession No. MIMAT0019073) described in SEQ ID NO: 79, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4534 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4534” (miRBase Accession No. MI0016901, SEQ ID NO: 263) having a hairpin-like structure is known as a precursor of “hsa-miR-4534”. 
     The term “hsa-miR-4675 gene” or “hsa-miR-4675” used in the present specification includes the hsa-miR-4675 gene (miRBase Accession No. MIMAT0019757) described in SEQ ID NO: 80, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4675 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4675” (miRBase Accession No. MI0017306, SEQ ID NO: 264) having a hairpin-like structure is known as a precursor of “hsa-miR-4675”. 
     The term “hsa-miR-7108-5p gene” or “hsa-miR-7108-5p” used in the present specification includes the hsa-miR-7108-5p gene (miRBase Accession No. MIMAT0028113) described in SEQ ID NO: 81, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-7108-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-7108” (miRBase Accession No. M10022959, SEQ ID NO: 265) having a hairpin-like structure is known as a precursor of “hsa-miR-7108-5p”. 
     The term “hsa-miR-6799-5p gene” or “hsa-miR-6799-5p” used in the present specification includes the hsa-miR-6799-5p gene (miRBase Accession No. MIMAT0027498) described in SEQ ID NO: 82, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6799-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6799” (miRBase Accession No. M10022644, SEQ ID NO: 266) having a hairpin-like structure is known as a precursor of “hsa-miR-6799-5p”. 
     The term “hsa-miR-4695-5p gene” or “hsa-miR-4695-5p” used in the present specification includes the hsa-miR-4695-5p gene (miRBase Accession No. MIMAT0019788) described in SEQ ID NO: 83, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4695-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4695” (miRBase Accession No. MI0017328, SEQ ID NO: 267) having a hairpin-like structure is known as a precursor of “hsa-miR-4695-5p”. 
     The term “hsa-miR-3178 gene” or “hsa-miR-3178” used in the present specification includes the hsa-miR-3178 gene (miRBase Accession No. MIMAT0015055) described in SEQ ID NO: 84, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3178 gene can be obtained by a method described in Stark M S et al., 2010, PLoS One, Vol. 5, e9685. Also, “hsa-mir-3178” (miRBase Accession No. MI0014212, SEQ ID NO: 268) having a hairpin-like structure is known as a precursor of “hsa-miR-3178”. 
     The term “hsa-miR-5090 gene” or “hsa-miR-5090” used in the present specification includes the hsa-miR-5090 gene (miRBase Accession No. MIMAT0021082) described in SEQ ID NO: 85, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-5090 gene can be obtained by a method described in Ding N et al., 2011, J Radiat Res, Vol. 52, p. 425-432. Also, “hsa-mir-5090” (miRBase Accession No. MI0017979, SEQ ID NO: 269) having a hairpin-like structure is known as a precursor of “hsa-miR-5090”. 
     The term “hsa-miR-3180 gene” or “hsa-miR-3180” used in the present specification includes the hsa-miR-3180 gene (miRBase Accession No. MIMAT0018178) described in SEQ ID NO: 86, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3180 gene can be obtained by a method described in Creighton C J et al., 2010, PLoS One, Vol. 5, e9637. Also, “hsa-mir-3180-4 and hsa-mir-3180-5” (miRBase Accession Nos. MI0016408 and M10016409, SEQ ID NOs: 270 and 271) having a hairpin-like structure is known as precursors of “hsa-miR-3180”. 
     The term “hsa-miR-1237-5p gene” or “hsa-miR-1237-5p” used in the present specification includes the hsa-miR-1237-5p gene (miRBase Accession No. MIMAT0022946) described in SEQ ID NO: 87, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1237-5p gene can be obtained by a method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, p. 328-336. Also, “hsa-mir-1237” (miRBase Accession No. MI0006327, SEQ ID NO: 272) having a hairpin-like structure is known as a precursor of “hsa-miR-1237-5p”. 
     The term “hsa-miR-4758-5p gene” or “hsa-miR-4758-5p” used in the present specification includes the hsa-miR-4758-5p gene (miRBase Accession No. MIMAT0019903) described in SEQ ID NO: 88, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4758-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4758” (miRBase Accession No. MI0017399, SEQ ID NO: 273) having a hairpin-like structure is known as a precursor of “hsa-miR-4758-5p”. 
     The term “hsa-miR-3184-5p gene” or “hsa-miR-3184-5p” used in the present specification includes the hsa-miR-3184-5p gene (miRBase Accession No. MIMAT0015064) described in SEQ ID NO: 89, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3184-5p gene can be obtained by a method described in Stark M S et al., 2010, PLoS One, Vol. 5, e9685. Also, “hsa-mir-3184” (miRBase Accession No. MI0014226, SEQ ID NO: 274) having a hairpin-like structure is known as a precursor of “hsa-miR-3184-5p”. 
     The term “hsa-miR-4286 gene” or “hsa-miR-4286” used in the present specification includes the hsa-miR-4286 gene (miRBase Accession No. MIMAT0016916) described in SEQ ID NO: 90, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4286 gene can be obtained by a method described in Goff L A et al., 2009, PLoS One, Vol. 4, e7192. Also, “hsa-mir-4286” (miRBase Accession No. MI0015894, SEQ ID NO: 275) having a hairpin-like structure is known as a precursor of “hsa-miR-4286”. 
     The term “hsa-miR-6784-5p gene” or “hsa-miR-6784-5p” used in the present specification includes the hsa-miR-6784-5p gene (miRBase Accession No. MIMAT0027468) described in SEQ ID NO: 91, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6784-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6784” (miRBase Accession No. M10022629, SEQ ID NO: 276) having a hairpin-like structure is known as a precursor of “hsa-miR-6784-5p”. 
     The term “hsa-miR-6768-5p gene” or “hsa-miR-6768-5p” used in the present specification includes the hsa-miR-6768-5p gene (miRBase Accession No. MIMAT0027436) described in SEQ ID NO: 92, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6768-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6768” (miRBase Accession No. M10022613, SEQ ID NO: 277) having a hairpin-like structure is known as a precursor of “hsa-miR-6768-5p”. 
     The term “hsa-miR-6785-5p gene” or “hsa-miR-6785-5p” used in the present specification includes the hsa-miR-6785-5p gene (miRBase Accession No. MIMAT0027470) described in SEQ ID NO: 93, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6785-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6785” (miRBase Accession No. M10022630, SEQ ID NO: 278) having a hairpin-like structure is known as a precursor of “hsa-miR-6785-5p”. 
     The term “hsa-miR-4706 gene” or “hsa-miR-4706” used in the present specification includes the hsa-miR-4706 gene (miRBase Accession No. MIMAT0019806) described in SEQ ID NO: 94, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4706 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4706” (miRBase Accession No. MI0017339, SEQ ID NO: 279) having a hairpin-like structure is known as a precursor of “hsa-miR-4706”. 
     The term “hsa-miR-711 gene” or “hsa-miR-711” used in the present specification includes the hsa-miR-711 gene (miRBase Accession No. MIMAT0012734) described in SEQ ID NO: 95, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-711 gene can be obtained by a method described in Artzi S et al., 2008, BMC Bioinformatics, Vol. 9, p. 39. Also, “hsa-mir-711” (miRBase Accession No. MI0012488, SEQ ID NO: 280) having a hairpin-like structure is known as a precursor of “hsa-miR-711”. 
     The term “hsa-miR-1260a gene” or “hsa-miR-1260a” used in the present specification includes the hsa-miR-1260a gene (miRBase Accession No. MIMAT0005911) described in SEQ ID NO: 96, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1260a gene can be obtained by a method described in Morin R D et al., 2008, Genome Res, Vol. 18, p. 610-621. Also, “hsa-mir-1260a” (miRBase Accession No. MI0006394, SEQ ID NO: 281) having a hairpin-like structure is known as a precursor of “hsa-miR-1260a”. 
     The term “hsa-miR-6746-5p gene” or “hsa-miR-6746-5p” used in the present specification includes the hsa-miR-6746-5p gene (miRBase Accession No. MIMAT0027392) described in SEQ ID NO: 97, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6746-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6746” (miRBase Accession No. M10022591, SEQ ID NO: 282) having a hairpin-like structure is known as a precursor of “hsa-miR-6746-5p”. 
     The term “hsa-miR-6089 gene” or “hsa-miR-6089” used in the present specification includes the hsa-miR-6089 gene (miRBase Accession No. MIMAT0023714) described in SEQ ID NO: 98, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6089 gene can be obtained by a method described in Yoo J K et al., 2012, Stem Cells Dev, Vol. 21, p. 2049-2057. Also, “hsa-mir-6089-1 and hsa-mir-6089-2” (miRBase Accession Nos. MI0020366 and MI0023563, SEQ ID NOs: 283 and 284) having a hairpin-like structure are known as precursors of “hsa-miR-6089”. 
     The term “hsa-miR-6821-5p gene” or “hsa-miR-6821-5p” used in the present specification includes the hsa-miR-6821-5p gene (miRBase Accession No. MIMAT0027542) described in SEQ ID NO: 99, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6821-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6821” (miRBase Accession No. MI0022666, SEQ ID NO: 285) having a hairpin-like structure is known as a precursor of “hsa-miR-6821-5p”. 
     The term “hsa-miR-4667-5p gene” or “hsa-miR-4667-5p” used in the present specification includes the hsa-miR-4667-5p gene (miRBase Accession No. MIMAT0019743) described in SEQ ID NO: 100, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4667-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4667” (miRBase Accession No. MI0017297, SEQ ID NO: 286) having a hairpin-like structure is known as a precursor of “hsa-miR-4667-5p”. 
     The term “hsa-miR-8069 gene” or “hsa-miR-8069” used in the present specification includes the hsa-miR-8069 gene (miRBase Accession No. MIMAT0030996) described in SEQ ID NO: 101, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-8069 gene can be obtained by a method described in Wang H J et al., 2013, Shock, Vol. 39, p. 480-487. Also, “hsa-mir-8069” (miRBase Accession No. MI0025905, SEQ ID NO: 287) having a hairpin-like structure is known as a precursor of “hsa-miR-8069”. 
     The term “hsa-miR-4726-5p gene” or “hsa-miR-4726-5p” used in the present specification includes the hsa-miR-4726-5p gene (miRBase Accession No. MIMAT0019845) described in SEQ ID NO: 102, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4726-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4726” (miRBase Accession No. MI0017363, SEQ ID NO: 288) having a hairpin-like structure is known as a precursor of “hsa-miR-4726-5p”. 
     The term “hsa-miR-6124 gene” or “hsa-miR-6124” used in the present specification includes the hsa-miR-6124 gene (miRBase Accession No. MIMAT0024597) described in SEQ ID NO: 103, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6124 gene can be obtained by a method described in Smith J L et al., 2012, J Virol, Vol. 86, p. 5278-5287. Also, “hsa-mir-6124” (miRBase Accession No. MI0021258, SEQ ID NO: 289) having a hairpin-like structure is known as a precursor of “hsa-miR-6124”. 
     The term “hsa-miR-4532 gene” or “hsa-miR-4532” used in the present specification includes the hsa-miR-4532 gene (miRBase Accession No. MIMAT0019071) described in SEQ ID NO: 104, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4532 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4532” (miRBase Accession No. MI0016899, SEQ ID NO: 290) having a hairpin-like structure is known as a precursor of “hsa-miR-4532”. 
     The term “hsa-miR-4486 gene” or “hsa-miR-4486” used in the present specification includes the hsa-miR-4486 gene (miRBase Accession No. MIMAT0019020) described in SEQ ID NO: 105, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4486 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4486” (miRBase Accession No. MI0016847, SEQ ID NO: 291) having a hairpin-like structure is known as a precursor of “hsa-miR-4486”. 
     The term “hsa-miR-4728-5p gene” or “hsa-miR-4728-5p” used in the present specification includes the hsa-miR-4728-5p gene (miRBase Accession No. MIMAT0019849) described in SEQ ID NO: 106, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4728-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4728” (miRBase Accession No. MI0017365, SEQ ID NO: 292) having a hairpin-like structure is known as a precursor of “hsa-miR-4728-5p”. 
     The term “hsa-miR-4508 gene” or “hsa-miR-4508” used in the present specification includes the hsa-miR-4508 gene (miRBase Accession No. MIMAT0019045) described in SEQ ID NO: 107, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4508 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4508” (miRBase Accession No. MI0016872, SEQ ID NO: 293) having a hairpin-like structure is known as a precursor of “hsa-miR-4508”. 
     The term “hsa-miR-128-1-5p gene” or “hsa-miR-128-1-5p” used in the present specification includes the hsa-miR-128-1-5p gene (miRBase Accession No. MIMAT0026477) described in SEQ ID NO: 108, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-128-1-5p gene can be obtained by a method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, p. 735-739. Also, “hsa-mir-128-1” (miRBase Accession No. M10000447, SEQ ID NO: 294) having a hairpin-like structure is known as a precursor of “hsa-miR-128-1-5p”. 
     The term “hsa-miR-4513 gene” or “hsa-miR-4513” used in the present specification includes the hsa-miR-4513 gene (miRBase Accession No. MIMAT0019050) described in SEQ ID NO: 109, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4513 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4513” (miRBase Accession No. MI0016879, SEQ ID NO: 295) having a hairpin-like structure is known as a precursor of “hsa-miR-4513”. 
     The term “hsa-miR-6795-5p gene” or “hsa-miR-6795-5p” used in the present specification includes the hsa-miR-6795-5p gene (miRBase Accession No. MIMAT0027490) described in SEQ ID NO: 110, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6795-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6795” (miRBase Accession No. M10022640, SEQ ID NO: 296) having a hairpin-like structure is known as a precursor of “hsa-miR-6795-5p”. 
     The term “hsa-miR-4689 gene” or “hsa-miR-4689” used in the present specification includes the hsa-miR-4689 gene (miRBase Accession No. MIMAT0019778) described in SEQ ID NO: 111, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4689 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4689” (miRBase Accession No. MI0017322, SEQ ID NO: 297) having a hairpin-like structure is known as a precursor of “hsa-miR-4689”. 
     The term “hsa-miR-6763-5p gene” or “hsa-miR-6763-5p” used in the present specification includes the hsa-miR-6763-5p gene (miRBase Accession No. MIMAT0027426) described in SEQ ID NO: 112, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6763-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6763” (miRBase Accession No. MI0022608, SEQ ID NO: 298) having a hairpin-like structure is known as a precursor of “hsa-miR-6763-5p”. 
     The term “hsa-miR-8072 gene” or “hsa-miR-8072” used in the present specification includes the hsa-miR-8072 gene (miRBase Accession No. MIMAT0030999) described in SEQ ID NO: 113, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-8072 gene can be obtained by a method described in Wang H J et al., 2013, Shock, Vol. 39, p. 480-487. Also, “hsa-mir-8072” (miRBase Accession No. MI0025908, SEQ ID NO: 299) having a hairpin-like structure is known as a precursor of “hsa-miR-8072”. 
     The term “hsa-miR-6765-5p gene” or “hsa-miR-6765-5p” used in the present specification includes the hsa-miR-6765-5p gene (miRBase Accession No. MIMAT0027430) described in SEQ ID NO: 114, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6765-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6765” (miRBase Accession No. MI0022610, SEQ ID NO: 218) having a hairpin-like structure is known as a precursor of “hsa-miR-6765-5p”. 
     The term “hsa-miR-4419b gene” or “hsa-miR-4419b” used in the present specification includes the hsa-miR-4419b gene (miRBase Accession No. MIMAT0019034) described in SEQ ID NO: 115, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4419b gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4419b” (miRBase Accession No. MI0016861, SEQ ID NO: 300) having a hairpin-like structure is known as a precursor of “hsa-miR-4419b”. 
     The term “hsa-miR-7641 gene” or “hsa-miR-7641” used in the present specification includes the hsa-miR-7641 gene (miRBase Accession No. MIMAT0029782) described in SEQ ID NO: 116, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-7641 gene can be obtained by a method described in Yoo J K et al., 2013, Arch Pharm Res, Vol. 36, p. 353-358. Also, “hsa-mir-7641-1 and hsa-mir-7641-2” (miRBase Accession Nos. MI0024975 and MI0024976, SEQ ID NOs: 301 and 302) having a hairpin-like structure are known as precursors of “hsa-miR-7641”. 
     The term “hsa-miR-3928-3p gene” or “hsa-miR-3928-3p” used in the present specification includes the hsa-miR-3928-3p gene (miRBase Accession No. MIMAT0018205) described in SEQ ID NO: 117, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3928-3p gene can be obtained by a method described in Creighton C J et al., 2010, PLoS One, Vol. 5, e9637. Also, “hsa-mir-3928” (miRBase Accession No. MI0016438, SEQ ID NO: 303) having a hairpin-like structure is known as a precursor of “hsa-miR-3928-3p”. 
     The term “hsa-miR-1227-5p gene” or “hsa-miR-1227-5p” used in the present specification includes the hsa-miR-1227-5p gene (miRBase Accession No. MIMAT0022941) described in SEQ ID NO: 118, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1227-5p gene can be obtained by a method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, p. 328-336. Also, “hsa-mir-1227” (miRBase Accession No. MI0006316, SEQ ID NO: 304) having a hairpin-like structure is known as a precursor of “hsa-miR-1227-5p”. 
     The term “hsa-miR-4492 gene” or “hsa-miR-4492” used in the present specification includes the hsa-miR-4492 gene (miRBase Accession No. MIMAT0019027) described in SEQ ID NO: 119, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4492 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4492” (miRBase Accession No. MI0016854, SEQ ID NO: 305) having a hairpin-like structure is known as a precursor of “hsa-miR-4492”. 
     The term “hsa-miR-296-3p gene” or “hsa-miR-296-3p” used in the present specification includes the hsa-miR-296-3p gene (miRBase Accession No. MIMAT0004679) described in SEQ ID NO: 120, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-296-3p gene can be obtained by a method described in Houbaviy H B et al., 2003, Dev Cell, Vol. 5, p. 351-358. Also, “hsa-mir-296” (miRBase Accession No. MI0000747, SEQ ID NO: 306) having a hairpin-like structure is known as a precursor of “hsa-miR-296-3p”. 
     The term “hsa-miR-6769a-5p gene” or “hsa-miR-6769a-5p” used in the present specification includes the hsa-miR-6769a-5p gene (miRBase Accession No. MIMAT0027438) described in SEQ ID NO: 121, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6769a-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6769a” (miRBase Accession No. MI0022614, SEQ ID NO: 307) having a hairpin-like structure is known as a precursor of “hsa-miR-6769a-5p”. 
     The term “hsa-miR-6889-5p gene” or “hsa-miR-6889-5p” used in the present specification includes the hsa-miR-6889-5p gene (miRBase Accession No. MIMAT0027678) described in SEQ ID NO: 122, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6889-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6889” (miRBase Accession No. M10022736, SEQ ID NO: 308) having a hairpin-like structure is known as a precursor of “hsa-miR-6889-5p”. 
     The term “hsa-miR-4632-5p gene” or “hsa-miR-4632-5p” used in the present specification includes the hsa-miR-4632-5p gene (miRBase Accession No. MIMAT0022977) described in SEQ ID NO: 123, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4632-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4632” (miRBase Accession No. MI0017259, SEQ ID NO: 309) having a hairpin-like structure is known as a precursor of “hsa-miR-4632-5p”. 
     The term “hsa-miR-4505 gene” or “hsa-miR-4505” used in the present specification includes the hsa-miR-4505 gene (miRBase Accession No. MIMAT0019041) described in SEQ ID NO: 124, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4505 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4505” (miRBase Accession No. MI0016868, SEQ ID NO: 310) having a hairpin-like structure is known as a precursor of “hsa-miR-4505”. 
     The term “hsa-miR-3154 gene” or “hsa-miR-3154” used in the present specification includes the hsa-miR-3154 gene (miRBase Accession No. MIMAT0015028) described in SEQ ID NO: 125, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3154 gene can be obtained by a method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p. 1289-1298. Also, “hsa-mir-3154” (miRBase Accession No. MI0014182, SEQ ID NO: 311) having a hairpin-like structure is known as a precursor of “hsa-miR-3154”. 
     The term “hsa-miR-3648 gene” or “hsa-miR-3648” used in the present specification includes the hsa-miR-3648 gene (miRBase Accession No. MIMAT0018068) described in SEQ ID NO: 126, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3648 gene can be obtained by a method described in Meiri E et al., 2010, Nucleic Acids Res, Vol. 38, p. 6234-6246. Also, “hsa-mir-3648” (miRBase Accession No. MI0016048, SEQ ID NO: 312) having a hairpin-like structure is known as a precursor of “hsa-miR-3648”. 
     The term “hsa-miR-4442 gene” or “hsa-miR-4442” used in the present specification includes the hsa-miR-4442 gene (miRBase Accession No. MIMAT0018960) described in SEQ ID NO: 127, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4442 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4442” (miRBase Accession No. MI0016785, SEQ ID NO: 313) having a hairpin-like structure is known as a precursor of “hsa-miR-4442”. 
     The term “hsa-miR-3141 gene” or “hsa-miR-3141” used in the present specification includes the hsa-miR-3141 gene (miRBase Accession No. MIMAT0015010) described in SEQ ID NO: 128, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3141 gene can be obtained by a method described in Stark M S et al., 2010, PLoS One, Vol. 5, e9685. Also, “hsa-mir-3141” (miRBase Accession No. MI0014165, SEQ ID NO: 314) having a hairpin-like structure is known as a precursor of “hsa-miR-3141”. 
     The term “hsa-miR-7113-3p gene” or “hsa-miR-7113-3p” used in the present specification includes the hsa-miR-7113-3p gene (miRBase Accession No. MIMAT0028124) described in SEQ ID NO: 129, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-7113-3p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-7113” (miRBase Accession No. MI0022964, SEQ ID NO: 315) having a hairpin-like structure is known as a precursor of “hsa-miR-7113-3p”. 
     The term “hsa-miR-6819-5p gene” or “hsa-miR-6819-5p” used in the present specification includes the hsa-miR-6819-5p gene (miRBase Accession No. MIMAT0027538) described in SEQ ID NO: 130, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6819-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6819” (miRBase Accession No. MI0022664, SEQ ID NO: 316) having a hairpin-like structure is known as a precursor of “hsa-miR-6819-5p”. 
     The term “hsa-miR-3195 gene” or “hsa-miR-3195” used in the present specification includes the hsa-miR-3195 gene (miRBase Accession No. MIMAT0015079) described in SEQ ID NO: 131, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3195 gene can be obtained by a method described in Stark M S et al., 2010, PLoS One, Vol. 5, e9685. Also, “hsa-mir-3195” (miRBase Accession No. MI0014240, SEQ ID NO: 317) having a hairpin-like structure is known as a precursor of “hsa-miR-3195”. 
     The term “hsa-miR-1199-5p gene” or “hsa-miR-1199-5p” used in the present specification includes the hsa-miR-1199-5p gene (miRBase Accession No. MIMAT0031119) described in SEQ ID NO: 132, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1199-5p gene can be obtained by a method described in Salvi A et al., 2013, Int J Oncol, Vol. 42, p. 391-402. Also, “hsa-mir-1199” (miRBase Accession No. MI0020340, SEQ ID NO: 318) having a hairpin-like structure is known as a precursor of “hsa-miR-1199-5p”. 
     The term “hsa-miR-6738-5p gene” or “hsa-miR-6738-5p” used in the present specification includes the hsa-miR-6738-5p gene (miRBase Accession No. MIMAT0027377) described in SEQ ID NO: 133, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6738-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6738” (miRBase Accession No. MI0022583, SEQ ID NO: 319) having a hairpin-like structure is known as a precursor of “hsa-miR-6738-5p”. 
     The term “hsa-miR-4656 gene” or “hsa-miR-4656” used in the present specification includes the hsa-miR-4656 gene (miRBase Accession No. MIMAT0019723) described in SEQ ID NO: 134, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4656 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4656” (miRBase Accession No. MI0017284, SEQ ID NO: 320) having a hairpin-like structure is known as a precursor of “hsa-miR-4656”. 
     The term “hsa-miR-6820-5p gene” or “hsa-miR-6820-5p” used in the present specification includes the hsa-miR-6820-5p gene (miRBase Accession No. MIMAT0027540) described in SEQ ID NO: 135, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6820-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6820” (miRBase Accession No. MI0022665, SEQ ID NO: 321) having a hairpin-like structure is known as a precursor of “hsa-miR-6820-5p”. 
     The term “hsa-miR-615-5p gene” or “hsa-miR-615-5p” used in the present specification includes the hsa-miR-615-5p gene (miRBase Accession No. MIMAT0004804) described in SEQ ID NO: 136, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-615-5p gene can be obtained by a method described in Cummins J M et al., 2006, Proc Natl Acad Sci USA, Vol. 103, p. 3687-3692. Also, “hsa-mir-615” (miRBase Accession No. MI0003628, SEQ ID NO: 322) having a hairpin-like structure is known as a precursor of “hsa-miR-615-5p”. 
     The term “hsa-miR-486-3p gene” or “hsa-miR-486-3p” used in the present specification includes the hsa-miR-486-3p gene (miRBase Accession No. MIMAT0004762) described in SEQ ID NO: 137, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-486-3p gene can be obtained by a method described in Fu H et al., 2005, FEBS Lett, Vol. 579, p. 3849-3854. Also, “hsa-mir-486 and hsa-mir-486-2” (miRBase Accession Nos. M10002470 and M10023622, SEQ ID NO: 323 and 324) having a hairpin-like structure are known as precursors of “hsa-miR-486-3p”. 
     The term “hsa-miR-1225-3p gene” or “hsa-miR-1225-3p” used in the present specification includes the hsa-miR-1225-3p gene (miRBase Accession No. MIMAT0005573) described in SEQ ID NO: 138, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1225-3p gene can be obtained by a method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, p. 328-336. Also, “hsa-mir-1225” (miRBase Accession No. MI0006311, SEQ ID NO: 325) having a hairpin-like structure is known as a precursor of “hsa-miR-1225-3p”. 
     The term “hsa-miR-760 gene” or “hsa-miR-760” used in the present specification includes the hsa-miR-760 gene (miRBase Accession No. MIMAT0004957) described in SEQ ID NO: 139, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-760 gene can be obtained by a method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p. 1289-1298. Also, “hsa-mir-760” (miRBase Accession No. MI0005567, SEQ ID NO: 326) having a hairpin-like structure is known as a precursor of “hsa-miR-760”. 
     The term “hsa-miR-187-5p gene” or “hsa-miR-187-5p” used in the present specification includes the hsa-miR-187-5p gene (miRBase Accession No. MIMAT0004561) described in SEQ ID NO: 140, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-187-5p gene can be obtained by a method described in Lim L P et al., 2003, Science, Vol. 299, p. 1540. Also, “hsa-mir-187” (miRBase Accession No. MI0000274, SEQ ID NO: 327) having a hairpin-like structure is known as a precursor of “hsa-miR-187-5p”. 
     The term “hsa-miR-1203 gene” or “hsa-miR-1203” used in the present specification includes the hsa-miR-1203 gene (miRBase Accession No. MIMAT0005866) described in SEQ ID NO: 141, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1203 gene can be obtained by a method described in Marton S et al., 2008, Leukemia, Vol. 22, p. 330-338. Also, “hsa-mir-1203” (miRBase Accession No. MI0006335, SEQ ID NO: 328) having a hairpin-like structure is known as a precursor of “hsa-miR-1203”. 
     The term “hsa-miR-7110-5p gene” or “hsa-miR-7110-5p” used in the present specification includes the hsa-miR-7110-5p gene (miRBase Accession No. MIMAT0028117) described in SEQ ID NO: 142, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-7110-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-7110” (miRBase Accession No. M10022961, SEQ ID NO: 329) having a hairpin-like structure is known as a precursor of “hsa-miR-7110-5p”. 
     The term “hsa-miR-371a-5p gene” or “hsa-miR-371a-5p” used in the present specification includes the hsa-miR-371a-5p gene (miRBase Accession No. MIMAT0004687) described in SEQ ID NO: 143, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-371a-5p gene can be obtained by a method described in Suh M R et al., 2004, Dev Biol, Vol. 270, p. 488-498. Also, “hsa-mir-371a” (miRBase Accession No. MI0000779, SEQ ID NO: 330) having a hairpin-like structure is known as a precursor of “hsa-miR-371a-5p”. 
     The term “hsa-miR-939-5p gene” or “hsa-miR-939-5p” used in the present specification includes the hsa-miR-939-5p gene (miRBase Accession No. MIMAT0004982) described in SEQ ID NO: 144, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-939-5p gene can be obtained by a method described in Lui W O et al., 2007, Cancer Res, Vol. 67, p. 6031-6043. Also, “hsa-mir-939” (miRBase Accession No. MI0005761, SEQ ID NO: 331) having a hairpin-like structure is known as a precursor of “hsa-miR-939-5p”. 
     The term “hsa-miR-575 gene” or “hsa-miR-575” used in the present specification includes the hsa-miR-575 gene (miRBase Accession No. MIMAT0003240) described in SEQ ID NO: 145, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-575 gene can be obtained by a method described in Cummins J M et al., 2006, Proc Natl Acad Sci USA, Vol. 103, p. 3687-3692. Also, “hsa-mir-575” (miRBase Accession No. MI0003582, SEQ ID NO: 332) having a hairpin-like structure is known as a precursor of “hsa-miR-575”. 
     The term “hsa-miR-92b-5p gene” or “hsa-miR-92b-5p” used in the present specification includes the hsa-miR-92b-5p gene (miRBase Accession No. MIMAT0004792) described in SEQ ID NO: 146, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-92b-5p gene can be obtained by a method described in Cummins J M et al., 2006, Proc Natl Acad Sci USA, Vol. 103, p. 3687-3692. Also, “hsa-mir-92b” (miRBase Accession No. MI0003560, SEQ ID NO: 333) having a hairpin-like structure is known as a precursor of “hsa-miR-92b-5p”. 
     The term “hsa-miR-887-3p gene” or “hsa-miR-887-3p” used in the present specification includes the hsa-miR-887-3p gene (miRBase Accession No. MIMAT0004951) described in SEQ ID NO: 147, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-887-3p gene can be obtained by a method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p. 1289-1298. Also, “hsa-mir-887” (miRBase Accession No. MI0005562, SEQ ID NO: 334) having a hairpin-like structure is known as a precursor of “hsa-miR-887-3p”. 
     The term “hsa-miR-920 gene” or “hsa-miR-920” used in the present specification includes the hsa-miR-920 gene (miRBase Accession No. MIMAT0004970) described in SEQ ID NO: 148, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-920 gene can be obtained by a method described in Novotny G W et al., 2007, Int J Androl, Vol. 30, p. 316-326. Also, “hsa-mir-920” (miRBase Accession No. MI0005712, SEQ ID NO: 335) having a hairpin-like structure is known as a precursor of “hsa-miR-920”. 
     The term “hsa-miR-1915-5p gene” or “hsa-miR-1915-5p” used in the present specification includes the hsa-miR-1915-5p gene (miRBase Accession No. MIMAT0007891) described in SEQ ID NO: 149, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1915-5p gene can be obtained by a method described in Bar M et al., 2008, Stem Cells, Vol. 26, p. 2496-2505. Also, “hsa-mir-1915” (miRBase Accession No. MI0008336, SEQ ID NO: 336) having a hairpin-like structure is known as a precursor of “hsa-miR-1915-5p”. 
     The term “hsa-miR-1231 gene” or “hsa-miR-1231” used in the present specification includes the hsa-miR-1231 gene (miRBase Accession No. MIMAT0005586) described in SEQ ID NO: 150, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1231 gene can be obtained by a method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, p. 328-336. Also, “hsa-mir-1231” (miRBase Accession No. MI0006321, SEQ ID NO: 337) having a hairpin-like structure is known as a precursor of “hsa-miR-1231”. 
     The term “hsa-miR-663b gene” or “hsa-miR-663b” used in the present specification includes the hsa-miR-663b gene (miRBase Accession No. MIMAT0005867) described in SEQ ID NO: 151, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-663b gene can be obtained by a method described in Takada S et al., 2008, Leukemia, Vol. 22, p. 1274-1278. Also, “hsa-mir-663b” (miRBase Accession No. MI0006336, SEQ ID NO: 338) having a hairpin-like structure is known as a precursor of “hsa-miR-663b”. 
     The term “hsa-miR-1225-5p gene” or “hsa-miR-1225-5p” used in the present specification includes the hsa-miR-1225-5p gene (miRBase Accession No. MIMAT0005572) described in SEQ ID NO: 152, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1225-5p gene can be obtained by a method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, p. 328-336. Also, “hsa-mir-1225” (miRBase Accession No. MI0006311, SEQ ID NO: 325) having a hairpin-like structure is known as a precursor of “hsa-miR-1225-5p”. 
     The term “hsa-miR-4763-3p gene” or “hsa-miR-4763-3p” used in the present specification includes the hsa-miR-4763-3p gene (miRBase Accession No. MIMAT0019913) described in SEQ ID NO: 153, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4763-3p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4763” (miRBase Accession No. MI0017404, SEQ ID NO: 339) having a hairpin-like structure is known as a precursor of “hsa-miR-4763-3p”. 
     The term “hsa-miR-3656 gene” or “hsa-miR-3656” used in the present specification includes the hsa-miR-3656 gene (miRBase Accession No. MIMAT0018076) described in SEQ ID NO: 154, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3656 gene can be obtained by a method described in Meiri E et al., 2010, Nucleic Acids Res, Vol. 38, p. 6234-6246. Also, “hsa-mir-3656” (miRBase Accession No. MI0016056, SEQ ID NO: 340) having a hairpin-like structure is known as a precursor of “hsa-miR-3656”. 
     The term “hsa-miR-4488 gene” or “hsa-miR-4488” used in the present specification includes the hsa-miR-4488 gene (miRBase Accession No. MIMAT0019022) described in SEQ ID NO: 155, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4488 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4488” (miRBase Accession No. MI0016849, SEQ ID NO: 341) having a hairpin-like structure is known as a precursor of “hsa-miR-4488”. 
     The term “hsa-miR-125a-3p gene” or “hsa-miR-125a-3p” used in the present specification includes the hsa-miR-125a-3p gene (miRBase Accession No. MIMAT0004602) described in SEQ ID NO: 156, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-125a-3p gene can be obtained by a method described in Lagos- Quintana  M et al., 2002, Curr Biol, Vol. 12, p. 735-739. Also, “hsa-mir-125a” (miRBase Accession No. M10000469, SEQ ID NO: 342) having a hairpin-like structure is known as a precursor of “hsa-miR-125a-3p”. 
     The term “hsa-miR-1469 gene” or “hsa-miR-1469” used in the present specification includes the hsa-miR-1469 gene (miRBase Accession No. MIMAT0007347) described in SEQ ID NO: 157, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1469 gene can be obtained by a method described in Kawaji H et al., 2008, BMC Genomics, Vol. 9, p. 157. Also, “hsa-mir-1469” (miRBase Accession No. MI0007074, SEQ ID NO: 343) having a hairpin-like structure is known as a precursor of “hsa-miR-1469”. 
     The term “hsa-miR-1228-5p gene” or “hsa-miR-1228-5p” used in the present specification includes the hsa-miR-1228-5p gene (miRBase Accession No. MIMAT0005582) described in SEQ ID NO: 158, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1228-5p gene can be obtained by a method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, p. 328-336. Also, “hsa-mir-1228” (miRBase Accession No. MI0006318, SEQ ID NO: 344) having a hairpin-like structure is known as a precursor of “hsa-miR-1228-5p”. 
     The term “hsa-miR-6798-5p gene” or “hsa-miR-6798-5p” used in the present specification includes the hsa-miR-6798-5p gene (miRBase Accession No. MIMAT0027496) described in SEQ ID NO: 159, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6798-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6798” (miRBase Accession No. MI0022643, SEQ ID NO: 345) having a hairpin-like structure is known as a precursor of “hsa-miR-6798-5p”. 
     The term “hsa-miR-1268b gene” or “hsa-miR-1268b” used in the present specification includes the hsa-miR-1268b gene (miRBase Accession No. MIMAT0018925) described in SEQ ID NO: 160, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1268b gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-1268b” (miRBase Accession No. MI0016748, SEQ ID NO: 346) having a hairpin-like structure is known as a precursor of “hsa-miR-1268b”. 
     The term “hsa-miR-6732-5p gene” or “hsa-miR-6732-5p” used in the present specification includes the hsa-miR-6732-5p gene (miRBase Accession No. MIMAT0027365) described in SEQ ID NO: 161, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6732-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6732” (miRBase Accession No. M10022577, SEQ ID NO: 347) having a hairpin-like structure is known as a precursor of “hsa-miR-6732-5p”. 
     The term “hsa-miR-1915-3p gene” or “hsa-miR-1915-3p” used in the present specification includes the hsa-miR-1915-3p gene (miRBase Accession No. MIMAT0007892) described in SEQ ID NO: 162, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1915-3p gene can be obtained by a method described in Bar M et al., 2008, Stem Cells, Vol. 26, p. 2496-2505. Also, “hsa-mir-1915” (miRBase Accession No. MI0008336, SEQ ID NO: 336) having a hairpin-like structure is known as a precursor of “hsa-miR-1915-3p”. 
     The term “hsa-miR-4433b-3p gene” or “hsa-miR-4433b-3p” used in the present specification includes the hsa-miR-4433b-3p gene (miRBase Accession No. MIMAT0030414) described in SEQ ID NO: 163, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4433b-3p gene can be obtained by a method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. Also, “hsa-mir-4433b” (miRBase Accession No. MI0025511, SEQ ID NO: 348) having a hairpin-like structure is known as a precursor of “hsa-miR-4433b-3p”. 
     The term “hsa-miR-1207-5p gene” or “hsa-miR-1207-5p” used in the present specification includes the hsa-miR-1207-5p gene (miRBase Accession No. MIMAT0005871) described in SEQ ID NO: 164, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1207-5p gene can be obtained by a method described in Huppi K et al., 2008, Mol Cancer Res, Vol. 6, p. 212-221. Also, “hsa-mir-1207” (miRBase Accession No. M10006340, SEQ ID NO: 349) having a hairpin-like structure is known as a precursor of “hsa-miR-1207-5p”. 
     The term “hsa-miR-4433-3p gene” or “hsa-miR-4433-3p” used in the present specification includes the hsa-miR-4433-3p gene (miRBase Accession No. MIMAT0018949) described in SEQ ID NO: 165, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4433-3p gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4433” (miRBase Accession No. MI0016773, SEQ ID NO: 350) having a hairpin-like structure is known as a precursor of “hsa-miR-4433-3p”. 
     The term “hsa-miR-6879-5p gene” or “hsa-miR-6879-5p” used in the present specification includes the hsa-miR-6879-5p gene (miRBase Accession No. MIMAT0027658) described in SEQ ID NO: 166, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6879-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6879” (miRBase Accession No. M10022726, SEQ ID NO: 351) having a hairpin-like structure is known as a precursor of “hsa-miR-6879-5p”. 
     The term “hsa-miR-4417 gene” or “hsa-miR-4417” used in the present specification includes the hsa-miR-4417 gene (miRBase Accession No. MIMAT0018929) described in SEQ ID NO: 167, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4417 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4417” (miRBase Accession No. MI0016753, SEQ ID NO: 352) having a hairpin-like structure is known as a precursor of “hsa-miR-4417”. 
     The term “hsa-miR-30c-1-3p gene” or “hsa-miR-30c-1-3p” used in the present specification includes the hsa-miR-30c-1-3p gene (miRBase Accession No. MIMAT0004674) described in SEQ ID NO: 168, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-30c-1-3p gene can be obtained by a method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, p. 735-739. Also, “hsa-mir-30c-1” (miRBase Accession No. MI0000736, SEQ ID NO: 353) having a hairpin-like structure is known as a precursor of “hsa-miR-30c-1-3p”. 
     The term “hsa-miR-4638-5p gene” or “hsa-miR-4638-5p” used in the present specification includes the hsa-miR-4638-5p gene (miRBase Accession No. MIMAT0019695) described in SEQ ID NO: 169, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4638-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4638” (miRBase Accession No. MI0017265, SEQ ID NO: 354) having a hairpin-like structure is known as a precursor of “hsa-miR-4638-5p”. 
     The term “hsa-miR-6088 gene” or “hsa-miR-6088” used in the present specification includes the hsa-miR-6088 gene (miRBase Accession No. MIMAT0023713) described in SEQ ID NO: 170, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6088 gene can be obtained by a method described in Yoo J K et al., 2012, Stem Cells Dev, Vol. 21, p. 2049-2057. Also, “hsa-mir-6088” (miRBase Accession No. MI0020365, SEQ ID NO: 355) having a hairpin-like structure is known as a precursor of “hsa-miR-6088”. 
     The term “hsa-miR-4270 gene” or “hsa-miR-4270” used in the present specification includes the hsa-miR-4270 gene (miRBase Accession No. MIMAT0016900) described in SEQ ID NO: 171, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4270 gene can be obtained by a method described in Goff L A et al., 2009, PLoS One, Vol. 4, e7192. Also, “hsa-mir-4270” (miRBase Accession No. MI0015878, SEQ ID NO: 356) having a hairpin-like structure is known as a precursor of “hsa-miR-4270”. 
     The term “hsa-miR-6782-5p gene” or “hsa-miR-6782-5p” used in the present specification includes the hsa-miR-6782-5p gene (miRBase Accession No. MIMAT0027464) described in SEQ ID NO: 172, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6782-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6782” (miRBase Accession No. M10022627, SEQ ID NO: 357) having a hairpin-like structure is known as a precursor of “hsa-miR-6782-5p”. 
     The term “hsa-miR-665 gene” or “hsa-miR-665” used in the present specification includes the hsa-miR-665 gene (miRBase Accession No. MIMAT0004952) described in SEQ ID NO: 173, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-665 gene can be obtained by a method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p. 1289-1298. Also, “hsa-mir-665” (miRBase Accession No. MI0005563, SEQ ID NO: 358) having a hairpin-like structure is known as a precursor of “hsa-miR-665”. 
     The term “hsa-miR-486-5p gene” or “hsa-miR-486-5p” used in the present specification includes the hsa-miR-486-5p gene (miRBase Accession No. MIMAT0002177) described in SEQ ID NO: 174, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-486-5p gene can be obtained by a method described in Fu H et al., 2005, FEBS Lett, Vol. 579, p. 3849-3854. Also, “hsa-mir-486 and hsa-mir-486-2” (miRBase Accession Nos. MI0002470 and MI0023622, SEQ ID NOs: 323 and 324) having a hairpin-like structure are known as precursors of “hsa-miR-486-5p”. 
     The term “hsa-miR-4655-5p gene” or “hsa-miR-4655-5p” used in the present specification includes the hsa-miR-4655-5p gene (miRBase Accession No. MIMAT0019721) described in SEQ ID NO: 175, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4655-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4655” (miRBase Accession No. MI0017283, SEQ ID NO: 359) having a hairpin-like structure is known as a precursor of “hsa-miR-4655-5p”. 
     The term “hsa-miR-1275 gene” or “hsa-miR-1275” used in the present specification includes the hsa-miR-1275 gene (miRBase Accession No. MIMAT0005929) described in SEQ ID NO: 176, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1275 gene can be obtained by a method described in Morin R D et al., 2008, Genome Res, Vol. 18, p. 610-621. Also, “hsa-mir-1275” (miRBase Accession No. MI0006415, SEQ ID NO: 360) having a hairpin-like structure is known as a precursor of “hsa-miR-1275”. 
     The term “hsa-miR-6806-5p gene” or “hsa-miR-6806-5p” used in the present specification includes the hsa-miR-6806-5p gene (miRBase Accession No. MIMAT0027512) described in SEQ ID NO: 177, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6806-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6806” (miRBase Accession No. MI0022651, SEQ ID NO: 361) having a hairpin-like structure is known as a precursor of “hsa-miR-6806-5p”. 
     The term “hsa-miR-614 gene” or “hsa-miR-614” used in the present specification includes the hsa-miR-614 gene (miRBase Accession No. MIMAT0003282) described in SEQ ID NO: 178, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-614 gene can be obtained by a method described in Cummins J M et al., 2006, Proc Natl Acad Sci USA, Vol. 103, p. 3687-3692. Also, “hsa-mir-614” (miRBase Accession No. MI0003627, SEQ ID NO: 362) having a hairpin-like structure is known as a precursor of “hsa-miR-614”. 
     The term “hsa-miR-3937 gene” or “hsa-miR-3937” used in the present specification includes the hsa-miR-3937 gene (miRBase Accession No. MIMAT0018352) described in SEQ ID NO: 179, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3937 gene can be obtained by a method described in Liao J Y et al., 2010, PLoS One, Vol. 5, e10563. Also, “hsa-mir-3937” (miRBase Accession No. MI0016593, SEQ ID NO: 363) having a hairpin-like structure is known as a precursor of “hsa-miR-3937”. 
     The term “hsa-miR-6752-5p gene” or “hsa-miR-6752-5p” used in the present specification includes the hsa-miR-6752-5p gene (miRBase Accession No. MIMAT0027404) described in SEQ ID NO: 180, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6752-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6752” (miRBase Accession No. M10022597, SEQ ID NO: 364) having a hairpin-like structure is known as a precursor of “hsa-miR-6752-5p”. 
     The term “hsa-miR-6771-5p gene” or “hsa-miR-6771-5p” used in the present specification includes the hsa-miR-6771-5p gene (miRBase Accession No. MIMAT0027442) described in SEQ ID NO: 181, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6771-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6771” (miRBase Accession No. MI0022616, SEQ ID NO: 365) having a hairpin-like structure is known as a precursor of “hsa-miR-6771-5p”. 
     The term “hsa-miR-4450 gene” or “hsa-miR-4450” used in the present specification includes the hsa-miR-4450 gene (miRBase Accession No. MIMAT0018971) described in SEQ ID NO: 182, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4450 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4450” (miRBase Accession No. MI0016795, SEQ ID NO: 366) having a hairpin-like structure is known as a precursor of “hsa-miR-4450”. 
     The term “hsa-miR-211-3p gene” or “hsa-miR-211-3p” used in the present specification includes the hsa-miR-211-3p gene (miRBase Accession No. MIMAT0022694) described in SEQ ID NO: 183, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-211-3p gene can be obtained by a method described in Lim L P et al., 2003, Science, Vol. 299, p. 1540. Also, “hsa-mir-211” (miRBase Accession No. MI0000287, SEQ ID NO: 367) having a hairpin-like structure is known as a precursor of “hsa-miR-211-3p”. 
     The term “hsa-miR-663a gene” or “hsa-miR-663a” used in the present specification includes the hsa-miR-663a gene (miRBase Accession No. MIMAT0003326) described in SEQ ID NO: 184, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-663a gene can be obtained by a method described in Cummins J M et al., 2006, Proc Natl Acad Sci USA, Vol. 103, p. 3687-3692. Also, “hsa-mir-663a” (miRBase Accession No. MI0003672, SEQ ID NO: 368) having a hairpin-like structure is known as a precursor of “hsa-miR-663a”. 
     The term “hsa-miR-6842-5p gene” or “hsa-miR-6842-5p” used in the present specification includes the hsa-miR-6842-5p gene (miRBase Accession No. MIMAT0027586) described in SEQ ID NO: 185, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6842-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6842” (miRBase Accession No. MI0022688, SEQ ID NO: 369) having a hairpin-like structure is known as a precursor of “hsa-miR-6842-5p”. 
     The term “hsa-miR-7114-5p gene” or “hsa-miR-7114-5p” used in the present specification includes the hsa-miR-7114-5p gene (miRBase Accession No. MIMAT0028125) described in SEQ ID NO: 186, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-7114-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-7114” (miRBase Accession No. MI0022965, SEQ ID NO: 370) having a hairpin-like structure is known as a precursor of “hsa-miR-7114-5p”. 
     The term “hsa-miR-6779-5p gene” or “hsa-miR-6779-5p” used in the present specification includes the hsa-miR-6779-5p gene (miRBase Accession No. MIMAT0027458) described in SEQ ID NO: 187, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6779-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6779” (miRBase Accession No. M10022624, SEQ ID NO: 371) having a hairpin-like structure is known as a precursor of “hsa-miR-6779-5p”. 
     The term “hsa-miR-204-3p gene” or “hsa-miR-204-3p” used in the present specification includes the hsa-miR-204-3p gene (miRBase Accession No. MIMAT0022693) described in SEQ ID NO: 580, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-204-3p gene can be obtained by a method described in Lim L P et al., 2003, Science., Vol. 299, p. 1540. Also, “hsa-mir-204” (miRBase Accession No. MI0000284, SEQ ID NO: 612) having a hairpin-like structure is known as a precursor of “hsa-miR-204-3p”. 
     The term “hsa-miR-642a-3p gene” or “hsa-miR-642a-3p” used in the present specification includes the hsa-miR-642a-3p gene (miRBase Accession No. MIMAT0020924) described in SEQ ID NO: 581, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-642a-3p gene can be obtained by a method described in Cummins J M et al., 2006, Proc Natl Acad Sci USA, Vol. 103, p. 3687-3692. Also, “hsa-mir-642a” (miRBase Accession No. MI0003657, SEQ ID NO: 613) having a hairpin-like structure is known as a precursor of “hsa-miR-642a-3p”. 
     The term “hsa-miR-762 gene” or “hsa-miR-762” used in the present specification includes the hsa-miR-762 gene (miRBase Accession No. MIMAT0010313) described in SEQ ID NO: 582, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-762 gene can be obtained by a method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p. 1289-1298. Also, “hsa-mir-762” (miRBase Accession No. MI0003892, SEQ ID NO: 614) having a hairpin-like structure is known as a precursor of “hsa-miR-762”. 
     The term “hsa-miR-1202 gene” or “hsa-miR-1202” used in the present specification includes the hsa-miR-1202 gene (miRBase Accession No. MIMAT0005865) described in SEQ ID NO: 583, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-1202 gene can be obtained by a method described in Marton S et al., 2008, Leukemia., Vol. 22, p. 330-338. Also, “hsa-mir-1202” (miRBase Accession No. MI0006334, SEQ ID NO: 615) having a hairpin-like structure is known as a precursor of “hsa-miR-1202”. 
     The term “hsa-miR-3162-5p gene” or “hsa-miR-3162-5p” used in the present specification includes the hsa-miR-3162-5p gene (miRBase Accession No. MIMAT0015036) described in SEQ ID NO: 584, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3162-5p gene can be obtained by a method described in Stark M S et al., 2010, PLoS One., Vol. 5, e9685. Also, “hsa-mir-3162” (miRBase Accession No. MI0014192, SEQ ID NO: 616) having a hairpin-like structure is known as a precursor of “hsa-miR-3162-5p”. 
     The term “hsa-miR-3196 gene” or “hsa-miR-3196” used in the present specification includes the hsa-miR-3196 gene (miRBase Accession No. MIMAT0015080) described in SEQ ID NO: 585, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3196 gene can be obtained by a method described in Stark M S et al., 2010, PLoS One, Vol. 5, e9685. Also, “hsa-mir-3196” (miRBase Accession No. MI0014241, SEQ ID NO: 617) having a hairpin-like structure is known as a precursor of “hsa-miR-3196”. 
     The term “hsa-miR-3622a-5p gene” or “hsa-miR-3622a-5p” used in the present specification includes the hsa-miR-3622a-5p gene (miRBase Accession No. MIMAT0018003) described in SEQ ID NO: 586, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3622a-5p gene can be obtained by a method described in Witten D et al., 2010, BMC Biol., Vol. 8, p. 58. Also, “hsa-mir-3622a” (miRBase Accession No. MI0016013, SEQ ID NO: 618) having a hairpin-like structure is known as a precursor of “hsa-miR-3622a-5p”. 
     The term “hsa-miR-3665 gene” or “hsa-miR-3665” used in the present specification includes the hsa-miR-3665 gene (miRBase Accession No. MIMAT0018087) described in SEQ ID NO: 587, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3665 gene can be obtained by a method described in Xie X et al., 2005, Nature, Vol. 434, p. 338-345. Also, “hsa-mir-3665” (miRBase Accession No. MI0016066, SEQ ID NO: 619) having a hairpin-like structure is known as a precursor of “hsa-miR-3665”. 
     The term “hsa-miR-3940-5p gene” or “hsa-miR-3940-5p” used in the present specification includes the hsa-miR-3940-5p gene (miRBase Accession No. MIMAT0019229) described in SEQ ID NO: 588, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-3940-5p gene can be obtained by a method described in Liao J Y et al., 2010, PLoS One, Vol. 5, e10563. Also, “hsa-mir-3940” (miRBase Accession No. MI0016597, SEQ ID NO: 620) having a hairpin-like structure is known as a precursor of “hsa-miR-3940-5p”. 
     The term “hsa-miR-4294 gene” or “hsa-miR-4294” used in the present specification includes the hsa-miR-4294 gene (miRBase Accession No. MIMAT0016849) described in SEQ ID NO: 589, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4294 gene can be obtained by a method described in Goff L A et al., 2009, PLoS One., Vol. 4, e7192. Also, “hsa-mir-4294” (miRBase Accession No. MI0015827, SEQ ID NO: 621) having a hairpin-like structure is known as a precursor of “hsa-miR-4294”. 
     The term “hsa-miR-4466 gene” or “hsa-miR-4466” used in the present specification includes the hsa-miR-4466 gene (miRBase Accession No. MIMAT0018993) described in SEQ ID NO: 590, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4466 gene can be obtained by a method described in Jima D D et al., 2010, Blood, Vol. 116, e118-e127. Also, “hsa-mir-4466” (miRBase Accession No. MI0016817, SEQ ID NO: 622) having a hairpin-like structure is known as a precursor of “hsa-miR-4466”. 
     The term “hsa-miR-4476 gene” or “hsa-miR-4476” used in the present specification includes the hsa-miR-4476 gene (miRBase Accession No. MIMAT0019003) described in SEQ ID NO: 591, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4476 gene can be obtained by a method described in Jima D D et al., 2010, Blood., Vol. 116, e118-e127. Also, “hsa-mir-4476” (miRBase Accession No. MI0016828, SEQ ID NO: 623) having a hairpin-like structure is known as a precursor of “hsa-miR-4476”. 
     The term “hsa-miR-4723-5p gene” or “hsa-miR-4723-5p” used in the present specification includes the hsa-miR-4723-5p gene (miRBase Accession No. MIMAT0019838) described in SEQ ID NO: 592, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4723-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res., Vol. 71, p. 78-86. Also, “hsa-mir-4723” (miRBase Accession No. MI0017359, SEQ ID NO: 624) having a hairpin-like structure is known as a precursor of “hsa-miR-4723-5p”. 
     The term “hsa-miR-4725-3p gene” or “hsa-miR-4725-3p” used in the present specification includes the hsa-miR-4725-3p gene (miRBase Accession No. MIMAT0019844) described in SEQ ID NO: 593, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4725-3p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4725” (miRBase Accession No. MI0017362, SEQ ID NO: 625) having a hairpin-like structure is known as a precursor of “hsa-miR-4725-3p”. 
     The term “hsa-miR-4730 gene” or “hsa-miR-4730” used in the present specification includes the hsa-miR-4730 gene (miRBase Accession No. MIMAT0019852) described in SEQ ID NO: 594, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4730 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4730” (miRBase Accession No. MI0017367, SEQ ID NO: 626) having a hairpin-like structure is known as a precursor of “hsa-miR-4730”. 
     The term “hsa-miR-4739 gene” or “hsa-miR-4739” used in the present specification includes the hsa-miR-4739 gene (miRBase Accession No. MIMAT0019868) described in SEQ ID NO: 595, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4739 gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4739” (miRBase Accession No. MI0017377, SEQ ID NO: 627) having a hairpin-like structure is known as a precursor of “hsa-miR-4739”. 
     The term “hsa-miR-4787-5p gene” or “hsa-miR-4787-5p” used in the present specification includes the hsa-miR-4787-5p gene (miRBase Accession No. MIMAT0019956) described in SEQ ID NO: 596, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-4787-5p gene can be obtained by a method described in Persson H et al., 2011, Cancer Res, Vol. 71, p. 78-86. Also, “hsa-mir-4787” (miRBase Accession No. MI0017434, SEQ ID NO: 628) having a hairpin-like structure is known as a precursor of “hsa-miR-4787-5p”. 
     The term “hsa-miR-5787 gene” or “hsa-miR-5787” used in the present specification includes the hsa-miR-5787 gene (miRBase Accession No. MIMAT0023252) described in SEQ ID NO: 597, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-5787 gene can be obtained by a method described in Yoo H et al., 2011, Biochem Biophys Res Commun, Vol. 415, p. 567-572. Also, “hsa-mir-5787” (miRBase Accession No. M10019797, SEQ ID NO: 629) having a hairpin-like structure is known as a precursor of “hsa-miR-5787”. 
     The term “hsa-miR-6085 gene” or “hsa-miR-6085” used in the present specification includes the hsa-miR-6085 gene (miRBase Accession No. MIMAT0023710) described in SEQ ID NO: 598, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6085 gene can be obtained by a method described in Voellenkle C et al., 2012, RNA., Vol. 18, p. 472-484. Also, “hsa-mir-6085” (miRBase Accession No. MI0020362, SEQ ID NO: 630) having a hairpin-like structure is known as a precursor of “hsa-miR-6085”. 
     The term “hsa-miR-6717-5p gene” or “hsa-miR-6717-5p” used in the present specification includes the hsa-miR-6717-5p gene (miRBase Accession No. MIMAT0025846) described in SEQ ID NO: 599, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6717-5p gene can be obtained by a method described in Li Y et al., 2012, Gene, Vol. 497, p. 330-335. Also, “hsa-mir-6717” (miRBase Accession No. MI0022551, SEQ ID NO: 631) having a hairpin-like structure is known as a precursor of “hsa-miR-6717-5p”. 
     The term “hsa-miR-6724-5p gene” or “hsa-miR-6724-5p” used in the present specification includes the hsa-miR-6724-5p gene (miRBase Accession No. MIMAT0025856) described in SEQ ID NO: 600, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6724-5p gene can be obtained by a method described in Li Y et al., 2012, Gene., Vol. 497, p. 330-335. Also, “hsa-mir-6724” (miRBase Accession No. MI0022559, SEQ ID NO: 632) having a hairpin-like structure is known as a precursor of “hsa-miR-6724-5p”. 
     The term “hsa-miR-6777-5p gene” or “hsa-miR-6777-5p” used in the present specification includes the hsa-miR-6777-5p gene (miRBase Accession No. MIMAT0027454) described in SEQ ID NO: 601, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6777-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6777” (miRBase Accession No. M10022622, SEQ ID NO: 633) having a hairpin-like structure is known as a precursor of “hsa-miR-6777-5p”. 
     The term “hsa-miR-6778-5p gene” or “hsa-miR-6778-5p” used in the present specification includes the hsa-miR-6778-5p gene (miRBase Accession No. MIMAT0027456) described in SEQ ID NO: 602, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6778-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res., Vol. 22, p. 1634-1645. Also, “hsa-mir-6778” (miRBase Accession No. M10022623, SEQ ID NO: 634) having a hairpin-like structure is known as a precursor of “hsa-miR-6778-5p”. 
     The term “hsa-miR-6787-5p gene” or “hsa-miR-6787-5p” used in the present specification includes the hsa-miR-6787-5p gene (miRBase Accession No. MIMAT0027474) described in SEQ ID NO: 603, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6787-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p. 1634-1645. Also, “hsa-mir-6787” (miRBase Accession No. MI0022632, SEQ ID NO: 635) having a hairpin-like structure is known as a precursor of “hsa-miR-6787-5p”. 
     The term “hsa-miR-6789-5p gene” or “hsa-miR-6789-5p” used in the present specification includes the hsa-miR-6789-5p gene (miRBase Accession No. MIMAT0027478) described in SEQ ID NO: 604, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6789-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res., Vol. 22, p. 1634-1645. Also, “hsa-mir-6789” (miRBase Accession No. MI0022634, SEQ ID NO: 636) having a hairpin-like structure is known as a precursor of “hsa-miR-6789-5p”. 
     The term “hsa-miR-6845-5p gene” or “hsa-miR-6845-5p” used in the present specification includes the hsa-miR-6845-5p gene (miRBase Accession No. MIMAT0027590) described in SEQ ID NO: 605, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6845-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res., Vol. 22, p. 1634-1645. Also, “hsa-mir-6845” (miRBase Accession No. MI0022691, SEQ ID NO: 637) having a hairpin-like structure is known as a precursor of “hsa-miR-6845-5p”. 
     The term “hsa-miR-6893-5p gene” or “hsa-miR-6893-5p” used in the present specification includes the hsa-miR-6893-5p gene (miRBase Accession No. MIMAT0027686) described in SEQ ID NO: 606, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-6893-5p gene can be obtained by a method described in Ladewig E et al., 2012, Genome Res., Vol. 22, p. 1634-1645. Also, “hsa-mir-6893” (miRBase Accession No. M10022740, SEQ ID NO: 638) having a hairpin-like structure is known as a precursor of “hsa-miR-6893-5p”. 
     The term “hsa-miR-16-5p gene” or “hsa-miR-16-5p” used in the present specification includes the hsa-miR-16-5p gene (miRBase Accession No. MIMAT0000069) described in SEQ ID NO: 607, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-16-5p gene can be obtained by a method described in Lagos-Quintana M et al., 2002, Curr Biol., Vol. 12, p. 735-739. Also, “hsa-mir-16-1 and hsa-mir-16-2” (miRBase Accession Nos. MI0000070 and MI0000115, SEQ ID NOs: 639 and 640) having a hairpin-like structure are known as precursors of “hsa-miR-16-5p”. 
     The term “hsa-miR-423-5p gene” or “hsa-miR-423-5p” used in the present specification includes the hsa-miR-423-5p gene (miRBase Accession No. MIMAT0004748) described in SEQ ID NO: 608, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-423-5p gene can be obtained by a method described in Kasashima K et al., 2004, Biochem Biophys Res Commun., Vol. 322, p. 403-410. Also, “hsa-mir-423” (miRBase Accession No. MI0001445, SEQ ID NO: 641) having a hairpin-like structure is known as a precursor of “hsa-miR-423-5p”. 
     The term “hsa-miR-451a gene” or “hsa-miR-451a” used in the present specification includes the hsa-miR-451a gene (miRBase Accession No. MIMAT0001631) described in SEQ ID NO: 609, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-451a gene can be obtained by a method described in Altuvia Y et al., 2005, Nucleic Acids Res., Vol. 33, p. 2697-2706. Also, “hsa-mir-451a” (miRBase Accession No. MI0001729, SEQ ID NO: 642) having a hairpin-like structure is known as a precursor of “hsa-miR-451a”. 
     The term “hsa-miR-564 gene” or “hsa-miR-564” used in the present specification includes the hsa-miR-564 gene (miRBase Accession No. MIMAT0003228) described in SEQ ID NO: 610, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-564 gene can be obtained by a method described in Cummins J M, 2006, Proc Natl. Acad Sci, Vol. 103, p. 3687-3692. Also, “hsa-mir-564” (miRBase Accession No. MI0003570, SEQ ID NO: 643) having a hairpin-like structure is known as a precursor of “hsa-miR-564”. 
     The term “hsa-miR-671-5p gene” or “hsa-miR-671-5p” used in the present specification includes the hsa-miR-671-5p gene (miRBase Accession No. MIMAT0003880) described in SEQ ID NO: 611, a homolog or an ortholog of a different organism species, and the like. The hsa-miR-671-5p gene can be obtained by a method described in Berezikov E et al., 2006, Genome Res, Vol. 16, p. 1289-1298. Also, “hsa-mir-671” (miRBase Accession No. M10003760, SEQ ID NO: 644) having a hairpin-like structure is known as a precursor of “hsa-miR-671-5p”. 
     A mature miRNA may become a variant due to the sequence cleaved shorter or longer by one to several upstream or downstream bases or base substitution when cleaved as the mature miRNA from its RNA precursor that has a hairpin-like structure. This variant is called isomiR (Morin R D. et al., 2008, Genome Res., Vol. 18, p. 610-621). miRBase Release 20 shows the nucleotide sequences represented by SEQ ID NOs: 1 to 187 and 580 to 611 as well as a large number of the nucleotide sequence variants and fragments represented by SEQ ID NOs: 137 to 579 and 645 to 684, called isomiRs. These variants can also be obtained as miRNAs having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 187 and 580 to 611. Specifically, among the variants of polynucleotides consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1, 2, 4, 5, 6, 7, 10, 12, 15, 16, 18, 19, 21, 22, 24, 25, 27, 30, 31, 33, 34, 36, 39, 41, 42, 43, 44, 45, 46, 48, 51, 53, 58, 61, 62, 63, 66, 69, 73, 75, 76, 77, 78, 83, 84, 85, 86, 87, 88, 90, 94, 95, 96, 98, 100, 102, 103, 104, 105, 106, 107, 108, 109, 111, 115, 117, 119, 120, 123, 124, 125, 126, 127, 128, 131, 136, 137, 139, 140, 143, 144, 147, 149, 151, 153, 154, 155, 156, 158, 160, 162, 165, 167, 168, 169, 170, 173, 174, 175, 176, 178, 182, 183, 184, 580, 581, 584, 585, 587, 588, 590, 591, 592, 593, 594, 595, 597, 599, 600, 607, 608, 609 and 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t according to the present invention, examples of the longest variants registered in miRBase Release 20 include polynucleotides represented by SEQ ID NOs: 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 492, 494, 496, 498, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, 556, 558, 560, 562, 564, 566, 568, 570, 572, 574, 576, 578, 645, 647, 650, 652, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, 679, 681 and 683, respectively. Also, among the variants of polynucleotides consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1, 2, 4, 5, 6, 7, 10, 12, 15, 16, 18, 19, 21, 22, 24, 25, 27, 30, 31, 33, 34, 36, 39, 41, 42, 43, 44, 45, 46, 48, 51, 53, 58, 61, 62, 63, 66, 69, 73, 75, 76, 77, 78, 83, 84, 85, 86, 87, 88, 90, 94, 95, 96, 98, 100, 102, 103, 104, 105, 106, 107, 108, 109, 111, 115, 117, 119, 120, 123, 124, 125, 126, 127, 128, 131, 136, 137, 139, 140, 143, 144, 147, 149, 151, 153, 154, 155, 156, 158, 160, 162, 165, 167, 168, 169, 170, 173, 174, 175, 176, 178, 182, 183, 184, 580, 581, 583, 584, 585, 586, 587, 588, 590, 591, 592, 593, 594, 595, 597, 599, 600, 607, 608, 609 and 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t according to the present invention, examples of the shortest variants registered in miRBase Release 20 include polynucleotides having sequences represented by SEQ ID NOs: 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 455, 457, 459, 461, 463, 465, 467, 469, 471, 473, 475, 477, 479, 481, 483, 485, 487, 489, 491, 493, 495, 497, 499, 501, 503, 505, 507, 509, 511, 513, 515, 517, 519, 521, 523, 525, 527, 529, 531, 533, 535, 537, 539, 541, 543, 545, 547, 549, 551, 553, 555, 557, 559, 561, 563, 565, 567, 569, 571, 573, 575, 577, 579, 646, 648, 649, 651, 653, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, 680, 682 and 684, respectively. In addition to these variants and fragments, examples thereof include a large number of isomiR polynucleotides of SEQ ID NOs: 1 to 187 and 580 to 611 registered in miRBase. Examples of the polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 187 and 580 to 611 include a polynucleotide represented by any of SEQ ID NOs: 188 to 371, and 612 to 644, which are their respective precursors. 
     The names and miRBase Accession Nos. (registration numbers) of the genes represented by SEQ ID NOs: 1 to 684 are shown in Table 1. 
     In the present specification, the term “capable of specifically binding” means that the nucleic acid probe or the primer used in the present invention binds to a particular target nucleic acid and cannot substantially bind to other nucleic acids. 
     
       
         
           
               
               
               
             
               
                 TABLE 1 
               
               
                   
               
               
                   
                   
                 miR Base registration  
               
               
                 SEQ ID NO: 
                 Gene name 
                 No. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 1 
                 hsa-miR-4443 
                 MIMAT0018961 
               
               
                 2 
                 hsa-miR-1908-5p 
                 MIMAT0007881 
               
               
                 3 
                 hsa-miR-4257 
                 MIMAT0016878 
               
               
                 4 
                 hsa-miR-3197 
                 MIMAT0015082 
               
               
                 5 
                 hsa-miR-3188 
                 MIMAT0015070 
               
               
                 6 
                 hsa-miR-4649-5p 
                 MIMAT0019711 
               
               
                 7 
                 hsa-miR-1343-3p 
                 MIMAT0019776 
               
               
                 8 
                 hsa-miR-6861-5p 
                 MIMAT0027623 
               
               
                 9 
                 hsa-miR-1343-5p 
                 MIMAT0027038 
               
               
                 10 
                 hsa-miR-642b-3p 
                 MIMAT0018444 
               
               
                 11 
                 hsa-miR-6741-5p 
                 MIMAT0027383 
               
               
                 12 
                 hsa-miR-4745-5p 
                 MIMAT0019878 
               
               
                 13 
                 hsa-miR-6826-5p 
                 MIMAT0027552 
               
               
                 14 
                 hsa-miR-3663-3p 
                 MIMAT0018085 
               
               
                 15 
                 hsa-miR-3131 
                 MIMAT0014996 
               
               
                 16 
                 hsa-miR-92a-2-5p 
                 MIMAT0004508 
               
               
                 17 
                 hsa-miR-4258 
                 MIMAT0016879 
               
               
                 18 
                 hsa-miR-4448 
                 MIMAT0018967 
               
               
                 19 
                 hsa-miR-6125 
                 MIMAT0024598 
               
               
                 20 
                 hsa-miR-6880-5p 
                 MIMAT0027660 
               
               
                 21 
                 hsa-miR-6132 
                 MIMAT0024616 
               
               
                 22 
                 hsa-miR-4467 
                 MIMAT0018994 
               
               
                 23 
                 hsa-miR-6749-5p 
                 MIMAT0027398 
               
               
                 24 
                 hsa-miR-2392 
                 MIMAT0019043 
               
               
                 25 
                 hsa-miR-1273g-3p 
                 MIMAT0022742 
               
               
                 26 
                 hsa-miR-4746-3p 
                 MIMAT0019881 
               
               
                 27 
                 hsa-miR-1914-3p 
                 MIMAT0007890 
               
               
                 28 
                 hsa-miR-7845-5p 
                 MIMAT0030420 
               
               
                 29 
                 hsa-miR-6726-5p 
                 MIMAT0027353 
               
               
                 30 
                 hsa-miR-128-2-5p 
                 MIMAT0031095 
               
               
                 31 
                 hsa-miR-4651 
                 MIMAT0019715 
               
               
                 32 
                 hsa-miR-6765-3p 
                 MIMAT0027431 
               
               
                 33 
                 hsa-miR-3185 
                 MIMAT0015065 
               
               
                 34 
                 hsa-miR-4792 
                 MIMAT0019964 
               
               
                 35 
                 hsa-miR-6887-5p 
                 MIMAT0027674 
               
               
                 36 
                 hsa-miR-5572 
                 MIMAT0022260 
               
               
                 37 
                 hsa-miR-3619-3p 
                 MIMAT0019219 
               
               
                 38 
                 hsa-miR-6780b-5p 
                 MIMAT0027572 
               
               
                 39 
                 hsa-miR-4707-5p 
                 MIMAT0019807 
               
               
                 40 
                 hsa-miR-8063 
                 MIMAT0030990 
               
               
                 41 
                 hsa-miR-4454 
                 MIMAT0018976 
               
               
                 42 
                 hsa-miR-4525 
                 MIMAT0019064 
               
               
                 43 
                 hsa-miR-7975 
                 MIMAT0031178 
               
               
                 44 
                 hsa-miR-744-5p 
                 MIMAT0004945 
               
               
                 45 
                 hsa-miR-3135b 
                 MIMAT0018985 
               
               
                 46 
                 hsa-miR-4648 
                 MIMAT0019710 
               
               
                 47 
                 hsa-miR-6816-5p 
                 MIMAT0027532 
               
               
                 48 
                 hsa-miR-4741 
                 MIMAT0019871 
               
               
                 49 
                 hsa-miR-7150 
                 MIMAT0028211 
               
               
                 50 
                 hsa-miR-6791-5p 
                 MIMAT0027482 
               
               
                 51 
                 hsa-miR-1247-3p 
                 MIMAT0022721 
               
               
                 52 
                 hsa-miR-7977 
                 MIMAT0031180 
               
               
                 53 
                 hsa-miR-4497 
                 MIMAT0019032 
               
               
                 54 
                 hsa-miR-6090 
                 MIMAT0023715 
               
               
                 55 
                 hsa-miR-6781-5p 
                 MIMAT0027462 
               
               
                 56 
                 hsa-miR-6870-5p 
                 MIMAT0027640 
               
               
                 57 
                 hsa-miR-6729-5p 
                 MIMAT0027359 
               
               
                 58 
                 hsa-miR-4530 
                 MIMAT0019069 
               
               
                 59 
                 hsa-miR-7847-3p 
                 MIMAT0030422 
               
               
                 60 
                 hsa-miR-6825-5p 
                 MIMAT0027550 
               
               
                 61 
                 hsa-miR-4674 
                 MIMAT0019756 
               
               
                 62 
                 hsa-miR-3917 
                 MIMAT0018191 
               
               
                 63 
                 hsa-miR-4707-3p 
                 MIMAT0019808 
               
               
                 64 
                 hsa-miR-6885-5p 
                 MIMAT0027670 
               
               
                 65 
                 hsa-miR-6722-3p 
                 MIMAT0025854 
               
               
                 66 
                 hsa-miR-4516 
                 MIMAT0019053 
               
               
                 67 
                 hsa-miR-6757-5p 
                 MIMAT0027414 
               
               
                 68 
                 hsa-miR-6840-3p 
                 MIMAT0027583 
               
               
                 69 
                 hsa-miR-5195-3p 
                 MIMAT0021127 
               
               
                 70 
                 hsa-miR-6756-5p 
                 MIMAT0027412 
               
               
                 71 
                 hsa-miR-6800-5p 
                 MIMAT0027500 
               
               
                 72 
                 hsa-miR-6727-5p 
                 MIMAT0027355 
               
               
                 73 
                 hsa-miR-6126 
                 MIMAT0024599 
               
               
                 74 
                 hsa-miR-6872-3p 
                 MIMAT0027645 
               
               
                 75 
                 hsa-miR-4446-3p 
                 MIMAT0018965 
               
               
                 76 
                 hsa-miR-1268a 
                 MIMAT0005922 
               
               
                 77 
                 hsa-miR-1908-3p 
                 MIMAT0026916 
               
               
                 78 
                 hsa-miR-3679-5p 
                 MIMAT0018104 
               
               
                 79 
                 hsa-miR-4534 
                 MIMAT0019073 
               
               
                 80 
                 hsa-miR-4675 
                 MIMAT0019757 
               
               
                 81 
                 hsa-miR-7108-5p 
                 MIMAT0028113 
               
               
                 82 
                 hsa-miR-6799-5p 
                 MIMAT0027498 
               
               
                 83 
                 hsa-miR-4695-5p 
                 MIMAT0019788 
               
               
                 84 
                 hsa-miR-3178 
                 MIMAT0015055 
               
               
                 85 
                 hsa-miR-5090 
                 MIMAT0021082 
               
               
                 86 
                 hsa-miR-3180 
                 MIMAT0018178 
               
               
                 87 
                 hsa-miR-1237-5p 
                 MIMAT0022946 
               
               
                 88 
                 hsa-miR-4758-5p 
                 MIMAT0019903 
               
               
                 89 
                 hsa-miR-3184-5p 
                 MIMAT0015064 
               
               
                 90 
                 hsa-miR-4286 
                 MIMAT0016916 
               
               
                 91 
                 hsa-miR-6784-5p 
                 MIMAT0027468 
               
               
                 92 
                 hsa-miR-6768-5p 
                 MIMAT0027436 
               
               
                 93 
                 hsa-miR-6785-5p 
                 MIMAT0027470 
               
               
                 94 
                 hsa-miR-4706 
                 MIMAT0019806 
               
               
                 95 
                 hsa-miR-711 
                 MIMAT0012734 
               
               
                 96 
                 hsa-miR-1260a 
                 MIMAT0005911 
               
               
                 97 
                 hsa-miR-6746-5p 
                 MIMAT0027392 
               
               
                 98 
                 hsa-miR-6089 
                 MIMAT0023714 
               
               
                 99 
                 hsa-miR-6821-5p 
                 MIMAT0027542 
               
               
                 100 
                 hsa-miR-4667-5p 
                 MIMAT0019743 
               
               
                 101 
                 hsa-miR-8069 
                 MIMAT0030996 
               
               
                 102 
                 hsa-miR-4726-5p 
                 MIMAT0019845 
               
               
                 103 
                 hsa-miR-6124 
                 MIMAT0024597 
               
               
                 104 
                 hsa-miR-4532 
                 MIMAT0019071 
               
               
                 105 
                 hsa-miR-4486 
                 MIMAT0019020 
               
               
                 106 
                 hsa-miR-4728-5p 
                 MIMAT0019849 
               
               
                 107 
                 hsa-miR-4508 
                 MIMAT0019045 
               
               
                 108 
                 hsa-miR-128-1-5p 
                 MIMAT0026477 
               
               
                 109 
                 hsa-miR-4513 
                 MIMAT0019050 
               
               
                 110 
                 hsa-miR-6795-5p 
                 MIMAT0027490 
               
               
                 111 
                 hsa-miR-4689 
                 MIMAT0019778 
               
               
                 112 
                 hsa-miR-6763-5p 
                 MIMAT0027426 
               
               
                 113 
                 hsa-miR-8072 
                 MIMAT0030999 
               
               
                 114 
                 hsa-miR-6765-5p 
                 MIMAT0027430 
               
               
                 115 
                 hsa-miR-4419b 
                 MIMAT0019034 
               
               
                 116 
                 hsa-miR-7641 
                 MIMAT0029782 
               
               
                 117 
                 hsa-miR-3928-3p 
                 MIMAT0018205 
               
               
                 118 
                 hsa-miR-1227-5p 
                 MIMAT0022941 
               
               
                 119 
                 hsa-miR-4492 
                 MIMAT0019027 
               
               
                 120 
                 hsa-miR-296-3p 
                 MIMAT0004679 
               
               
                 121 
                 hsa-miR-6769a-5p 
                 MIMAT0027438 
               
               
                 122 
                 hsa-miR-6889-5p 
                 MIMAT0027678 
               
               
                 123 
                 hsa-miR-4632-5p 
                 MIMAT0022977 
               
               
                 124 
                 hsa-miR-4505 
                 MIMAT0019041 
               
               
                 125 
                 hsa-miR-3154 
                 MIMAT0015028 
               
               
                 126 
                 hsa-miR-3648 
                 MIMAT0018068 
               
               
                 127 
                 hsa-miR-4442 
                 MIMAT0018960 
               
               
                 128 
                 hsa-miR-3141 
                 MIMAT0015010 
               
               
                 129 
                 hsa-miR-7113-3p 
                 MIMAT0028124 
               
               
                 130 
                 hsa-miR-6819-5p 
                 MIMAT0027538 
               
               
                 131 
                 hsa-miR-3195 
                 MIMAT0015079 
               
               
                 132 
                 hsa-miR-1199-5p 
                 MIMAT0031119 
               
               
                 133 
                 hsa-miR-6738-5p 
                 MIMAT0027377 
               
               
                 134 
                 hsa-miR-4656 
                 MIMAT0019723 
               
               
                 135 
                 hsa-miR-6820-5p 
                 MIMAT0027540 
               
               
                 136 
                 hsa-miR-615-5p 
                 MIMAT0004804 
               
               
                 137 
                 hsa-miR-486-3p 
                 MIMAT0004762 
               
               
                 138 
                 hsa-miR-1225-3p 
                 MIMAT0005573 
               
               
                 139 
                 hsa-miR-760 
                 MIMAT0004957 
               
               
                 140 
                 hsa-miR-187-5p 
                 MIMAT0004561 
               
               
                 141 
                 hsa-miR-1203 
                 MIMAT0005866 
               
               
                 142 
                 hsa-miR-7110-5p 
                 MIMAT0028117 
               
               
                 143 
                 hsa-miR-371a-5p 
                 MIMAT0004687 
               
               
                 144 
                 hsa-miR-939-5p 
                 MIMAT0004982 
               
               
                 145 
                 hsa-miR-575 
                 MIMAT0003240 
               
               
                 146 
                 hsa-miR-92b-5p 
                 MIMAT0004792 
               
               
                 147 
                 hsa-miR-887-3p 
                 MIMAT0004951 
               
               
                 148 
                 hsa-miR-920 
                 MIMAT0004970 
               
               
                 149 
                 hsa-miR-1915-5p 
                 MIMAT0007891 
               
               
                 150 
                 hsa-miR-1231 
                 MIMAT0005586 
               
               
                 151 
                 hsa-miR-663b 
                 MIMAT0005867 
               
               
                 152 
                 hsa-miR-1225-5p 
                 MIMAT0005572 
               
               
                 153 
                 hsa-miR-4763-3p 
                 MIMAT0019913 
               
               
                 154 
                 hsa-miR-3656 
                 MIMAT0018076 
               
               
                 155 
                 hsa-miR-4488 
                 MIMAT0019022 
               
               
                 156 
                 hsa-miR-125a-3p 
                 MIMAT0004602 
               
               
                 157 
                 hsa-miR-1469 
                 MIMAT0007347 
               
               
                 158 
                 hsa-miR-1228-5p 
                 MIMAT0005582 
               
               
                 159 
                 hsa-miR-6798-5p 
                 MIMAT0027496 
               
               
                 160 
                 hsa-miR-1268b 
                 MIMAT0018925 
               
               
                 161 
                 hsa-miR-6732-5p 
                 MIMAT0027365 
               
               
                 162 
                 hsa-miR-1915-3p 
                 MIMAT0007892 
               
               
                 163 
                 hsa-miR-4433b-3p 
                 MIMAT0030414 
               
               
                 164 
                 hsa-miR-1207-5p 
                 MIMAT0005871 
               
               
                 165 
                 hsa-miR-4433-3p 
                 MIMAT0018949 
               
               
                 166 
                 hsa-miR-6879-5p 
                 MIMAT0027658 
               
               
                 167 
                 hsa-miR-4417 
                 MIMAT0018929 
               
               
                 168 
                 hsa-miR-30c-1-3p 
                 MIMAT0004674 
               
               
                 169 
                 hsa-miR-4638-5p 
                 MIMAT0019695 
               
               
                 170 
                 hsa-miR-6088 
                 MIMAT0023713 
               
               
                 171 
                 hsa-miR-4270 
                 MIMAT0016900 
               
               
                 172 
                 hsa-miR-6782-5p 
                 MIMAT0027464 
               
               
                 173 
                 hsa-miR-665 
                 MIMAT0004952 
               
               
                 174 
                 hsa-miR-486-5p 
                 MIMAT0002177 
               
               
                 175 
                 hsa-miR-4655-5p 
                 MIMAT0019721 
               
               
                 176 
                 hsa-miR-1275 
                 MIMAT0005929 
               
               
                 177 
                 hsa-miR-6806-5p 
                 MIMAT0027512 
               
               
                 178 
                 hsa-miR-614 
                 MIMAT0003282 
               
               
                 179 
                 hsa-miR-3937 
                 MIMAT0018352 
               
               
                 180 
                 hsa-miR-6752-5p 
                 MIMAT0027404 
               
               
                 181 
                 hsa-miR-6771-5p 
                 MIMAT0027442 
               
               
                 182 
                 hsa-miR-4450 
                 MIMAT0018971 
               
               
                 183 
                 hsa-miR-211-3p 
                 MIMAT0022694 
               
               
                 184 
                 hsa-miR-663a 
                 MIMAT0003326 
               
               
                 185 
                 hsa-miR-6842-5p 
                 MIMAT0027586 
               
               
                 186 
                 hsa-miR-7114-5p 
                 MIMAT0028125 
               
               
                 187 
                 hsa-miR-6779-5p 
                 MIMAT0027458 
               
               
                 188 
                 hsa-mir-4443 
                 MI0016786 
               
               
                 189 
                 hsa-mir-1908 
                 MI0008329 
               
               
                 190 
                 hsa-mir-4257 
                 MI0015856 
               
               
                 191 
                 hsa-mir-3197 
                 MI0014245 
               
               
                 192 
                 hsa-mir-3188 
                 MI0014232 
               
               
                 193 
                 hsa-mir-4649 
                 MI0017276 
               
               
                 194 
                 hsa-mir-1343 
                 MI0017320 
               
               
                 195 
                 hsa-mir-6861 
                 MI0022708 
               
               
                 196 
                 hsa-mir-642b 
                 MI0016685 
               
               
                 197 
                 hsa-mir-6741 
                 MI0022586 
               
               
                 198 
                 hsa-mir-4745 
                 MI0017384 
               
               
                 199 
                 hsa-mir-6826 
                 MI0022671 
               
               
                 200 
                 hsa-mir-3663 
                 MI0016064 
               
               
                 201 
                 hsa-mir-3131 
                 MI0014151 
               
               
                 202 
                 hsa-mir-92a-2 
                 MI0000094 
               
               
                 203 
                 hsa-mir-4258 
                 MI0015857 
               
               
                 204 
                 hsa-mir-4448 
                 MI0016791 
               
               
                 205 
                 hsa-mir-6125 
                 MI0021259 
               
               
                 206 
                 hsa-mir-6880 
                 MI0022727 
               
               
                 207 
                 hsa-mir-6132 
                 MI0021277 
               
               
                 208 
                 hsa-mir-4467 
                 MI0016818 
               
               
                 209 
                 hsa-mir-6749 
                 MI0022594 
               
               
                 210 
                 hsa-mir-2392 
                 MI0016870 
               
               
                 211 
                 hsa-mir-1273g 
                 MI0018003 
               
               
                 212 
                 hsa-mir-4746 
                 MI0017385 
               
               
                 213 
                 hsa-mir-1914 
                 MI0008335 
               
               
                 214 
                 hsa-mir-7845 
                 MI0025515 
               
               
                 215 
                 hsa-mir-6726 
                 MI0022571 
               
               
                 216 
                 hsa-mir-128-2 
                 MI0000727 
               
               
                 217 
                 hsa-mir-4651 
                 MI0017279 
               
               
                 218 
                 hsa-mir-6765 
                 MI0022610 
               
               
                 219 
                 hsa-mir-3185 
                 MI0014227 
               
               
                 220 
                 hsa-mir-4792 
                 MI0017439 
               
               
                 221 
                 hsa-mir-6887 
                 MI0022734 
               
               
                 222 
                 hsa-mir-5572 
                 MI0019117 
               
               
                 223 
                 hsa-mir-3619 
                 MI0016009 
               
               
                 224 
                 hsa-mir-6780b 
                 MI0022681 
               
               
                 225 
                 hsa-mir-4707 
                 MI0017340 
               
               
                 226 
                 hsa-mir-8063 
                 MI0025899 
               
               
                 227 
                 hsa-mir-4454 
                 MI0016800 
               
               
                 228 
                 hsa-mir-4525 
                 MI0016892 
               
               
                 229 
                 hsa-mir-7975 
                 MI0025751 
               
               
                 230 
                 hsa-mir-744 
                 MI0005559 
               
               
                 231 
                 hsa-mir-3135b 
                 MI0016809 
               
               
                 232 
                 hsa-mir-4648 
                 MI0017275 
               
               
                 233 
                 hsa-mir-6816 
                 MI0022661 
               
               
                 234 
                 hsa-mir-4741 
                 MI0017379 
               
               
                 235 
                 hsa-mir-7150 
                 MI0023610 
               
               
                 236 
                 hsa-mir-6791 
                 MI0022636 
               
               
                 237 
                 hsa-mir-1247 
                 MI0006382 
               
               
                 238 
                 hsa-mir-7977 
                 MI0025753 
               
               
                 239 
                 hsa-mir-4497 
                 MI0016859 
               
               
                 240 
                 hsa-mir-6090 
                 MI0020367 
               
               
                 241 
                 hsa-mir-6781 
                 MI0022626 
               
               
                 242 
                 hsa-mir-6870 
                 MI0022717 
               
               
                 243 
                 hsa-mir-6729 
                 MI0022574 
               
               
                 244 
                 hsa-mir-4530 
                 MI0016897 
               
               
                 245 
                 hsa-mir-7847 
                 MI0025517 
               
               
                 246 
                 hsa-mir-6825 
                 MI0022670 
               
               
                 247 
                 hsa-mir-4674 
                 MI0017305 
               
               
                 248 
                 hsa-mir-3917 
                 MI0016423 
               
               
                 249 
                 hsa-mir-6885 
                 MI0022732 
               
               
                 250 
                 hsa-mir-6722 
                 MI0022557 
               
               
                 251 
                 hsa-mir-4516 
                 MI0016882 
               
               
                 252 
                 hsa-mir-6757 
                 MI0022602 
               
               
                 253 
                 hsa-mir-6840 
                 MI0022686 
               
               
                 254 
                 hsa-mir-5195 
                 MI0018174 
               
               
                 255 
                 hsa-mir-6756 
                 MI0022601 
               
               
                 256 
                 hsa-mir-6800 
                 MI0022645 
               
               
                 257 
                 hsa-mir-6727 
                 MI0022572 
               
               
                 258 
                 hsa-mir-6126 
                 MI0021260 
               
               
                 259 
                 hsa-mir-6872 
                 MI0022719 
               
               
                 260 
                 hsa-mir-4446 
                 MI0016789 
               
               
                 261 
                 hsa-mir-1268a 
                 MI0006405 
               
               
                 262 
                 hsa-mir-3679 
                 MI0016080 
               
               
                 263 
                 hsa-mir-4534 
                 MI0016901 
               
               
                 264 
                 hsa-mir-4675 
                 MI0017306 
               
               
                 265 
                 hsa-mir-7108 
                 MI0022959 
               
               
                 266 
                 hsa-mir-6799 
                 MI0022644 
               
               
                 267 
                 hsa-mir-4695 
                 MI0017328 
               
               
                 268 
                 hsa-mir-3178 
                 MI0014212 
               
               
                 269 
                 hsa-mir-5090 
                 MI0017979 
               
               
                 270 
                 hsa-mir-3180-4 
                 MI0016408 
               
               
                 271 
                 hsa-mir-3180-5 
                 MI0016409 
               
               
                 272 
                 hsa-mir-1237 
                 MI0006327 
               
               
                 273 
                 hsa-mir-4758 
                 MI0017399 
               
               
                 274 
                 hsa-mir-3184 
                 MI0014226 
               
               
                 275 
                 hsa-mir-4286 
                 MI0015894 
               
               
                 276 
                 hsa-mir-6784 
                 MI0022629 
               
               
                 277 
                 hsa-mir-6768 
                 MI0022613 
               
               
                 278 
                 hsa-mir-6785 
                 MI0022630 
               
               
                 279 
                 hsa-mir-4706 
                 MI0017339 
               
               
                 280 
                 hsa-mir-711 
                 MI0012488 
               
               
                 281 
                 hsa-mir-1260a 
                 MI0006394 
               
               
                 282 
                 hsa-mir-6746 
                 MI0022591 
               
               
                 283 
                 hsa-mir-6089-1 
                 MI0020366 
               
               
                 284 
                 hsa-mir-6089-2 
                 MI0023563 
               
               
                 285 
                 hsa-mir-6821 
                 MI0022666 
               
               
                 286 
                 hsa-mir-4667 
                 MI0017297 
               
               
                 287 
                 hsa-mir-8069 
                 MI0025905 
               
               
                 288 
                 hsa-mir-4726 
                 MI0017363 
               
               
                 289 
                 hsa-mir-6124 
                 MI0021258 
               
               
                 290 
                 hsa-mir-4532 
                 MI0016899 
               
               
                 291 
                 hsa-mir-4486 
                 MI0016847 
               
               
                 292 
                 hsa-mir-4728 
                 MI0017365 
               
               
                 293 
                 hsa-mir-4508 
                 MI0016872 
               
               
                 294 
                 hsa-mir-128-1 
                 MI0000447 
               
               
                 295 
                 hsa-mir-4513 
                 MI0016879 
               
               
                 296 
                 hsa-mir-6795 
                 MI0022640 
               
               
                 297 
                 hsa-mir-4689 
                 MI0017322 
               
               
                 298 
                 hsa-mir-6763 
                 MI0022608 
               
               
                 299 
                 hsa-mir-8072 
                 MI0025908 
               
               
                 300 
                 hsa-mir-4419b 
                 MI0016861 
               
               
                 301 
                 hsa-mir-7641-1 
                 MI0024975 
               
               
                 302 
                 hsa-mir-7641-2 
                 MI0024976 
               
               
                 303 
                 hsa-mir-3928 
                 MI0016438 
               
               
                 304 
                 hsa-mir-1227 
                 MI0006316 
               
               
                 305 
                 hsa-mir-4492 
                 MI0016854 
               
               
                 306 
                 hsa-mir-296 
                 MI0000747 
               
               
                 307 
                 hsa-mir-6769a 
                 MI0022614 
               
               
                 308 
                 hsa-mir-6889 
                 MI0022736 
               
               
                 309 
                 hsa-mir-4632 
                 MI0017259 
               
               
                 310 
                 hsa-mir-4505 
                 MI0016868 
               
               
                 311 
                 hsa-mir-3154 
                 MI0014182 
               
               
                 312 
                 hsa-mir-3648 
                 MI0016048 
               
               
                 313 
                 hsa-mir-4442 
                 MI0016785 
               
               
                 314 
                 hsa-mir-3141 
                 MI0014165 
               
               
                 315 
                 hsa-mir-7113 
                 MI0022964 
               
               
                 316 
                 hsa-mir-6819 
                 MI0022664 
               
               
                 317 
                 hsa-mir-3195 
                 MI0014240 
               
               
                 318 
                 hsa-mir-1199 
                 MI0020340 
               
               
                 319 
                 hsa-mir-6738 
                 MI0022583 
               
               
                 320 
                 hsa-mir-4656 
                 MI0017284 
               
               
                 321 
                 hsa-mir-6820 
                 MI0022665 
               
               
                 322 
                 hsa-mir-615 
                 MI0003628 
               
               
                 323 
                 hsa-mir-486 
                 MI0002470 
               
               
                 324 
                 hsa-mir-486-2 
                 MI0023622 
               
               
                 325 
                 hsa-mir-1225 
                 MI0006311 
               
               
                 326 
                 hsa-mir-760 
                 MI0005567 
               
               
                 327 
                 hsa-mir-187 
                 MI0000274 
               
               
                 328 
                 hsa-mir-1203 
                 MI0006335 
               
               
                 329 
                 hsa-mir-7110 
                 MI0022961 
               
               
                 330 
                 hsa-mir-371a 
                 MI0000779 
               
               
                 331 
                 hsa-mir-939 
                 MI0005761 
               
               
                 332 
                 hsa-mir-575 
                 MI0003582 
               
               
                 333 
                 hsa-mir-92b 
                 MI0003560 
               
               
                 334 
                 hsa-mir-887 
                 MI0005562 
               
               
                 335 
                 hsa-mir-920 
                 MI0005712 
               
               
                 336 
                 hsa-mir-1915 
                 MI0008336 
               
               
                 337 
                 hsa-mir-1231 
                 MI0006321 
               
               
                 338 
                 hsa-mir-663b 
                 MI0006336 
               
               
                 339 
                 hsa-mir-4763 
                 MI0017404 
               
               
                 340 
                 hsa-mir-3656 
                 MI0016056 
               
               
                 341 
                 hsa-mir-4488 
                 MI0016849 
               
               
                 342 
                 hsa-mir-125a 
                 MI0000469 
               
               
                 343 
                 hsa-mir-1469 
                 MI0007074 
               
               
                 344 
                 hsa-mir-1228 
                 MI0006318 
               
               
                 345 
                 hsa-mir-6798 
                 MI0022643 
               
               
                 346 
                 hsa-mir-1268b 
                 MI0016748 
               
               
                 347 
                 hsa-mir-6732 
                 MI0022577 
               
               
                 348 
                 hsa-mir-4433b 
                 MI0025511 
               
               
                 349 
                 hsa-mir-1207 
                 MI0006340 
               
               
                 350 
                 hsa-mir-4433 
                 MI0016773 
               
               
                 351 
                 hsa-mir-6879 
                 MI0022726 
               
               
                 352 
                 hsa-mir-4417 
                 MI0016753 
               
               
                 353 
                 hsa-mir-30c-1 
                 MI0000736 
               
               
                 354 
                 hsa-mir-4638 
                 MI0017265 
               
               
                 355 
                 hsa-mir-6088 
                 MI0020365 
               
               
                 356 
                 hsa-mir-4270 
                 MI0015878 
               
               
                 357 
                 hsa-mir-6782 
                 MI0022627 
               
               
                 358 
                 hsa-mir-665 
                 MI0005563 
               
               
                 359 
                 hsa-mir-4655 
                 MI0017283 
               
               
                 360 
                 hsa-mir-1275 
                 MI0006415 
               
               
                 361 
                 hsa-mir-6806 
                 MI0022651 
               
               
                 362 
                 hsa-mir-614 
                 MI0003627 
               
               
                 363 
                 hsa-mir-3937 
                 MI0016593 
               
               
                 364 
                 hsa-mir-6752 
                 MI0022597 
               
               
                 365 
                 hsa-mir-6771 
                 MI0022616 
               
               
                 366 
                 hsa-mir-4450 
                 MI0016795 
               
               
                 367 
                 hsa-mir-211 
                 MI0000287 
               
               
                 368 
                 hsa-mir-663a 
                 MI0003672 
               
               
                 369 
                 hsa-mir-6842 
                 MI0022688 
               
               
                 370 
                 hsa-mir-7114 
                 MI0022965 
               
               
                 371 
                 hsa-mir-6779 
                 MI0022624 
               
               
                 372 
                 isomiR example 1 of SEQ ID NO: 1 
                 — 
               
               
                 373 
                 isomiR example 2 of SEQ ID NO: 1 
                 — 
               
               
                 374 
                 isomiR example 1 of SEQ ID NO: 2 
                 — 
               
               
                 375 
                 isomiR example 2 of SEQ ID NO: 2 
                 — 
               
               
                 376 
                 isomiR example 1 of SEQ ID NO: 4 
                 — 
               
               
                 377 
                 isomiR example 2 of SEQ ID NO: 4 
                 — 
               
               
                 378 
                 isomiR example 1 of SEQ ID NO: 5 
                 — 
               
               
                 379 
                 isomiR example 2 of SEQ ID NO: 5 
                 — 
               
               
                 380 
                 isomiR example 1 of SEQ ID NO: 6 
                 — 
               
               
                 381 
                 isomiR example 2 of SEQ ID NO: 6 
                 — 
               
               
                 382 
                 isomiR example 1 of SEQ ID NO: 7 
                 — 
               
               
                 383 
                 isomiR example 2 of SEQ ID NO: 7 
                 — 
               
               
                 384 
                 isomiR example 1 of SEQ ID NO: 10 
                 — 
               
               
                 385 
                 isomiR example 2 of SEQ lD NO: 10 
                 — 
               
               
                 386 
                 isomiR example 1 of SEQ ID NO: 12 
                 — 
               
               
                 387 
                 isomiR example 2 of SEQ lD NO: 12 
                 — 
               
               
                 388 
                 isomiR example 1 of SEQ ID NO: 15 
                 — 
               
               
                 389 
                 isomiR example 2 of SEQ lD NO: 15 
                 — 
               
               
                 390 
                 isomiR example 1 of SEQ lD NO: 16 
                 — 
               
               
                 391 
                 isomiR example 2 of SEQ lD NO: 16 
                 — 
               
               
                 392 
                 isomiR example 1 of SEQ lD NO: 18 
                 — 
               
               
                 393 
                 isomiR example 2 of SEQ lD NO: 18 
                 — 
               
               
                 394 
                 isomiR example 1 of SEQ ID NO: 19 
                 — 
               
               
                 395 
                 isomiR example 2 of SEQ lD NO: 19 
                 — 
               
               
                 396 
                 isomiR example 1 of SEQ ID NO: 21 
                 — 
               
               
                 397 
                 isomiR example 2 of SEQ ID NO: 21 
                 — 
               
               
                 398 
                 isomiR example 1 of SEQ ID NO: 22 
                 — 
               
               
                 399 
                 isomiR example 2 of SEQ ID NO: 22 
                 — 
               
               
                 400 
                 isomiR example 1 of SEQ ID NO: 24 
                 — 
               
               
                 401 
                 isomiR example 2 of SEQ ID NO: 24 
                 — 
               
               
                 402 
                 isomiR example 1 of SEQ ID NO: 25 
                 — 
               
               
                 403 
                 isomiR example 2 of SEQ ID NO: 25 
                 — 
               
               
                 404 
                 isomiR example 1 of SEQ ID NO: 27 
                 — 
               
               
                 405 
                 isomiR example 2 of SEQ ID NO: 27 
                 — 
               
               
                 406 
                 isomiR example 1 of SEQ ID NO: 30 
                 — 
               
               
                 407 
                 isomiR example 2 of SEQ ID NO: 30 
                 — 
               
               
                 408 
                 isomiR example 1 of SEQ ID NO: 31 
                 — 
               
               
                 409 
                 isomiR example 2 of SEQ ID NO: 31 
                 — 
               
               
                 410 
                 isomiR example 1 of SEQ ID NO: 33 
                 — 
               
               
                 411 
                 isomiR example 2 of SEQ ID NO: 33 
                 — 
               
               
                 412 
                 isomiR example 1 of SEQ ID NO: 34 
                 — 
               
               
                 413 
                 isomiR example 2 of SEQ ID NO: 34 
                 — 
               
               
                 414 
                 isomiR example 1 of SEQ ID NO: 36 
                 — 
               
               
                 415 
                 isomiR example 2 of SEQ ID NO: 36 
                 — 
               
               
                 416 
                 isomiR example 1 of SEQ ID NO: 39 
                 — 
               
               
                 417 
                 isomiR example 2 of SEQ ID NO: 39 
                 — 
               
               
                 418 
                 isomiR example 1 of SEQ ID NO: 41 
                 — 
               
               
                 419 
                 isomiR example 2 of SEQ ID NO: 41 
                 — 
               
               
                 420 
                 isomiR example 1 of SEQ ID NO: 42 
                 — 
               
               
                 421 
                 isomiR example 2 of SEQ ID NO: 42 
                 — 
               
               
                 422 
                 isomiR example 1 of SEQ ID NO: 43 
                 — 
               
               
                 423 
                 isomiR example 2 of SEQ ID NO: 43 
                 — 
               
               
                 424 
                 isomiR example 1 of SEQ ID NO: 44 
                 — 
               
               
                 425 
                 isomiR example 2 of SEQ ID NO: 44 
                 — 
               
               
                 426 
                 isomiR example 1 of SEQ ID NO: 45 
                 — 
               
               
                 427 
                 isomiR example 2 of SEQ ID NO: 45 
                 — 
               
               
                 428 
                 isomiR example 1 of SEQ ID NO: 46 
                 — 
               
               
                 429 
                 isomiR example 2 of SEQ ID NO: 46 
                 — 
               
               
                 430 
                 isomiR example 1 of SEQ ID NO: 48 
                 — 
               
               
                 431 
                 isomiR example 2 of SEQ ID NO: 48 
                 — 
               
               
                 432 
                 isomiR example 1 of SEQ ID NO: 51 
                 — 
               
               
                 433 
                 isomiR example 2 of SEQ ID NO: 51 
                 — 
               
               
                 434 
                 isomiR example 1 of SEQ ID NO: 53 
                 — 
               
               
                 435 
                 isomiR example 2 of SEQ ID NO: 53 
                 — 
               
               
                 436 
                 isomiR example 1 of SEQ ID NO: 58 
                 — 
               
               
                 437 
                 isomiR example 2 of SEQ ID NO: 58 
                 — 
               
               
                 438 
                 isomiR example 1 of SEQ ID NO: 61 
                 — 
               
               
                 439 
                 isomiR example 2 of SEQ ID NO: 61 
                 — 
               
               
                 440 
                 isomiR example 1 of SEQ ID NO: 62 
                 — 
               
               
                 441 
                 isomiR example 2 of SEQ ID NO: 62 
                 — 
               
               
                 442 
                 isomiR example 1 of SEQ ID NO: 63 
                 — 
               
               
                 443 
                 isomiR example 2 of SEQ ID NO: 63 
                 — 
               
               
                 444 
                 isomiR example 1 of SEQ ID NO: 66 
                 — 
               
               
                 445 
                 isomiR example 2 of SEQ ID NO: 66 
                 — 
               
               
                 446 
                 isomiR example 1 of SEQ ID NO: 69 
                 — 
               
               
                 447 
                 isomiR example 2 of SEQ ID NO: 69 
                 — 
               
               
                 448 
                 isomiR example 1 of SEQ ID NO: 73 
                 — 
               
               
                 449 
                 isomiR example 2 of SEQ ID NO: 73 
                 — 
               
               
                 450 
                 isomiR example 1 of SEQ ID NO: 75 
                 — 
               
               
                 451 
                 isomiR example 2 of SEQ ID NO: 75 
                 — 
               
               
                 452 
                 isomiR example 1 of SEQ ID NO: 76 
                 — 
               
               
                 453 
                 isomiR example 2 of SEQ ID NO: 76 
                 — 
               
               
                 454 
                 isomiR example 1 of SEQ ID NO: 77 
                 — 
               
               
                 455 
                 isomiR example 2 of SEQ ID NO: 77 
                 — 
               
               
                 456 
                 isomiR example 1 of SEQ ID NO: 78 
                 — 
               
               
                 457 
                 isomiR example 2 of SEQ ID NO: 78 
                 — 
               
               
                 458 
                 isomiR example 1 of SEQ ID NO: 83 
                 — 
               
               
                 459 
                 isomiR example 2 of SEQ ID NO: 83 
                 — 
               
               
                 460 
                 isomiR example 1 of SEQ ID NO: 84 
                 — 
               
               
                 461 
                 isomiR example 2 of SEQ ID NO: 84 
                 — 
               
               
                 462 
                 isomiR example 1 of SEQ ID NO: 85 
                 — 
               
               
                 463 
                 isomiR example 2 of SEQ ID NO: 85 
                 — 
               
               
                 464 
                 isomiR example 1 of SEQ ID NO: 86 
                 — 
               
               
                 465 
                 isomiR example 2 of SEQ ID NO: 86 
                 — 
               
               
                 466 
                 isomiR example 1 of SEQ ID NO: 87 
                 — 
               
               
                 467 
                 isomiR example 2 of SEQ ID NO: 87 
                 — 
               
               
                 468 
                 isomiR example 1 of SEQ ID NO: 88 
                 — 
               
               
                 469 
                 isomiR example 2 of SEQ ID NO: 88 
                 — 
               
               
                 470 
                 isomiR example 1 of SEQ ID NO: 90 
                 — 
               
               
                 471 
                 isomiR example 2 of SEQ ID NO: 90 
                 — 
               
               
                 472 
                 isomiR example 1 of SEQ ID NO: 94 
                 — 
               
               
                 473 
                 isomiR example 2 of SEQ ID NO: 94 
                 — 
               
               
                 474 
                 isomiR example 1 of SEQ ID NO: 95 
                 — 
               
               
                 475 
                 isomiR example 2 of SEQ ID NO: 95 
                 — 
               
               
                 476 
                 isomiR example 1 of SEQ ID NO: 96 
                 — 
               
               
                 477 
                 isomiR example 2 of SEQ ID NO: 96 
                 — 
               
               
                 478 
                 isomiR example 1 of SEQ ID NO: 98 
                 — 
               
               
                 479 
                 isomiR example 2 of SEQ ID NO: 98 
                 — 
               
               
                 480 
                 isomiR example 1 of SEQ ID NO: 100 
                 — 
               
               
                 481 
                 isomiR example 2 of SEQ ID NO: 100 
                 — 
               
               
                 482 
                 isomiR example 1 of SEQ ID NO: 102 
                 — 
               
               
                 483 
                 isomiR example 2 of SEQ ID NO: 102 
                 — 
               
               
                 484 
                 isomiR example 1 of SEQ ID NO: 103 
                 — 
               
               
                 485 
                 isomiR example 2 of SEQ ID NO: 103 
                 — 
               
               
                 486 
                 isomiR example 1 of SEQ ID NO: 104 
                 — 
               
               
                 487 
                 isomiR example 2 of SEQ ID NO: 104 
                 — 
               
               
                 488 
                 isomiR example 1 of SEQ ID NO: 105 
                 — 
               
               
                 489 
                 isomiR example 2 of SEQ ID NO: 105 
                 — 
               
               
                 490 
                 isomiR example 1 of SEQ ID NO: 106 
                 — 
               
               
                 491 
                 isomiR example 2 of SEQ ID NO: 106 
                 — 
               
               
                 492 
                 isomiR example 1 of SEQ ID NO: 107 
                 — 
               
               
                 493 
                 isomiR example 2 of SEQ ID NO: 107 
                 — 
               
               
                 494 
                 isomiR example 1 of SEQ ID NO: 108 
                 — 
               
               
                 495 
                 isomiR example 2 of SEQ ID NO: 108 
                 — 
               
               
                 496 
                 isomiR example 1 of SEQ ID NO: 109 
                 — 
               
               
                 497 
                 isomiR example 2 of SEQ ID NO: 109 
                 — 
               
               
                 498 
                 isomiR example 1 of SEQ ID NO: 111 
                 — 
               
               
                 499 
                 isomiR example 2 of SEQ ID NO: 111 
                 — 
               
               
                 500 
                 isomiR example 1 of SEQ ID NO: 115 
                 — 
               
               
                 501 
                 isomiR example 2 of SEQ ID NO: 115 
                 — 
               
               
                 502 
                 isomiR example 1 of SEQ ID NO: 117 
                 — 
               
               
                 503 
                 isomiR example 2 of SEQ ID NO: 117 
                 — 
               
               
                 504 
                 isomiR example 1 of SEQ ID NO: 119 
                 — 
               
               
                 505 
                 isomiR example 2 of SEQ ID NO: 119 
                 — 
               
               
                 506 
                 isomiR example 1 of SEQ ID NO: 120 
                 — 
               
               
                 507 
                 isomiR example 2 of SEQ ID NO: 120 
                 — 
               
               
                 508 
                 isomiR example 1 of SEQ ID NO: 123 
                 — 
               
               
                 509 
                 isomiR example 2 of SEQ ID NO: 123 
                 — 
               
               
                 510 
                 isomiR example 1 of SEQ ID NO: 124 
                 — 
               
               
                 511 
                 isomiR example 2 of SEQ ID NO: 124 
                 — 
               
               
                 512 
                 isomiR example 1 of SEQ ID NO: 125 
                 — 
               
               
                 513 
                 isomiR example 2 of SEQ ID NO: 125 
                 — 
               
               
                 514 
                 isomiR example 1 of SEQ ID NO: 126 
                 — 
               
               
                 515 
                 isomiR example 2 of SEQ ID NO: 126 
                 — 
               
               
                 516 
                 isomiR example 1 of SEQ ID NO: 127 
                 — 
               
               
                 517 
                 isomiR example 2 of SEQ ID NO: 127 
                 — 
               
               
                 518 
                 isomiR example 1 of SEQ ID NO: 128 
                 — 
               
               
                 519 
                 isomiR example 2 of SEQ ID NO: 128 
                 — 
               
               
                 520 
                 isomiR example 1 of SEQ ID NO: 131 
                 — 
               
               
                 521 
                 isomiR example 2 of SEQ ID NO: 131 
                 — 
               
               
                 522 
                 isomiR example 1 of SEQ ID NO: 136 
                 — 
               
               
                 523 
                 isomiR example 2 of SEQ ID NO: 136 
                 — 
               
               
                 524 
                 isomiR example 1 of SEQ ID NO: 137 
                 — 
               
               
                 525 
                 isomiR example 2 of SEQ ID NO: 137 
                 — 
               
               
                 526 
                 isomiR example 1 of SEQ ID NO: 139 
                 — 
               
               
                 527 
                 isomiR example 2 of SEQ ID NO: 139 
                 — 
               
               
                 528 
                 isomiR example 1 of SEQ ID NO: 140 
                 — 
               
               
                 529 
                 isomiR example 2 of SEQ ID NO: 140 
                 — 
               
               
                 530 
                 isomiR example 1 of SEQ ID NO: 143 
                 — 
               
               
                 531 
                 isomiR example 2 of SEQ ID NO: 143 
                 — 
               
               
                 532 
                 isomiR example 1 of SEQ ID NO: 144 
                 — 
               
               
                 533 
                 isomiR example 2 of SEQ ID NO: 144 
                 — 
               
               
                 534 
                 isomiR example 1 of SEQ ID NO: 147 
                 — 
               
               
                 535 
                 isomiR example 2 of SEQ ID NO: 147 
                 — 
               
               
                 536 
                 isomiR example 1 of SEQ ID NO: 149 
                 — 
               
               
                 537 
                 isomiR example 2 of SEQ ID NO: 149 
                 — 
               
               
                 538 
                 isomiR example 1 of SEQ ID NO: 151 
                 — 
               
               
                 539 
                 isomiR example 2 of SEQ ID NO: 151 
                 — 
               
               
                 540 
                 isomiR example 1 of SEQ ID NO: 153 
                 — 
               
               
                 541 
                 isomiR example 2 of SEQ ID NO: 153 
                 — 
               
               
                 542 
                 isomiR example 1 of SEQ ID NO: 154 
                 — 
               
               
                 543 
                 isomiR example 2 of SEQ ID NO: 154 
                 — 
               
               
                 544 
                 isomiR example 1 of SEQ ID NO: 155 
                 — 
               
               
                 545 
                 isomiR example 2 of SEQ ID NO: 155 
                 — 
               
               
                 546 
                 isomiR example 1 of SEQ ID NO: 156 
                 — 
               
               
                 547 
                 isomiR example 2 of SEQ ID NO: 156 
                 — 
               
               
                 548 
                 isomiR example 1 of SEQ ID NO: 158 
                 — 
               
               
                 549 
                 isomiR example 2 of SEQ ID NO: 158 
                 — 
               
               
                 550 
                 isomiR example 1 of SEQ ID NO: 160 
                 — 
               
               
                 551 
                 isomiR example 2 of SEQ ID NO: 160 
                 — 
               
               
                 552 
                 isomiR example 1 of SEQ ID NO: 162 
                 — 
               
               
                 553 
                 isomiR example 2 of SEQ ID NO: 162 
                 — 
               
               
                 554 
                 isomiR example 1 of SEQ ID NO: 165 
                 — 
               
               
                 555 
                 isomiR example 2 of SEQ ID NO: 165 
                 — 
               
               
                 556 
                 isomiR example 1 of SEQ ID NO: 167 
                 — 
               
               
                 557 
                 isomiR example 2 of SEQ ID NO: 167 
                 — 
               
               
                 558 
                 isomiR example 1 of SEQ ID NO: 168 
                 — 
               
               
                 559 
                 isomiR example 2 of SEQ ID NO: 168 
                 — 
               
               
                 560 
                 isomiR example 1 of SEQ ID NO: 169 
                 — 
               
               
                 561 
                 isomiR example 2 of SEQ ID NO: 169 
                 — 
               
               
                 562 
                 isomiR example 1 of SEQ ID NO: 170 
                 — 
               
               
                 563 
                 isomiR example 2 of SEQ ID NO: 170 
                 — 
               
               
                 564 
                 isomiR example 1 of SEQ ID NO: 173 
                 — 
               
               
                 565 
                 isomiR example 2 of SEQ ID NO: 173 
                 — 
               
               
                 566 
                 isomiR example 1 of SEQ ID NO: 174 
                 — 
               
               
                 567 
                 isomiR example 2 of SEQ ID NO: 174 
                 — 
               
               
                 568 
                 isomiR example 1 of SEQ ID NO: 175 
                 — 
               
               
                 569 
                 isomiR example 2 of SEQ ID NO: 175 
                 — 
               
               
                 570 
                 isomiR example 1 of SEQ ID NO: 176 
                 — 
               
               
                 571 
                 isomiR example 2 of SEQ ID NO: 176 
                 — 
               
               
                 572 
                 isomiR example 1 of SEQ ID NO: 178 
                 — 
               
               
                 573 
                 isomiR example 2 of SEQ ID NO: 178 
                 — 
               
               
                 574 
                 isomiR example 1 of SEQ ID NO: 182 
                 — 
               
               
                 575 
                 isomiR example 2 of SEQ ID NO: 182 
                 — 
               
               
                 576 
                 isomiR example 1 of SEQ ID NO: 183 
                 — 
               
               
                 577 
                 isomiR example 2 of SEQ ID NO: 183 
                 — 
               
               
                 578 
                 isomiR example 1 of SEQ ID NO: 184 
                 — 
               
               
                 579 
                 isomiR example 1 of SEQ ID NO: 184 
                 — 
               
               
                 580 
                 hsa-miR-204-3p 
                 MIMAT0022693 
               
               
                 581 
                 hsa-miR-642a-3p 
                 MIMAT0020924 
               
               
                 582 
                 hsa-miR-762 
                 MIMAT0010313 
               
               
                 583 
                 hsa-miR-1202 
                 MIMAT0005865 
               
               
                 584 
                 hsa-miR-3162-5p 
                 MIMAT0015036 
               
               
                 585 
                 hsa-miR-3196 
                 MIMAT0015080 
               
               
                 586 
                 hsa-miR-3622a-5p 
                 MIMAT0018003 
               
               
                 587 
                 hsa-miR-3665 
                 MIMAT0018087 
               
               
                 588 
                 hsa-miR-3940-5p 
                 MIMAT0019229 
               
               
                 589 
                 hsa-miR-4294 
                 MIMAT0016849 
               
               
                 590 
                 hsa-miR-4466 
                 MIMAT0018993 
               
               
                 591 
                 hsa-miR-4476 
                 MIMAT0019003 
               
               
                 592 
                 hsa-miR-4723-5p 
                 MIMAT0019838 
               
               
                 593 
                 hsa-miR-4725-3p 
                 MIMAT0019844 
               
               
                 594 
                 hsa-miR-4730 
                 MIMAT0019852 
               
               
                 595 
                 hsa-miR-4739 
                 MIMAT0019868 
               
               
                 596 
                 hsa-miR-4787-5p 
                 MIMAT0019956 
               
               
                 597 
                 hsa-miR-5787 
                 MIMAT0023252 
               
               
                 598 
                 hsa-miR-6085 
                 MIMAT0023710 
               
               
                 599 
                 hsa-miR-6717-5p 
                 MIMAT0025846 
               
               
                 600 
                 hsa-miR-6724-5p 
                 MIMAT0025856 
               
               
                 601 
                 hsa-miR-6777-5p 
                 MIMAT0027454 
               
               
                 602 
                 hsa-miR-6778-5p 
                 MIMAT0027456 
               
               
                 603 
                 hsa-miR-6787-5p 
                 MIMAT0027474 
               
               
                 604 
                 hsa-miR-6789-5p 
                 MIMAT0027478 
               
               
                 605 
                 hsa-miR-6845-5p 
                 MIMAT0027590 
               
               
                 606 
                 hsa-miR-6893-5p 
                 MIMAT0027686 
               
               
                 607 
                 hsa-miR-16-5p 
                 MIMAT0000069 
               
               
                 608 
                 hsa-miR-423-5p 
                 MIMAT0004748 
               
               
                 609 
                 hsa-miR-451a 
                 MIMAT0001631 
               
               
                 610 
                 hsa-miR-564 
                 MIMAT0003228 
               
               
                 611 
                 hsa-miR-671-5p 
                 MIMAT0003880 
               
               
                 612 
                 hsa-mir-204 
                 MI0000284 
               
               
                 613 
                 hsa-mir-642a 
                 MI0003657 
               
               
                 614 
                 hsa-mir-762 
                 MI0003892 
               
               
                 615 
                 hsa-mir-1202 
                 MI0006334 
               
               
                 616 
                 hsa-mir-3162 
                 MI0014192 
               
               
                 617 
                 hsa-mir-3196 
                 MI0014241 
               
               
                 618 
                 hsa-mir-3622a 
                 MI0016013 
               
               
                 619 
                 hsa-mir-3665 
                 MI0016066 
               
               
                 620 
                 hsa-mir-3940 
                 MI0016597 
               
               
                 621 
                 hsa-mir-4294 
                 MI0015827 
               
               
                 622 
                 hsa-mir-4466 
                 MI0016817 
               
               
                 623 
                 hsa-mir-4476 
                 MI0016828 
               
               
                 624 
                 hsa-mir-4723 
                 MI0017359 
               
               
                 625 
                 hsa-mir-4725 
                 MI0017362 
               
               
                 626 
                 hsa-mir-4730 
                 MI0017367 
               
               
                 627 
                 hsa-mir-4739 
                 MI0017377 
               
               
                 628 
                 hsa-mir-4787 
                 MI0017434 
               
               
                 629 
                 hsa-mir-5787 
                 MI0019797 
               
               
                 630 
                 hsa-mir-6085 
                 MI0020362 
               
               
                 631 
                 hsa-mir-6717 
                 MI0022551 
               
               
                 632 
                 hsa-mir-6724 
                 MI0022559 
               
               
                 633 
                 hsa-mir-6777 
                 MI0022622 
               
               
                 634 
                 hsa-mir-6778 
                 MI0022623 
               
               
                 635 
                 hsa-mir-6787 
                 MI0022632 
               
               
                 636 
                 hsa-mir-6789 
                 MI0022634 
               
               
                 637 
                 hsa-mir-6845 
                 MI0022691 
               
               
                 638 
                 hsa-mir-6893 
                 MI0022740 
               
               
                 639 
                 hsa-mir-16-1 
                 MI0000070 
               
               
                 640 
                 hsa-mir-16-2 
                 MI0000115 
               
               
                 641 
                 hsa-mir-423 
                 MI0001445 
               
               
                 642 
                 hsa-mir-451a 
                 MI0001729 
               
               
                 643 
                 hsa-mir-564 
                 MI0003570 
               
               
                 644 
                 hsa-mir-671 
                 MI0003760 
               
               
                 645 
                 isomiR example 1 of SEQ ID NO: 580 
                 — 
               
               
                 646 
                 isomiR example 2 of SEQ ID NO: 580 
                 — 
               
               
                 647 
                 isomiR example 1 of SEQ ID NO: 581 
                 — 
               
               
                 648 
                 isomiR example 2 of SEQ ID NO: 581 
                 — 
               
               
                 649 
                 isomiR example 1 of SEQ ID NO: 583 
                 — 
               
               
                 650 
                 isomiR example 1 of SEQ ID NO: 584 
                 — 
               
               
                 651 
                 isomiR example 2 of SEQ ID NO: 584 
                 — 
               
               
                 652 
                 isomiR example 1 of SEQ ID NO: 585 
                 — 
               
               
                 653 
                 isomiR example 2 of SEQ ID NO: 585 
                 — 
               
               
                 654 
                 isomiR example 1 of SEQ ID NO: 586 
                 — 
               
               
                 655 
                 isomiR example 1 of SEQ ID NO: 587 
                 — 
               
               
                 656 
                 isomiR example 2 of SEQ ID NO: 587 
                 — 
               
               
                 657 
                 isomiR example 1 of SEQ ID NO: 588 
                 — 
               
               
                 658 
                 isomiR example 2 of SEQ ID NO: 588 
                 — 
               
               
                 659 
                 isomiR example 1 of SEQ ID NO: 590 
                 — 
               
               
                 660 
                 isomiR example 2 of SEQ ID NO: 590 
                 — 
               
               
                 661 
                 isomiR example 1 of SEQ ID NO: 591 
                 — 
               
               
                 662 
                 isomiR example 2 of SEQ ID NO: 591 
                 — 
               
               
                 663 
                 isomiR example 1 of SEQ ID NO: 592 
                 — 
               
               
                 664 
                 isomiR example 2 of SEQ ID NO: 592 
                 — 
               
               
                 665 
                 isomiR example 1 of SEQ ID NO: 593 
                 — 
               
               
                 666 
                 isomiR example 2 of SEQ ID NO: 593 
                 — 
               
               
                 667 
                 isomiR example 1 of SEQ ID NO: 594 
                 — 
               
               
                 668 
                 isomiR example 2 of SEQ ID NO: 594 
                 — 
               
               
                 669 
                 isomiR example 1 of SEQ ID NO: 595 
                 — 
               
               
                 670 
                 isomiR example 2 of SEQ ID NO: 595 
                 — 
               
               
                 671 
                 isomiR example 1 of SEQ ID NO: 597 
                 — 
               
               
                 672 
                 isomiR example 2 of SEQ ID NO: 597 
                 — 
               
               
                 673 
                 isomiR example 1 of SEQ ID NO: 599 
                 — 
               
               
                 674 
                 isomiR example 2 of SEQ ID NO: 599 
                 — 
               
               
                 675 
                 isomiR example 1 of SEQ ID NO: 600 
                 — 
               
               
                 676 
                 isomiR example 2 of SEQ ID NO: 600 
                 — 
               
               
                 677 
                 isomiR example 1 of SEQ ID NO: 607 
                 — 
               
               
                 678 
                 isomiR example 2 of SEQ ID NO: 607 
                 — 
               
               
                 679 
                 isomiR example 1 of SEQ ID NO: 608 
                 — 
               
               
                 680 
                 isomiR example 2 of SEQ ID NO: 608 
                 — 
               
               
                 681 
                 isomiR example 1 of SEQ ID NO: 609 
                 — 
               
               
                 682 
                 isomiR example 2 of SEQ ID NO: 609 
                 — 
               
               
                 683 
                 isomiR example 1 of SEQ ID NO: 611 
                 — 
               
               
                 684 
                 isomiR example 2 of SEQ ID NO: 611 
                 — 
               
               
                   
               
            
           
         
       
     
     The present application claims the priority of Japanese Patent Application No. 2014-121377 filed on Jun. 12, 2014 and Japanese Patent Application No. 2015-71756 filed on Mar. 31, 2015, and encompasses the contents described in the specifications of these patent applications. 
     Advantageous Effects of Invention 
     According to the present invention, prostate cancer can be detected easily and highly accurately. For example, the presence or absence of prostate cancer in a patient can be easily detected by using, as an index, the measurement values of several miRNAs in blood, serum, and/or plasma of the patient, which can be collected with limited invasiveness. 
    
    
     
       BRIEF DESCRIPTION OF DRAWINGS 
         FIG.  1    This figure shows the relationship between the nucleotide sequences of hsa-miR-1343-3p represented by SEQ ID NO: 7 and hsa-miR-1343-5p represented by SEQ ID NO: 9, which are formed from a precursor hsa-mir-1343 represented by SEQ ID NO: 194. 
         FIG.  2    Left diagram: the measurement values of hsa-miR-4443 (SEQ ID NO: 1) in healthy subjects (100 persons) and in prostate cancer patients (35 persons) selected as the training cohort were each plotted on the ordinate. The horizontal line in the diagram depicts a threshold (6.84) that was optimized by Fisher&#39;s linear discriminant analysis and discriminated between the two groups. Right diagram: the measurement values of hsa-miR-4443 (SEQ ID NO: 1) in healthy subjects (50 persons) and in prostate cancer patients (17 persons) selected as the validation cohort were each plotted on the ordinate. The horizontal line in the diagram depicts the threshold (6.84) that was set in the training cohort and discriminated between the two groups. 
         FIG.  3    Left diagram: the measurement values of hsa-miR-4443 (SEQ ID NO: 1) in healthy subjects (100 persons, circles) and in prostate cancer patients (35 persons, triangles) selected as the training cohort were each plotted on the abscissa against their measurement values of hsa-miR-1908-5p (SEQ ID NO: 2) on the ordinate. The line in the diagram depicts a discriminant function (0=1.15x+y+19.53) that was optimized by Fisher&#39;s linear discriminant analysis and discriminated between the two groups. Right diagram: the measurement values of hsa-miR-4443 (SEQ ID NO: 1) in healthy subjects (50 persons, circles) and in prostate cancer patients (17 persons, triangles) selected as the validation cohort were each plotted on the abscissa against their measurement values of hsa-miR-1908-5p (SEQ ID NO: 2) on the ordinate. The line in the diagram depicts the threshold (0=1.15x+y+19.53) that was set in the training cohort and discriminated between the two groups. 
         FIG.  4    Upper diagram: a discriminant (1.34×miR-92a-2-5p+1.56×miR-6820-5p−1.29×miR-4745-5p−0.76×miR-125a-3p−4.31) was prepared by use of Fisher&#39;s linear discriminant analysis from the measurement values of hsa-miR-4745-5p (SEQ ID NO: 12), hsa-miR-92a-2-5p (SEQ ID NO: 16), hsa-miR-6820-5p (SEQ ID NO: 135), and hsa-miR-125a-3p (SEQ ID NO: 156) in 35 prostate cancer patients, 99 healthy subjects, and 63 breast cancer patients selected as the training cohort, and discriminant scores obtained from the discriminant were plotted on the ordinate against the sample groups on the abscissa. The dotted line in the diagram depicts a discriminant boundary that offered a discriminant score of 0 and discriminated between the groups. Lower diagram: discriminant scores obtained from the discriminant prepared in the training cohort as to the measurement values of hsa-miR-4745-5p (SEQ ID NO: 12), hsa-miR-92a-2-5p (SEQ ID NO: 16), hsa-miR-6820-5p (SEQ ID NO: 135), and hsa-miR-125a-3p (SEQ ID NO: 156) in 17 prostate cancer patients, 51 healthy subjects, and 30 breast cancer patients selected as the validation cohort were plotted on the ordinate against the sample groups on the abscissa. The dotted line in the diagram depicts the discriminant boundary that offered a discriminant score of 0 and discriminated between the two groups. 
     
    
    
     DESCRIPTION OF EMBODIMENTS 
     Hereinafter, the present invention will be described further specifically. 
     1. Target Nucleic Acid for Prostate Cancer 
     A primary target nucleic acid as a prostate cancer marker for detecting the presence and/or absence of prostate cancer or prostate cancer cells using the nucleic acid probe or the primer for the detection of prostate cancer defined above according to the present invention comprises at least one or more miRNA(s) selected from the group consisting of hsa-miR-4443, hsa-miR-1908-5p, hsa-miR-4257, hsa-miR-3197, hsa-miR-3188, hsa-miR-4649-5p, hsa-miR-1343-3p, hsa-miR-6861-5p, hsa-miR-1343-5p, hsa-miR-642b-3p, hsa-miR-6741-5p, hsa-miR-4745-5p, hsa-miR-6826-5p, hsa-miR-3663-3p, hsa-miR-3131, hsa-miR-92a-2-5p, hsa-miR-4258, hsa-miR-4448, hsa-miR-6125, hsa-miR-6880-5p, hsa-miR-6132, hsa-miR-4467, hsa-miR-6749-5p, hsa-miR-2392, hsa-miR-1273g-3p, hsa-miR-4746-3p, hsa-miR-1914-3p, hsa-miR-7845-5p, hsa-miR-6726-5p, hsa-miR-128-2-5p, hsa-miR-4651, hsa-miR-6765-3p, hsa-miR-3185, hsa-miR-4792, hsa-miR-6887-5p, hsa-miR-5572, hsa-miR-3619-3p, hsa-miR-6780b-5p, hsa-miR-4707-5p, hsa-miR-8063, hsa-miR-4454, hsa-miR-4525, hsa-miR-7975, hsa-miR-744-5p, hsa-miR-3135b, hsa-miR-4648, hsa-miR-6816-5p, hsa-miR-4741, hsa-miR-7150, hsa-miR-6791-5p, hsa-miR-1247-3p, hsa-miR-7977, hsa-miR-4497, hsa-miR-6090, hsa-miR-6781-5p, hsa-miR-6870-5p, hsa-miR-6729-5p, hsa-miR-4530, hsa-miR-7847-3p, hsa-miR-6825-5p, hsa-miR-4674, hsa-miR-3917, hsa-miR-4707-3p, hsa-miR-6885-5p, hsa-miR-6722-3p, hsa-miR-4516, hsa-miR-6757-5p, hsa-miR-6840-3p, hsa-miR-5195-3p, hsa-miR-6756-5p, hsa-miR-6800-5p, hsa-miR-6727-5p, hsa-miR-6126, hsa-miR-6872-3p, hsa-miR-4446-3p, hsa-miR-1268a, hsa-miR-1908-3p, hsa-miR-3679-5p, hsa-miR-4534, hsa-miR-4675, hsa-miR-7108-5p, hsa-miR-6799-5p, hsa-miR-4695-5p, hsa-miR-3178, hsa-miR-5090, hsa-miR-3180, hsa-miR-1237-5p, hsa-miR-4758-5p, hsa-miR-3184-5p, hsa-miR-4286, hsa-miR-6784-5p, hsa-miR-6768-5p, hsa-miR-6785-5p, hsa-miR-4706, hsa-miR-711, hsa-miR-1260a, hsa-miR-6746-5p, hsa-miR-6089, hsa-miR-6821-5p, hsa-miR-4667-5p, hsa-miR-8069, hsa-miR-4726-5p, hsa-miR-6124, hsa-miR-4532, hsa-miR-4486, hsa-miR-4728-5p, hsa-miR-4508, hsa-miR-128-1-5p, hsa-miR-4513, hsa-miR-6795-5p, hsa-miR-4689, hsa-miR-6763-5p, hsa-miR-8072, hsa-miR-6765-5p, hsa-miR-4419b, hsa-miR-7641, hsa-miR-3928-3p, hsa-miR-1227-5p, hsa-miR-4492, hsa-miR-296-3p, hsa-miR-6769a-5p, hsa-miR-6889-5p, hsa-miR-4632-5p, hsa-miR-4505, hsa-miR-3154, hsa-miR-3648, hsa-miR-4442, hsa-miR-3141, hsa-miR-7113-3p, hsa-miR-6819-5p, hsa-miR-3195, hsa-miR-1199-5p, hsa-miR-6738-5p, hsa-miR-4656, hsa-miR-6820-5p, hsa-miR-204-3p, hsa-miR-642a-3p, hsa-miR-762, hsa-miR-1202, hsa-miR-3162-5p, hsa-miR-3196, hsa-miR-3622a-5p, hsa-miR-3665, hsa-miR-3940-5p, hsa-miR-4294, hsa-miR-4466, hsa-miR-4476, hsa-miR-4723-5p, hsa-miR-4725-3p, hsa-miR-4730, hsa-miR-4739, hsa-miR-4787-5p, hsa-miR-5787, hsa-miR-6085, hsa-miR-6717-5p, hsa-miR-6724-5p, hsa-miR-6777-5p, hsa-miR-6778-5p, hsa-miR-6787-5p, hsa-miR-6789-5p, hsa-miR-6845-5p and hsa-miR-6893-5p. Furthermore, at least one or more miRNA(s) selected from the group consisting of other prostate cancer markers that can be combined with these miRNAs, i.e., hsa-miR-615-5p, hsa-miR-486-3p, hsa-miR-1225-3p, hsa-miR-760, hsa-miR-187-5p, hsa-miR-1203, hsa-miR-7110-5p, hsa-miR-371a-5p, hsa-miR-939-5p, hsa-miR-575, hsa-miR-92b-5p, hsa-miR-887-3p, hsa-miR-920, hsa-miR-1915-5p, hsa-miR-1231, hsa-miR-663b, hsa-miR-1225-5p, hsa-miR-16-5p, hsa-miR-423-5p, hsa-miR-451a, hsa-miR-564 and hsa-miR-671-5p can also be preferably used as a target nucleic acid(s). Moreover, at least one or more miRNA(s) selected from the group consisting of other prostate cancer markers that can be combined with these miRNAs, i.e., hsa-miR-4763-3p, hsa-miR-3656, hsa-miR-4488, hsa-miR-125a-3p, hsa-miR-1469, hsa-miR-1228-5p, hsa-miR-6798-5p, hsa-miR-1268b, hsa-miR-6732-5p, hsa-miR-1915-3p, hsa-miR-4433b-3p, hsa-miR-1207-5p, hsa-miR-4433-3p, hsa-miR-6879-5p, hsa-miR-4417, hsa-miR-30c-1-3p, hsa-miR-4638-5p, hsa-miR-6088, hsa-miR-4270, hsa-miR-6782-5p, hsa-miR-665, hsa-miR-486-5p, hsa-miR-4655-5p, hsa-miR-1275, hsa-miR-6806-5p, hsa-miR-614, hsa-miR-3937, hsa-miR-6752-5p, hsa-miR-6771-5p, hsa-miR-4450, hsa-miR-211-3p, hsa-miR-663a, hsa-miR-6842-5p, hsa-miR-7114-5p and hsa-miR-6779-5p can also be preferably used as a target nucleic acid(s). 
     These miRNAs include, for example, a human gene comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 187 and 580 to 611 (i.e., hsa-miR-4443, hsa-miR-1908-5p, hsa-miR-4257, hsa-miR-3197, hsa-miR-3188, hsa-miR-4649-5p, hsa-miR-1343-3p, hsa-miR-6861-5p, hsa-miR-1343-5p, hsa-miR-642b-3p, hsa-miR-6741-5p, hsa-miR-4745-5p, hsa-miR-6826-5p, hsa-miR-3663-3p, hsa-miR-3131, hsa-miR-92a-2-5p, hsa-miR-4258, hsa-miR-4448, hsa-miR-6125, hsa-miR-6880-5p, hsa-miR-6132, hsa-miR-4467, hsa-miR-6749-5p, hsa-miR-2392, hsa-miR-1273g-3p, hsa-miR-4746-3p, hsa-miR-1914-3p, hsa-miR-7845-5p, hsa-miR-6726-5p, hsa-miR-128-2-5p, hsa-miR-4651, hsa-miR-6765-3p, hsa-miR-3185, hsa-miR-4792, hsa-miR-6887-5p, hsa-miR-5572, hsa-miR-3619-3p, hsa-miR-6780b-5p, hsa-miR-4707-5p, hsa-miR-8063, hsa-miR-4454, hsa-miR-4525, hsa-miR-7975, hsa-miR-744-5p, hsa-miR-3135b, hsa-miR-4648, hsa-miR-6816-5p, hsa-miR-4741, hsa-miR-7150, hsa-miR-6791-5p, hsa-miR-1247-3p, hsa-miR-7977, hsa-miR-4497, hsa-miR-6090, hsa-miR-6781-5p, hsa-miR-6870-5p, hsa-miR-6729-5p, hsa-miR-4530, hsa-miR-7847-3p, hsa-miR-6825-5p, hsa-miR-4674, hsa-miR-3917, hsa-miR-4707-3p, hsa-miR-6885-5p, hsa-miR-6722-3p, hsa-miR-4516, hsa-miR-6757-5p, hsa-miR-6840-3p, hsa-miR-5195-3p, hsa-miR-6756-5p, hsa-miR-6800-5p, hsa-miR-6727-5p, hsa-miR-6126, hsa-miR-6872-3p, hsa-miR-4446-3p, hsa-miR-1268a, hsa-miR-1908-3p, hsa-miR-3679-5p, hsa-miR-4534, hsa-miR-4675, hsa-miR-7108-5p, hsa-miR-6799-5p, hsa-miR-4695-5p, hsa-miR-3178, hsa-miR-5090, hsa-miR-3180, hsa-miR-1237-5p, hsa-miR-4758-5p, hsa-miR-3184-5p, hsa-miR-4286, hsa-miR-6784-5p, hsa-miR-6768-5p, hsa-miR-6785-5p, hsa-miR-4706, hsa-miR-711, hsa-miR-1260a, hsa-miR-6746-5p, hsa-miR-6089, hsa-miR-6821-5p, hsa-miR-4667-5p, hsa-miR-8069, hsa-miR-4726-5p, hsa-miR-6124, hsa-miR-4532, hsa-miR-4486, hsa-miR-4728-5p, hsa-miR-4508, hsa-miR-128-1-5p, hsa-miR-4513, hsa-miR-6795-5p, hsa-miR-4689, hsa-miR-6763-5p, hsa-miR-8072, hsa-miR-6765-5p, hsa-miR-4419b, hsa-miR-7641, hsa-miR-3928-3p, hsa-miR-1227-5p, hsa-miR-4492, hsa-miR-296-3p, hsa-miR-6769a-5p, hsa-miR-6889-5p, hsa-miR-4632-5p, hsa-miR-4505, hsa-miR-3154, hsa-miR-3648, hsa-miR-4442, hsa-miR-3141, hsa-miR-7113-3p, hsa-miR-6819-5p, hsa-miR-3195, hsa-miR-1199-5p, hsa-miR-6738-5p, hsa-miR-4656, hsa-miR-6820-5p, hsa-miR-204-3p, hsa-miR-642a-3p, hsa-miR-762, hsa-miR-1202, hsa-miR-3162-5p, hsa-miR-3196, hsa-miR-3622a-5p, hsa-miR-3665, hsa-miR-3940-5p, hsa-miR-4294, hsa-miR-4466, hsa-miR-4476, hsa-miR-4723-5p, hsa-miR-4725-3p, hsa-miR-4730, hsa-miR-4739, hsa-miR-4787-5p, hsa-miR-5787, hsa-miR-6085, hsa-miR-6717-5p, hsa-miR-6724-5p, hsa-miR-6777-5p, hsa-miR-6778-5p, hsa-miR-6787-5p, hsa-miR-6789-5p, hsa-miR-6845-5p and hsa-miR-6893-5p, hsa-miR-615-5p, hsa-miR-486-3p, hsa-miR-1225-3p, hsa-miR-760, hsa-miR-187-5p, hsa-miR-1203, hsa-miR-7110-5p, hsa-miR-371a-5p, hsa-miR-939-5p, hsa-miR-575, hsa-miR-92b-5p, hsa-miR-887-3p, hsa-miR-920, hsa-miR-1915-5p, hsa-miR-1231, hsa-miR-663b, hsa-miR-1225-5p, hsa-miR-16-5p, hsa-miR-423-5p, hsa-miR-451a, hsa-miR-564 and hsa-miR-671-5p, hsa-miR-4763-3p, hsa-miR-3656, hsa-miR-4488, hsa-miR-125a-3p, hsa-miR-1469, hsa-miR-1228-5p, hsa-miR-6798-5p, hsa-miR-1268b, hsa-miR-6732-5p, hsa-miR-1915-3p, hsa-miR-4433b-3p, hsa-miR-1207-5p, hsa-miR-4433-3p, hsa-miR-6879-5p, hsa-miR-4417, hsa-miR-30c-1-3p, hsa-miR-4638-5p, hsa-miR-6088, hsa-miR-4270, hsa-miR-6782-5p, hsa-miR-665, hsa-miR-486-5p, hsa-miR-4655-5p, hsa-miR-1275, hsa-miR-6806-5p, hsa-miR-614, hsa-miR-3937, hsa-miR-6752-5p, hsa-miR-6771-5p, hsa-miR-4450, hsa-miR-211-3p, hsa-miR-663a, hsa-miR-6842-5p, hsa-miR-7114-5p and hsa-miR-6779-5p, respectively), any congener thereof, any transcript thereof, and any variant or any derivative thereof. In this context, the gene, the congener, the transcript, the variant, and the derivative are as defined above. 
     The target nucleic acid is preferably a human gene comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 684 or a transcript thereof, more preferably the transcript, i.e., a miRNA or its precursor RNA (pri-miRNA or pre-miRNA). 
     The first target gene is the hsa-miR-4443 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The second target gene is the hsa-miR-1908-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The third target gene is the hsa-miR-4257 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The fourth target gene is the hsa-miR-3197 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The fifth target gene is the hsa-miR-3188 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The sixth target gene is the hsa-miR-4649-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The seventh target gene is the hsa-miR-1343-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The eighth target gene is the hsa-miR-6861-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The ninth target gene is the hsa-miR-1343-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 10th target gene is the hsa-miR-642b-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 11th target gene is the hsa-miR-6741-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 12th target gene is the hsa-miR-4745-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 13th target gene is the hsa-miR-6826-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 14th target gene is the hsa-miR-3663-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 15th target gene is the hsa-miR-3131 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 16th target gene is the hsa-miR-92a-2-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 17th target gene is the hsa-miR-4258 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 18th target gene is the hsa-miR-4448 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 19th target gene is the hsa-miR-6125 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 20th target gene is the hsa-miR-6880-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 21st target gene is the hsa-miR-6132 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 22nd target gene is the hsa-miR-4467 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 23rd target gene is the hsa-miR-6749-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 24th target gene is the hsa-miR-2392 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 25th target gene is the hsa-miR-1273g-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 26th target gene is the hsa-miR-4746-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 27th target gene is the hsa-miR-1914-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 28th target gene is the hsa-miR-7845-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 29th target gene is the hsa-miR-6726-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 30th target gene is the hsa-miR-128-2-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 31st target gene is the hsa-miR-4651 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 32nd target gene is the hsa-miR-6765-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 33rd target gene is the hsa-miR-3185 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 34th target gene is the hsa-miR-4792 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 35th target gene is the hsa-miR-6887-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 36th target gene is the hsa-miR-5572 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 37th target gene is the hsa-miR-3619-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 38th target gene is the hsa-miR-6780b-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 39th target gene is the hsa-miR-4707-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 40th target gene is the hsa-miR-8063 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 41st target gene is the hsa-miR-4454 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 42nd target gene is the hsa-miR-4525 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 43rd target gene is the hsa-miR-7975 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 44th target gene is the hsa-miR-744-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 45th target gene is the hsa-miR-3135b gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 46th target gene is the hsa-miR-4648 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 47th target gene is the hsa-miR-6816-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 48th target gene is the hsa-miR-4741 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 49th target gene is the hsa-miR-7150 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 50th target gene is the hsa-miR-6791-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 51st target gene is the hsa-miR-1247-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 52nd target gene is the hsa-miR-7977 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 53rd target gene is the hsa-miR-4497 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 54th target gene is the hsa-miR-6090 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 55th target gene is the hsa-miR-6781-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 56th target gene is the hsa-miR-6870-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 57th target gene is the hsa-miR-6729-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 58th target gene is the hsa-miR-4530 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 59th target gene is the hsa-miR-7847-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 60th target gene is the hsa-miR-6825-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 61st target gene is the hsa-miR-4674 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 62nd target gene is the hsa-miR-3917 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 63rd target gene is the hsa-miR-4707-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 64th target gene is the hsa-miR-6885-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 65th target gene is the hsa-miR-6722-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 66th target gene is the hsa-miR-4516 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 67th target gene is the hsa-miR-6757-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 68th target gene is the hsa-miR-6840-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 69th target gene is the hsa-miR-5195-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 70th target gene is the hsa-miR-6756-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 71st target gene is the hsa-miR-6800-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 72nd target gene is the hsa-miR-6727-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 73rd target gene is the hsa-miR-6126 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 74th target gene is the hsa-miR-6872-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 75th target gene is the hsa-miR-4446-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 76th target gene is the hsa-miR-1268a gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 77th target gene is the hsa-miR-1908-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 78th target gene is the hsa-miR-3679-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 79th target gene is the hsa-miR-4534 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 80th target gene is the hsa-miR-4675 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 81st target gene is the hsa-miR-7108-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 82nd target gene is the hsa-miR-6799-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 83rd target gene is the hsa-miR-4695-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 84th target gene is the hsa-miR-3178 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 85th target gene is the hsa-miR-5090 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 86th target gene is the hsa-miR-3180 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 87th target gene is the hsa-miR-1237-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 88th target gene is the hsa-miR-4758-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 89th target gene is the hsa-miR-3184-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 90th target gene is the hsa-miR-4286 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 91st target gene is the hsa-miR-6784-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 92nd target gene is the hsa-miR-6768-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 93rd target gene is the hsa-miR-6785-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 94th target gene is the hsa-miR-4706 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 95th target gene is the hsa-miR-711 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 96th target gene is the hsa-miR-1260a gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 97th target gene is the hsa-miR-6746-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 98th target gene is the hsa-miR-6089 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 99th target gene is the hsa-miR-6821-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 100th target gene is the hsa-miR-4667-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 101st target gene is the hsa-miR-8069 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 102nd target gene is the hsa-miR-4726-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 103rd target gene is the hsa-miR-6124 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 104th target gene is the hsa-miR-4532 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 105th target gene is the hsa-miR-4486 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 106th target gene is the hsa-miR-4728-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 107th target gene is the hsa-miR-4508 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 108th target gene is the hsa-miR-128-1-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 109th target gene is the hsa-miR-4513 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 110th target gene is the hsa-miR-6795-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 111th target gene is the hsa-miR-4689 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 112th target gene is the hsa-miR-6763-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 113th target gene is the hsa-miR-8072 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 114th target gene is the hsa-miR-6765-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 115th target gene is the hsa-miR-4419b gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 116th target gene is the hsa-miR-7641 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 117th target gene is the hsa-miR-3928-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 118th target gene is the hsa-miR-1227-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 119th target gene is the hsa-miR-4492 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 120th target gene is the hsa-miR-296-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 121st target gene is the hsa-miR-6769a-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 122nd target gene is the hsa-miR-6889-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 123rd target gene is the hsa-miR-4632-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 124th target gene is the hsa-miR-4505 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 125th target gene is the hsa-miR-3154 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 126th target gene is the hsa-miR-3648 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 127th target gene is the hsa-miR-4442 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 128th target gene is the hsa-miR-3141 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 129th target gene is the hsa-miR-7113-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 130th target gene is the hsa-miR-6819-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 131st target gene is the hsa-miR-3195 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 132nd target gene is the hsa-miR-1199-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 133rd target gene is the hsa-miR-6738-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 134th target gene is the hsa-miR-4656 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 135th target gene is the hsa-miR-6820-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 136th target gene is the hsa-miR-615-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 137th target gene is the hsa-miR-486-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 138th target gene is the hsa-miR-1225-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 139th target gene is the hsa-miR-760 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 140th target gene is the hsa-miR-187-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 141st target gene is the hsa-miR-1203 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 142nd target gene is the hsa-miR-7110-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 143rd target gene is the hsa-miR-371a-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 144th target gene is the hsa-miR-939-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 145th target gene is the hsa-miR-575 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 146th target gene is the hsa-miR-92b-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 2). 
     The 147th target gene is the hsa-miR-887-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 148th target gene is the hsa-miR-920 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 149th target gene is the hsa-miR-1915-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 150th target gene is the hsa-miR-1231 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 151st target gene is the hsa-miR-663b gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 152nd target gene is the hsa-miR-1225-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 153rd target gene is the hsa-miR-4763-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 154th target gene is the hsa-miR-3656 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 155th target gene is the hsa-miR-4488 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 156th target gene is the hsa-miR-125a-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 157th target gene is the hsa-miR-1469 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 158th target gene is the hsa-miR-1228-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 159th target gene is the hsa-miR-6798-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 160th target gene is the hsa-miR-1268b gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 161st target gene is the hsa-miR-6732-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 162nd target gene is the hsa-miR-1915-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 163rd target gene is the hsa-miR-4433b-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 164th target gene is the hsa-miR-1207-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 165th target gene is the hsa-miR-4433-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 166th target gene is the hsa-miR-6879-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 167th target gene is the hsa-miR-4417 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 168th target gene is the hsa-miR-30c-1-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 169th target gene is the hsa-miR-4638-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 170th target gene is the hsa-miR-6088 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 171st target gene is the hsa-miR-4270 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 172nd target gene is the hsa-miR-6782-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 173rd target gene is the hsa-miR-665 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 174th target gene is the hsa-miR-486-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 175th target gene is the hsa-miR-4655-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 176th target gene is the hsa-miR-1275 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 177th target gene is the hsa-miR-6806-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 178th target gene is the hsa-miR-614 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 179th target gene is the hsa-miR-3937 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 180th target gene is the hsa-miR-6752-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 181st target gene is the hsa-miR-6771-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 182nd target gene is the hsa-miR-4450 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 183rd target gene is the hsa-miR-211-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 184th target gene is the hsa-miR-663a gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 1). 
     The 185th target gene is the hsa-miR-6842-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 186th target gene is the hsa-miR-7114-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 187th target gene is the hsa-miR-6779-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 580th target gene is the hsa-miR-204-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 581st target gene is the hsa-miR-642a-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 582nd target gene is the hsa-miR-762 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 583rd target gene is the hsa-miR-1202 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 584th target gene is the hsa-miR-3162-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 585th target gene is the hsa-miR-3196 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 586th target gene is the hsa-miR-3622a-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 587th target gene is the hsa-miR-3665 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 588th target gene is the hsa-miR-3940-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 589th target gene is the hsa-miR-4294 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 590th target gene is the hsa-miR-4466 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 591st target gene is the hsa-miR-4476 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 592nd target gene is the hsa-miR-4723-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 593rd target gene is the hsa-miR-4725-3p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 594th target gene is the hsa-miR-4730 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 595th target gene is the hsa-miR-4739 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 596th target gene is the hsa-miR-4787-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 597th target gene is the hsa-miR-5787 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 598th target gene is the hsa-miR-6085 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 599th target gene is the hsa-miR-6717-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 600th target gene is the hsa-miR-6724-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 601st target gene is the hsa-miR-6777-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 602nd target gene is the hsa-miR-6778-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 603rd target gene is the hsa-miR-6787-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 604th target gene is the hsa-miR-6789-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 605th target gene is the hsa-miR-6845-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 606th target gene is the hsa-miR-6893-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. None of the previously known reports show that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer. 
     The 607th target gene is the hsa-miR-16-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 2). 
     The 608th target gene is the hsa-miR-423-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 2). 
     The 609th target gene is the hsa-miR-451a gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 2). 
     The 610th target gene is the hsa-miR-564 gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 2). 
     The 611th target gene is the hsa-miR-671-5p gene, a congener thereof, a transcript thereof, or a variant or a derivative thereof. The previously known report shows that change in the expression of the gene or the transcript thereof can serve as a marker for prostate cancer (Patent Literature 2). 
     2. Nucleic Acid Probe or Primer for Detection of Prostate Cancer 
     In the present invention, a nucleic acid capable of specifically binding to any of the target nucleic acids as the prostate cancer markers described above can be used as a nucleic acid, for example, a nucleic acid probe or a primer, for the detection or diagnosis of prostate cancer. 
     In the present invention, the nucleic acid probe or the primer that can be used for detecting prostate cancer or for diagnosing prostate cancer permits qualitative and/or quantitative measurement of the presence, expression level, or abundance of any of the target nucleic acids as the prostate cancer markers described above, for example, human-derived hsa-miR-4443, hsa-miR-1908-5p, hsa-miR-4257, hsa-miR-3197, hsa-miR-3188, hsa-miR-4649-5p, hsa-miR-1343-3p, hsa-miR-6861-5p, hsa-miR-1343-5p, hsa-miR-642b-3p, hsa-miR-6741-5p, hsa-miR-4745-5p, hsa-miR-6826-5p, hsa-miR-3663-3p, hsa-miR-3131, hsa-miR-92a-2-5p, hsa-miR-4258, hsa-miR-4448, hsa-miR-6125, hsa-miR-6880-5p, hsa-miR-6132, hsa-miR-4467, hsa-miR-6749-5p, hsa-miR-2392, hsa-miR-1273g-3p, hsa-miR-4746-3p, hsa-miR-1914-3p, hsa-miR-7845-5p, hsa-miR-6726-5p, hsa-miR-128-2-5p, hsa-miR-4651, hsa-miR-6765-3p, hsa-miR-3185, hsa-miR-4792, hsa-miR-6887-5p, hsa-miR-5572, hsa-miR-3619-3p, hsa-miR-6780b-5p, hsa-miR-4707-5p, hsa-miR-8063, hsa-miR-4454, hsa-miR-4525, hsa-miR-7975, hsa-miR-744-5p, hsa-miR-3135b, hsa-miR-4648, hsa-miR-6816-5p, hsa-miR-4741, hsa-miR-7150, hsa-miR-6791-5p, hsa-miR-1247-3p, hsa-miR-7977, hsa-miR-4497, hsa-miR-6090, hsa-miR-6781-5p, hsa-miR-6870-5p, hsa-miR-6729-5p, hsa-miR-4530, hsa-miR-7847-3p, hsa-miR-6825-5p, hsa-miR-4674, hsa-miR-3917, hsa-miR-4707-3p, hsa-miR-6885-5p, hsa-miR-6722-3p, hsa-miR-4516, hsa-miR-6757-5p, hsa-miR-6840-3p, hsa-miR-5195-3p, hsa-miR-6756-5p, hsa-miR-6800-5p, hsa-miR-6727-5p, hsa-miR-6126, hsa-miR-6872-3p, hsa-miR-4446-3p, hsa-miR-1268a, hsa-miR-1908-3p, hsa-miR-3679-5p, hsa-miR-4534, hsa-miR-4675, hsa-miR-7108-5p, hsa-miR-6799-5p, hsa-miR-4695-5p, hsa-miR-3178, hsa-miR-5090, hsa-miR-3180, hsa-miR-1237-5p, hsa-miR-4758-5p, hsa-miR-3184-5p, hsa-miR-4286, hsa-miR-6784-5p, hsa-miR-6768-5p, hsa-miR-6785-5p, hsa-miR-4706, hsa-miR-711, hsa-miR-1260a, hsa-miR-6746-5p, hsa-miR-6089, hsa-miR-6821-5p, hsa-miR-4667-5p, hsa-miR-8069, hsa-miR-4726-5p, hsa-miR-6124, hsa-miR-4532, hsa-miR-4486, hsa-miR-4728-5p, hsa-miR-4508, hsa-miR-128-1-5p, hsa-miR-4513, hsa-miR-6795-5p, hsa-miR-4689, hsa-miR-6763-5p, hsa-miR-8072, hsa-miR-6765-5p, hsa-miR-4419b, hsa-miR-7641, hsa-miR-3928-3p, hsa-miR-1227-5p, hsa-miR-4492, hsa-miR-296-3p, hsa-miR-6769a-5p, hsa-miR-6889-5p, hsa-miR-4632-5p, hsa-miR-4505, hsa-miR-3154, hsa-miR-3648, hsa-miR-4442, hsa-miR-3141, hsa-miR-7113-3p, hsa-miR-6819-5p, hsa-miR-3195, hsa-miR-1199-5p, hsa-miR-6738-5p, hsa-miR-4656, hsa-miR-6820-5p, hsa-miR-204-3p, hsa-miR-642a-3p, hsa-miR-762, hsa-miR-1202, hsa-miR-3162-5p, hsa-miR-3196, hsa-miR-3622a-5p, hsa-miR-3665, hsa-miR-3940-5p, hsa-miR-4294, hsa-miR-4466, hsa-miR-4476, hsa-miR-4723-5p, hsa-miR-4725-3p, hsa-miR-4730, hsa-miR-4739, hsa-miR-4787-5p, hsa-miR-5787, hsa-miR-6085, hsa-miR-6717-5p, hsa-miR-6724-5p, hsa-miR-6777-5p, hsa-miR-6778-5p, hsa-miR-6787-5p, hsa-miR-6789-5p, hsa-miR-6845-5p, or hsa-miR-6893-5p, or combinations thereof, congeners thereof, transcripts thereof, or variants or derivatives thereof. 
     The expression level of each target nucleic acid described above is increased or decreased (hereinafter, referred to as “increased/decreased”) according to the type of the target nucleic acid(s) in a subject having prostate cancer as compared with a healthy subject. Hence, the nucleic acid of the present invention can be effectively used for measuring the expression level of the target nucleic acid(s) in a body fluid derived from a subject (e.g., a human) suspected of having prostate cancer and a body fluid derived from a healthy subject and detecting prostate cancer by the comparison thereof. 
     The nucleic acid probe or the primer that can be used in the present invention is a nucleic acid probe capable of specifically binding to a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs: 1 to 135 and 580 to 606, or a primer for amplifying a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs: 1 to 135 and 580 to 606. 
     The nucleic acid probe or the primer that can be further used in the present invention can comprise a nucleic acid probe capable of specifically binding to a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs: 136 to 152 and 607 to 611, or a primer for amplifying a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs: 136 to 152 and 607 to 611. 
     The nucleic acid probe or the primer that can be further used in the present invention can comprise a nucleic acid probe capable of specifically binding to a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs: 153 to 187, or a primer for amplifying a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs: 153 to 187. 
     Specifically, these nucleic acid probes or primers comprise a combination of one or more polynucleotides selected from a polynucleotide group comprising nucleotide sequences represented by any of SEQ ID NOs: 1 to 684 or nucleotide sequences derived from the nucleotide sequences by the replacement of u with t, and a complementary polynucleotide group thereof, a polynucleotide group respectively hybridizing under stringent conditions (mentioned later) to DNAs consisting of nucleotide sequences complementary to these nucleotide sequences, and a complementary polynucleotide group thereof, and a polynucleotide group comprising 15 or more, preferably 17 or more consecutive nucleotides in the nucleotide sequences of these polynucleotide groups. These polynucleotides can be used as nucleic acid probes and primers for detecting the prostate cancer markers as target nucleic acids. 
     More specifically, examples of the nucleic acid probe or the primer that can be used in the present invention include one or more polynucleotide(s) selected from the group consisting of the following polynucleotides (a) to (e): 
     (a) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135, 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(b) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135, 580 to 606,
 
(c) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135, 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(d) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135, 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(e) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (a) to (d).
 
     In addition to at least one or more polynucleotide(s) selected from the polynucleotides (a) to (e), the nucleic acid probe or the primer that can be further used in the present invention can comprise any of the following polynucleotides (f) to (j): 
     (f) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152, 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(g) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152, 607 to 611,
 
(h) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152, 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(i) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152, 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(j) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (f) to (i).
 
     In addition to at least one or more polynucleotide(s) selected from the polynucleotides (a) to (j), the nucleic acid probe or the primer that can be further used in the present invention can comprise any of the following polynucleotides (k) to (o): 
     (k) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(l) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187,
 
(m) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(n) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(o) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (k) to (n).
 
     For these polynucleotides, the “fragment thereof comprising 15 or more consecutive nucleotides” can contain the number of nucleotides in the range of, for example, 15 consecutive nucleotides to less than the total number of nucleotides of the sequence, 17 consecutive nucleotides to less than the total number of nucleotides of the sequence, or 19 consecutive nucleotides to less than the total number of nucleotides of the sequence, in the nucleotide sequence of each polynucleotide, though the fragment is not limited thereto. 
     These polynucleotides or the fragments thereof used in the present invention may each be DNA or may each be RNA. 
     The polynucleotides that can be used in the present invention can each be prepared by use of a general technique such as a DNA recombination technique, PCR, or a method using an automatic DNA/RNA synthesizer. 
     The DNA recombination technique and the PCR can employ a technique described in, for example, Ausubel et al., Current Protocols in Molecular Biology, John Willey &amp; Sons, US (1993); and Sambrook et al., Molecular Cloning—A Laboratory Manual, Cold Spring Harbor Laboratory Press, US (1989). 
     The human-derived hsa-miR-4443, hsa-miR-1908-5p, hsa-miR-4257, hsa-miR-3197, hsa-miR-3188, hsa-miR-4649-5p, hsa-miR-1343-3p, hsa-miR-6861-5p, hsa-miR-1343-5p, hsa-miR-642b-3p, hsa-miR-6741-5p, hsa-miR-4745-5p, hsa-miR-6826-5p, hsa-miR-3663-3p, hsa-miR-3131, hsa-miR-92a-2-5p, hsa-miR-4258, hsa-miR-4448, hsa-miR-6125, hsa-miR-6880-5p, hsa-miR-6132, hsa-miR-4467, hsa-miR-6749-5p, hsa-miR-2392, hsa-miR-1273g-3p, hsa-miR-4746-3p, hsa-miR-1914-3p, hsa-miR-7845-5p, hsa-miR-6726-5p, hsa-miR-128-2-5p, hsa-miR-4651, hsa-miR-6765-3p, hsa-miR-3185, hsa-miR-4792, hsa-miR-6887-5p, hsa-miR-5572, hsa-miR-3619-3p, hsa-miR-6780b-5p, hsa-miR-4707-5p, hsa-miR-8063, hsa-miR-4454, hsa-miR-4525, hsa-miR-7975, hsa-miR-744-5p, hsa-miR-3135b, hsa-miR-4648, hsa-miR-6816-5p, hsa-miR-4741, hsa-miR-7150, hsa-miR-6791-5p, hsa-miR-1247-3p, hsa-miR-7977, hsa-miR-4497, hsa-miR-6090, hsa-miR-6781-5p, hsa-miR-6870-5p, hsa-miR-6729-5p, hsa-miR-4530, hsa-miR-7847-3p, hsa-miR-6825-5p, hsa-miR-4674, hsa-miR-3917, hsa-miR-4707-3p, hsa-miR-6885-5p, hsa-miR-6722-3p, hsa-miR-4516, hsa-miR-6757-5p, hsa-miR-6840-3p, hsa-miR-5195-3p, hsa-miR-6756-5p, hsa-miR-6800-5p, hsa-miR-6727-5p, hsa-miR-6126, hsa-miR-6872-3p, hsa-miR-4446-3p, hsa-miR-1268a, hsa-miR-1908-3p, hsa-miR-3679-5p, hsa-miR-4534, hsa-miR-4675, hsa-miR-7108-5p, hsa-miR-6799-5p, hsa-miR-4695-5p, hsa-miR-3178, hsa-miR-5090, hsa-miR-3180, hsa-miR-1237-5p, hsa-miR-4758-5p, hsa-miR-3184-5p, hsa-miR-4286, hsa-miR-6784-5p, hsa-miR-6768-5p, hsa-miR-6785-5p, hsa-miR-4706, hsa-miR-711, hsa-miR-1260a, hsa-miR-6746-5p, hsa-miR-6089, hsa-miR-6821-5p, hsa-miR-4667-5p, hsa-miR-8069, hsa-miR-4726-5p, hsa-miR-6124, hsa-miR-4532, hsa-miR-4486, hsa-miR-4728-5p, hsa-miR-4508, hsa-miR-128-1-5p, hsa-miR-4513, hsa-miR-6795-5p, hsa-miR-4689, hsa-miR-6763-5p, hsa-miR-8072, hsa-miR-6765-5p, hsa-miR-4419b, hsa-miR-7641, hsa-miR-3928-3p, hsa-miR-1227-5p, hsa-miR-4492, hsa-miR-296-3p, hsa-miR-6769a-5p, hsa-miR-6889-5p, hsa-miR-4632-5p, hsa-miR-4505, hsa-miR-3154, hsa-miR-3648, hsa-miR-4442, hsa-miR-3141, hsa-miR-7113-3p, hsa-miR-6819-5p, hsa-miR-3195, hsa-miR-1199-5p, hsa-miR-6738-5p, hsa-miR-4656, hsa-miR-6820-5p, hsa-miR-204-3p, hsa-miR-642a-3p, hsa-miR-762, hsa-miR-1202, hsa-miR-3162-5p, hsa-miR-3196, hsa-miR-3622a-5p, hsa-miR-3665, hsa-miR-3940-5p, hsa-miR-4294, hsa-miR-4466, hsa-miR-4476, hsa-miR-4723-5p, hsa-miR-4725-3p, hsa-miR-4730, hsa-miR-4739, hsa-miR-4787-5p, hsa-miR-5787, hsa-miR-6085, hsa-miR-6717-5p, hsa-miR-6724-5p, hsa-miR-6777-5p, hsa-miR-6778-5p, hsa-miR-6787-5p, hsa-miR-6789-5p, hsa-miR-6845-5p, hsa-miR-6893-5p, hsa-miR-615-5p, hsa-miR-486-3p, hsa-miR-1225-3p, hsa-miR-760, hsa-miR-187-5p, hsa-miR-1203, hsa-miR-7110-5p, hsa-miR-371a-5p, hsa-miR-939-5p, hsa-miR-575, hsa-miR-92b-5p, hsa-miR-887-3p, hsa-miR-920, hsa-miR-1915-5p, hsa-miR-1231, hsa-miR-663b, hsa-miR-1225-5p, hsa-miR-16-5p, hsa-miR-423-5p, hsa-miR-451a, hsa-miR-564, hsa-miR-671-5p, hsa-miR-4763-3p, hsa-miR-3656, hsa-miR-4488, hsa-miR-125a-3p, hsa-miR-1469, hsa-miR-1228-5p, hsa-miR-6798-5p, hsa-miR-1268b, hsa-miR-6732-5p, hsa-miR-1915-3p, hsa-miR-4433b-3p, hsa-miR-1207-5p, hsa-miR-4433-3p, hsa-miR-6879-5p, hsa-miR-4417, hsa-miR-30c-1-3p, hsa-miR-4638-5p, hsa-miR-6088, hsa-miR-4270, hsa-miR-6782-5p, hsa-miR-665, hsa-miR-486-5p, hsa-miR-4655-5p, hsa-miR-1275, hsa-miR-6806-5p, hsa-miR-614, hsa-miR-3937, hsa-miR-6752-5p, hsa-miR-6771-5p, hsa-miR-4450, hsa-miR-211-3p, hsa-miR-663a, hsa-miR-6842-5p, hsa-miR-7114-5p and hsa-miR-6779-5p represented by SEQ ID NOs: 1 to 187, and 580 to 611 are known in the art, and their obtainment methods are also known as mentioned above. Therefore, each polynucleotide that can be used as a nucleic acid probe or a primer in the present invention can be prepared by cloning the gene. 
     Such a nucleic acid probe or a primer can be chemically synthesized using an automatic DNA synthesis apparatus. In general, a phosphoramidite method is used in this synthesis, and single-stranded DNA up to approximately 100 bases can be automatically synthesized by this method. The automatic DNA synthesis apparatus is commercially available from, for example, Polygen GmbH, ABI, or Applied Biosystems, Inc. 
     Alternatively, the polynucleotide of the present invention can also be prepared by a cDNA cloning method. The cDNA cloning technique can employ, for example, microRNA Cloning Kit Wako. 
     In this context, the sequences of the nucleic acid probes and the primers for detecting the polynucleotides consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 187, and 580 to 611 do not exist as miRNAs or precursors thereof in vivo. For example, the nucleotide sequences represented by SEQ ID NO: 7 and SEQ ID NO: 9 are formed from the precursor represented by SEQ ID NO: 194. This precursor has a hairpin-like structure as shown in  FIG.  1   , and the nucleotide sequences represented by SEQ ID NO: 7 and SEQ ID NO: 9 have mismatch sequences with each other. Therefore, a nucleotide sequence completely complementary to the nucleotide sequence represented by SEQ ID NO: 7 or SEQ ID NO: 9 does not naturally occur in vivo. Likewise, the nucleic acid probe and the primer for detecting the nucleotide sequence represented by any of SEQ ID NOs: 1 to 187, and 580 to 611 each have an artificial nucleotide sequence that does not exist in vivo. 
     3. Kit or Device for Detection of Prostate Cancer 
     The present invention also provides a kit or a device for the detection of prostate cancer, comprising one or more polynucleotide(s) (which can include a variant, a fragment, and a derivative; hereinafter, also referred to as a polynucleotide for detection) that can be used as a nucleic acid probe or a primer in the present invention for measuring a target nucleic acid as a prostate cancer marker. 
     The target nucleic acid as a prostate cancer marker according to the present invention is selected from the following group 1: 
     miR-4443, miR-1908-5p, miR-4257, miR-3197, miR-3188, miR-4649-5p, miR-1343-3p, miR-6861-5p, miR-1343-5p, miR-642b-3p, miR-6741-5p, miR-4745-5p, miR-6826-5p, miR-3663-3p, miR-3131, miR-92a-2-5p, miR-4258, miR-4448, miR-6125, miR-6880-5p, miR-6132, miR-4467, miR-6749-5p, miR-2392, miR-1273g-3p, miR-4746-3p, miR-1914-3p, miR-7845-5p, miR-6726-5p, miR-128-2-5p, miR-4651, miR-6765-3p, miR-3185, miR-4792, miR-6887-5p, miR-5572, miR-3619-3p, miR-6780b-5p, miR-4707-5p, miR-8063, miR-4454, miR-4525, miR-7975, miR-744-5p, miR-3135b, miR-4648, miR-6816-5p, miR-4741, miR-7150, miR-6791-5p, miR-1247-3p, miR-7977, miR-4497, miR-6090, miR-6781-5p, miR-6870-5p, miR-6729-5p, miR-4530, miR-7847-3p, miR-6825-5p, miR-4674, miR-3917, miR-4707-3p, miR-6885-5p, miR-6722-3p, miR-4516, miR-6757-5p, miR-6840-3p, miR-5195-3p, miR-6756-5p, miR-6800-5p, miR-6727-5p, miR-6126, miR-6872-3p, miR-4446-3p, miR-1268a, miR-1908-3p, miR-3679-5p, miR-4534, miR-4675, miR-7108-5p, miR-6799-5p, miR-4695-5p, miR-3178, miR-5090, miR-3180, miR-1237-5p, miR-4758-5p, miR-3184-5p, miR-4286, miR-6784-5p, miR-6768-5p, miR-6785-5p, miR-4706, miR-711, miR-1260a, miR-6746-5p, miR-6089, miR-6821-5p, miR-4667-5p, miR-8069, miR-4726-5p, miR-6124, miR-4532, miR-4486, miR-4728-5p, miR-4508, miR-128-1-5p, miR-4513, miR-6795-5p, miR-4689, miR-6763-5p, miR-8072, miR-6765-5p, miR-4419b, miR-7641, miR-3928-3p, miR-1227-5p, miR-4492, miR-296-3p, miR-6769a-5p, miR-6889-5p, miR-4632-5p, miR-4505, miR-3154, miR-3648, miR-4442, miR-3141, miR-7113-3p, miR-6819-5p, miR-3195, miR-1199-5p, miR-6738-5p, miR-4656, miR-6820-5p, miR-204-3p, miR-642a-3p, miR-762, miR-1202, miR-3162-5p, miR-3196, miR-3622a-5p, miR-3665, miR-3940-5p, miR-4294, miR-4466, miR-4476, miR-4723-5p, miR-4725-3p, miR-4730, miR-4739, miR-4787-5p, miR-5787, miR-6085, miR-6717-5p, miR-6724-5p, miR-6777-5p, miR-6778-5p, miR-6787-5p, miR-6789-5p, miR-6845-5p and miR-6893-5p. 
     An additional target nucleic acid that can be optionally used in the measurement is selected from the following group 2: miR-615-5p, miR-486-3p, miR-1225-3p, miR-760, miR-187-5p, miR-1203, miR-7110-5p, miR-371a-5p, miR-939-5p, miR-575, miR-92b-5p, miR-887-3p, miR-920, miR-1915-5p, miR-1231, miR-663b, miR-1225-5p, miR-16-5p, miR-423-5p, miR-451a, miR-564 and miR-671-5p. 
     An additional target nucleic acid that can be optionally further used in the measurement is selected from the following group 3: miR-4763-3p, miR-3656, miR-4488, miR-125a-3p, miR-1469, miR-1228-5p, miR-6798-5p, miR-1268b, miR-6732-5p, miR-1915-3p, miR-4433b-3p, miR-1207-5p, miR-4433-3p, miR-6879-5p, miR-4417, miR-30c-1-3p, miR-4638-5p, miR-6088, miR-4270, miR-6782-5p, miR-665, miR-486-5p, miR-4655-5p, miR-1275, miR-6806-5p, miR-614, miR-3937, miR-6752-5p, miR-6771-5p, miR-4450, miR-211-3p, miR-663a, miR-6842-5p, miR-7114-5p and miR-6779-5p. 
     The kit or the device of the present invention comprises nucleic acid(s) capable of specifically binding to any of the target nucleic acids as the prostate cancer markers described above, preferably one or more polynucleotide(s) selected from the nucleic acid probes or the primers described in the preceding Section 2, specifically, the polynucleotides described in the preceding Section 2, or variant(s) thereof, etc. 
     Specifically, the kit or the device of the present invention can comprise at least one or more polynucleotide(s) comprising (or consisting of) a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135, 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, polynucleotide(s) comprising (or consisting of) a complementary sequence thereof, polynucleotide(s) hybridizing under stringent conditions to any of these polynucleotides, or variant(s) or fragment(s) comprising 15 or more consecutive nucleotides of any of these polynucleotide sequences. 
     The kit or the device of the present invention can further comprise one or more polynucleotide(s) comprising (or consisting of) a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152, 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, polynucleotide(s) comprising (or consisting of) a complementary sequence thereof, polynucleotide(s) hybridizing under stringent conditions to any of these polynucleotides, variant(s) or fragment(s) comprising 15 or more consecutive nucleotides of any of these polynucleotide sequences. 
     The kit or the device of the present invention can further comprise one or more polynucleotide(s) comprising (or consisting of) a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, polynucleotide(s) comprising (or consisting of) a complementary sequence thereof, polynucleotide(s) hybridizing under stringent conditions to any of these polynucleotides, variant(s) or fragment(s) comprising 15 or more consecutive nucleotides of any of these polynucleotide sequences. 
     The fragment that can be contained in the kit or the device of the present invention is, for example, one or more, preferably two or more polynucleotides selected from the group consisting of the following polynucleotides (1) to (3): 
     (1) a polynucleotide comprising 15 or more consecutive nucleotides in a nucleotide sequence derived from a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135, 580 to 606 by the replacement of u with t, or a complementary sequence thereof;
 
(2) a polynucleotide comprising 15 or more consecutive nucleotides in a nucleotide sequence derived from a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152, 607 to 611 by the replacement of u with t, or a complementary sequence thereof; and
 
(3) a polynucleotide comprising 15 or more consecutive nucleotides in a nucleotide sequence derived from a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 by the replacement of u with t, or a complementary sequence thereof.
 
     In a preferred embodiment, the polynucleotide is a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135, 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a polynucleotide consisting of a complementary sequence thereof, a polynucleotide hybridizing under stringent conditions to any of these polynucleotides, or a variant thereof comprising 15 or more, preferably 17 or more, more preferably 19 or more consecutive nucleotides. 
     In a preferred embodiment, the polynucleotide is a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152, 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a polynucleotide consisting of a complementary sequence thereof, a polynucleotide hybridizing under stringent conditions to any of these polynucleotides, or a variant thereof comprising 15 or more, preferably 17 or more, more preferably 19 or more consecutive nucleotides. 
     In a preferred embodiment, the polynucleotide is a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a polynucleotide consisting of a complementary sequence thereof, a polynucleotide hybridizing under stringent conditions to any of these polynucleotides, or a variant thereof comprising 15 or more, preferably 17 or more, more preferably 19 or more consecutive nucleotides. 
     In a preferred embodiment, the fragment can be a polynucleotide comprising 15 or more, preferably 17 or more, more preferably 19 or more consecutive nucleotides. 
     In the present invention, the size of the polynucleotide fragment is the number of bases in the range of, for example, 15 consecutive nucleotides to less than the total number of bases of the sequence, 17 consecutive nucleotides to less than the total number of bases of the sequence, or 19 consecutive nucleotides to less than the total number of bases of the sequence, in the nucleotide sequence of each polynucleotide. 
     Specific examples of the aforementioned polynucleotide combination constituting the kit or the device of the present invention can include combinations of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs as shown in Table 1 (SEQ ID NOs: 1 to 187 and 580 to 611 corresponding to the miRNA markers in the table). However, these are given merely for illustrative purposes, and various other possible combinations are included in the present invention. 
     The aforementioned combination constituting the kit or the device for discriminating a prostate cancer patient from a healthy subject according to the present invention is desirably, for example, a combination of two or more of the polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs shown in Table 1. Usually, a combination of two of these polynucleotides can produce adequate performance. 
     The combination of two polynucleotides consisting of the nucleotide sequences or the complementary sequences thereof for specifically discriminating a prostate cancer patient from a healthy subject is preferably a combination comprising at least one or more of newly found polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 135, among the combinations constituted by two of the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 187, and 580 to 611. 
     The combination of polynucleotides with cancer type specificity capable of discriminating a prostate cancer patient not only from a healthy subject but also from other cancer patients is preferably, for example, a combination of multiple polynucleotides comprising at least one polynucleotide selected from the group consisting of polynucleotides of SEQ ID NOs: 1, 3, 4, 5, 6, 7, 9, 10, 12, 14, 15, 16, 17, 18, 20, 24, 29, 35, 37, 42, 51, 55, 58, 61, 63, 64, 67, 70, 72, 79, 82, 89, 91, 97, 98, 101, 103, 104, 112, 113, 114, 116, 119, 126, 135, 136, 139, 140, 141, 145, 147, 154, 155, 156, 158, 169, 173, 175, 178, 182, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610 and 611 (hereinafter, this group is referred to as “cancer type-specific polynucleotide group 1”), with any of the polynucleotides of the other SEQ ID NOs. 
     The combination of polynucleotides with cancer type specificity capable of discriminating a prostate cancer patient not only from a healthy subject but also from other cancer patients is more preferably a combination of multiple polynucleotides selected from the cancer type-specific polynucleotide group 1. 
     The combination of polynucleotides with cancer type specificity capable of discriminating a prostate cancer patient not only from a healthy subject but also from other cancer patients is more preferably a combination comprising at least one or more polynucleotide(s) selected from the group consisting of polynucleotides of SEQ ID NOs: 1, 12, 16, 37, 42, 63, 119, 126, 139 173, 178, 599. 609, and 611 (hereinafter, this group is referred to as “cancer type-specific polynucleotide group 2”) included in the cancer type-specific polynucleotide group 1, among the combinations of multiple polynucleotides selected from the cancer type-specific polynucleotide group 1. 
     The number of the aforementioned polynucleotides with cancer type specificity used in the combination can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more for the combination and is more preferably 4 or more for the combination. Usually, the combination of 4 of these polynucleotides can produce adequate performance. 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be listed below. 
     (1) a combination of SEQ ID NOs: 1, 63, 139, and 600 (markers: hsa-miR-4443, hsa-miR-4707-3p, hsa-miR-760, and hsa-miR-6724-5p); 
     (2) a combination of SEQ ID NOs: 1, 12, 63, and 599 (markers: hsa-miR-4443, hsa-miR-4745-5p, hsa-miR-4707-3p, and hsa-miR-6717-5p); 
     (3) a combination of SEQ ID NOs: 1, 141, 173, and 599 (markers: hsa-miR-4443, hsa-miR-1203, hsa-miR-665, and hsa-miR-6717-5p); 
     (4) a combination of SEQ ID NOs: 1, 16, 139, and 178 (markers: hsa-miR-4443, hsa-miR-92a-2-5p, hsa-miR-760, and hsa-miR-614); and 
     (5) a combination of SEQ ID NOs: 1, 63, 173, and 599 (markers: hsa-miR-4443, hsa-miR-4707-3p, hsa-miR-665, and hsa-miR-6717-5p). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 12 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 12, 42, 63, and 609 (markers: hsa-miR-4745-5p, hsa-miR-4525, hsa-miR-4707-3p, and hsa-miR-451a); 
     (2) a combination of SEQ ID NOs: 12, 16, 135, and 156 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-6820-5p, and hsa-miR-125a-3p); 
     (3) a combination of SEQ ID NOs: 12, 16, 169, and 178 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-4638-5p, and hsa-miR-614); 
     (4) a combination of SEQ ID NOs: 12, 16, 139, and 601 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-760, and hsa-miR-6777-5p); and 
     (5) a combination of SEQ ID NOs: 12, 16, 42, and 607 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-4525, and hsa-miR-16-5p). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 16 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 16, 18, 139, and 178 (markers: hsa-miR-92a-2-5p, hsa-miR-4448, hsa-miR-760, and hsa-miR-614); 
     (2) a combination of SEQ ID NOs: 12, 16, 37, and 178 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-3619-3p, and hsa-miR-614); 
     (3) a combination of SEQ ID NOs: 12, 16, 37, and 599 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-3619-3p, and hsa-miR-6717-5p); 
     (4) a combination of SEQ ID NOs: 12, 16, 37, and 97 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-3619-3p, and hsa-miR-6746-5p); and 
     (5) a combination of SEQ ID NOs: 12, 14, 16, and 599 (markers: hsa-miR-4745-5p, hsa-miR-3663-3p, hsa-miR-92a-2-5p, and hsa-miR-6717-5p). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 37 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 37, 63, 139, and 611 (markers: hsa-miR-3619-3p, hsa-miR-4707-3p, hsa-miR-760, and hsa-miR-671-5p); 
     (2) a combination of SEQ ID NOs: 37, 42, 63, and 178 (markers: hsa-miR-3619-3p, hsa-miR-4525, hsa-miR-4707-3p, and hsa-miR-614); 
     (3) a combination of SEQ ID NOs: 37, 42, 63, and 599 (markers: hsa-miR-3619-3p, hsa-miR-4525, hsa-miR-4707-3p, and hsa-miR-6717-5p); 
     (4) a combination of SEQ ID NOs: 37, 42, 63, and 139 (markers: hsa-miR-3619-3p, hsa-miR-4525, hsa-miR-4707-3p, and hsa-miR-760); and 
     (5) a combination of SEQ ID NOs: 12, 16, 37, and 603 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-3619-3p, and hsa-miR-6787-5p). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 42 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 42, 63, 607, and 611 (markers: hsa-miR-4525, hsa-miR-4707-3p, hsa-miR-16-5p, and hsa-miR-671-5p); 
     (2) a combination of SEQ ID NOs: 42, 63, 609, and 611 (markers: hsa-miR-4525, hsa-miR-4707-3p, hsa-miR-451a, and hsa-miR-671-5p); 
     (3) a combination of SEQ ID NOs: 42, 63, 173, and 599 (markers: hsa-miR-4525, hsa-miR-4707-3p, hsa-miR-665, and hsa-miR-6717-5p); 
     (4) a combination of SEQ ID NOs: 12, 16, 42, and 609 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-4525, and hsa-miR-451a); and 
     (5) a combination of SEQ ID NOs: 42, 63, 91, and 609 (markers: hsa-miR-4525, hsa-miR-4707-3p, hsa-miR-6784-5p, and hsa-miR-451a). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 63 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 10, 42, 63, and 599 (markers: hsa-miR-642b-3p, hsa-miR-4525, hsa-miR-4707-3p, and hsa-miR-6717-5p); 
     (2) a combination of SEQ ID NOs: 42, 63, 599, and 609 (markers: hsa-miR-4525, hsa-miR-4707-3p, hsa-miR-6717-5p, and hsa-miR-451a); 
     (3) a combination of SEQ ID NOs: 42, 63, 583, and 609 (markers: hsa-miR-4525, hsa-miR-4707-3p, hsa-miR-1202, and hsa-miR-451a); 
     (4) a combination of SEQ ID NOs: 37, 42, 63, and 611 (markers: hsa-miR-3619-3p, hsa-miR-4525, hsa-miR-4707-3p, and hsa-miR-671-5p); and 
     (5) a combination of SEQ ID NOs: 12, 63, 70, and 599 (markers: hsa-miR-4745-5p, hsa-miR-4707-3p, hsa-miR-6756-5p, and hsa-miR-6717-5p). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 119 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 12, 16, 37, and 119 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-3619-3p, and hsa-miR-4492); 
     (2) a combination of SEQ ID NOs: 37, 63, 119, and 584 (markers: hsa-miR-3619-3p, hsa-miR-4707-3p, hsa-miR-4492, and hsa-miR-3162-5p); 
     (3) a combination of SEQ ID NOs: 63, 119, 173, and 178 (markers: hsa-miR-4707-3p, hsa-miR-4492, hsa-miR-665, and hsa-miR-614); 
     (4) a combination of SEQ ID NOs: 63, 119, 158, and 173 (markers: hsa-miR-4707-3p, hsa-miR-4492, hsa-miR-1228-5p, and hsa-miR-665); and 
     (5) a combination of SEQ ID NOs: 63, 119, 173, and 605 (markers: hsa-miR-4707-3p, hsa-miR-4492, hsa-miR-665, and hsa-miR-6845-5p). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 126 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 16, 126, 597, and 599 (markers: hsa-miR-92a-2-5p, hsa-miR-3648, hsa-miR-5787, and hsa-miR-6717-5p); 
     (2) a combination of SEQ ID NOs: 16, 42, 126, and 599 (markers: hsa-miR-92a-2-5p, hsa-miR-4525, hsa-miR-3648, and hsa-miR-6717-5p); 
     (3) a combination of SEQ ID NOs: 16, 126, 139, and 601 (markers: hsa-miR-92a-2-5p, hsa-miR-3648, hsa-miR-760, and hsa-miR-6777-5p); 
     (4) a combination of SEQ ID NOs: 16, 126, 593, and 599 (markers: hsa-miR-92a-2-5p, hsa-miR-3648, hsa-miR-4725-3p, and hsa-miR-6717-5p); and 
     (5) a combination of SEQ ID NOs: 15, 16, 126, and 599 (markers: hsa-miR-3131, hsa-miR-92a-2-5p, hsa-miR-3648, and hsa-miR-6717-5p). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 139 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 37, 63, 139, and 584 (markers: hsa-miR-3619-3p, hsa-miR-4707-3p, hsa-miR-760, and hsa-miR-3162-5p); 
     (2) a combination of SEQ ID NOs: 63, 139, 173, and 178 (markers: hsa-miR-4707-3p, hsa-miR-760, hsa-miR-665, and hsa-miR-614); 
     (3) a combination of SEQ ID NOs: 16, 63, 139, and 601 (markers: hsa-miR-92a-2-5p, hsa-miR-4707-3p, hsa-miR-760, and hsa-miR-6777-5p); 
     (4) a combination of SEQ ID NOs: 37, 63, 139, and 600 (markers: hsa-miR-3619-3p, hsa-miR-4707-3p, hsa-miR-760, and hsa-miR-6724-5p); and 
     (5) a combination of SEQ ID NOs: 16, 139, 178, and 586 (markers: hsa-miR-92a-2-5p, hsa-miR-760, hsa-miR-614, and hsa-miR-3622a-5p). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 173 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 63, 139, 173, and 599 (markers: hsa-miR-4707-3p, hsa-miR-760, hsa-miR-665, and hsa-miR-6717-5p); 
     (2) a combination of SEQ ID NOs: 63, 119, 173, and 581 (markers: hsa-miR-4707-3p, hsa-miR-4492, hsa-miR-665, and hsa-miR-642a-3p); 
     (3) a combination of SEQ ID NOs: 63, 173, 582, and 599 (markers: hsa-miR-4707-3p, hsa-miR-665, hsa-miR-762, and hsa-miR-6717-5p); 
     (4) a combination of SEQ ID NOs: 63, 136, 173, and 599 (markers: hsa-miR-4707-3p, hsa-miR-615-5p, hsa-miR-665, and hsa-miR-6717-5p); and 
     (5) a combination of SEQ ID NOs: 29, 63, 173, and 178 (markers: hsa-miR-6726-5p, hsa-miR-4707-3p, hsa-miR-665, and hsa-miR-614). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 178 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 16, 139, 178, and 601 (markers: hsa-miR-92a-2-5p, hsa-miR-760, hsa-miR-614, and hsa-miR-6777-5p); 
     (2) a combination of SEQ ID NOs: 16, 37, 139, and 178 (markers: hsa-miR-92a-2-5p, hsa-miR-3619-3p, hsa-miR-760, and hsa-miR-614); 
     (3) a combination of SEQ ID NOs: 1, 12, 16, and 178 (markers: hsa-miR-4443, hsa-miR-4745-5p, hsa-miR-92a-2-5p, and hsa-miR-614); 
     (4) a combination of SEQ ID NOs: 1, 63, 173, and 178 (markers: hsa-miR-4443, hsa-miR-4707-3p, hsa-miR-665, and hsa-miR-614); and 
     (5) a combination of SEQ ID NOs: 16, 139, 178, and 597 (markers: hsa-miR-92a-2-5p, hsa-miR-760, hsa-miR-614, and hsa-miR-5787). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 599 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 12, 37, 63, and 599 (markers: hsa-miR-4745-5p, hsa-miR-3619-3p, hsa-miR-4707-3p, and hsa-miR-6717-5p); 
     (2) a combination of SEQ ID NOs: 42, 58, 63, and 599 (markers: hsa-miR-4525, hsa-miR-4530, hsa-miR-4707-3p, and hsa-miR-6717-5p); 
     (3) a combination of SEQ ID NOs: 1, 12, 16, and 599 (markers: hsa-miR-4443, hsa-miR-4745-5p, hsa-miR-92a-2-5p, and hsa-miR-6717-5p); 
     (4) a combination of SEQ ID NOs: 63, 119, 173, and 599 (markers: hsa-miR-4707-3p, hsa-miR-4492, hsa-miR-665, and hsa-miR-6717-5p); and 
     (5) a combination of SEQ ID NOs: 16, 18, 139, and 599 (markers: hsa-miR-92a-2-5p, hsa-miR-4448, hsa-miR-760, and hsa-miR-6717-5p). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 609 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 42, 63, 585, and 609 (markers: hsa-miR-4525, hsa-miR-4707-3p, hsa-miR-3196, and hsa-miR-451a); 
     (2) a combination of SEQ ID NOs: 42, 63, 592, and 609 (markers: hsa-miR-4525, hsa-miR-4707-3p, hsa-miR-4723-5p, and hsa-miR-451a); 
     (3) a combination of SEQ ID NOs: 18, 42, 581, and 609 (markers: hsa-miR-4448, hsa-miR-4525, hsa-miR-642a-3p, and hsa-miR-451a); 
     (4) a combination of SEQ ID NOs: 12, 16, 599, and 609 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-6717-5p, and hsa-miR-451a); and 
     (5) a combination of SEQ ID NOs: 16, 126, 599, and 609 (markers: hsa-miR-92a-2-5p, hsa-miR-3648, hsa-miR-6717-5p, and hsa-miR-451a). 
     Non-limiting examples of the combination of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 611 or a complementary sequence thereof with polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs of three polynucleotides selected from the cancer type-specific polynucleotide group 1 or complementary sequences thereof will be further listed. 
     (1) a combination of SEQ ID NOs: 12, 16, 37, and 611 (markers: hsa-miR-4745-5p, hsa-miR-92a-2-5p, hsa-miR-3619-3p, and hsa-miR-671-5p); 
     (2) a combination of SEQ ID NOs: 1, 63, 139, and 611 (markers: hsa-miR-4443, hsa-miR-4707-3p, hsa-miR-760, and hsa-miR-671-5p); 
     (3) a combination of SEQ ID NOs: 63, 158, 173, and 611 (markers: hsa-miR-4707-3p, hsa-miR-1228-5p, hsa-miR-665, and hsa-miR-671-5p); 
     (4) a combination of SEQ ID NOs: 16, 37, 139, and 611 (markers: hsa-miR-92a-2-5p, hsa-miR-3619-3p, hsa-miR-760, and hsa-miR-671-5p); and 
     (5) a combination of SEQ ID NOs: 16, 37, 595, and 611 (markers: hsa-miR-92a-2-5p, hsa-miR-3619-3p, hsa-miR-4739, and hsa-miR-671-5p). 
     The kit or the device of the present invention can also contain a polynucleotide that is already known or that will be found in future, to enable detection of prostate cancer, in addition to the polynucleotide(s) (which can include a variant, a fragment, and a derivative) according to the present invention described above. 
     The kit of the present invention can also contain an antibody for measuring a marker for prostate cancer examination known in the art, such as PSA, in addition to the polynucleotide(s) according to the present invention described above, and a variant thereof or a fragment thereof. 
     These polynucleotides and the variants thereof or the fragments thereof contained in the kit of the present invention can be packaged in different containers either individually or in any combination. 
     The kit of the present invention can contain a kit for extracting a nucleic acid (e.g., total RNA) from body fluids, cells, or tissues, a fluorescent material for labeling, an enzyme and a medium for nucleic acid amplification, an instruction manual, etc. 
     The device of the present invention is a device for cancer marker measurement in which nucleic acids such as the polynucleotides according to the present invention described above, variants thereof, derivatives thereof, or fragments thereof are bonded or attached to, for example, a solid phase. Examples of the material for the solid phase include plastics, paper, glass, and silicon. The material for the solid phase is preferably a plastic from the viewpoint of easy processability. The solid phase has any shape and is, for example, square, round, reed-shaped, or film-shaped. The device of the present invention includes, for example, a device for measurement by a hybridization technique. Specific examples thereof include blotting devices and nucleic acid arrays (e.g., microarrays, DNA chips, and RNA chips). 
     The nucleic acid array technique is a technique which involves bonding or attaching the nucleic acids one by one by use of a method [e.g., a method of spotting the nucleic acids using a high-density dispenser called spotter or arrayer onto the surface of the solid phase surface-treated, if necessary, by coating with L-lysine or the introduction of a functional group such as an amino group or a carboxyl group, a method of spraying the nucleic acids onto the solid phase using an inkjet which injects very small liquid droplets by a piezoelectric element or the like from a nozzle, or a method of sequentially synthesizing nucleotides on the solid phase] to prepare an array such as a chip and measuring a target nucleic acid(s) through the use of hybridization using this array. 
     The kit or the device of the present invention comprises nucleic acids capable of specifically binding to the polynucleotides of at least one or more, preferably at least two or more, more preferably at least three or more, most preferably at least five or more to all of the prostate cancer marker miRNAs, respectively, of the group 1 described above. The kit or the device of the present invention can optionally further comprise nucleic acids capable of specifically binding to the polynucleotides of at least one or more, preferably at least two or more, more preferably at least three or more, most preferably at least five or more to all of the prostate cancer marker miRNAs, respectively, of the group 2 described above. The kit or the device of the present invention can optionally further comprise nucleic acids capable of specifically binding to the polynucleotides of at least one or more, preferably at least two or more, more preferably at least three or more, most preferably at least five or more to all of the prostate cancer marker miRNAs, respectively, of the group 3 described above. 
     The kit or the device of the present invention can be used for detecting prostate cancer as described in the Section 4 below. 
     4. Method for Detecting Prostate Cancer 
     The present invention further provides a method for detecting prostate cancer, comprising using the kit or the device of the present invention (including the nucleic acid(s) that can be used in the present invention) described in the preceding Section 3 to measure an expression level(s) of one or more prostate cancer-derived gene(s) represented by an expression level(s) of prostate cancer-derived gene(s) selected from the following group: miR-4443, miR-1908-5p, miR-4257, miR-3197, miR-3188, miR-4649-5p, miR-1343-3p, miR-6861-5p, miR-1343-5p, miR-642b-3p, miR-6741-5p, miR-4745-5p, miR-6826-5p, miR-3663-3p, miR-3131, miR-92a-2-5p, miR-4258, miR-4448, miR-6125, miR-6880-5p, miR-6132, miR-4467, miR-6749-5p, miR-2392, miR-1273g-3p, miR-4746-3p, miR-1914-3p, miR-7845-5p, miR-6726-5p, miR-128-2-5p, miR-4651, miR-6765-3p, miR-3185, miR-4792, miR-6887-5p, miR-5572, miR-3619-3p, miR-6780b-5p, miR-4707-5p, miR-8063, miR-4454, miR-4525, miR-7975, miR-744-5p, miR-3135b, miR-4648, miR-6816-5p, miR-4741, miR-7150, miR-6791-5p, miR-1247-3p, miR-7977, miR-4497, miR-6090, miR-6781-5p, miR-6870-5p, miR-6729-5p, miR-4530, miR-7847-3p, miR-6825-5p, miR-4674, miR-3917, miR-4707-3p, miR-6885-5p, miR-6722-3p, miR-4516, miR-6757-5p, miR-6840-3p, miR-5195-3p, miR-6756-5p, miR-6800-5p, miR-6727-5p, miR-6126, miR-6872-3p, miR-4446-3p, miR-1268a, miR-1908-3p, miR-3679-5p, miR-4534, miR-4675, miR-7108-5p, miR-6799-5p, miR-4695-5p, miR-3178, miR-5090, miR-3180, miR-1237-5p, miR-4758-5p, miR-3184-5p, miR-4286, miR-6784-5p, miR-6768-5p, miR-6785-5p, miR-4706, miR-711, miR-1260a, miR-6746-5p, miR-6089, miR-6821-5p, miR-4667-5p, miR-8069, miR-4726-5p, miR-6124, miR-4532, miR-4486, miR-4728-5p, miR-4508, miR-128-1-5p, miR-4513, miR-6795-5p, miR-4689, miR-6763-5p, miR-8072, miR-6765-5p, miR-4419b, miR-7641, miR-3928-3p, miR-1227-5p, miR-4492, miR-296-3p, miR-6769a-5p, miR-6889-5p, miR-4632-5p, miR-4505, miR-3154, miR-3648, miR-4442, miR-3141, miR-7113-3p, miR-6819-5p, miR-3195, miR-1199-5p, miR-6738-5p, miR-4656, miR-6820-5p, miR-204-3p, miR-642a-3p, miR-762, miR-1202, miR-3162-5p, miR-3196, miR-3622a-5p, miR-3665, miR-3940-5p, miR-4294, miR-4466, miR-4476, miR-4723-5p, miR-4725-3p, miR-4730, miR-4739, miR-4787-5p, miR-5787, miR-6085, miR-6717-5p, miR-6724-5p, miR-6777-5p, miR-6778-5p, miR-6787-5p, miR-6789-5p, miR-6845-5p and miR-6893-5p, optionally an expression level of prostate cancer-derived gene(s) selected from the following group: miR-615-5p, miR-486-3p, miR-1225-3p, miR-760, miR-187-5p, miR-1203, miR-7110-5p, miR-371a-5p, miR-939-5p, miR-575, miR-92b-5p, miR-887-3p, miR-920, miR-1915-5p, miR-1231, miR-663b, miR-1225-5p, miR-16-5p, miR-423-5p, miR-451a, miR-564 and miR-671-5p, and optionally an expression level of prostate cancer-derived gene(s) selected from the following group: miR-4763-3p, miR-3656, miR-4488, miR-125a-3p, miR-1469, miR-1228-5p, miR-6798-5p, miR-1268b, miR-6732-5p, miR-1915-3p, miR-4433b-3p, miR-1207-5p, miR-4433-3p, miR-6879-5p, miR-4417, miR-30c-1-3p, miR-4638-5p, miR-6088, miR-4270, miR-6782-5p, miR-665, miR-486-5p, miR-4655-5p, miR-1275, miR-6806-5p, miR-614, miR-3937, miR-6752-5p, miR-6771-5p, miR-4450, miR-211-3p, miR-663a, miR-6842-5p, miR-7114-5p and miR-6779-5p in a sample in vitro, further comparing, for example, the expression level(s) of the gene(s) in the sample (e.g., blood, serum, or plasma) collected from a subject suspected of having prostate cancer with a control expression level in the sample collected from a healthy subject (including a non-prostate cancer patient), and evaluating the subject as having prostate cancer when the expression level of the target nucleic acid is statistically significantly different between the samples. 
     This method of the present invention permits limitedly invasive early diagnosis of cancer with high sensitivity and specificity and thereby brings about early treatment and improved prognosis. In addition, exacerbation of the disease or the effectiveness of surgical, radiotherapeutic, and chemotherapeutic treatments can be monitored. 
     The method for extracting the prostate cancer-derived gene from the sample such as blood, serum, or plasma according to the present invention is particularly preferably prepared by the addition of a reagent for RNA extraction in 3D-Gene™ RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). A general acidic phenol method (acid guanidinium-phenol-chloroform (AGPC)) may be used, or Trizol® (Life Technologies Corp.) may be used. The prostate cancer-derived genes may be prepared by the addition of a reagent for RNA extraction containing acidic phenol, such as Trizol (Life Technologies Corp.) or Isogen (Nippon Gene Co., Ltd). Alternatively, a kit such as miRNeasy® Mini Kit (Qiagen N.V.) can be used, though the method is not limited thereto. 
     The present invention also provides use of the kit or the device of the present invention for detecting in vitro an expression product of a prostate cancer-derived miRNA gene(s) in a sample derived from a subject. 
     In the method of the present invention, a kit or a device comprising, each alone or in every possible composition, the polynucleotides that can be used in the present invention as described above is used as the kit or the device. 
     In the detection or (genetic) diagnosis of prostate cancer according to the present invention, each polynucleotide contained in the kit or the device of the present invention can be used as a probe or a primer. In the case of using the polynucleotide as a primer, TaqMan® MicroRNA Assays from Life Technologies Corp., miScript PCR System from Qiagen N.V., or the like can be used, though the method is not limited thereto. 
     The polynucleotide contained in the kit or the device of the present invention can be used as a primer or a probe according to a routine method in a method known in the art for specifically detecting the particular gene, for example, a hybridization technique such as Northern blot, Southern blot, in situ hybridization, Northern hybridization, or Southern hybridization, or a quantitative amplification technique such as quantitative RT-PCR. A body fluid such as blood, serum, plasma, or urine of the subject is collected as a sample to be assayed according to the type of the detection method used. Alternatively, total RNA prepared from such a body fluid by the method described above may be used, and various polynucleotides including cDNA prepared on the basis of the RNA may be used. 
     The kit or the device of the present invention is useful for the diagnosis of prostate cancer or the detection of the presence or absence of prostate cancer. Specifically, the detection of prostate cancer using the kit or the device can be performed by detecting in vitro an expression level(s) of a gene(s) using the nucleic acid probe(s) or the primer(s) contained in the kit or the device in a sample such as blood, serum, plasma, or urine from a subject suspected of having prostate cancer. The subject suspected of having prostate cancer can be evaluated as having prostate cancer when the expression level(s) of a target miRNA marker(s) measured using polynucleotide(s) (including any variant, any fragment, and any derivative thereof) consisting of a nucleotide sequence(s) represented by at least one or more of SEQ ID NOs: 1 to 135, 580 to 606, or a complementary sequence(s) thereof, optionally a nucleotide sequence(s) represented by one or more of SEQ ID NOs: 136 to 152, 607 to 611 or a complementary sequence(s) thereof, and optionally a nucleotide sequence(s) represented by one or more of SEQ ID NOs: 153 to 187 or a complementary sequence(s) thereof in the sample such as blood, serum, plasma, or urine of the subject is statistically significantly different from the expression level(s) thereof in the sample such as blood, serum, or plasma, or urine of a healthy subject. 
     The method of the present invention can be combined with rectal examination, transrectal ultrasonography of the prostate, or a diagnostic imaging method such as CT scan, MRI scan, or bone scintigraphy. The method of the present invention is capable of specifically detecting prostate cancer and can substantially discriminate prostate cancer from the other cancers. 
     The method for detecting the absence of an expression product of a prostate cancer-derived gene(s) or the presence of the expression product of a prostate cancer-derived gene(s) in a sample using the kit or the device of the present invention comprises collecting a body fluid such as blood, serum, plasma, or urine of a subject, and measuring the expression level(s) of the target gene(s) contained therein using one or more polynucleotide(s) (including a variant, a fragment, and a derivative) selected from the polynucleotide group of the present invention, to evaluate the presence or absence of prostate cancer or to detect prostate cancer. The method for detecting prostate cancer according to the present invention can also evaluate or diagnose, for example, the presence or absence of amelioration of the disease or the degree of amelioration thereof in a prostate cancer patient given a therapeutic drug for the amelioration of the disease. 
     The method of the present invention can comprise, for example, the following steps (a), (b), and (c): 
     (a) contacting a sample derived from a subject with a polynucleotide(s) in the kit or the device of the present invention in vitro; 
     (b) measuring an expression level(s) of the target nucleic acid(s) in the sample using the polynucleotide(s) as a nucleic acid probe(s) or a primer(s); and 
     (c) evaluating the presence or absence of prostate cancer (cells) in the subject on the basis of the step (b). 
     Specifically, the present invention provides a method for detecting prostate cancer, comprising measuring an expression level(s) of a target nucleic acid(s) in a sample of a subject using a nucleic acid(s) capable of specifically binding to at least one or more (preferably at least two or more) polynucleotide(s) selected from miR-4443, miR-1908-5p, miR-4257, miR-3197, miR-3188, miR-4649-5p, miR-1343-3p, miR-6861-5p, miR-1343-5p, miR-642b-3p, miR-6741-5p, miR-4745-5p, miR-6826-5p, miR-3663-3p, miR-3131, miR-92a-2-5p, miR-4258, miR-4448, miR-6125, miR-6880-5p, miR-6132, miR-4467, miR-6749-5p, miR-2392, miR-1273g-3p, miR-4746-3p, miR-1914-3p, miR-7845-5p, miR-6726-5p, miR-128-2-5p, miR-4651, miR-6765-3p, miR-3185, miR-4792, miR-6887-5p, miR-5572, miR-3619-3p, miR-6780b-5p, miR-4707-5p, miR-8063, miR-4454, miR-4525, miR-7975, miR-744-5p, miR-3135b, miR-4648, miR-6816-5p, miR-4741, miR-7150, miR-6791-5p, miR-1247-3p, miR-7977, miR-4497, miR-6090, miR-6781-5p, miR-6870-5p, miR-6729-5p, miR-4530, miR-7847-3p, miR-6825-5p, miR-4674, miR-3917, miR-4707-3p, miR-6885-5p, miR-6722-3p, miR-4516, miR-6757-5p, miR-6840-3p, miR-5195-3p, miR-6756-5p, miR-6800-5p, miR-6727-5p, miR-6126, miR-6872-3p, miR-4446-3p, miR-1268a, miR-1908-3p, miR-3679-5p, miR-4534, miR-4675, miR-7108-5p, miR-6799-5p, miR-4695-5p, miR-3178, miR-5090, miR-3180, miR-1237-5p, miR-4758-5p, miR-3184-5p, miR-4286, miR-6784-5p, miR-6768-5p, miR-6785-5p, miR-4706, miR-711, miR-1260a, miR-6746-5p, miR-6089, miR-6821-5p, miR-4667-5p, miR-8069, miR-4726-5p, miR-6124, miR-4532, miR-4486, miR-4728-5p, miR-4508, miR-128-1-5p, miR-4513, miR-6795-5p, miR-4689, miR-6763-5p, miR-8072, miR-6765-5p, miR-4419b, miR-7641, miR-3928-3p, miR-1227-5p, miR-4492, miR-296-3p, miR-6769a-5p, miR-6889-5p, miR-4632-5p, miR-4505, miR-3154, miR-3648, miR-4442, miR-3141, miR-7113-3p, miR-6819-5p, miR-3195, miR-1199-5p, miR-6738-5p, miR-4656, miR-6820-5p, miR-204-3p, miR-642a-3p, miR-762, miR-1202, miR-3162-5p, miR-3196, miR-3622a-5p, miR-3665, miR-3940-5p, miR-4294, miR-4466, miR-4476, miR-4723-5p, miR-4725-3p, miR-4730, miR-4739, miR-4787-5p, miR-5787, miR-6085, miR-6717-5p, miR-6724-5p, miR-6777-5p, miR-6778-5p, miR-6787-5p, miR-6789-5p, miR-6845-5p and miR-6893-5p and evaluating in vitro the presence or absence of prostate cancer in the subject using the measured expression level(s) and a control expression level(s) of a healthy subject measured in the same way as above. 
     In the present specification, the term “evaluation” is evaluation support based on results of in vitro examination, not physician&#39;s judgment. 
     As described above, in the method of the present invention, specifically, miR-4443 is hsa-miR-4443, miR-1908-5p is hsa-miR-1908-5p, miR-4257 is hsa-miR-4257, miR-3197 is hsa-miR-3197, miR-3188 is hsa-miR-3188, miR-4649-5p is hsa-miR-4649-5p, miR-1343-3p is hsa-miR-1343-3p, miR-6861-5p is hsa-miR-6861-5p, miR-1343-5p is hsa-miR-1343-5p, miR-642b-3p is hsa-miR-642b-3p, miR-6741-5p is hsa-miR-6741-5p, miR-4745-5p is hsa-miR-4745-5p, miR-6826-5p is hsa-miR-6826-5p, miR-3663-3p is hsa-miR-3663-3p, miR-3131 is hsa-miR-3131, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-4258 is hsa-miR-4258, miR-4448 is hsa-miR-4448, miR-6125 is hsa-miR-6125, miR-6880-5p is hsa-miR-6880-5p, miR-6132 is hsa-miR-6132, miR-4467 is hsa-miR-4467, miR-6749-5p is hsa-miR-6749-5p, miR-2392 is hsa-miR-2392, miR-1273g-3p is hsa-miR-1273g-3p, miR-4746-3p is hsa-miR-4746-3p, miR-1914-3p is hsa-miR-1914-3p, miR-7845-5p is hsa-miR-7845-5p, miR-6726-5p is hsa-miR-6726-5p, miR-128-2-5p is hsa-miR-128-2-5p, miR-4651 is hsa-miR-4651, miR-6765-3p is hsa-miR-6765-3p, miR-3185 is hsa-miR-3185, miR-4792 is hsa-miR-4792, miR-6887-5p is hsa-miR-6887-5p, miR-5572 is hsa-miR-5572, miR-3619-3p is hsa-miR-3619-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-4707-5p is hsa-miR-4707-5p, miR-8063 is hsa-miR-8063, miR-4454 is hsa-miR-4454, miR-4525 is hsa-miR-4525, miR-7975 is hsa-miR-7975, miR-744-5p is hsa-miR-744-5p, miR-3135b is hsa-miR-3135b, miR-4648 is hsa-miR-4648, miR-6816-5p is hsa-miR-6816-5p, miR-4741 is hsa-miR-4741, miR-7150 is hsa-miR-7150, miR-6791-5p is hsa-miR-6791-5p, miR-1247-3p is hsa-miR-1247-3p, miR-7977 is hsa-miR-7977, miR-4497 is hsa-miR-4497, miR-6090 is hsa-miR-6090, miR-6781-5p is hsa-miR-6781-5p, miR-6870-5p is hsa-miR-6870-5p, miR-6729-5p is hsa-miR-6729-5p, miR-4530 is hsa-miR-4530, miR-7847-3p is hsa-miR-7847-3p, miR-6825-5p is hsa-miR-6825-5p, miR-4674 is hsa-miR-4674, miR-3917 is hsa-miR-3917, miR-4707-3p is hsa-miR-4707-3p, miR-6885-5p is hsa-miR-6885-5p, miR-6722-3p is hsa-miR-6722-3p, miR-4516 is hsa-miR-4516, miR-6757-5p is hsa-miR-6757-5p, miR-6840-3p is hsa-miR-6840-3p, miR-5195-3p is hsa-miR-5195-3p, miR-6756-5p is hsa-miR-6756-5p, miR-6800-5p is hsa-miR-6800-5p, miR-6727-5p is hsa-miR-6727-5p, miR-6126 is hsa-miR-6126, miR-6872-3p is hsa-miR-6872-3p, miR-4446-3p is hsa-miR-4446-3p, miR-1268a is hsa-miR-1268a, miR-1908-3p is hsa-miR-1908-3p, miR-3679-5p is hsa-miR-3679-5p, miR-4534 is hsa-miR-4534, miR-4675 is hsa-miR-4675, miR-7108-5p is hsa-miR-7108-5p, miR-6799-5p is hsa-miR-6799-5p, miR-4695-5p is hsa-miR-4695-5p, miR-3178 is hsa-miR-3178, miR-5090 is hsa-miR-5090, miR-3180 is hsa-miR-3180, miR-1237-5p is hsa-miR-1237-5p, miR-4758-5p is hsa-miR-4758-5p, miR-3184-5p is hsa-miR-3184-5p, miR-4286 is hsa-miR-4286, miR-6784-5p is hsa-miR-6784-5p, miR-6768-5p is hsa-miR-6768-5p, miR-6785-5p is hsa-miR-6785-5p, miR-4706 is hsa-miR-4706, miR-711 is hsa-miR-711, miR-1260a is hsa-miR-1260a, miR-6746-5p is hsa-miR-6746-5p, miR-6089 is hsa-miR-6089, miR-6821-5p is hsa-miR-6821-5p, miR-4667-5p is hsa-miR-4667-5p, miR-8069 is hsa-miR-8069, miR-4726-5p is hsa-miR-4726-5p, miR-6124 is hsa-miR-6124, miR-4532 is hsa-miR-4532, miR-4486 is hsa-miR-4486, miR-4728-5p is hsa-miR-4728-5p, miR-4508 is hsa-miR-4508, miR-128-1-5p is hsa-miR-128-1-5p, miR-4513 is hsa-miR-4513, miR-6795-5p is hsa-miR-6795-5p, miR-4689 is hsa-miR-4689, miR-6763-5p is hsa-miR-6763-5p, miR-8072 is hsa-miR-8072, miR-6765-5p is hsa-miR-6765-5p, miR-4419b is hsa-miR-4419b, miR-7641 is hsa-miR-7641, miR-3928-3p is hsa-miR-3928-3p, miR-1227-5p is hsa-miR-1227-5p, miR-4492 is hsa-miR-4492, miR-296-3p is hsa-miR-296-3p, miR-6769a-5p is hsa-miR-6769a-5p, miR-6889-5p is hsa-miR-6889-5p, miR-4632-5p is hsa-miR-4632-5p, miR-4505 is hsa-miR-4505, miR-3154 is hsa-miR-3154, miR-3648 is hsa-miR-3648, miR-4442 is hsa-miR-4442, miR-3141 is hsa-miR-3141, miR-7113-3p is hsa-miR-7113-3p, miR-6819-5p is hsa-miR-6819-5p, miR-3195 is hsa-miR-3195, miR-1199-5p is hsa-miR-1199-5p, miR-6738-5p is hsa-miR-6738-5p, miR-4656 is hsa-miR-4656, miR-6820-5p is hsa-miR-6820-5p, miR-204-3p is hsa-miR-204-3p, miR-642a-3p is hsa-miR-642a-3p, miR-762 is hsa-miR-762, miR-1202 is hsa-miR-1202, miR-3162-5p is hsa-miR-3162-5p, miR-3196 is hsa-miR-3196, miR-3622a-5p is hsa-miR-3622a-5p, miR-3665 is hsa-miR-3665, miR-3940-5p is hsa-miR-3940-5p, miR-4294 is hsa-miR-4294, miR-4466 is hsa-miR-4466, miR-4476 is hsa-miR-4476, miR-4723-5p is hsa-miR-4723-5p, miR-4725-3p is hsa-miR-4725-3p, miR-4730 is hsa-miR-4730, miR-4739 is hsa-miR-4739, miR-4787-5p is hsa-miR-4787-5p, miR-5787 is hsa-miR-5787, miR-6085 is hsa-miR-6085, miR-6717-5p is hsa-miR-6717-5p, miR-6724-5p is hsa-miR-6724-5p, miR-6777-5p is hsa-miR-6777-5p, miR-6778-5p is hsa-miR-6778-5p, miR-6787-5p is hsa-miR-6787-5p, miR-6789-5p is hsa-miR-6789-5p, miR-6845-5p is hsa-miR-6845-5p, and miR-6893-5p is hsa-miR-6893-5p. 
     In the method of the present invention, specifically, the nucleic acid(s) (specifically, probe(s) or primer(s)) is selected from the group consisting of the following polynucleotides (a) to (e): 
     (a) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(b) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606,
 
(c) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(d) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 and 580 to 606 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(e) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (a) to (d).
 
     The method of the present invention can further use a nucleic acid capable of specifically binding to at least one or more polynucleotide(s) selected from miR-615-5p, miR-486-3p, miR-1225-3p, miR-760, miR-187-5p, miR-1203, miR-7110-5p, miR-371a-5p, miR-939-5p, miR-575, miR-92b-5p, miR-887-3p, miR-920, miR-1915-5p, miR-1231, miR-663b, miR-1225-5p, miR-16-5p, miR-423-5p, miR-451a, miR-564 and miR-671-5p. 
     Specifically, miR-615-5p is hsa-miR-615-5p, miR-486-3p is hsa-miR-486-3p, miR-1225-3p is hsa-miR-1225-3p, miR-760 is hsa-miR-760, miR-187-5p is hsa-miR-187-5p, miR-1203 is hsa-miR-1203, miR-7110-5p is hsa-miR-7110-5p, miR-371a-5p is hsa-miR-371a-5p, miR-939-5p is hsa-miR-939-5p, miR-575 is hsa-miR-575, miR-92b-5p is hsa-miR-92b-5p, miR-887-3p is hsa-miR-887-3p, miR-920 is hsa-miR-920, miR-1915-5p is hsa-miR-1915-5p, miR-1231 is hsa-miR-1231, miR-663b is hsa-miR-663b, miR-1225-5p is hsa-miR-1225-5p, miR-16-5p is hsa-miR-16-5p, miR-423-5p is hsa-miR-423-5p, miR-451a is hsa-miR-451a, miR-564 is hsa-miR-564, and miR-671-5p is hsa-miR-671-5p. 
     Specifically, the nucleic acid(s) is further selected from the group consisting of the following polynucleotides (f) to (j): 
     (f) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(g) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611,
 
(h) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(i) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152 and 607 to 611 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(j) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (f) to (i).
 
     The method of the present invention can further use a nucleic acid(s) capable of specifically binding to at least one or more polynucleotide(s) selected from miR-4763-3p, miR-3656, miR-4488, miR-125a-3p, miR-1469, miR-1228-5p, miR-6798-5p, miR-1268b, miR-6732-5p, miR-1915-3p, miR-4433b-3p, miR-1207-5p, miR-4433-3p, miR-6879-5p, miR-4417, miR-30c-1-3p, miR-4638-5p, miR-6088, miR-4270, miR-6782-5p, miR-665, miR-486-5p, miR-4655-5p, miR-1275, miR-6806-5p, miR-614, miR-3937, miR-6752-5p, miR-6771-5p, miR-4450, miR-211-3p, miR-663a, miR-6842-5p, miR-7114-5p and miR-6779-5p. 
     Specifically, miR-4763-3p is hsa-miR-4763-3p, miR-3656 is hsa-miR-3656, miR-4488 is hsa-miR-4488, miR-125a-3p is hsa-miR-125a-3p, miR-1469 is hsa-miR-1469, miR-1228-5p is hsa-miR-1228-5p, miR-6798-5p is hsa-miR-6798-5p, miR-1268b is hsa-miR-1268b, miR-6732-5p is hsa-miR-6732-5p, miR-1915-3p is hsa-miR-1915-3p, miR-4433b-3p is hsa-miR-4433b-3p, miR-1207-5p is hsa-miR-1207-5p, miR-4433-3p is hsa-miR-4433-3p, miR-6879-5p is hsa-miR-6879-5p, miR-4417 is hsa-miR-4417, miR-30c-1-3p is hsa-miR-30c-1-3p, miR-4638-5p is hsa-miR-4638-5p, miR-6088 is hsa-miR-6088, miR-4270 is hsa-miR-4270, miR-6782-5p is hsa-miR-6782-5p, miR-665 is hsa-miR-665, miR-486-5p is hsa-miR-486-5p, miR-4655-5p is hsa-miR-4655-5p, miR-1275 is hsa-miR-1275, miR-6806-5p is hsa-miR-6806-5p, miR-614 is hsa-miR-614, miR-3937 is hsa-miR-3937, miR-6752-5p is hsa-miR-6752-5p, miR-6771-5p is hsa-miR-6771-5p, miR-4450 is hsa-miR-4450, miR-211-3p is hsa-miR-211-3p, miR-663a is hsa-miR-663a, miR-6842-5p is hsa-miR-6842-5p, miR-7114-5p is hsa-miR-7114-5p, and miR-6779-5p is hsa-miR-6779-5p. 
     Specifically, the nucleic acid further used is a polynucleotide selected from the group consisting of the following polynucleotides (k) to (o): 
     (k) a polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(l) a polynucleotide comprising a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187,
 
(m) a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,
 
(n) a polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a nucleotide sequence derived from the nucleotide sequence by the replacement of u with t, and
 
(o) a polynucleotide hybridizing under stringent conditions to any of the polynucleotides (k) to (n).
 
     Examples of the sample used in the method of the present invention can include samples prepared from a living tissue (preferably a prostate tissue) or a body fluid such as blood, serum, plasma, or urine of the subject. The sample includes, specifically, for example, an RNA-containing sample prepared from the tissue, a polynucleotide-containing sample further prepared therefrom, a body fluid such as blood, serum, plasma, or urine, a portion or the whole of a living tissue collected from the subject by biopsy or the like, or a living tissue excised by surgery can be used, and the sample for measurement can be prepared therefrom. 
     In the present specification, the subject refers to a mammal, for example, a human, a monkey, a mouse or a rat without any limitation, and is preferably a human. 
     The steps of the method of the present invention can be changed according to the type of the sample to be assayed. 
     In the case of using RNA as an analyte, the detection of prostate cancer (cells) can comprise, for example, the following steps (a), (b), and (c): 
     (a) binding RNA prepared from the sample of the subject or a complementary polynucleotide (cDNA) transcribed therefrom to a polynucleotide in the kit or the device of the present invention; 
     (b) measuring the sample-derived RNA or the cDNA synthesized from the RNA, bound with the polynucleotide by hybridization using the polynucleotide as a nucleic acid probe or by quantitative RT-PCR using the polynucleotide as a primer; and 
     (c) evaluating the presence or absence of prostate cancer (or prostate cancer-derived gene expression) on the basis of the measurement results of the step (b). 
     For example, various hybridization methods can be used for detecting, examining, evaluating, or diagnosing prostate cancer (or prostate cancer-derived gene expression) in vitro according to the present invention. For example, Northern blot, Southern blot, RT-PCR, DNA chip analysis, in situ hybridization, Northern hybridization, or Southern hybridization can be used as such a hybridization method. 
     In the case of using the Northern blot, the presence or absence of expression of each gene or the expression level thereof in the RNA can be detected or measured by use of the nucleic acid probe that can be used in the present invention. Specific examples thereof can include a method which involves labeling the nucleic acid probe (or its complementary strand) with a radioisotope ( 32 P,  33 P,  35 S, etc.), a fluorescent material, or the like, hybridizing the labeled product with the living tissue-derived RNA of the subject transferred to a nylon membrane or the like according to a routine method, and then detecting and measuring a signal derived from the label (radioisotope or fluorescent material) on the formed DNA/RNA duplex using a radiation detector (examples thereof can include BAS-1800 II (Fujifilm Corp.)) or a fluorescence detector (examples thereof can include STORM 865 (GE Healthcare Japan Corp.)). 
     In the case of using the quantitative RT-PCR, the presence or absence of expression of each gene or the expression level thereof in the RNA can be detected or measured by use of the primer that can be used in the present invention. Specific examples thereof can include a method which involves preparing cDNA from the living tissue-derived RNA of the subject according to a routine method, hybridizing a pair of primers (consisting of a plus strand and a reverse strand binding to the cDNA) prepared from the polynucleotide for detection of the present invention with the cDNA such that the region of each target gene can be amplified with the cDNA as a template, and performing PCR according to a routine method to detect the obtained double-stranded DNA. The method for detecting the double-stranded DNA can include a method of performing the PCR using the primers labeled in advance with a radioisotope or a fluorescent material, a method of electrophoresing the PCR product on an agarose gel and staining the double-stranded DNA with ethidium bromide or the like for detection, and a method of transferring the produced double-stranded DNA to a nylon membrane or the like according to a routine method and hybridizing the double-stranded DNA to a labeled nucleic acid probe for detection. 
     In the case of using the nucleic acid array analysis, an RNA chip or a DNA chip in which the nucleic acid probes (single-stranded or double-stranded) of the present invention is attached to a substrate (solid phase) is used. Regions having the attached nucleic acid probes are referred to as probe spots, and regions having no attached nucleic acid probe are referred to as blank spots. Array in which a gene group immobilized on a solid-phase substrate is generally called a nucleic acid chip, a nucleic acid array, a microarray, or the like. The DNA or RNA array includes a DNA or RNA macroarray and a DNA or RNA microarray. In the present specification, the term “chip” includes all of these arrays. 3D-Gene® Human miRNA Oligo chip (Toray Industries, Inc.) can be used as the DNA chip, though the DNA chip is not limited thereto. 
     Examples of the measurement using the DNA chip can include, but are not limited to, a method of detecting and measuring a signal derived from the label on the nucleic acid probe using an image detector (examples thereof can include Typhoon 9410 (GE Healthcare Japan Corp.) and 3D-Gene® scanner (Toray Industries, Inc.)). 
     The “stringent conditions” used in the present specification are, as mentioned above, conditions under which a nucleic acid probe hybridizes to its target sequence to a larger extent (e.g., a measurement value equal to or larger than a mean of background measurement values+a standard deviation of the background measurement values×2) than that for other sequences. 
     The stringent conditions are defined by hybridization and subsequent conditions of washing. The hybridization conditions involves, for example, but not limited to, 30° C. to 60° C. for 1 to 24 hours in a solution containing SSC, a surfactant, formamide, dextran sulfate, a blocking agent, etc. In this context, 1×SSC is an aqueous solution (pH 7.0) containing 150 mM sodium chloride and 15 mM sodium citrate. The surfactant includes, for example, SDS (sodium dodecyl sulfate), Triton, or Tween. The hybridization conditions more preferably involve 3 to 10×SSC and 0.1 to 1% SDS. Examples of the washing conditions, following the hybridization, which is another condition to define the stringent conditions, can include conditions involving continuous washing at 30° C. in a solution containing 0.5×SSC and 0.1% SDS, at 30° C. in a solution containing 0.2×SSC and 0.1% SDS, and at 30° C. in a 0.05×SSC solution. It is desirable that the complementary strand should maintain its hybridized state with a target plus strand even by washing under such conditions. Specifically, examples of such a complementary strand can include a strand consisting of a nucleotide sequence in a completely complementary relationship with the nucleotide sequence of the target plus strand, and a strand consisting of a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90% or at least 95%, for example, at least 98% or at least 99% identity to the strand. 
     Other examples of the “stringent conditions” for the hybridization are described in, for example, Sambrook, J. &amp; Russel, D., Molecular Cloning, A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, published on Jan. 15, 2001, Vol. 1, 7.42 to 7.45 and Vol. 2, 8.9 to 8.17, and can be used in the present invention. 
     Examples of the conditions for carrying out PCR using a polynucleotide fragment in the kit of the present invention as a primer include a treatment for approximately 15 seconds to 1 minute at 5 to 10° C. plus a Tm value calculated from the sequence of the primer, using a PCR buffer having composition such as 10 mM Tris-HCL (pH 8.3), 50 mM KCL, and 1 to 2 mM MgCl 2 . Examples of the method for calculating such a Tm value include Tm value=2×(the number of adenine residues+the number of thymine residues)+4×(the number of guanine residues+the number of cytosine residues). 
     In the case of using the quantitative RT-PCR, a commercially available kit for measurement specially designed for quantitatively measuring miRNA, such as TaqMan® MicroRNA Assays (Life Technologies Corp.), LNA®-based MicroRNA PCR (Exiqon), or Ncode® miRNA qRT-PCT kit (Invitrogen Corp.) may be used. 
     For the calculation of gene expression levels, statistical analysis described in, for example, Statistical analysis of gene expression microarray data (Speed T., Chapman and Hall/CRC), and A beginner&#39;s guide Microarray gene expression data analysis (Causton H. C. et al., Blackwell publishing) can be used in the present invention, though the calculation method is not limited thereto. For example, twice, preferably 3 times, more preferably 6 times the standard deviation of the measurement values of the blank spots are added to the average measurement value of the blank spots on the DNA chip, and probe spots having a signal value equal to or larger than the resulting value can be regarded as detection spots. Alternatively, the average measurement value of the blank spots is regarded as a background and can be subtracted from the measurement values of the probe spots to determine gene expression levels. A missing value for a gene expression level can be excluded from the analyte, preferably replaced with the smallest value of the gene expression level in each DNA chip, or more preferably replaced with a value obtained by subtracting 0.1 from a logarithmic value of the smallest value of the gene expression level. In order to eliminate low-signal genes, only a gene having a gene expression level of 2 6 , preferably 2 8 , more preferably 2 10  or larger in 20% or more, preferably 50%, more preferably 80% or more of the number of measured samples can be selected as the analyte. Examples of the normalization of the gene expression level include, but are not limited to, global normalization and quantile normalization (Bolstad, B. M. et al., 2003, Bioinformatics, Vol. 19, p. 185-193). 
     The present invention also provides a method comprising measuring a target gene or gene expression level in a sample derived from a subject using the polynucleotide, the kit, or the device (e.g., chip) for detection of the present invention, or a combination thereof, preparing a discriminant (discriminant function) with gene expression levels in a sample derived from a prostate cancer patient and a sample derived from a healthy subject as supervising samples, and determining or evaluating the presence and/or absence of the prostate cancer-derived gene in the sample. 
     Specifically, the present invention further provides the method comprising: a first step of measuring in vitro an expression level of a target gene in multiple samples known to be able to determine or evaluate the presence and/or absence of the prostate cancer-derived gene in the samples, using the polynucleotide, the kit, or the device (e.g., chip) for detection of the present invention, or a combination thereof; a second step of preparing a discriminant with the measurement values of the expression level of the target gene (target nucleic acid) obtained in the first step as supervising samples; a third step of measuring in vitro an expression level of the target gene in a sample derived from a subject in the same way as in the first step; and a fourth step of substituting the measurement value of the expression level of the target gene obtained in the third step into the discriminant obtained in the second step, and determining or evaluating the presence and/or absence of the prostate cancer-derived gene in the sample on the basis of the results obtained from the discriminant, wherein the target gene can be detected using the polynucleotide or using a polynucleotide for detection, a variant thereof, or a fragment thereof contained in the kit or the device (e.g., chip). In this context, the discriminant can be prepared by use of Fisher&#39;s linear discriminant analysis, nonlinear discriminant analysis based on Mahalanobis&#39; distance, neural network, Support Vector Machine (SVM), or the like, though the method is not limited thereto. 
     When a clustering boundary is a straight line or a hyperplane, the linear discriminant analysis is a method for determining the association of a cluster using Formula 1 as a discriminant. In this context, x represents an explanatory variable, w represents a coefficient of the explanatory variable, and w0 represents a constant term. 
     
       
         
           
             
               
                 
                   
                     f 
                     ⁡ 
                     ( 
                     x 
                     ) 
                   
                   = 
                   
                     
                       w 
                       0 
                     
                     + 
                     
                       
                         ∑ 
                         
                           i 
                           = 
                           1 
                         
                         n 
                       
                       
                         
                           w 
                           i 
                         
                         ⁢ 
                         
                           x 
                           i 
                         
                       
                     
                   
                 
               
               
                 
                   Formula 
                   ⁢ 
                       
                   1 
                 
               
             
           
         
       
     
     Values obtained from the discriminant are referred to as discriminant scores. The measurement values of a newly offered data set can be substituted as explanatory variables into the discriminant to determine clusters on the basis of the signs of the discriminant scores. 
     The Fisher&#39;s linear discriminant analysis, one type of linear discriminant analysis, is a dimension reduction method for selecting a dimension suitable for classification, and constructs a synthetic variable with high discriminant performance by focusing on the variance of the synthetic variables and minimizing the variance of data having the same label (Venables, W. N. et al., Modem Applied Statistics with S. Fourth edition. Springer., 2002). In the Fisher&#39;s linear discriminant analysis, direction w of projection is determined so as to maximize Formula 2. In this context, μ represents an average input, ng represents the number of data associated to class g, and μg represents an average input of the data associated to class g. The numerator and the denominator are intra-class variance and inter-class variance, respectively, when each data is projected in the direction of the vector w. Discriminant coefficient wi is determined by maximizing this ratio (Takafumi Kanamori et al., “Pattern Recognition”, Kyoritsu Shuppan Co., Ltd., (2009); and Richard O. et al., Pattern Classification Second Edition., Wiley-Interscience, 2000). 
     
       
         
           
             
               
                 
                   
                     J 
                     ⁡ 
                     ( 
                     w 
                     ) 
                   
                   = 
                   
                     
                       
                         ∑ 
                         
                           g 
                           = 
                           1 
                         
                         G 
                       
                       
                         
                           
                             n 
                             g 
                           
                           ( 
                           
                             
                               
                                 w 
                                 T 
                               
                               ⁢ 
                               
                                 μ 
                                 g 
                               
                             
                             - 
                             
                               
                                 w 
                                 T 
                               
                               ⁢ 
                               μ 
                             
                           
                           ) 
                         
                         ⁢ 
                         
                           
                             ( 
                             
                               
                                 
                                   w 
                                   T 
                                 
                                 ⁢ 
                                 
                                   μ 
                                   g 
                                 
                               
                               - 
                               
                                 
                                   w 
                                   T 
                                 
                                 ⁢ 
                                 μ 
                               
                             
                             ) 
                           
                           T 
                         
                       
                     
                     
                       
                         ∑ 
                         
                           g 
                           = 
                           1 
                         
                         G 
                       
                       
                         
                           ∑ 
                           
                             
                               i 
                               : 
                               
                                 y 
                                 i 
                               
                             
                             = 
                             g 
                           
                         
                         
                           
                             ( 
                             
                               
                                 
                                   w 
                                   T 
                                 
                                 ⁢ 
                                 
                                   x 
                                   i 
                                 
                               
                               - 
                               
                                 
                                   w 
                                   T 
                                 
                                 ⁢ 
                                 
                                   μ 
                                   g 
                                 
                               
                             
                             ) 
                           
                           ⁢ 
                           
                             ( 
                             
                               
                                 
                                   w 
                                   T 
                                 
                                 ⁢ 
                                 
                                   x 
                                   i 
                                 
                               
                               - 
                               
                                 
                                   w 
                                   T 
                                 
                                 ⁢ 
                                 
                                   μ 
                                   g 
                                 
                               
                             
                             ) 
                           
                         
                       
                     
                   
                 
               
               
                 
                   Formula 
                   ⁢ 
                       
                   2 
                 
               
             
           
         
       
       
         
           
             
               
                 subject 
                 ⁢ 
                    
                 to 
                 ⁢ 
                 
                     
                       
                 
                 ⁢ 
                 μ 
               
               = 
               
                 
                   ∑ 
                   
                     i 
                     = 
                     1 
                   
                   n 
                 
                 
                   
                     x 
                     i 
                   
                   n 
                 
               
             
             , 
                 
             
               
                 μ 
                 g 
               
               = 
               
                 
                   ∑ 
                   
                     
                       i 
                       : 
                       
                         u 
                         i 
                       
                     
                     = 
                     g 
                   
                   n 
                 
                 
                   
                     x 
                     i 
                   
                   
                     n 
                     g 
                   
                 
               
             
           
         
       
     
     The Mahalanobis&#39; distance is calculated according to Formula 3 in consideration of data correlation and can be used as nonlinear discriminant analysis for determining, an associated cluster which has a closer Mahalanobis&#39; distance from each cluster. In this context, μ represents a central vector of each cluster, and S-1 represents an inverse matrix of the variance-covariance matrix of the cluster. The central vector is calculated from explanatory variable x, and an average vector, a median value vector, or the like can be used. 
     
       
         
           
             
               
                 
                   
                     D 
                     ⁡ 
                     ( 
                     
                       x 
                       , 
                       μ 
                     
                     ) 
                   
                   = 
                   
                     
                       { 
                       
                         
                           
                             ( 
                             
                               x 
                               - 
                               μ 
                             
                             ) 
                           
                           t 
                         
                         ⁢ 
                         
                           
                             S 
                             
                               - 
                               1 
                             
                           
                           ( 
                           
                             x 
                             - 
                             μ 
                           
                           ) 
                         
                       
                       } 
                     
                     
                       1 
                       2 
                     
                   
                 
               
               
                 
                      
                   
                     Formula 
                     ⁢ 
                         
                     3 
                   
                 
               
             
           
         
       
     
     SVM is a discriminant analysis method devised by V. Vapnik (The Nature of Statistical Leaning Theory, Springer, 1995). Particular data points of a data set that has known classes are defined as explanatory variables, and classes are defined as objective variables. A boundary plane called hyperplane for correctly classifying the data set into the known classes is determined, and a discriminant for data classification is determined using the boundary plane. Then, the measurement values of a newly offered data set can be substituted as explanatory variables into the discriminant to determine classes. In this respect, the results of the discriminant analysis may be classes, may be a probability of being classified into correct classes, or may be the distance from the hyperplane. In SVM, a method of nonlinearly converting a feature vector to a high dimension and performing linear discriminant analysis in the space is known as a method for tackling nonlinear problems. An expression in which an inner product of two factors in a nonlinearly mapped space is expressed only by inputs in their original spaces is called kernel. Examples of the kernel can include a linear kernel, a RBF (radial basis function) kernel, and a Gaussian kernel. While highly dimensional mapping is performed according to the kernel, the optimum discriminant, i.e., a discriminant, can be actually constructed by mere calculation according to the kernel, which avoids calculating features in the mapped space (e.g., Hideki Aso et al., Frontier of Statistical Science 6 “Statistics of pattern recognition and learning—New concepts and approaches”, Iwanami Shoten, Publishers (2004); Nello Cristianini et al., Introduction to SVM, Kyoritsu Shuppan Co., Ltd. (2008)). 
     C-support vector classification (C-SVC), one type of SVM, involves preparing a hyperplane by supervising with the explanatory variables of two groups and classifying an unknown data set into either of the groups (C. Cortes et al., 1995, Machine Learning, Vol. 20, p. 273-297). 
     Exemplary calculation of a C-SVC discriminant that can be used in the method of the present invention will be given below. First, all subjects are divided into two groups, i.e., a prostate cancer patient group and a healthy subject group. For example, prostate tissue examination can be used for a reference under which each subject is confirmed as a prostate cancer patient or a healthy subject. 
     Next, a data set consisting of comprehensive gene expression levels of serum-derived samples of the two divided groups (hereinafter, this data set is referred to as a training cohort) is prepared, and a C-SVC discriminant is determined by using genes found to differ clearly in their gene expression levels between the two groups as explanatory variables, and this grouping as objective variables (e.g., −1 and +1). An optimizing objective function is represented by Formula 4 wherein e represents all input vectors, y represents an objective variable, a represents a Lagrange&#39;s undetermined multiplier vector, Q represents a positive definite matrix, and C represents a parameter for adjusting constrained conditions. 
     
       
         
           
             
               
                 
                   
                     
                       
                         
                           min 
                               
                         
                         a 
                       
                       ⁢ 
                       
                         1 
                         2 
                       
                       ⁢ 
                       
                         a 
                         T 
                       
                       ⁢ 
                       Qa 
                     
                     - 
                     
                       
                         e 
                         T 
                       
                       ⁢ 
                       a 
                     
                   
                   
                     
                       
                         subject 
                         ⁢ 
                            
                         to 
                         ⁢ 
                             
                         
                           y 
                           T 
                         
                         ⁢ 
                         a 
                       
                       = 
                       0 
                     
                     , 
                         
                     
                       0 
                       ≤ 
                       
                         a 
                         i 
                       
                       ≤ 
                       C 
                     
                     , 
                        
                     
                       i 
                       = 
                       1 
                     
                     , 
                        
                     … 
                         
                     , 
                         
                     l 
                     , 
                   
                 
               
               
                 
                   Formula 
                   ⁢ 
                       
                   4 
                 
               
             
           
         
       
     
     Formula 5 is a finally obtained discriminant, and an associated group can be determined on the basis of the sign of a value obtained according to the discriminant. In this context, x represents a support vector, y represents a label indicating the association with a group, a represents the corresponding coefficient, b represents a constant term, and K represents a kernel function. 
     
       
         
           
             
               
                 
                   
                     f 
                     ⁡ 
                     ( 
                     x 
                     ) 
                   
                   = 
                   
                     sgn 
                     ⁢ 
                     
                       ( 
                       
                         
                           
                             ∑ 
                             
                               i 
                               = 
                               1 
                             
                             l 
                           
                           
                             
                               y 
                               i 
                             
                             ⁢ 
                             
                               a 
                               i 
                             
                             ⁢ 
                             
                               K 
                               ⁡ 
                               ( 
                               
                                 
                                   x 
                                   i 
                                 
                                 , 
                                 x 
                               
                               ) 
                             
                           
                         
                         + 
                         b 
                       
                       ) 
                     
                   
                 
               
               
                 
                   Formula 
                   ⁢ 
                       
                   5 
                 
               
             
           
         
       
     
     For example, a RBF kernel defined by Formula 6 can be used as the kernel function. In this context, x represents a support vector, and y represents a kernel parameter for adjusting the complexity of the hyperplane. 
     
       
         
           
             
               
                 
                   
                     
                       K 
                       ⁡ 
                       ( 
                       
                         
                           x 
                           i 
                         
                         , 
                         
                           x 
                           j 
                         
                       
                       ) 
                     
                     = 
                     
                       exp 
                       ⁡ 
                       ( 
                       
                         
                           - 
                           r 
                         
                         ⁢ 
                         
                           
                              
                             
                               
                                 x 
                                 i 
                               
                               - 
                               
                                 x 
                                 j 
                               
                             
                               
                              
                           
                           2 
                         
                       
                       ) 
                     
                   
                   , 
                      
                   
                     r 
                     &lt; 
                     0 
                   
                 
               
               
                 
                      
                   
                     Formula 
                     ⁢ 
                         
                     6 
                   
                 
               
             
           
         
       
     
     In addition, an approach such as neural network, k-nearest neighbor algorithms, decision trees, or logistic regression analysis can be selected as a method for determining or evaluating the presence and/or absence of expression of a prostate cancer-derived target gene in a sample derived from a subject, or for evaluating the expression level thereof by comparison with a control derived from a healthy subject. 
     The method of the present invention can comprise, for example, the following steps (a), (b), and (c): 
     (a) measuring an expression level of a target gene in tissues containing prostate cancer-derived genes derived from prostate cancer patients and/or samples already known to be tissues containing no prostate cancer-derived gene derived from healthy subjects, using the polynucleotide, the kit, or the device (e.g., DNA chip) for detection according to the present invention; 
     (b) preparing the discriminants of Formulae 1 to 3, 5, and 6 described above from the measurement values of the expression level measured in the step (a); and 
     (c) measuring an expression level of the target gene in a sample derived from a subject using the polynucleotide, the kit, or the device (e.g., DNA chip) for detection according to the present invention, substituting the obtained measurement value into the discriminants prepared in the step (b), and determining or evaluating the presence and/or absence of the prostate cancer-derived target gene in the sample, or evaluating the expression level thereof by comparison with a healthy subject-derived control, on the basis of the obtained results. 
     In this context, in the discriminants of Formulae 1 to 3, 5, and 6, x represents an explanatory variable and includes a value obtained by measuring a polynucleotide selected from the polynucleotides described above in the Section 2, or any fragment thereof. Specifically, the explanatory variable for discriminating a prostate cancer patient from a healthy subject according to the present invention is a gene expression level selected from, for example, the following expression levels (1) to (3): 
     (1) a gene expression level in the serum of a prostate cancer patient or a healthy subject measured by any DNA comprising 15 or more consecutive nucleotides in a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135, 580 to 606 or a complementary sequence thereof, 
     (2) a gene expression level in the serum of a prostate cancer patient or a healthy subject measured by any DNA comprising 15 or more consecutive nucleotides in a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152, 607 to 611 or a complementary sequence thereof, and 
     (3) a gene expression level in the serum of a prostate cancer patient or a healthy subject measured by any DNA comprising 15 or more consecutive nucleotides in a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187 or a complementary sequence thereof. 
     As described above, for the method for determining or evaluating the presence and/or absence of a prostate cancer-derived gene in a sample derived from a subject, a discriminant prepared from a training cohort is required. For enhancing the discriminant accuracy of the discriminant, it is necessary for the discriminant to use genes that show clear difference between two groups in the training cohort. 
     Each gene that is used for an explanatory variable in a discriminant is preferably determined as follows. First, comprehensive gene expression levels of a prostate cancer patient group and comprehensive gene expression levels of a healthy subject group in a training cohort are used as a data set, the degree of difference in the expression level of each gene between the two groups is determined through the use of, for example, the P value of t test, which is parametric analysis, or the P value of Mann-Whitney&#39;s U test or Wilcoxon test, which is nonparametric analysis. 
     The gene can be regarded as being statistically significant when the critical rate (significance level) of the P value obtained by the test is smaller than, for example, 5%, 1%, or 0.01%. 
     In order to correct an increased probability of type I error attributed to the repetition of an analytical test, a method known in the art, for example, Bonferroni or Holm method, can be used for the correction (e.g., Yasushi Nagata et al., “Basics of statistical multiple comparison methods”, Scientist Press Co., Ltd. (2007)). As an example of the Bonferroni correction, for example, the P value obtained by an analytical test is multiplied by the number of repetitions of the test, i.e., the number of genes used in the analysis, and the obtained value can be compared with a desired significance level to suppress a probability of causing type I error in the whole test. 
     Instead of the test, the absolute value (fold change) of an expression ratio of a median value of each gene expression level between gene expression levels of a prostate cancer patient group and gene expression levels of a healthy subject group may be calculated to select a gene that is used for an explanatory variable for a discriminant. Alternatively, ROC curves based on the gene expression levels of a prostate cancer patient group and a healthy subject group may be used, and a gene that is used for an explanatory variable in a discriminant can be selected on the basis of an AUROC value. 
     Next, a discriminant that can be calculated by various methods described above is prepared using any number of genes having large difference in their gene expression levels determined here. Examples of the method for constructing a discriminant that produces the largest discriminant accuracy include a method of constructing a discriminant in every combination of genes that satisfy the significance level of a P value, and a method of constructing a discriminant by repetitively evaluating the genes for use while adding the genes one by one in a descending order of the gene expression difference (Furey T S. et al., 2000, Bioinformatics., Vol. 16, p. 906-14). A gene expression level of another independent prostate cancer patient or healthy subject is substituted as an explanatory variable into this discriminant to calculate a result of the discriminant analysis that indicates the group to which this independent prostate cancer patient or healthy subject associated. Specifically, the found gene set for diagnosis and the discriminant constructed using the gene set for diagnosis can be evaluated in an independent sample group to find a more universal gene set for diagnosis capable of detecting prostate cancer and a more universal method for discriminating prostate cancer. 
     Split-sample method is preferably used for evaluating the discriminant performance (generality) of the discriminant. Specifically, a data set is divided into a training cohort and a validation cohort, and gene selection by a statistical test and construction of a discriminant are performed in the training cohort. Accuracy, sensitivity, and specificity are calculated using results of discriminant analysis in a validation cohort according to the discriminant and a true group to which the validation cohort associated, to evaluate the discriminant performance. On the other hand, instead of dividing a data set, gene selection by a statistical test and construction of a discriminant may be performed using all of samples, and accuracy, sensitivity, and specificity can be calculated by the discriminant of newly prepared samples according to the discriminant to evaluate the discriminant performance. 
     The present invention provides a polynucleotide for detection or for disease diagnosis useful in the diagnosis and treatment of prostate cancer, a method for detecting prostate cancer using the polynucleotide, and a kit and a device for the detection of prostate cancer, comprising the polynucleotide. Particularly, in order to select a gene for diagnosis and prepare a discriminant so as to exhibit accuracy beyond a prostate cancer diagnosis method using existing tumor markers PSA, a gene set for diagnosis and a discriminant for the method of the present invention can be constructed, which exhibit accuracy beyond PSA, for example, by comparing genes expressed in serum derived from a patient who is confirmed to be negative using PSA but finally found to have prostate cancer by detailed examination such as computed tomography using a contrast medium, with genes expressed in serum derived from a patient who has no prostate cancer. 
     For example, the gene set for diagnosis is set to any combination selected from one or two or more of the polynucleotides based on a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135, 580 to 606, or a complementary sequence thereof as described above, optionally one or two or more of the polynucleotides based on a nucleotide sequence represented by any of SEQ ID NOs: 136 to 152, 607 to 611, or a complementary sequence thereof, and optionally one or two or more of the polynucleotides based on a nucleotide sequence represented by any of SEQ ID NOs: 153 to 187, or a complementary sequence thereof. Further, a discriminant is constructed using expression levels of the gene set for diagnosis in samples derived from class I prostate cancer patients and samples derived from class II healthy subjects as a result of tissue diagnosis. As a result, the presence or absence of prostate cancer-derived genes in an unknown sample can be determined with 100% accuracy at the maximum by measuring expression levels of the gene set for diagnosis in the unknown sample. 
     EXAMPLES 
     Hereinafter, the present invention will be described further specifically with reference to Examples below. However, the scope of the present invention is not intended to be limited by these Examples. 
     Reference Example 1 
     &lt;Collection of Samples from Prostate Cancer Patient and Healthy Subject&gt; 
     Serum was collected after obtainment of informed consent, using VENOJECT II vacuum blood collecting tube VP-AS109K60 (Terumo Corp.) from each of 94 healthy male subjects, and 35 prostate cancer patients (30 cases with stage II, 1 case with stage III, and 4 cases with stage IV) (Table 2-1) who were confirmed to have no cancer in organs other than the prostate, and used as a training cohort. Likewise, serum was collected after obtainment of informed consent, using VENOJECT II vacuum blood collecting tube VP-AS109K60 (Terumo Corp.) from each of 47 healthy male subjects, and 17 prostate cancer patients (15 cases with stage II and 2 cases with stage III) (Table 2-2) who were confirmed to have no cancer in organs other than the prostate, and used as a validation cohort. 
     &lt;Extraction of Total RNA&gt; 
     Total RNA was obtained from 300 μL of the serum sample obtained from each of 193 persons in total of 141 healthy male subjects and 52 prostate cancer patients in the training cohort and the validation cohort, using a reagent for RNA extraction in 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.) according to the protocol provided by the manufacturer. 
     &lt;Measurement of Gene Expression Level&gt; 
     miRNAs in the total RNA obtained from the serum sample of each of 193 persons in total of 141 healthy male subjects and 52 prostate cancer patients in the aforementioned training cohort and the validation cohort were fluorescently labeled using 3D-Gene® miRNA Labeling kit (Toray Industries, Inc.) according to the protocol (ver 2.20) provided by the manufacturer. The oligo DNA chip used was 3D-Gene® Human miRNA Oligo chip (Toray Industries, Inc.) with mounted probes having sequences complementary to 2,555 miRNAs among the miRNAs registered in miRBase Release 20. Hybridization of the miRNAs in the total RNA with the probes on the DNA chip under stringent conditions and washing following the hybridization were performed according to the protocol provided by the manufacturer. The DNA chip was scanned using 3D-Gene® scanner (Toray Industries, Inc.) to obtain images. Fluorescence intensity was digitized using 3D-Gene® Extraction (Toray Industries, Inc.). The digitized fluorescence intensity was converted to a logarithmic value having a base of 2 and used as a gene expression level, from which a blank value was subtracted. A missing value was replaced with a value obtained by subtracting 0.1 from a logarithmic value of the smallest value of the gene expression level in each DNA chip. As a result, the comprehensive gene expression levels of the miRNAs in the serum were obtained for the 52 prostate cancer patients and the 141 healthy male subjects. Calculation and statistical analysis using the digitized gene expression levels of the miRNAs were carried out using R language 3.0.2 (R Development Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, URL http://www.R-project.org/.) and MASS package 7.3-30 (Venables, W. N. &amp; Ripley, B. D. (2002) Modern Applied Statistics with S. Fourth Edition. Springer, New York. ISBN 0-387-95457-0). 
     Reference Example 2 
     &lt;Collection of Sample from Patients with Cancer Other than Prostate Cancer&gt; 
     Serum was collected using VENOJECT II vacuum blood collecting tube VP-AS109K60 (Terumo Corp.) from each of 63 breast cancer patients who were confirmed to have no cancer in other organs after obtainment of informed consent, and used as a training cohort together with the samples of 35 prostate cancer patients and 99 healthy male subjects of Reference Example 1. Likewise, serum was collected using VENOJECT II vacuum blood collecting tube VP-AS109K60 (Terumo Corp.) from each of 30 breast cancer patients who were confirmed to have no cancer in other organs after obtainment of informed consent, and used as a validation cohort together with the samples of 17 prostate cancer patients who were confirmed to have no cancer in organs other than the prostate and 51 healthy male subjects of Reference Example 1. Subsequent operations were conducted in the same way as in Reference Example 1. 
     Example 1 
     &lt;Selection of Gene Marker Using Samples in the Training Cohort, and Method for Evaluating Prostate Cancer Discriminant Performance with the Single Gene Marker Using Samples in the Validation Cohort&gt; 
     In this Example, a gene marker for discriminating a prostate cancer patient from a healthy subject was selected from the training cohort and studied in samples of the validation cohort independent of the training cohort. 
     Specifically, first, the miRNA expression levels of the training cohort and the validation cohort obtained in the preceding Reference Examples 1 were combined and normalized by quantile normalization. 
     Next, genes for diagnosis were selected in the training cohort. Here, in order to acquire diagnostic markers with higher reliability, only genes that showed gene expression levels of 2 6  or higher in 50% or more of the samples in either of the prostate cancer patient group in the training cohort or the healthy subject group in the training cohort were selected. In order to further acquire statistically significant genes for discriminating a prostate cancer patient group from a healthy subject group, the P value obtained by two-tailed t-test assuming equal variance as to each gene expression level was corrected by the Bonferroni method, and genes that satisfied p&lt;0.01 were acquired as gene markers for use in explanatory variables of a discriminant. The obtained genes are described in Table 2. 
     In this way, hsa-miR-4443, hsa-miR-1908-5p, hsa-miR-4257, hsa-miR-3197, hsa-miR-3188, hsa-miR-4649-5p, hsa-miR-1343-3p, hsa-miR-6861-5p, hsa-miR-1343-5p, hsa-miR-642b-3p, hsa-miR-6741-5p, hsa-miR-4745-5p, hsa-miR-6826-5p, hsa-miR-3663-3p, hsa-miR-3131, hsa-miR-92a-2-5p, hsa-miR-4258, hsa-miR-4448, hsa-miR-6125, hsa-miR-6880-5p, hsa-miR-6132, hsa-miR-4467, hsa-miR-6749-5p, hsa-miR-2392, hsa-miR-1273g-3p, hsa-miR-4746-3p, hsa-miR-1914-3p, hsa-miR-7845-5p, hsa-miR-6726-5p, hsa-miR-128-2-5p, hsa-miR-4651, hsa-miR-6765-3p, hsa-miR-3185, hsa-miR-4792, hsa-miR-6887-5p, hsa-miR-5572, hsa-miR-3619-3p, hsa-miR-6780b-5p, hsa-miR-4707-5p, hsa-miR-8063, hsa-miR-4454, hsa-miR-4525, hsa-miR-7975, hsa-miR-744-5p, hsa-miR-3135b, hsa-miR-4648, hsa-miR-6816-5p, hsa-miR-4741, hsa-miR-7150, hsa-miR-6791-5p, hsa-miR-1247-3p, hsa-miR-7977, hsa-miR-4497, hsa-miR-6090, hsa-miR-6781-5p, hsa-miR-6870-5p, hsa-miR-6729-5p, hsa-miR-4530, hsa-miR-7847-3p, hsa-miR-6825-5p, hsa-miR-4674, hsa-miR-3917, hsa-miR-4707-3p, hsa-miR-6885-5p, hsa-miR-6722-3p, hsa-miR-4516, hsa-miR-6757-5p, hsa-miR-6840-3p, hsa-miR-5195-3p, hsa-miR-6756-5p, hsa-miR-6800-5p, hsa-miR-6727-5p, hsa-miR-6126, hsa-miR-6872-3p, hsa-miR-4446-3p, hsa-miR-1268a, hsa-miR-1908-3p, hsa-miR-3679-5p, hsa-miR-4534, hsa-miR-4675, hsa-miR-7108-5p, hsa-miR-6799-5p, hsa-miR-4695-5p, hsa-miR-3178, hsa-miR-5090, hsa-miR-3180, hsa-miR-1237-5p, hsa-miR-4758-5p, hsa-miR-3184-5p, hsa-miR-4286, hsa-miR-6784-5p, hsa-miR-6768-5p, hsa-miR-6785-5p, hsa-miR-4706, hsa-miR-711, hsa-miR-1260a, hsa-miR-6746-5p, hsa-miR-6089, hsa-miR-6821-5p, hsa-miR-4667-5p, hsa-miR-8069, hsa-miR-4726-5p, hsa-miR-6124, hsa-miR-4532, hsa-miR-4486, hsa-miR-4728-5p, hsa-miR-4508, hsa-miR-128-1-5p, hsa-miR-4513, hsa-miR-6795-5p, hsa-miR-4689, hsa-miR-6763-5p, hsa-miR-8072, hsa-miR-6765-5p, hsa-miR-4419b, hsa-miR-7641, hsa-miR-3928-3p, hsa-miR-1227-5p, hsa-miR-4492, hsa-miR-296-3p, hsa-miR-6769a-5p, hsa-miR-6889-5p, hsa-miR-4632-5p, hsa-miR-4505, hsa-miR-3154, hsa-miR-3648, hsa-miR-4442, hsa-miR-3141, hsa-miR-7113-3p, hsa-miR-6819-5p, hsa-miR-3195, hsa-miR-1199-5p, hsa-miR-6738-5p, hsa-miR-4656, hsa-miR-6820-5p, hsa-miR-615-5p, hsa-miR-486-3p, hsa-miR-1225-3p, hsa-miR-760, hsa-miR-187-5p, hsa-miR-1203, hsa-miR-7110-5p, hsa-miR-371a-5p, hsa-miR-939-5p, hsa-miR-575, hsa-miR-92b-5p, hsa-miR-887-3p, hsa-miR-920, hsa-miR-1915-5p, hsa-miR-1231, hsa-miR-663 and hsa-miR-1225-5p genes, and the nucleotide sequences of SEQ ID NOs: 1 to 152 related thereto were found. 
     A discriminant for determining the presence or absence of prostate cancer was further prepared by Fisher&#39;s linear discriminant analysis with the expression levels of these genes as an index. Specifically, any newly found polynucleotide consisting of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 135 among the 152 genes selected in the training cohort was applied to Formula 2 to construct a discriminant. Calculated accuracy, sensitivity, and specificity are shown in Table 4. In this respect, a discriminant coefficient and a constant term are shown in Table 5. 
     Next, accuracy, sensitivity, and specificity in the validation cohort were calculated using the discriminant thus prepared, and the discriminant performance of the selected polynucleotides was validated using the independent samples (Table 4). For example, the expression level measurement value of the nucleotide sequence represented by SEQ ID NO: 1 was compared between the healthy subjects (47 persons) and the prostate cancer patients (17 persons) in the validation cohort. The results showing that the gene expression level measurement values in the training cohort were significantly lower in the prostate cancer patient group than in the healthy subject group (see the left diagram of  FIG.  2   ), were also reproducible in the validation cohort (see the right diagram of  FIG.  2   ). Likewise, the results obtained about the other polynucleotides shown in SEQ ID NOs: 2 to 152 showed that the gene expression level measurement values were significantly lower (−) or higher (+) in the prostate cancer patient group than in the healthy subject group. These results were able to be validated in the validation cohort. For example, as for this nucleotide sequence represented by SEQ ID NO: 1, the number of samples that were correctly identified in the detection of prostate cancer was calculated using the threshold (6.84) that was set in the training cohort and discriminated between the two groups. As a result, 15 true positives, 44 true negatives, 3 false positive, and 2 false negatives were obtained. From these values, 92.2% accuracy, 88.2% sensitivity, and 93.6% specificity were obtained as detection performance. In this way, the detection performance was calculated as to all of the polynucleotides shown in SEQ ID NOs: 1 to 152, and described in Table 4. 
     Among the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 152 shown in Table 3, for example, 141 polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 116, 119, 120, 121, 123, 124, 126, 127, 128, 131, 132, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151 and 152 exhibited sensitivity of 88.2%, 94.1%, 76.5%, 88.2%, 88.2%, 94.1%, 76.5%, 64.7%, 88.2%, 76.5%, 64.7%, 82.4%, 70.6%, 88.2%, 52.9%, 47.1%, 70.6%, 94.1%, 70.6%, 76.5%, 76.5%, 70.6%, 70.6%, 29.4%, 58.8%, 88.2%, 58.8%, 76.5%, 64.7%, 76.5%, 64.7%, 47.1%, 76.5%, 82.4%, 70.6%, 47.1%, 64.7%, 58.8%, 52.9%, 82.4%, 64.7%, 70.6%, 64.7%, 70.6%, 70.6%, 76.5%, 58.8%, 58.8%, 52.9%, 64.7%, 47.1%, 41.2%, 70.6%, 52.9%, 29.4%, 35.3%, 41.2%, 58.8%, 52.9%, 41.2%, 70.6%, 52.9%, 35.3%, 64.7%, 29.4%, 70.6%, 70.6%, 76.5%, 58.8%, 70.6%, 35.3%, 58.8%, 58.8%, 47.1%, 70.6%, 76.5%, 58.8%, 82.4%, 23.5%, 52.9%, 41.2%, 47.1%, 64.7%, 41.2%, 41.2%, 35.3%, 47.1%, 47.1%, 41.2%, 29.4%, 41.2%, 64.7%, 35.3%, 70.6%, 29.4%, 47.1%, 29.4%, 52.9%, 64.7%, 47.1%, 23.5%, 35.3%, 47.1%, 35.3%, 35.3%, 52.9%, 23.5%, 35.3%, 47.1%, 52.9%, 23.5%, 23.5%, 29.4%, 52.9%, 41.2%, 23.5%, 23.5%, 41.2%, 47.1%, 29.4%, 58.8%, 29.4%, 23.5%, 29.4%, 58.8%, 88.2%, 76.5%, 58.8%, 52.9%, 47.1%, 35.3%, 52.9%, 29.4%, 47.1%, 76.5%, 58.8%, 29.4%, 29.4%, 29.4%, 41.2% and 23.5% respectively, in the validation cohort (Table 4). Non-Patent Literature 3 has reported that the existing prostate cancer marker PSA has general sensitivity of 20.5%. These results were able to demonstrate that, for example, the 141 polynucleotides consisting of the nucleotide sequences represented by SEQ ID Nos: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 116, 119, 120, 121, 123, 124, 126, 127, 128, 131, 132, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151 and 152 can discriminate, each alone, prostate cancer in the validation cohort with sensitivity beyond PSA. 
     Example 2 
     &lt;Method for Evaluating Prostate Cancer Discriminant Performance with Combination of Multiple Gene Markers Using Samples in the Validation Cohort&gt; 
     In this Example, a method for evaluating prostate cancer discriminant performance with combination of the gene markers selected in Example 1 was studied. 
     Specifically, Fisher&#39;s linear discriminant analysis was conducted as to 11,340 combinations of two expression level measurement values comprising at least one or more of the expression level measurement values of the newly found polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 135 among the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 152 selected in Example 1, to construct a discriminant for determining the presence or absence of prostate cancer. Next, accuracy, sensitivity, and specificity in the validation cohort were calculated using the discriminant thus prepared, and the discriminant performance of the selected polynucleotides was validated using the independent samples. For example, the expression level measurement values of the nucleotide sequences represented by SEQ ID NO: 1 and SEQ ID NO: 2 were compared between the healthy subjects (47 persons) and the prostate cancer patients (17 persons) in the validation cohort. As a result, a scatter diagram that significantly separated the gene expression level measurement values of the prostate cancer patient group from those of the healthy subject group was obtained in the training cohort (see the left diagram of  FIG.  3   ). These results were also reproducible for the validation cohort (see the right diagram of  FIG.  3   ). Likewise, a scatter diagram that significantly separated the gene expression level measurement values of the prostate cancer patient group from those of the healthy subject group was also obtained as to the other combinations of two expression level measurement values comprising at least one or more of the expression level measurement values of the newly found polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 135 among the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 152. These results were able to be validated in the validation cohort. For example, as for these nucleotide sequences represented by SEQ ID NO: 1 and SEQ ID NO: 2, the number of samples correctly identified in the detection of prostate cancer was calculated using the threshold (0=1.15x+y+19.53) that was set in the training cohort and discriminated between the two groups. As a result, 16 true positives, 45 true negatives, 2 false positive, and 1 false negatives were obtained. From these values, 95.3% accuracy, 94.1% sensitivity, and 95.7% specificity were obtained as detection performance. 
     In this way, the detection performance was calculated as to all combinations (11,340 combinations) of two expression level measurement values comprising at least one or more of the expression level measurement values of the newly found polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 135 among the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 152. Among them, 151 combinations comprising the expression level measurement value of the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 and their detection performance are described in Table 6 as an example. For example, the combinations of the expression level measurement values of the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 and 2, SEQ ID NOs: 1 and 3, SEQ ID NOs: 1 and 4, and SEQ ID NOs: 1 and 5 exhibited sensitivity of 94.1%, 88.2%, 88.2%, and 94.1%, respectively, in the validation cohort (Table 6). In this way, 11,326 combinations of two expression level measurement values of the polynucleotides having sensitivity beyond the existing prostate cancer marker PSA (general sensitivity: 20.5%) were obtained in the validation cohort. All of the polynucleotides represented by the nucleotide sequences 1 to 152 described in Table 3 obtained in Example 1 were employed at least once in these combinations. These results were able to demonstrate that the combinations of two expression level measurement values comprising at least one or more of the expression level measurement values of the newly found polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 135 among the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 152 has the performance of detecting prostate cancer with sensitivity beyond PSA. 
     Thus, markers capable of detecting prostate cancer with excellent sensitivity are obtained even if 3, 4, 5, 6, 7, 8, 9, 10 or more of the expression level measurement values of the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 152 are combined. For example, the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 135 newly found in Example 1 were ranked in the descending order of their P values which indicates statistical significance, and prostate cancer detection sensitivity was evaluated using combinations of one or more polynucleotides to which the polynucleotides (miRNAs) were added one by one from the top to the bottom of the rank accordingly. In short, the order to combine the polynucleotides (miRNAs) in this evaluation is in reverse in terms of SEQ ID NOs, such as SEQ ID NO: 135 to SEQ ID NOs: 134, 133, . . . , shown in Table 3. As a result, the sensitivity in the validation cohort was 29.4% for 1 polynucleotide, 47.1% for 2 polynucleotides, 76.5% for 3 polynucleotides, 82.4% for 5 polynucleotides, 82.4% for 10 polynucleotides, 88.2% for 20 polynucleotides, 100% for 50 polynucleotides, and 100% for 100 polynucleotides. These values of the sensitivity were higher than the general sensitivity (20.5%) of the existing prostate cancer marker PSA, demonstrating that even combinations of multiple (i.e., two or more) miRNAs can serve as excellent markers for the detection of prostate cancer. In this context, the combinations of multiple miRNAs are not limited to the combinations of the miRNAs added in the order of the statistically significant difference as described above, and any combination of multiple polynucleotides (miRNAs) can be used in the detection of prostate cancer. 
     From these results, it can be concluded that all of the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 152 serve as excellent diagnostic markers. 
     
       
         
           
               
               
               
             
               
                   
                   
               
               
                   
                 Sample name 
                 Cancer stage 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
            
               
                 [Table 2-1] 
               
               
                 Training cohort 
               
            
           
           
               
               
               
            
               
                   
                 PR04 
                 II 
               
               
                   
                 PR06 
                 IV 
               
               
                   
                 PR08 
                 II 
               
               
                   
                 PR09 
                 II 
               
               
                   
                 PR12 
                 II 
               
               
                   
                 PR19 
                 II 
               
               
                   
                 PR21 
                 II 
               
               
                   
                 PR22 
                 II 
               
               
                   
                 PR23 
                 II 
               
               
                   
                 PR29 
                 II 
               
               
                   
                 PR30 
                 II 
               
               
                   
                 PR32 
                 III 
               
               
                   
                 PR46 
                 II 
               
               
                   
                 PR48 
                 II 
               
               
                   
                 PR51 
                 II 
               
               
                   
                 PR52 
                 II 
               
               
                   
                 PR53 
                 II 
               
               
                   
                 PR64 
                 II 
               
               
                   
                 PR65 
                 II 
               
               
                   
                 PR66 
                 II 
               
               
                   
                 PR69 
                 IV 
               
               
                   
                 PR73 
                 II 
               
               
                   
                 PR75 
                 II 
               
               
                   
                 PR80 
                 IV 
               
               
                   
                 PR81 
                 II 
               
               
                   
                 PR83 
                 II 
               
               
                   
                 PR84 
                 II 
               
               
                   
                 PR85 
                 II 
               
               
                   
                 PR87 
                 II 
               
               
                   
                 PR90 
                 II 
               
               
                   
                 PR93 
                 II 
               
               
                   
                 PR94 
                 II 
               
               
                   
                 PR97 
                 II 
               
               
                   
                 PR99 
                 IV 
               
               
                   
                 PR101 
                 II 
               
               
                   
                   
               
            
           
           
               
            
               
                 [Table 2-2] 
               
               
                 Validation cohort 
               
            
           
           
               
               
               
            
               
                   
                 PR01 
                 II 
               
               
                   
                 PR17 
                 II 
               
               
                   
                 PR26 
                 III 
               
               
                   
                 PR27 
                 II 
               
               
                   
                 PR28 
                 III 
               
               
                   
                 PR33 
                 II 
               
               
                   
                 PR40 
                 II 
               
               
                   
                 PR45 
                 II 
               
               
                   
                 PR59 
                 II 
               
               
                   
                 PR62 
                 II 
               
               
                   
                 PR67 
                 II 
               
               
                   
                 PR71 
                 II 
               
               
                   
                 PR82 
                 II 
               
               
                   
                 PR91 
                 II 
               
               
                   
                 PR92 
                 II 
               
               
                   
                 PR96 
                 II 
               
               
                   
                 PR100 
                 II 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
             
               
                 TABLE 3 
               
               
                   
               
               
                   
                   
                   
                 Expression level  
               
               
                   
                   
                   
                 in prostate cancer 
               
               
                   
                   
                 P value after 
                 patient relative to 
               
               
                 SEQ ID NO: 
                 Gene name 
                 Bonferroni correction 
                 healthy subject 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 1 
                 hsa-miR-4443 
                 2.10E−23 
                 + 
               
               
                 2 
                 hsa-miR-1908-5p 
                 7.83E−18 
                 + 
               
               
                 3 
                 hsa-miR-4257 
                 2.21E−17 
                 − 
               
               
                 4 
                 hsa-miR-3197 
                 5.78E−17 
                 + 
               
               
                 5 
                 hsa-miR-3188 
                 5.96.E−17 
                 + 
               
               
                 6 
                 hsa-miR-4649-5p 
                 6.34.E−17 
                 − 
               
               
                 7 
                 hsa-miR-1343-3p 
                 2.48.E−16 
                 − 
               
               
                 8 
                 hsa-miR-6861-5p 
                 1.15.E−15 
                 − 
               
               
                 9 
                 hsa-miR-1343-5p 
                 3.73.E−15 
                 + 
               
               
                 10 
                 hsa-miR-642b-3p 
                 3.94.E−15 
                 − 
               
               
                 11 
                 hsa-miR-6741-5p 
                 3.03.E−14 
                 − 
               
               
                 12 
                 hsa-miR-4745-5p 
                 4.76.E−14 
                 − 
               
               
                 13 
                 hsa-miR-6826-5p 
                 1.27.E−13 
                 − 
               
               
                 14 
                 hsa-miR-3663-3p 
                 1.61.E−13 
                 − 
               
               
                 15 
                 hsa-miR-3131 
                 5.67.E−13 
                 − 
               
               
                 16 
                 hsa-miR-92a-2-5p 
                 1.04.E−12 
                 + 
               
               
                 17 
                 hsa-miR-4258 
                 1.59.E−12 
                 − 
               
               
                 18 
                 hsa-miR-4448 
                 2.54.E−12 
                 + 
               
               
                 19 
                 hsa-miR-6125 
                 4.39.E−12 
                 + 
               
               
                 20 
                 hsa-miR-6880-5p 
                 6.24.E−12 
                 + 
               
               
                 21 
                 hsa-miR-6132 
                 8.70.E−12 
                 + 
               
               
                 22 
                 hsa-miR-4467 
                 1.45.E−11 
                 + 
               
               
                 23 
                 hsa-miR-6749-5p 
                 1.46.E−11 
                 − 
               
               
                 24 
                 hsa-miR-2392 
                 1.68.E−11 
                 + 
               
               
                 25 
                 hsa-miR-1273g-3p 
                 2.09.E−11 
                 − 
               
               
                 26 
                 hsa-miR-4746-3p 
                 2.43.E−11 
                 + 
               
               
                 27 
                 hsa-miR-1914-3p 
                 2.94.E−11 
                 − 
               
               
                 28 
                 hsa-miR-7845-5p 
                 3.03.E−11 
                 + 
               
               
                 29 
                 hsa-miR-6726-5p 
                 5.00.E−11 
                 − 
               
               
                 30 
                 hsa-miR-128-2-5p 
                 5.60.E−11 
                 − 
               
               
                 31 
                 hsa-miR-4651 
                 6.14.E−11 
                 − 
               
               
                 32 
                 hsa-miR-6765-3p 
                 6.43.E−11 
                 − 
               
               
                 33 
                 hsa-miR-3185 
                 7.07.E−11 
                 + 
               
               
                 34 
                 hsa-miR-4792 
                 7.39.E−11 
                 + 
               
               
                 35 
                 hsa-miR-6887-5p 
                 9.57.E−11 
                 − 
               
               
                 36 
                 hsa-miR-5572 
                 1.01.E−10 
                 + 
               
               
                 37 
                 hsa-miR-3619-3p 
                 1.89.E−10 
                 − 
               
               
                 38 
                 hsa-miR-6780b-5p 
                 2.55.E−10 
                 + 
               
               
                 39 
                 hsa-miR-4707-5p 
                 2.83.E−10 
                 + 
               
               
                 40 
                 hsa-miR-8063 
                 2.93.E−10 
                 − 
               
               
                 41 
                 hsa-miR-4454 
                 3.34.E−10 
                 − 
               
               
                 42 
                 hsa-miR-4525 
                 3.73.E−10 
                 − 
               
               
                 43 
                 hsa-miR-7975 
                 3.87.E−10 
                 − 
               
               
                 44 
                 hsa-miR-744-5p 
                 4.00.E−10 
                 + 
               
               
                 45 
                 hsa-miR-3135b 
                 4.73.E−10 
                 − 
               
               
                 46 
                 hsa-miR-4648 
                 5.10.E−10 
                 + 
               
               
                 47 
                 hsa-miR-6816-5p 
                 6.76.E−10 
                 + 
               
               
                 48 
                 hsa-miR-4741 
                 9.16.E−10 
                 + 
               
               
                 49 
                 hsa-miR-7150 
                 1.34.E−09 
                 + 
               
               
                 50 
                 hsa-miR-6791-5p 
                 2.31.E−09 
                 + 
               
               
                 51 
                 hsa-miR-1247-3p 
                 3.07.E−09 
                 + 
               
               
                 52 
                 hsa-miR-7977 
                 3.35.E−09 
                 − 
               
               
                 53 
                 hsa-miR-4497 
                 4.19.E−09 
                 − 
               
               
                 54 
                 hsa-miR-6090 
                 5.36.E−09 
                 + 
               
               
                 55 
                 hsa-miR-6781-5p 
                 8.00.E−09 
                 + 
               
               
                 56 
                 hsa-miR-6870-5p 
                 1.48.E−08 
                 + 
               
               
                 57 
                 hsa-miR-6729-5p 
                 1.56.E−08 
                 + 
               
               
                 58 
                 hsa-miR-4530 
                 2.60.E−08 
                 + 
               
               
                 59 
                 hsa-miR-7847-3p 
                 3.09.E−08 
                 − 
               
               
                 60 
                 hsa-miR-6825-5p 
                 3.86.E−08 
                 + 
               
               
                 61 
                 hsa-miR-4674 
                 3.88.E−08 
                 − 
               
               
                 62 
                 hsa-miR-3917 
                 4.11.E−08 
                 − 
               
               
                 63 
                 hsa-miR-4707-3p 
                 4.52.E−08 
                 + 
               
               
                 64 
                 hsa-miR-6885-5p 
                 5.06.E−08 
                 − 
               
               
                 65 
                 hsa-miR-6722-3p 
                 5.76.E−08 
                 + 
               
               
                 66 
                 hsa-miR-4516 
                 6.32.E−08 
                 − 
               
               
                 67 
                 hsa-miR-6757-5p 
                 6.81.E−08 
                 − 
               
               
                 68 
                 hsa-miR-6840-3p 
                 1.30.E−07 
                 − 
               
               
                 69 
                 hsa-miR-5195-3p 
                 1.45.E−07 
                 − 
               
               
                 70 
                 hsa-miR-6756-5p 
                 1.48.E−07 
                 − 
               
               
                 71 
                 hsa-miR-6800-5p 
                 1.61.E−07 
                 + 
               
               
                 72 
                 hsa-miR-6727-5p 
                 1.65.E−07 
                 − 
               
               
                 73 
                 hsa-miR-6126 
                 1.87.E−07 
                 + 
               
               
                 74 
                 hsa-miR-6872-3p 
                 2.21.E−07 
                 − 
               
               
                 75 
                 hsa-miR-4446-3p 
                 3.28.E−07 
                 − 
               
               
                 76 
                 hsa-miR-1268a 
                 4.54.E−07 
                 + 
               
               
                 77 
                 hsa-miR-1908-3p 
                 5.41.E−07 
                 − 
               
               
                 78 
                 hsa-miR-3679-5p 
                 5.53.E−07 
                 + 
               
               
                 79 
                 hsa-miR-4534 
                 7.45.E−07 
                 + 
               
               
                 80 
                 hsa-miR-4675 
                 7.91.E−07 
                 − 
               
               
                 81 
                 hsa-miR-7108-5p 
                 1.01.E−06 
                 + 
               
               
                 82 
                 hsa-miR-6799-5p 
                 1.57.E−06 
                 + 
               
               
                 83 
                 hsa-miR-4695-5p 
                 3.59.E−06 
                 + 
               
               
                 84 
                 hsa-miR-3178 
                 4.54.E−06 
                 + 
               
               
                 85 
                 hsa-miR-5090 
                 4.93.E−06 
                 − 
               
               
                 86 
                 hsa-miR-3180 
                 6.40.E−06 
                 + 
               
               
                 87 
                 hsa-miR-1237-5p 
                 9.54.E−06 
                 + 
               
               
                 88 
                 hsa-miR-4758-5p 
                 1.50.E−05 
                 − 
               
               
                 89 
                 hsa-miR-3184-5p 
                 1.60.E−05 
                 + 
               
               
                 90 
                 hsa-miR-4286 
                 1.96.E−05 
                 − 
               
               
                 91 
                 hsa-miR-6784-5p 
                 2.81.E−05 
                 + 
               
               
                 92 
                 hsa-miR-6768-5p 
                 3.47.E−05 
                 + 
               
               
                 93 
                 hsa-miR-6785-5p 
                 3.51.E−05 
                 − 
               
               
                 94 
                 hsa-miR-4706 
                 3.72.E−05 
                 − 
               
               
                 95 
                 hsa-miR-711 
                 4.59.E−05 
                 + 
               
               
                 96 
                 hsa-miR-1260a 
                 5.06.E−05 
                 − 
               
               
                 97 
                 hsa-miR-6746-5p 
                 5.35.E−05 
                 − 
               
               
                 98 
                 hsa-miR-6089 
                 7.26.E−05 
                 + 
               
               
                 99 
                 hsa-miR-6821-5p 
                 7.94.E−05 
                 + 
               
               
                 100 
                 hsa-miR-4667-5p 
                 8.38.E−05 
                 + 
               
               
                 101 
                 hsa-miR-8069 
                 9.70.E−05 
                 + 
               
               
                 102 
                 hsa-miR-4726-5p 
                 1.11.E−04 
                 − 
               
               
                 103 
                 hsa-miR-6124 
                 1.59.E−04 
                 + 
               
               
                 104 
                 hsa-miR-4532 
                 1.87.E−04 
                 − 
               
               
                 105 
                 hsa-miR-4486 
                 1.92.E−04 
                 + 
               
               
                 106 
                 hsa-miR-4728-5p 
                 1.96.E−04 
                 − 
               
               
                 107 
                 hsa-miR-4508 
                 2.20.E−04 
                 + 
               
               
                 108 
                 hsa-miR-128-1-5p 
                 3.56.E−04 
                 + 
               
               
                 109 
                 hsa-miR-4513 
                 3.75.E−04 
                 − 
               
               
                 110 
                 hsa-miR-6795-5p 
                 5.28.E−04 
                 − 
               
               
                 111 
                 hsa-miR-4689 
                 5.85.E−04 
                 − 
               
               
                 112 
                 hsa-miR-6763-5p 
                 6.01.E−04 
                 + 
               
               
                 113 
                 hsa-miR-8072 
                 6.56.E−04 
                 + 
               
               
                 114 
                 hsa-miR-6765-5p 
                 6.67.E−04 
                 + 
               
               
                 115 
                 hsa-miR-4419b 
                 7.40.E−04 
                 − 
               
               
                 116 
                 hsa-miR-7641 
                 8.72.E−04 
                 − 
               
               
                 117 
                 hsa-miR-3928-3p 
                 9.57.E−04 
                 + 
               
               
                 118 
                 hsa-miR-1227-5p 
                 9.66.E−04 
                 + 
               
               
                 119 
                 hsa-miR-4492 
                 1.12.E−03 
                 − 
               
               
                 120 
                 hsa-miR-296-3p 
                 1.39.E−03 
                 − 
               
               
                 121 
                 hsa-miR-6769a-5p 
                 1.42.E−03 
                 − 
               
               
                 122 
                 hsa-miR-6889-5p 
                 1.46.E−03 
                 + 
               
               
                 123 
                 hsa-miR-4632-5p 
                 1.74.E−03 
                 + 
               
               
                 124 
                 hsa-miR-4505 
                 1.94.E−03 
                 + 
               
               
                 125 
                 hsa-miR-3154 
                 1.97.E−03 
                 + 
               
               
                 126 
                 hsa-miR-3648 
                 2.03.E−03 
                 − 
               
               
                 127 
                 hsa-miR-4442 
                 2.15.E−03 
                 − 
               
               
                 128 
                 hsa-miR-3141 
                 3.29.E−03 
                 + 
               
               
                 129 
                 hsa-miR-7113-3p 
                 3.29.E−03 
                 + 
               
               
                 130 
                 hsa-miR-6819-5p 
                 5.95.E−03 
                 − 
               
               
                 131 
                 hsa-miR-3195 
                 6.78.E−03 
                 + 
               
               
                 132 
                 hsa-miR-1199-5p 
                 7.39.E−03 
                 − 
               
               
                 133 
                 hsa-miR-6738-5p 
                 8.00.E−03 
                 − 
               
               
                 134 
                 hsa-miR-4656 
                 8.53.E−03 
                 − 
               
               
                 135 
                 hsa-miR-6820-5p 
                 9.18.E−03 
                 + 
               
               
                 136 
                 hsa-miR-615-5p 
                 1.89.E−11 
                 − 
               
               
                 137 
                 hsa-miR-486-3p 
                 4.76.E−11 
                 − 
               
               
                 138 
                 hsa-miR-1225-3p 
                 8.87.E−11 
                 + 
               
               
                 139 
                 hsa-miR-760 
                 1.05.E−10 
                 − 
               
               
                 140 
                 hsa-miR-187-5p 
                 9.50.E−09 
                 − 
               
               
                 141 
                 hsa-miR-1203 
                 6.86.E−08 
                 + 
               
               
                 142 
                 hsa-miR-7110-5p 
                 2.08.E−07 
                 + 
               
               
                 143 
                 hsa-miR-371a-5p 
                 4.75.E−07 
                 − 
               
               
                 144 
                 hsa-miR-939-5p 
                 9.56.E−07 
                 + 
               
               
                 145 
                 hsa-miR-575 
                 2.41.E−06 
                 + 
               
               
                 146 
                 hsa-miR-92b-5p 
                 2.89.E−06 
                 + 
               
               
                 147 
                 hsa-miR-887-3p 
                 1.35.E−05 
                 + 
               
               
                 148 
                 hsa-miR-920 
                 3.39.E−05 
                 − 
               
               
                 149 
                 hsa-miR-1915-5p 
                 2.55.E−04 
                 − 
               
               
                 150 
                 hsa-miR-1231 
                 3.11.E−04 
                 + 
               
               
                 151 
                 hsa-miR-663b 
                 1.18.E−03 
                 − 
               
               
                 152 
                 hsa-miR-1225-5p 
                 8.49.E−03 
                 + 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 SEQ ID 
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 NO: 
                 Accuracy (%) 
                 Sensitivity (%) 
                 Specificity (%) 
                 Accuracy (%) 
                 Sensitivity (%) 
                 Specificity (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 1 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 2 
                 87.6 
                 85.7 
                 88.3 
                 92.2 
                 94.1 
                 91.5 
               
               
                 3 
                 89.9 
                 77.1 
                 94.7 
                 89.1 
                 76.5 
                 93.6 
               
               
                 4 
                 85.3 
                 71.4 
                 90.4 
                 95.3 
                 88.2 
                 97.9 
               
               
                 5 
                 89.1 
                 77.1 
                 93.6 
                 92.2 
                 88.2 
                 93.6 
               
               
                 6 
                 88.4 
                 77.1 
                 92.6 
                 92.2 
                 94.1 
                 91.5 
               
               
                 7 
                 86 
                 74.3 
                 90.4 
                 82.8 
                 76.5 
                 85.1 
               
               
                 8 
                 86.8 
                 74.3 
                 91.5 
                 84.4 
                 64.7 
                 91.5 
               
               
                 9 
                 83.7 
                 74.3 
                 87.2 
                 92.2 
                 88.2 
                 93.6 
               
               
                 10 
                 86.8 
                 68.6 
                 93.6 
                 92.2 
                 76.5 
                 97.9 
               
               
                 11 
                 86 
                 68.6 
                 92.6 
                 85.9 
                 64.7 
                 93.6 
               
               
                 12 
                 86 
                 74.3 
                 90.4 
                 90.6 
                 82.4 
                 93.6 
               
               
                 13 
                 89.1 
                 77.1 
                 93.6 
                 89.1 
                 70.6 
                 95.7 
               
               
                 14 
                 79.8 
                 42.9 
                 93.6 
                 95.3 
                 88.2 
                 97.9 
               
               
                 15 
                 83.7 
                 68.6 
                 89.4 
                 76.6 
                 52.9 
                 85.1 
               
               
                 16 
                 87.6 
                 77.1 
                 91.5 
                 73.4 
                 47.1 
                 83 
               
               
                 17 
                 82.9 
                 57.1 
                 92.6 
                 81.2 
                 70.6 
                 85.1 
               
               
                 18 
                 88.4 
                 65.7 
                 96.8 
                 93.8 
                 94.1 
                 93.6 
               
               
                 19 
                 88.4 
                 82.9 
                 90.4 
                 84.4 
                 70.6 
                 89.4 
               
               
                 20 
                 82.9 
                 57.1 
                 92.6 
                 92.2 
                 76.5 
                 97.9 
               
               
                 21 
                 87.6 
                 62.9 
                 96.8 
                 92.2 
                 76.5 
                 97.9 
               
               
                 22 
                 82.2 
                 60 
                 90.4 
                 89.1 
                 70.6 
                 95.7 
               
               
                 23 
                 82.2 
                 60 
                 90.4 
                 89.1 
                 70.6 
                 95.7 
               
               
                 24 
                 84.5 
                 57.1 
                 94.7 
                 71.9 
                 29.4 
                 87.2 
               
               
                 25 
                 87.6 
                 62.9 
                 96.8 
                 82.8 
                 58.8 
                 91.5 
               
               
                 26 
                 84.5 
                 65.7 
                 91.5 
                 93.8 
                 88.2 
                 95.7 
               
               
                 27 
                 82.2 
                 65.7 
                 88.3 
                 76.6 
                 58.8 
                 83 
               
               
                 28 
                 81.4 
                 57.1 
                 90.4 
                 89.1 
                 76.5 
                 93.6 
               
               
                 29 
                 87.6 
                 68.6 
                 94.7 
                 85.9 
                 64.7 
                 93.6 
               
               
                 30 
                 85.3 
                 60 
                 94.7 
                 87.5 
                 76.5 
                 91.5 
               
               
                 31 
                 82.2 
                 57.1 
                 91.5 
                 82.8 
                 64.7 
                 89.4 
               
               
                 32 
                 84.5 
                 60 
                 93.6 
                 79.7 
                 47.1 
                 91.5 
               
               
                 33 
                 83.7 
                 65.7 
                 90.4 
                 90.6 
                 76.5 
                 95.7 
               
               
                 34 
                 89.9 
                 74.3 
                 95.7 
                 87.5 
                 82.4 
                 89.4 
               
               
                 35 
                 81.4 
                 57.1 
                 90.4 
                 85.9 
                 70.6 
                 91.5 
               
               
                 36 
                 79.8 
                 57.1 
                 88.3 
                 78.1 
                 47.1 
                 89.4 
               
               
                 37 
                 84.5 
                 60 
                 93.6 
                 87.5 
                 64.7 
                 95.7 
               
               
                 38 
                 81.4 
                 54.3 
                 91.5 
                 82.8 
                 58.8 
                 91.5 
               
               
                 39 
                 79.1 
                 54.3 
                 88.3 
                 87.5 
                 52.9 
                 100 
               
               
                 40 
                 83.7 
                 74.3 
                 87.2 
                 90.6 
                 82.4 
                 93.6 
               
               
                 41 
                 85.3 
                 60 
                 94.7 
                 79.7 
                 64.7 
                 85.1 
               
               
                 42 
                 79.1 
                 48.6 
                 90.4 
                 89.1 
                 70.6 
                 95.7 
               
               
                 43 
                 81.4 
                 54.3 
                 91.5 
                 85.9 
                 64.7 
                 93.6 
               
               
                 44 
                 85.3 
                 54.3 
                 96.8 
                 90.6 
                 70.6 
                 97.9 
               
               
                 45 
                 89.9 
                 74.3 
                 95.7 
                 89.1 
                 70.6 
                 95.7 
               
               
                 46 
                 82.9 
                 60 
                 91.5 
                 84.4 
                 76.5 
                 87.2 
               
               
                 47 
                 83.7 
                 60 
                 92.6 
                 79.7 
                 58.8 
                 87.2 
               
               
                 48 
                 82.9 
                 54.3 
                 93.6 
                 82.8 
                 58.8 
                 91.5 
               
               
                 49 
                 84.5 
                 57.1 
                 94.7 
                 79.7 
                 52.9 
                 89.4 
               
               
                 50 
                 78.3 
                 48.6 
                 89.4 
                 87.5 
                 64.7 
                 95.7 
               
               
                 51 
                 82.2 
                 48.6 
                 94.7 
                 75 
                 47.1 
                 85.1 
               
               
                 52 
                 80.6 
                 51.4 
                 91.5 
                 79.7 
                 41.2 
                 93.6 
               
               
                 53 
                 79.8 
                 60 
                 87.2 
                 85.9 
                 70.6 
                 91.5 
               
               
                 54 
                 80.6 
                 42.9 
                 94.7 
                 87.5 
                 52.9 
                 100 
               
               
                 55 
                 82.9 
                 57.1 
                 92.6 
                 76.6 
                 29.4 
                 93.6 
               
               
                 56 
                 80.6 
                 54.3 
                 90.4 
                 76.6 
                 35.3 
                 91.5 
               
               
                 57 
                 85.3 
                 51.4 
                 97.9 
                 81.2 
                 41.2 
                 95.7 
               
               
                 58 
                 80.6 
                 54.3 
                 90.4 
                 81.2 
                 58.8 
                 89.4 
               
               
                 59 
                 79.1 
                 51.4 
                 89.4 
                 81.2 
                 52.9 
                 91.5 
               
               
                 60 
                 78.3 
                 51.4 
                 88.3 
                 76.6 
                 41.2 
                 89.4 
               
               
                 61 
                 81.4 
                 48.6 
                 93.6 
                 85.9 
                 70.6 
                 91.5 
               
               
                 62 
                 82.9 
                 54.3 
                 93.6 
                 82.8 
                 52.9 
                 93.6 
               
               
                 63 
                 82.9 
                 60 
                 91.5 
                 78.1 
                 35.3 
                 93.6 
               
               
                 64 
                 80.6 
                 42.9 
                 94.7 
                 89.1 
                 64.7 
                 97.9 
               
               
                 65 
                 78.3 
                 40 
                 92.6 
                 79.7 
                 29.4 
                 97.9 
               
               
                 66 
                 80.6 
                 45.7 
                 93.6 
                 84.4 
                 70.6 
                 89.4 
               
               
                 67 
                 80.6 
                 57.1 
                 89.4 
                 84.4 
                 70.6 
                 89.4 
               
               
                 68 
                 79.1 
                 42.9 
                 92.6 
                 85.9 
                 76.5 
                 89.4 
               
               
                 69 
                 82.2 
                 48.6 
                 94.7 
                 81.2 
                 58.8 
                 89.4 
               
               
                 70 
                 79.8 
                 51.4 
                 90.4 
                 92.2 
                 70.6 
                 100 
               
               
                 71 
                 79.8 
                 45.7 
                 92.6 
                 79.7 
                 35.3 
                 95.7 
               
               
                 72 
                 79.8 
                 51.4 
                 90.4 
                 78.1 
                 58.8 
                 85.1 
               
               
                 73 
                 77.5 
                 42.9 
                 90.4 
                 81.2 
                 58.8 
                 89.4 
               
               
                 74 
                 81.4 
                 51.4 
                 92.6 
                 73.4 
                 47.1 
                 83 
               
               
                 75 
                 79.1 
                 54.3 
                 88.3 
                 82.8 
                 70.6 
                 87.2 
               
               
                 76 
                 76 
                 42.9 
                 88.3 
                 84.4 
                 76.5 
                 87.2 
               
               
                 77 
                 78.3 
                 51.4 
                 88.3 
                 79.7 
                 58.8 
                 87.2 
               
               
                 78 
                 80.6 
                 51.4 
                 91.5 
                 92.2 
                 82.4 
                 95.7 
               
               
                 79 
                 78.3 
                 42.9 
                 91.5 
                 68.8 
                 23.5 
                 85.1 
               
               
                 80 
                 79.1 
                 40 
                 93.6 
                 84.4 
                 52.9 
                 95.7 
               
               
                 81 
                 79.1 
                 45.7 
                 91.5 
                 81.2 
                 41.2 
                 95.7 
               
               
                 82 
                 79.1 
                 45.7 
                 91.5 
                 78.1 
                 47.1 
                 89.4 
               
               
                 83 
                 76.7 
                 42.9 
                 89.4 
                 89.1 
                 64.7 
                 97.9 
               
               
                 84 
                 80.6 
                 45.7 
                 93.6 
                 78.1 
                 41.2 
                 91.5 
               
               
                 85 
                 79.8 
                 37.1 
                 95.7 
                 84.4 
                 41.2 
                 100 
               
               
                 86 
                 79.8 
                 45.7 
                 92.6 
                 75 
                 35.3 
                 89.4 
               
               
                 87 
                 78.1 
                 32.4 
                 94.7 
                 85.9 
                 47.1 
                 100 
               
               
                 88 
                 79.1 
                 31.4 
                 96.8 
                 84.4 
                 47.1 
                 97.9 
               
               
                 89 
                 75.2 
                 34.3 
                 90.4 
                 76.6 
                 41.2 
                 89.4 
               
               
                 90 
                 76.7 
                 37.1 
                 91.5 
                 76.6 
                 29.4 
                 93.6 
               
               
                 91 
                 74.4 
                 34.3 
                 89.4 
                 70.3 
                 17.6 
                 89.4 
               
               
                 92 
                 83.7 
                 51.4 
                 95.7 
                 79.7 
                 41.2 
                 93.6 
               
               
                 93 
                 77.5 
                 42.9 
                 90.4 
                 84.4 
                 64.7 
                 91.5 
               
               
                 94 
                 79.8 
                 42.9 
                 93.6 
                 76.6 
                 35.3 
                 91.5 
               
               
                 95 
                 82.2 
                 48.6 
                 94.7 
                 89.1 
                 70.6 
                 95.7 
               
               
                 96 
                 78.3 
                 45.7 
                 90.4 
                 73.4 
                 29.4 
                 89.4 
               
               
                 97 
                 76 
                 34.3 
                 91.5 
                 75 
                 47.1 
                 85.1 
               
               
                 98 
                 74.4 
                 25.7 
                 92.6 
                 76.6 
                 29.4 
                 93.6 
               
               
                 99 
                 78.3 
                 42.9 
                 91.5 
                 85.9 
                 52.9 
                 97.9 
               
               
                 100 
                 73.6 
                 22.9 
                 92.6 
                 87.5 
                 64.7 
                 95.7 
               
               
                 101 
                 79.8 
                 45.7 
                 92.6 
                 84.4 
                 47.1 
                 97.9 
               
               
                 102 
                 76 
                 37.1 
                 90.4 
                 67.2 
                 17.6 
                 85.1 
               
               
                 103 
                 79.1 
                 31.4 
                 96.8 
                 76.6 
                 23.5 
                 95.7 
               
               
                 104 
                 77.5 
                 28.6 
                 95.7 
                 81.2 
                 35.3 
                 97.9 
               
               
                 105 
                 77.5 
                 34.3 
                 93.6 
                 81.2 
                 47.1 
                 93.6 
               
               
                 106 
                 73.6 
                 31.4 
                 89.4 
                 79.7 
                 35.3 
                 95.7 
               
               
                 107 
                 77.5 
                 25.7 
                 96.8 
                 75 
                 35.3 
                 89.4 
               
               
                 108 
                 76 
                 34.3 
                 91.5 
                 84.4 
                 52.9 
                 95.7 
               
               
                 109 
                 76.7 
                 34.3 
                 92.6 
                 75 
                 23.5 
                 93.6 
               
               
                 110 
                 76 
                 22.9 
                 95.7 
                 78.1 
                 35.3 
                 93.6 
               
               
                 111 
                 75.2 
                 14.3 
                 97.9 
                 84.4 
                 47.1 
                 97.9 
               
               
                 112 
                 72.9 
                 20 
                 92.6 
                 85.9 
                 52.9 
                 97.9 
               
               
                 113 
                 75.2 
                 22.9 
                 94.7 
                 78.1 
                 23.5 
                 97.9 
               
               
                 114 
                 73.6 
                 17.1 
                 94.7 
                 76.6 
                 23.5 
                 95.7 
               
               
                 115 
                 76.7 
                 28.6 
                 94.7 
                 73.4 
                 17.6 
                 93.6 
               
               
                 116 
                 73.6 
                 28.6 
                 90.4 
                 75 
                 29.4 
                 91.5 
               
               
                 117 
                 79.1 
                 34.3 
                 95.7 
                 75 
                 17.6 
                 95.7 
               
               
                 118 
                 74.4 
                 22.9 
                 93.6 
                 71.9 
                 17.6 
                 91.5 
               
               
                 119 
                 73.6 
                 22.9 
                 92.6 
                 85.9 
                 52.9 
                 97.9 
               
               
                 120 
                 73.6 
                 25.7 
                 91.5 
                 79.7 
                 41.2 
                 93.6 
               
               
                 121 
                 77.5 
                 34.3 
                 93.6 
                 75 
                 23.5 
                 93.6 
               
               
                 122 
                 74.4 
                 25.7 
                 92.6 
                 70.3 
                 11.8 
                 91.5 
               
               
                 123 
                 76.7 
                 25.7 
                 95.7 
                 78.1 
                 23.5 
                 97.9 
               
               
                 124 
                 81.4 
                 40 
                 96.8 
                 84.4 
                 41.2 
                 100 
               
               
                 125 
                 74.4 
                 20 
                 94.7 
                 71.9 
                 17.6 
                 91.5 
               
               
                 126 
                 76.7 
                 28.6 
                 94.7 
                 82.8 
                 47.1 
                 95.7 
               
               
                 127 
                 75.2 
                 31.4 
                 91.5 
                 76.6 
                 29.4 
                 93.6 
               
               
                 128 
                 76.7 
                 22.9 
                 96.8 
                 87.5 
                 58.8 
                 97.9 
               
               
                 129 
                 69.8 
                 22.9 
                 87.2 
                 73.4 
                 11.8 
                 95.7 
               
               
                 130 
                 74.4 
                 22.9 
                 93.6 
                 75 
                 11.8 
                 97.9 
               
               
                 131 
                 74.4 
                 28.6 
                 91.5 
                 81.2 
                 29.4 
                 100 
               
               
                 132 
                 74.4 
                 22.9 
                 93.6 
                 75 
                 23.5 
                 93.6 
               
               
                 133 
                 68.2 
                 11.4 
                 89.4 
                 75 
                 11.8 
                 97.9 
               
               
                 134 
                 75.2 
                 20 
                 95.7 
                 76.6 
                 17.6 
                 97.9 
               
               
                 135 
                 73.6 
                 22.9 
                 92.6 
                 78.1 
                 29.4 
                 95.7 
               
               
                 136 
                 86.8 
                 65.7 
                 94.7 
                 75 
                 58.8 
                 80.9 
               
               
                 137 
                 86 
                 68.6 
                 92.6 
                 93.8 
                 88.2 
                 95.7 
               
               
                 138 
                 86.8 
                 68.6 
                 93.6 
                 85.9 
                 76.5 
                 89.4 
               
               
                 139 
                 79.8 
                 54.3 
                 89.4 
                 81.2 
                 58.8 
                 89.4 
               
               
                 140 
                 80.6 
                 51.4 
                 91.5 
                 73.4 
                 52.9 
                 80.9 
               
               
                 141 
                 80.6 
                 45.7 
                 93.6 
                 84.4 
                 47.1 
                 97.9 
               
               
                 142 
                 76 
                 48.6 
                 86.2 
                 78.1 
                 35.3 
                 93.6 
               
               
                 143 
                 79.8 
                 42.9 
                 93.6 
                 79.7 
                 52.9 
                 89.4 
               
               
                 144 
                 72.9 
                 42.9 
                 84 
                 76.6 
                 29.4 
                 93.6 
               
               
                 145 
                 79.8 
                 48.6 
                 91.5 
                 82.8 
                 47.1 
                 95.7 
               
               
                 146 
                 79.1 
                 48.6 
                 90.4 
                 92.2 
                 76.5 
                 97.9 
               
               
                 147 
                 74.4 
                 34.3 
                 89.4 
                 87.5 
                 58.8 
                 97.9 
               
               
                 148 
                 75.2 
                 34.3 
                 90.4 
                 67.2 
                 29.4 
                 80.9 
               
               
                 149 
                 76 
                 28.6 
                 93.6 
                 78.1 
                 29.4 
                 95.7 
               
               
                 150 
                 76 
                 28.6 
                 93.6 
                 78.1 
                 29.4 
                 95.7 
               
               
                 151 
                 79.8 
                 34.3 
                 96.8 
                 81.2 
                 41.2 
                 95.7 
               
               
                 152 
                 72.9 
                 14.3 
                 94.7 
                 78.1 
                 23.5 
                 97.9 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 5 
               
               
                   
               
               
                   
                 Discriminant 
                   
               
               
                 SEQ ID NO: 
                 coefficient 
                 Constant term 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 1 
                 2.841 
                 19.421 
               
               
                 2 
                 4.435 
                 51.871 
               
               
                 3 
                 3.207 
                 21.845 
               
               
                 4 
                 3.253 
                 31.499 
               
               
                 5 
                 4.075 
                 25.795 
               
               
                 6 
                 2.840 
                 29.134 
               
               
                 7 
                 2.539 
                 19.203 
               
               
                 8 
                 4.359 
                 31.785 
               
               
                 9 
                 4.100 
                 43.343 
               
               
                 10 
                 2.475 
                 23.187 
               
               
                 11 
                 4.875 
                 33.924 
               
               
                 12 
                 2.662 
                 31.800 
               
               
                 13 
                 2.576 
                 15.891 
               
               
                 14 
                 3.758 
                 45.427 
               
               
                 15 
                 3.007 
                 21.322 
               
               
                 16 
                 2.086 
                 20.103 
               
               
                 17 
                 2.415 
                 21.597 
               
               
                 18 
                 1.386 
                 8.309 
               
               
                 19 
                 5.265 
                 63.510 
               
               
                 20 
                 2.601 
                 20.485 
               
               
                 21 
                 3.480 
                 28.174 
               
               
                 22 
                 2.098 
                 21.131 
               
               
                 23 
                 5.034 
                 50.773 
               
               
                 24 
                 4.361 
                 26.275 
               
               
                 25 
                 2.837 
                 21.020 
               
               
                 26 
                 3.180 
                 21.510 
               
               
                 27 
                 4.832 
                 36.754 
               
               
                 28 
                 3.240 
                 22.334 
               
               
                 29 
                 3.297 
                 32.746 
               
               
                 30 
                 2.751 
                 29.763 
               
               
                 31 
                 5.736 
                 63.070 
               
               
                 32 
                 1.809 
                 15.805 
               
               
                 33 
                 2.566 
                 18.600 
               
               
                 34 
                 1.963 
                 13.501 
               
               
                 35 
                 3.448 
                 22.503 
               
               
                 36 
                 2.577 
                 17.708 
               
               
                 37 
                 2.326 
                 19.136 
               
               
                 38 
                 3.057 
                 27.631 
               
               
                 39 
                 4.748 
                 35.803 
               
               
                 40 
                 2.880 
                 23.980 
               
               
                 41 
                 2.262 
                 26.203 
               
               
                 42 
                 2.961 
                 20.754 
               
               
                 43 
                 2.220 
                 21.988 
               
               
                 44 
                 2.353 
                 16.969 
               
               
                 45 
                 3.102 
                 24.441 
               
               
                 46 
                 1.594 
                 9.958 
               
               
                 47 
                 4.468 
                 45.625 
               
               
                 48 
                 3.732 
                 37.591 
               
               
                 49 
                 4.378 
                 34.624 
               
               
                 50 
                 4.896 
                 45.653 
               
               
                 51 
                 4.268 
                 27.572 
               
               
                 52 
                 2.192 
                 21.441 
               
               
                 53 
                 3.013 
                 38.151 
               
               
                 54 
                 6.888 
                 90.453 
               
               
                 55 
                 5.516 
                 58.347 
               
               
                 56 
                 3.641 
                 27.465 
               
               
                 57 
                 7.874 
                 99.518 
               
               
                 58 
                 2.492 
                 24.657 
               
               
                 59 
                 4.058 
                 26.380 
               
               
                 60 
                 2.350 
                 15.623 
               
               
                 61 
                 3.450 
                 35.983 
               
               
                 62 
                 3.384 
                 20.446 
               
               
                 63 
                 3.330 
                 22.289 
               
               
                 64 
                 2.906 
                 32.309 
               
               
                 65 
                 6.296 
                 54.722 
               
               
                 66 
                 4.911 
                 64.684 
               
               
                 67 
                 3.206 
                 23.658 
               
               
                 68 
                 3.285 
                 29.269 
               
               
                 69 
                 3.237 
                 22.571 
               
               
                 70 
                 5.038 
                 42.229 
               
               
                 71 
                 4.159 
                 36.268 
               
               
                 72 
                 6.806 
                 87.077 
               
               
                 73 
                 3.063 
                 33.575 
               
               
                 74 
                 2.552 
                 15.751 
               
               
                 75 
                 2.791 
                 20.526 
               
               
                 76 
                 3.285 
                 37.356 
               
               
                 77 
                 3.362 
                 22.864 
               
               
                 78 
                 2.811 
                 19.633 
               
               
                 79 
                 3.759 
                 26.864 
               
               
                 80 
                 2.982 
                 22.991 
               
               
                 81 
                 3.997 
                 37.078 
               
               
                 82 
                 4.484 
                 37.972 
               
               
                 83 
                 4.600 
                 35.223 
               
               
                 84 
                 6.026 
                 73.901 
               
               
                 85 
                 4.239 
                 33.902 
               
               
                 86 
                 5.314 
                 47.015 
               
               
                 87 
                 4.798 
                 61.512 
               
               
                 88 
                 6.806 
                 59.152 
               
               
                 89 
                 2.706 
                 22.080 
               
               
                 90 
                 2.498 
                 18.719 
               
               
                 91 
                 3.833 
                 48.285 
               
               
                 92 
                 3.325 
                 32.674 
               
               
                 93 
                 2.793 
                 25.551 
               
               
                 94 
                 3.860 
                 30.344 
               
               
                 95 
                 3.878 
                 32.579 
               
               
                 96 
                 2.688 
                 18.916 
               
               
                 97 
                 4.301 
                 28.806 
               
               
                 98 
                 6.386 
                 86.216 
               
               
                 99 
                 3.660 
                 32.730 
               
               
                 100 
                 4.747 
                 30.458 
               
               
                 101 
                 5.928 
                 76.530 
               
               
                 102 
                 4.003 
                 27.083 
               
               
                 103 
                 2.947 
                 21.339 
               
               
                 104 
                 3.195 
                 38.076 
               
               
                 105 
                 3.103 
                 22.617 
               
               
                 106 
                 5.105 
                 36.656 
               
               
                 107 
                 8.087 
                 105.473 
               
               
                 108 
                 2.927 
                 22.240 
               
               
                 109 
                 4.111 
                 25.157 
               
               
                 110 
                 4.803 
                 30.149 
               
               
                 111 
                 3.332 
                 31.704 
               
               
                 112 
                 3.855 
                 27.615 
               
               
                 113 
                 4.606 
                 57.067 
               
               
                 114 
                 4.801 
                 51.079 
               
               
                 115 
                 3.144 
                 19.952 
               
               
                 116 
                 1.519 
                 11.331 
               
               
                 117 
                 3.217 
                 19.269 
               
               
                 118 
                 6.074 
                 58.552 
               
               
                 119 
                 5.508 
                 57.411 
               
               
                 120 
                 2.408 
                 14.813 
               
               
                 121 
                 4.332 
                 28.554 
               
               
                 122 
                 3.286 
                 24.338 
               
               
                 123 
                 4.276 
                 34.402 
               
               
                 124 
                 3.879 
                 33.369 
               
               
                 125 
                 4.935 
                 30.296 
               
               
                 126 
                 2.311 
                 30.293 
               
               
                 127 
                 3.246 
                 31.192 
               
               
                 128 
                 4.684 
                 33.975 
               
               
                 129 
                 3.468 
                 20.714 
               
               
                 130 
                 6.033 
                 46.013 
               
               
                 131 
                 3.614 
                 30.304 
               
               
                 132 
                 2.869 
                 19.654 
               
               
                 133 
                 4.117 
                 30.189 
               
               
                 134 
                 3.842 
                 27.896 
               
               
                 135 
                 3.012 
                 23.016 
               
               
                 136 
                 2.496 
                 16.713 
               
               
                 137 
                 3.062 
                 24.479 
               
               
                 138 
                 3.805 
                 22.035 
               
               
                 139 
                 3.410 
                 30.192 
               
               
                 140 
                 2.159 
                 21.828 
               
               
                 141 
                 2.667 
                 17.063 
               
               
                 142 
                 1.850 
                 14.572 
               
               
                 143 
                 3.628 
                 27.064 
               
               
                 144 
                 2.613 
                 20.101 
               
               
                 145 
                 1.927 
                 12.938 
               
               
                 146 
                 3.654 
                 29.801 
               
               
                 147 
                 2.419 
                 17.967 
               
               
                 148 
                 2.581 
                 15.080 
               
               
                 149 
                 1.552 
                 10.112 
               
               
                 150 
                 3.511 
                 23.568 
               
               
                 151 
                 3.078 
                 27.364 
               
               
                 152 
                 3.739 
                 27.780 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 1_2 
                 96.1 
                 91.4 
                 97.9 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_3 
                 94.6 
                 94.3 
                 94.7 
                 96.9 
                 88.2 
                 100 
               
               
                 1_4 
                 94.6 
                 91.4 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_5 
                 93.8 
                 88.6 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_6 
                 93 
                 88.6 
                 94.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_7 
                 96.1 
                 94.3 
                 96.8 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_8 
                 94.6 
                 91.4 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_9 
                 93.8 
                 88.6 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_10 
                 93.8 
                 88.6 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_11 
                 96.1 
                 97.1 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_12 
                 94.6 
                 94.3 
                 94.7 
                 96.9 
                 94.1 
                 97.9 
               
               
                 1_13 
                 96.1 
                 91.4 
                 97.9 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_14 
                 93.8 
                 85.7 
                 96.8 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_15 
                 94.6 
                 91.4 
                 95.7 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_16 
                 96.9 
                 94.3 
                 97.9 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_17 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_18 
                 93.8 
                 88.6 
                 95.7 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_19 
                 93.8 
                 88.6 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_20 
                 93 
                 85.7 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_21 
                 91.5 
                 77.1 
                 96.8 
                 96.9 
                 88.2 
                 100 
               
               
                 1_22 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_23 
                 91.5 
                 82.9 
                 94.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_24 
                 93.8 
                 88.6 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_25 
                 93.8 
                 88.6 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_26 
                 93.8 
                 88.6 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_27 
                 92.2 
                 82.9 
                 95.7 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_28 
                 93.8 
                 88.6 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_29 
                 93 
                 88.6 
                 94.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_30 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_31 
                 94.6 
                 91.4 
                 95.7 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_32 
                 93.8 
                 91.4 
                 94.7 
                 90.6 
                 88.2 
                 91.5 
               
               
                 1_33 
                 94.6 
                 91.4 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_34 
                 96.1 
                 94.3 
                 96.8 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_35 
                 94.6 
                 91.4 
                 95.7 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_36 
                 93 
                 85.7 
                 95.7 
                 90.6 
                 88.2 
                 91.5 
               
               
                 1_37 
                 93 
                 88.6 
                 94.7 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_38 
                 93 
                 82.9 
                 96.8 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_39 
                 92.2 
                 82.9 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_40 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_41 
                 94.6 
                 88.6 
                 96.8 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_42 
                 95.3 
                 91.4 
                 96.8 
                 98.4 
                 94.1 
                 100 
               
               
                 1_43 
                 94.6 
                 91.4 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_44 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_45 
                 94.6 
                 88.6 
                 96.8 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_46 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_47 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_48 
                 94.6 
                 91.4 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_49 
                 93.8 
                 85.7 
                 96.8 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_50 
                 95.3 
                 91.4 
                 96.8 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_51 
                 93.8 
                 85.7 
                 96.8 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_52 
                 93.8 
                 88.6 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_53 
                 92.2 
                 85.7 
                 94.7 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_54 
                 92.2 
                 82.9 
                 95.7 
                 96.9 
                 94.1 
                 97.9 
               
               
                 1_55 
                 92.2 
                 82.9 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_56 
                 92.2 
                 85.7 
                 94.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_57 
                 93 
                 85.7 
                 95.7 
                 96.9 
                 94.1 
                 97.9 
               
               
                 1_58 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_59 
                 92.2 
                 85.7 
                 94.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_60 
                 92.2 
                 85.7 
                 94.7 
                 90.6 
                 88.2 
                 91.5 
               
               
                 1_61 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_62 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_63 
                 93.8 
                 91.4 
                 94.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_64 
                 93.8 
                 88.6 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_65 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_66 
                 91.5 
                 82.9 
                 94.7 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_67 
                 92.2 
                 85.7 
                 94.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_68 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_69 
                 93 
                 82.9 
                 96.8 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_70 
                 93.8 
                 94.3 
                 93.6 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_71 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_72 
                 91.5 
                 85.7 
                 93.6 
                 90.6 
                 88.2 
                 91.5 
               
               
                 1_73 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_74 
                 94.6 
                 88.6 
                 96.8 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_75 
                 92.2 
                 85.7 
                 94.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_76 
                 92.2 
                 82.9 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_77 
                 93.8 
                 88.6 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_78 
                 94.6 
                 91.4 
                 95.7 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_79 
                 95.3 
                 91.4 
                 96.8 
                 96.9 
                 94.1 
                 97.9 
               
               
                 1_80 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_81 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_82 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_83 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_84 
                 94.6 
                 91.4 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_85 
                 94.6 
                 91.4 
                 95.7 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_86 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_87 
                 93 
                 85.3 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_88 
                 91.5 
                 80 
                 95.7 
                 96.9 
                 94.1 
                 97.9 
               
               
                 1_89 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 94.1 
                 91.5 
               
               
                 1_90 
                 94.6 
                 91.4 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_91 
                 92.2 
                 82.9 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_92 
                 92.2 
                 82.9 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_93 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_94 
                 92.2 
                 85.7 
                 94.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_95 
                 95.3 
                 91.4 
                 96.8 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_96 
                 94.6 
                 88.6 
                 96.8 
                 90.6 
                 88.2 
                 91.5 
               
               
                 1_97 
                 94.6 
                 91.4 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_98 
                 92.2 
                 82.9 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_99 
                 93.8 
                 91.4 
                 94.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_100 
                 94.6 
                 88.6 
                 96.8 
                 90.6 
                 88.2 
                 91.5 
               
               
                 1_101 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_102 
                 94.6 
                 88.6 
                 96.8 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_103 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_104 
                 93 
                 82.9 
                 96.8 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_105 
                 92.2 
                 85.7 
                 94.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_106 
                 93 
                 88.6 
                 94.7 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_107 
                 92.2 
                 85.7 
                 94.7 
                 92.2 
                 94.1 
                 91.5 
               
               
                 1_108 
                 93.8 
                 88.6 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_109 
                 93.8 
                 85.7 
                 96.8 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_110 
                 93.8 
                 88.6 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_111 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_112 
                 91.5 
                 82.9 
                 94.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_113 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_114 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_115 
                 92.2 
                 85.7 
                 94.7 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_116 
                 93 
                 88.6 
                 94.7 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_117 
                 93 
                 88.6 
                 94.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_118 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_119 
                 93.8 
                 85.7 
                 96.8 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_120 
                 92.2 
                 82.9 
                 95.7 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_121 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_122 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_123 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_124 
                 91.5 
                 80 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_125 
                 94.6 
                 88.6 
                 96.8 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_126 
                 93.8 
                 85.7 
                 96.8 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_127 
                 93.8 
                 88.6 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_128 
                 93.8 
                 91.4 
                 94.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_129 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_130 
                 93 
                 82.9 
                 96.8 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_131 
                 90.7 
                 82.9 
                 93.6 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_132 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_133 
                 94.6 
                 88.6 
                 96.8 
                 95.3 
                 88.2 
                 97.9 
               
               
                 1_134 
                 93.8 
                 88.6 
                 95.7 
                 95.3 
                 94.1 
                 95.7 
               
               
                 1_135 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_136 
                 96.9 
                 97.1 
                 96.8 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_137 
                 91.5 
                 80 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_138 
                 93.8 
                 88.6 
                 95.7 
                 93.8 
                 94.1 
                 93.6 
               
               
                 1_139 
                 92.2 
                 85.7 
                 94.7 
                 96.9 
                 94.1 
                 97.9 
               
               
                 1_140 
                 94.6 
                 88.6 
                 96.8 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_141 
                 95.3 
                 91.4 
                 96.8 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_142 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_143 
                 92.2 
                 82.9 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_144 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_145 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_146 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_147 
                 93 
                 85.7 
                 95.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                 1_148 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_149 
                 92.2 
                 82.9 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_150 
                 93.8 
                 88.6 
                 95.7 
                 96.9 
                 94.1 
                 97.9 
               
               
                 1_151 
                 93 
                 85.7 
                 95.7 
                 93.8 
                 88.2 
                 95.7 
               
               
                 1_152 
                 92.2 
                 85.7 
                 94.7 
                 92.2 
                 88.2 
                 93.6 
               
               
                   
               
            
           
         
       
     
     Example 3 
     &lt;Selection of Gene Marker Using all Samples and Method for Evaluating Prostate Cancer Discriminant Performance with Acquired Gene Marker&gt; 
     In this Example, the samples in the training cohort and the validation cohort used in Examples 1 and 2 were integrated, and selection of a gene marker and evaluation of its prostate cancer discriminant performance were conducted using all of the samples. 
     Specifically, the miRNA expression levels in the serum of the 52 prostate cancer patients and the 141 healthy male subjects obtained in the preceding Reference Examples were normalized by quantile normalization. In order to acquire diagnostic markers with higher reliability, only genes that showed gene expression levels of 2 6  or higher in 50% or more of the samples in either of the prostate cancer patient group or the healthy subject group were selected in the gene marker selection. In order to further acquire statistical significance for discriminating a prostate cancer patient group from a healthy subject group, the P value obtained by two-tailed t-test assuming equal variance as to each gene expression level was corrected by the Bonferroni method, and genes that satisfied p&lt;0.01 were selected as gene markers for use in explanatory variables of a discriminant. The obtained genes are described in Table 7. In this way, hsa-miR-4763-3p, hsa-miR-3656, hsa-miR-4488, hsa-miR-125a-3p, hsa-miR-1469, hsa-miR-1228-5p, hsa-miR-6798-5p, hsa-miR-1268b, hsa-miR-6732-5p, hsa-miR-1915-3p, hsa-miR-4433b-3p, hsa-miR-1207-5p, hsa-miR-4433-3p, hsa-miR-6879-5p, hsa-miR-4417, hsa-miR-30c-1-3p, hsa-miR-4638-5p, hsa-miR-6088, hsa-miR-4270, hsa-miR-6782-5p, hsa-miR-665, hsa-miR-486-5p, hsa-miR-4655-5p, hsa-miR-1275, hsa-miR-6806-5p, hsa-miR-614, hsa-miR-3937, hsa-miR-6752-5p, hsa-miR-6771-5p, hsa-miR-4450, hsa-miR-211-3p, hsa-miR-663a, hsa-miR-6842-5p, hsa-miR-7114-5p and hsa-miR-6779-5p genes, and the nucleotide sequences of SEQ ID NOs: 153 to 187 related thereto were found in addition to the genes described in Table 3. As with the nucleotide sequences of SEQ ID NOs: 1 to 152, the results obtained about the polynucleotides shown in the nucleotide sequences of SEQ ID NOs: 153 to 187 also showed that the measurement values were significantly lower (−) or higher (+) in the prostate cancer patient group than in the healthy subject group (Table 7). These results were able to be validated in the validation cohort. The presence or absence of prostate cancer in the newly obtained samples can be determined by the methods described in Examples 1 and 2 by using the gene expression level measurement values described in Table 7 either alone or in combination with the gene expression level measurement values described in Table 3. 
     
       
         
           
               
               
               
               
             
               
                 TABLE 7 
               
               
                   
               
               
                   
                   
                   
                 Expression level in 
               
               
                   
                   
                 P value after 
                 prostate cancer 
               
               
                   
                   
                 Bonferroni  
                 patient with relative 
               
               
                 SEQ ID NO: 
                 Gene name 
                 correction 
                 to healthy subject 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 1 
                 hsa-miR-4443 
                 1.11E−37 
                 + 
               
               
                 2 
                 hsa-miR-1908-5p 
                 1.13E−31 
                 + 
               
               
                 3 
                 hsa-miR-4257 
                 6.48E−24 
                 − 
               
               
                 4 
                 hsa-miR-3197 
                 1.28E−30 
                 + 
               
               
                 5 
                 hsa-miR-3188 
                 5.67E−27 
                 + 
               
               
                 6 
                 hsa-miR-4649-5p 
                 3.70E−27 
                 − 
               
               
                 7 
                 hsa-miR-1343-3p 
                 7.09E−23 
                 − 
               
               
                 8 
                 hsa-miR-6861-5p 
                 1.80E−24 
                 − 
               
               
                 9 
                 hsa-miR-1343-5p 
                 2.82E−24 
                 + 
               
               
                 10 
                 hsa-miR-642b-3p 
                 1.07E−27 
                 − 
               
               
                 11 
                 hsa-miR-6741-5p 
                 6.82E−22 
                 − 
               
               
                 12 
                 hsa-miR-4745-5p 
                 1.13E−23 
                 − 
               
               
                 13 
                 hsa-miR-6826-5p 
                 3.61E−19 
                 − 
               
               
                 14 
                 hsa-miR-3663-3p 
                 3.08E−23 
                 − 
               
               
                 15 
                 hsa-miR-3131 
                 3.50E−15 
                 − 
               
               
                 16 
                 hsa-miR-92a-2-5p 
                 4.74E−16 
                 + 
               
               
                 17 
                 hsa-miR-4258 
                 5.92E−20 
                 − 
               
               
                 18 
                 hsa-miR-4448 
                 7.18E−20 
                 + 
               
               
                 19 
                 hsa-miR-6125 
                 2.60E−19 
                 + 
               
               
                 20 
                 hsa-miR-6880-5p 
                 4.86E−19 
                 + 
               
               
                 21 
                 hsa-miR-6132 
                 2.01E−19 
                 + 
               
               
                 22 
                 hsa-miR-4467 
                 7.91E−20 
                 + 
               
               
                 23 
                 hsa-miR-6749-5p 
                 1.81E−19 
                 − 
               
               
                 24 
                 hsa-miR-2392 
                 2.70E−11 
                 + 
               
               
                 25 
                 hsa-miR-1273g-3p 
                 3.27E−19 
                 − 
               
               
                 26 
                 hsa-miR-4746-3p 
                 4.55E−21 
                 + 
               
               
                 27 
                 hsa-miR-1914-3p 
                 8.27E−15 
                 − 
               
               
                 28 
                 hsa-miR-7845-5p 
                 5.79E−19 
                 + 
               
               
                 29 
                 hsa-miR-6726-5p 
                 7.72E−19 
                 − 
               
               
                 30 
                 hsa-miR-128-2-5p 
                 5.33E−19 
                 − 
               
               
                 31 
                 hsa-miR-4651 
                 5.90E−18 
                 − 
               
               
                 32 
                 hsa-miR-6765-3p 
                 8.39E−16 
                 − 
               
               
                 33 
                 hsa-miR-3185 
                 1.60E−19 
                 + 
               
               
                 34 
                 hsa-miR-4792 
                 1.45E−17 
                 + 
               
               
                 35 
                 hsa-miR-6887-5p 
                 1.16E−14 
                 − 
               
               
                 36 
                 hsa-miR-5572 
                 4.90E−16 
                 + 
               
               
                 37 
                 hsa-miR-3619-3p 
                 2.51E−16 
                 − 
               
               
                 38 
                 hsa-miR-6780b-5p 
                 1.37E−16 
                 + 
               
               
                 39 
                 hsa-miR-4707-5p 
                 1.51E−17 
                 + 
               
               
                 40 
                 hsa-miR-8063 
                 5.05E−20 
                 − 
               
               
                 41 
                 hsa-miR-4454 
                 6.07E−14 
                 − 
               
               
                 42 
                 hsa-miR-4525 
                 6.00E−19 
                 − 
               
               
                 43 
                 hsa-miR-7975 
                 6.13E−15 
                 − 
               
               
                 44 
                 hsa-miR-744-5p 
                 5.25E−18 
                 + 
               
               
                 45 
                 hsa-miR-3135b 
                 1.17E−09 
                 − 
               
               
                 46 
                 hsa-miR-4648 
                 9.53E−17 
                 + 
               
               
                 47 
                 hsa-miR-6816-5p 
                 2.60E−15 
                 + 
               
               
                 48 
                 hsa-miR-4741 
                 5.52E−16 
                 + 
               
               
                 49 
                 hsa-miR-7150 
                 2.35E−13 
                 + 
               
               
                 50 
                 hsa-miR-6791-5p 
                 6.63E−17 
                 + 
               
               
                 51 
                 hsa-miR-1247-3p 
                 6.77E−13 
                 + 
               
               
                 52 
                 hsa-miR-7977 
                 2.22E−14 
                 − 
               
               
                 53 
                 hsa-miR-4497 
                 4.39E−16 
                 − 
               
               
                 54 
                 hsa-miR-6090 
                 4.58E−17 
                 + 
               
               
                 55 
                 hsa-miR-6781-5p 
                 1.08E−11 
                 + 
               
               
                 56 
                 hsa-miR-6870-5p 
                 4.41E−09 
                 + 
               
               
                 57 
                 hsa-miR-6729-5p 
                 6.57E−14 
                 + 
               
               
                 58 
                 hsa-miR-4530 
                 1.48E−10 
                 + 
               
               
                 59 
                 hsa-miR-7847-3p 
                 6.31E−12 
                 − 
               
               
                 60 
                 hsa-miR-6825-5p 
                 3.31E−12 
                 + 
               
               
                 61 
                 hsa-miR-4674 
                 7.19E−14 
                 − 
               
               
                 62 
                 hsa-miR-3917 
                 1.78E−12 
                 − 
               
               
                 63 
                 hsa-miR-4707-3p 
                 6.32E−12 
                 + 
               
               
                 64 
                 hsa-miR-6885-5p 
                 1.69E−14 
                 − 
               
               
                 65 
                 hsa-miR-6722-3p 
                 1.09E−10 
                 + 
               
               
                 66 
                 hsa-miR-4516 
                 9.57E−15 
                 − 
               
               
                 67 
                 hsa-miR-6757-5p 
                 1.02E−11 
                 − 
               
               
                 68 
                 hsa-miR-6840-3p 
                 6.73E−14 
                 − 
               
               
                 69 
                 hsa-miR-5195-3p 
                 1.21E−11 
                 − 
               
               
                 70 
                 hsa-miR-6756-5p 
                 1.46E−15 
                 − 
               
               
                 71 
                 hsa-miR-6800-5p 
                 3.18E−11 
                 + 
               
               
                 72 
                 hsa-miR-6727-5p 
                 2.88E−09 
                 − 
               
               
                 73 
                 hsa-miR-6126 
                 4.50E−12 
                 + 
               
               
                 74 
                 hsa-miR-6872-3p 
                 4.58E−09 
                 − 
               
               
                 75 
                 hsa-miR-4446-3p 
                 1.90E−12 
                 − 
               
               
                 76 
                 hsa-miR-1268a 
                 1.09E−13 
                 + 
               
               
                 77 
                 hsa-miR-1908-3p 
                 2.75E−10 
                 − 
               
               
                 78 
                 hsa-miR-3679-5p 
                 4.14E−15 
                 + 
               
               
                 79 
                 hsa-miR-4534 
                 1.65E−06 
                 + 
               
               
                 80 
                 hsa-miR-4675 
                 8.56E−11 
                 − 
               
               
                 81 
                 hsa-miR-7108-5p 
                 5.97E−11 
                 + 
               
               
                 82 
                 hsa-miR-6799-5p 
                 1.21E−10 
                 + 
               
               
                 83 
                 hsa-miR-4695-5p 
                 2.08E−13 
                 + 
               
               
                 84 
                 hsa-miR-3178 
                 1.33E−10 
                 + 
               
               
                 85 
                 hsa-miR-5090 
                 6.85E−11 
                 − 
               
               
                 86 
                 hsa-miR-3180 
                 1.01E−09 
                 + 
               
               
                 87 
                 hsa-miR-1237-5p 
                 7.78E−13 
                 + 
               
               
                 88 
                 hsa-miR-4758-5p 
                 1.97E−09 
                 − 
               
               
                 89 
                 hsa-miR-3184-5p 
                 4.70E−10 
                 + 
               
               
                 90 
                 hsa-miR-4286 
                 2.39E−08 
                 − 
               
               
                 91 
                 hsa-miR-6784-5p 
                 1.24E−07 
                 + 
               
               
                 92 
                 hsa-miR-6768-5p 
                 2.85E−07 
                 + 
               
               
                 93 
                 hsa-miR-6785-5p 
                 2.78E−10 
                 − 
               
               
                 94 
                 hsa-miR-4706 
                 3.20E−06 
                 − 
               
               
                 95 
                 hsa-miR-711 
                 7.50E−11 
                 + 
               
               
                 96 
                 hsa-miR-1260a 
                 3.06E−07 
                 − 
               
               
                 97 
                 hsa-miR-6746-5p 
                 6.04E−06 
                 − 
               
               
                 98 
                 hsa-miR-6089 
                 1.19E−08 
                 + 
               
               
                 99 
                 hsa-miR-6821-5p 
                 4.27E−10 
                 + 
               
               
                 100 
                 hsa-miR-4667-5p 
                 9.12E−07 
                 + 
               
               
                 101 
                 hsa-miR-8069 
                 1.81E−09 
                 + 
               
               
                 102 
                 hsa-miR-4726-5p 
                 2.71E−05 
                 − 
               
               
                 103 
                 hsa-miR-6124 
                 9.11E−05 
                 + 
               
               
                 104 
                 hsa-miR-4532 
                 2.46E−09 
                 − 
               
               
                 105 
                 hsa-miR-4486 
                 6.30E−09 
                 + 
               
               
                 106 
                 hsa-miR-4728-5p 
                 8.48E−09 
                 − 
               
               
                 107 
                 hsa-miR-4508 
                 1.66E−06 
                 + 
               
               
                 108 
                 hsa-miR-128-1-5p 
                 2.04E−08 
                 + 
               
               
                 109 
                 hsa-miR-4513 
                 1.44E−06 
                 − 
               
               
                 110 
                 hsa-miR-6795-5p 
                 1.12E−06 
                 − 
               
               
                 111 
                 hsa-miR-4689 
                 8.95E−09 
                 − 
               
               
                 112 
                 hsa-miR-6763-5p 
                 2.59E−09 
                 + 
               
               
                 113 
                 hsa-miR-8072 
                 1.32E−07 
                 + 
               
               
                 114 
                 hsa-miR-6765-5p 
                 4.48E−05 
                 + 
               
               
                 115 
                 hsa-miR-4419b 
                 1.22E−04 
                 − 
               
               
                 116 
                 hsa-miR-7641 
                 3.99E−08 
                 − 
               
               
                 117 
                 hsa-miR-3928-3p 
                 7.30E−06 
                 + 
               
               
                 118 
                 hsa-miR-1227-5p 
                 6.47E−06 
                 + 
               
               
                 119 
                 hsa-miR-4492 
                 3.11E−10 
                 − 
               
               
                 120 
                 hsa-miR-296-3p 
                 1.31E−06 
                 − 
               
               
                 121 
                 hsa-miR-6769a-5p 
                 2.26E−05 
                 − 
               
               
                 122 
                 hsa-miR-6889-5p 
                 5.29E−04 
                 + 
               
               
                 123 
                 hsa-miR-4632-5p 
                 3.39E−05 
                 + 
               
               
                 124 
                 hsa-miR-4505 
                 6.21E−06 
                 + 
               
               
                 125 
                 hsa-miR-3154 
                 1.41E−05 
                 + 
               
               
                 126 
                 hsa-miR-3648 
                 2.83E−06 
                 − 
               
               
                 127 
                 hsa-miR-4442 
                 2.03E−07 
                 − 
               
               
                 128 
                 hsa-miR-3141 
                 3.73E−07 
                 + 
               
               
                 129 
                 hsa-miR-7113-3p 
                 4.11E−05 
                 + 
               
               
                 130 
                 hsa-miR-6819-5p 
                 5.08E−03 
                 − 
               
               
                 131 
                 hsa-miR-3195 
                 1.18E−04 
                 + 
               
               
                 132 
                 hsa-miR-1199-5p 
                 8.59E−05 
                 − 
               
               
                 133 
                 hsa-miR-6738-5p 
                 2.49E−05 
                 − 
               
               
                 134 
                 hsa-miR-4656 
                 1.45E−05 
                 − 
               
               
                 135 
                 hsa-miR-6820-5p 
                 3.40E−04 
                 + 
               
               
                 136 
                 hsa-miR-615-5p 
                 1.98E−14 
                 − 
               
               
                 137 
                 hsa-miR-486-3p 
                 9.28E−17 
                 − 
               
               
                 138 
                 hsa-miR-1225-3p 
                 3.41E−16 
                 + 
               
               
                 139 
                 hsa-miR-760 
                 4.58E−15 
                 − 
               
               
                 140 
                 hsa-miR-187-5p 
                 7.21E−11 
                 − 
               
               
                 141 
                 hsa-miR-1203 
                 8.06E−14 
                 + 
               
               
                 142 
                 hsa-miR-7110-5p 
                 7.39E−11 
                 + 
               
               
                 143 
                 hsa-miR-371a-5p 
                 3.27E−12 
                 − 
               
               
                 144 
                 hsa-miR-939-5p 
                 2.77E−11 
                 + 
               
               
                 145 
                 hsa-miR-575 
                 1.85E−10 
                 + 
               
               
                 146 
                 hsa-miR-92b-5p 
                 7.45E−16 
                 + 
               
               
                 147 
                 hsa-miR-887-3p 
                 3.99E−12 
                 + 
               
               
                 148 
                 hsa-miR-920 
                 1.63E−05 
                 − 
               
               
                 149 
                 hsa-miR-1915-5p 
                 1.24E−07 
                 − 
               
               
                 150 
                 hsa-miR-1231 
                 1.35E−07 
                 + 
               
               
                 151 
                 hsa-miR-663b 
                 6.03E−07 
                 − 
               
               
                 152 
                 hsa-miR-1225-5p 
                 2.89E−06 
                 + 
               
               
                 153 
                 hsa-miR-4763-3p 
                 1.50E−07 
                 + 
               
               
                 154 
                 hsa-miR-3656 
                 2.20E−06 
                 + 
               
               
                 155 
                 hsa-miR-4488 
                 3.80E−06 
                 + 
               
               
                 156 
                 hsa-miR-125a-3p 
                 8.47E−06 
                 − 
               
               
                 157 
                 hsa-miR-1469 
                 8.73E−06 
                 + 
               
               
                 158 
                 hsa-miR-1228-5p 
                 1.34E−05 
                 + 
               
               
                 159 
                 hsa-miR-6798-5p 
                 1.73E−05 
                 + 
               
               
                 160 
                 hsa-miR-1268b 
                 1.93E−05 
                 + 
               
               
                 161 
                 hsa-miR-6732-5p 
                 2.42E−05 
                 + 
               
               
                 162 
                 hsa-miR-1915-3p 
                 3.96E−05 
                 + 
               
               
                 163 
                 hsa-miR-4433b-3p 
                 4.24E−05 
                 + 
               
               
                 164 
                 hsa-miR-1207-5p 
                 4.14E−05 
                 + 
               
               
                 165 
                 hsa-miR-4433-3p 
                 4.84E−05 
                 + 
               
               
                 166 
                 hsa-miR-6879-5p 
                 5.79E−05 
                 + 
               
               
                 167 
                 hsa-miR-4417 
                 8.44E−05 
                 + 
               
               
                 168 
                 hsa-miR-30c-1-3p 
                 8.49E−05 
                 + 
               
               
                 169 
                 hsa-miR-4638-5p 
                 7.97E−05 
                 + 
               
               
                 170 
                 hsa-miR-6088 
                 2.07E−04 
                 − 
               
               
                 171 
                 hsa-miR-4270 
                 2.44E−04 
                 − 
               
               
                 172 
                 hsa-miR-6782-5p 
                 6.53E−04 
                 + 
               
               
                 173 
                 hsa-miR-665 
                 7.52E−04 
                 − 
               
               
                 174 
                 hsa-miR-486-5p 
                 9.25E−04 
                 + 
               
               
                 175 
                 hsa-miR-4655-5p 
                 1.04E−03 
                 + 
               
               
                 176 
                 hsa-miR-1275 
                 1.11E−03 
                 + 
               
               
                 177 
                 hsa-miR-6806-5p 
                 1.78E−03 
                 − 
               
               
                 178 
                 hsa-miR-614 
                 1.92E−03 
                 − 
               
               
                 179 
                 hsa-miR-3937 
                 2.41E−03 
                 + 
               
               
                 180 
                 hsa-miR-6752-5p 
                 2.47E−03 
                 + 
               
               
                 181 
                 hsa-miR-6771-5p 
                 3.30E−03 
                 − 
               
               
                 182 
                 hsa-miR-4450 
                 3.79E−03 
                 + 
               
               
                 183 
                 hsa-miR-211-3p 
                 6.22E−03 
                 − 
               
               
                 184 
                 hsa-miR-663a 
                 5.44E−03 
                 + 
               
               
                 185 
                 hsa-miR-6842-5p 
                 8.58E−03 
                 + 
               
               
                 186 
                 hsa-miR-7114-5p 
                 8.30E−03 
                 − 
               
               
                 187 
                 hsa-miR-6779-5p 
                 8.35E−03 
                 − 
               
               
                   
               
            
           
         
       
     
     Example 4 
     &lt;Method for Evaluating Prostate Cancer-Specific Discriminant Performance with Combination of Multiple Gene Markers Using Samples in the Validation Cohort&gt; 
     In this Example, gene expression levels of miRNAs in serum were compared between prostate cancer patients and a control group that consists of healthy subjects and breast cancer patients, in the same way as the method described in Example 1 in the training cohort obtained in Reference Example 2 to select a statistically significant gene for diagnosis. Polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 580 to 611 thus newly selected were each further combined with the gene markers selected in Example 1 to study a method for evaluating prostate cancer-specific discriminant performance. 
     Specifically, first, the miRNA expression levels in the training cohort and the validation cohort obtained in Reference Example 2 mentioned above were combined and normalized by quantile normalization. Next, Fisher&#39;s linear discriminant analysis was conducted as to combinations of 1 to 4 expression level measurement values comprising at least one or more of the expression level measurement values of the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1 to 187, 580 to 611, to construct a discriminant for determining the presence or absence of prostate cancer. Next, accuracy, sensitivity, and specificity in the validation cohort obtained in Reference Example 2 were calculated using the discriminant thus prepared, with the prostate cancer patient group as a positive sample group, and the healthy subject group and the breast cancer patient group as a negative sample group. The discriminant performance of the selected polynucleotides was validated using the independent samples. 
     Most of polynucleotides consisting of the nucleotide sequences represented by these SEQ ID NOs (SEQ ID NOs: 1 to 187, and 580 to 611 corresponding to the miRNA markers of Table 1) or complementary sequences thereof mentioned above were able to provide relatively high accuracy, sensitivity, and specificity in the determination of the presence or absence of prostate cancer, and furthermore, were able to specifically discriminate prostate cancer from the other cancers. For example, among the combinations of multiple polynucleotides selected from the group consisting of polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 1, 3, 4, 5, 6, 7, 9, 10, 12, 14, 15, 16, 17, 18, 20, 24, 29, 35, 37, 42, 51, 55, 58, 61, 63, 64, 67, 70, 72, 79, 82, 89, 91, 97, 98, 101, 103, 104, 112, 113, 114, 116, 119, 126, 135, 136, 139, 140, 141, 145, 147, 154, 155, 156, 158, 169, 173, 175, 178, 182, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610 and 611, or complementary sequences thereof (the cancer type-specific polynucleotide group 1) as polynucleotides capable of specifically binding to target markers, combinations comprising at least one or more polynucleotide(s) selected from the group consisting of polynucleotides of SEQ ID NOs: 1, 12, 16, 37, 42, 63, 119, 126, 139, 173, 178, 599, 609 and 611 (the cancer type-specific polynucleotide group 2) that were included in the cancer type-specific polynucleotide group 1, were able to specifically discriminate prostate cancer from the other cancers with high accuracy. 
     The number of the aforementioned polynucleotides with cancer type specificity in the combination can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more for the combination. The combinations of 4 or more of these polynucleotides were able to exhibit discriminant accuracy of 85% or higher. 
     Specifically, the discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 or a complementary sequence thereof is shown in Table 8-1. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 or a complementary sequence thereof exhibited accuracy of 94.4% in the training cohort and accuracy of 91.8% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 or a complementary sequence thereof exhibited the highest accuracy of 96.4% in the training cohort and the highest accuracy of 90.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 or a complementary sequence thereof exhibited the highest accuracy of 98.5% in the training cohort and the highest accuracy of 92.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 or a complementary sequence thereof exhibited the highest accuracy of 95.4% in the training cohort and the highest accuracy of 92.9% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 12 or a complementary sequence thereof is shown in Table 8-2. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 12 or a complementary sequence thereof exhibited accuracy of 65.5% in the training cohort and accuracy of 56.1% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 12 or a complementary sequence thereof exhibited the highest accuracy of 94.9% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 12 or a complementary sequence thereof exhibited the highest accuracy of 98.0% in the training cohort and the highest accuracy of 93.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 12 or a complementary sequence thereof exhibited the highest accuracy of 98.5% in the training cohort and the highest accuracy of 94.9% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 16 or a complementary sequence thereof is shown in Table 8-3. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 16 or a complementary sequence thereof exhibited accuracy of 71.6% in the training cohort and accuracy of 74.5% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 16 or a complementary sequence thereof exhibited the highest accuracy of 95.4% in the training cohort and the highest accuracy of 93.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 16 or a complementary sequence thereof exhibited the highest accuracy of 97.5% in the training cohort and the highest accuracy of 94.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 16 or a complementary sequence thereof exhibited the highest accuracy of 98.0% in the training cohort and the highest accuracy of 88.8% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 37 or a complementary sequence thereof is shown in Table 8-4. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 37 or a complementary sequence thereof exhibited accuracy of 73.6% in the training cohort and accuracy of 72.4% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 37 or a complementary sequence thereof exhibited the highest accuracy of 95.9% in the training cohort and the highest accuracy of 92.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 37 or a complementary sequence thereof exhibited the highest accuracy of 97.0% in the training cohort and the highest accuracy of 92.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 37 or a complementary sequence thereof exhibited the highest accuracy of 97.0% in the training cohort and the highest accuracy of 89.8% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 42 or a complementary sequence thereof is shown in Table 8-5. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 42 or a complementary sequence thereof exhibited accuracy of 57.4% in the training cohort and accuracy of 59.2% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 42 or a complementary sequence thereof exhibited the highest accuracy of 95.4% in the training cohort and the highest accuracy of 93.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 42 or a complementary sequence thereof exhibited the highest accuracy of 97.5% in the training cohort and the highest accuracy of 95.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 42 or a complementary sequence thereof exhibited the highest accuracy of 96.9% in the training cohort and the highest accuracy of 94.9% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 63 or a complementary sequence thereof is shown in Table 8-6. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 63 or a complementary sequence thereof exhibited accuracy of 72.6% in the training cohort and accuracy of 73.5% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 63 or a complementary sequence thereof exhibited the highest accuracy of 94.9% in the training cohort and the highest accuracy of 92.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 63 or a complementary sequence thereof exhibited the highest accuracy of 95.9% in the training cohort and the highest accuracy of 95.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 63 or a complementary sequence thereof exhibited the highest accuracy of 94.4% in the training cohort and the highest accuracy of 89.8% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 119 or a complementary sequence thereof is shown in Table 8-7. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 119 or a complementary sequence thereof exhibited accuracy of 46.9% in the training cohort and accuracy of 48.0% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 119 or a complementary sequence thereof exhibited the highest accuracy of 94.9% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 119 or a complementary sequence thereof exhibited the highest accuracy of 97.4% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 119 or a complementary sequence thereof exhibited the highest accuracy of 96.4% in the training cohort and the highest accuracy of 89.8% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 126 or a complementary sequence thereof is shown in Table 8-8. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 126 or a complementary sequence thereof exhibited accuracy of 66.0% in the training cohort and accuracy of 53.1% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 126 or a complementary sequence thereof exhibited the highest accuracy of 94.4% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 126 or a complementary sequence thereof exhibited the highest accuracy of 96.4% in the training cohort and the highest accuracy of 90.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 126 or a complementary sequence thereof exhibited the highest accuracy of 93.9% in the training cohort and the highest accuracy of 91.8% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 139 or a complementary sequence thereof is shown in Table 8-9. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 139 or a complementary sequence thereof exhibited accuracy of 43.7% in the training cohort and accuracy of 40.8% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 139 or a complementary sequence thereof exhibited the highest accuracy of 94.4% in the training cohort and the highest accuracy of 92.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 139 or a complementary sequence thereof exhibited the highest accuracy of 96.4% in the training cohort and the highest accuracy of 94.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 139 or a complementary sequence thereof exhibited the highest accuracy of 92.4% in the training cohort and the highest accuracy of 91.8% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 173 or a complementary sequence thereof is shown in Table 8-10. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 173 or a complementary sequence thereof exhibited accuracy of 43.7% in the training cohort and accuracy of 55.1% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 173 or a complementary sequence thereof exhibited the highest accuracy of 94.9% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 173 or a complementary sequence thereof exhibited the highest accuracy of 97.0% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 173 or a complementary sequence thereof exhibited the highest accuracy of 92.4% in the training cohort and the highest accuracy of 95.9% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 178 or a complementary sequence thereof is shown in Table 8-11. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 178 or a complementary sequence thereof exhibited accuracy of 68.0% in the training cohort and the highest accuracy of 72.4% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 178 or a complementary sequence thereof exhibited the highest accuracy of 94.4% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 178 or a complementary sequence thereof exhibited the highest accuracy of 96.4% in the training cohort and the highest accuracy of 94.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 178 or a complementary sequence thereof exhibited the highest accuracy of 96.4% in the training cohort and the highest accuracy of 93.9% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 599 or a complementary sequence thereof is shown in Table 8-12. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 599 or a complementary sequence thereof exhibited accuracy of 61.4% in the training cohort and the highest accuracy of 65.3% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 599 or a complementary sequence thereof exhibited the highest accuracy of 94.4% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 599 or a complementary sequence thereof exhibited the highest accuracy of 97.5% in the training cohort and the highest accuracy of 92.9% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 599 or a complementary sequence thereof exhibited the highest accuracy of 96.4% in the training cohort and the highest accuracy of 94.9% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 609 or a complementary sequence thereof is shown in Table 8-13. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 609 or a complementary sequence thereof exhibited accuracy of 59.7% in the training cohort and accuracy of 65.3% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 609 or a complementary sequence thereof exhibited the highest accuracy of 95.4% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 609 or a complementary sequence thereof exhibited the highest accuracy of 96.4% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 609 or a complementary sequence thereof exhibited the highest accuracy of 96.4% in the training cohort and the highest accuracy of 88.8% in the validation cohort. 
     The discriminant accuracy of the measurement using the polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 611 or a complementary sequence thereof is shown in Table 8-14. The measurement using the combination of one polynucleotide comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 611 or a complementary sequence thereof exhibited accuracy of 55.8% in the training cohort and accuracy of 62.2% in the validation cohort. Also, for example, the measurement using the combination of two polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 611 or a complementary sequence thereof exhibited the highest accuracy of 94.9% in the training cohort and the highest accuracy of 91.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of three polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 611 or a complementary sequence thereof exhibited the highest accuracy of 98.0% in the training cohort and the highest accuracy of 90.8% in the validation cohort. Furthermore, for example, the measurement using the combinations of four polynucleotides comprising at least one polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 611 or a complementary sequence thereof exhibited the highest accuracy of 96.4% in the training cohort and the highest accuracy of 90.8% in the validation cohort. 
     The expression level measurement values of the nucleotide sequences represented by SEQ ID NOs: 12, 16, 135, and 156 were compared among 35 prostate cancer patients, 99 healthy subjects, and 63 breast cancer patients in the training cohort. As a result, a scatter diagram that significantly separated the discriminant score of the prostate cancer patient group from the discriminant scores of the other groups was obtained in the training cohort (see the upper diagram of  FIG.  4   ). These results were also reproducible in the validation cohort (see the lower diagram of  FIG.  4   ). 
     
       
         
           
               
               
               
             
               
                 TABLE 8-1 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 1 
                 94.4 
                 91.4 
                 95.1 
                 91.8 
                 94.1 
                 91.4 
               
               
                 1_597 
                 96.4 
                 97.1 
                 96.3 
                 90.8 
                 88.2 
                 91.4 
               
               
                 1_7_29 
                 98.5 
                 100 
                 98.1 
                 92.9 
                 94.1 
                 92.6 
               
               
                 1_63_139_600 
                 94.9 
                 91.4 
                 95.7 
                 91.8 
                 88.2 
                 92.6 
               
               
                 1_12_63_599 
                 95.4 
                 100 
                 94.4 
                 91.8 
                 94.1 
                 91.4 
               
               
                 1_141_173_599 
                 95.4 
                 97.1 
                 95.1 
                 91.8 
                 94.1 
                 91.4 
               
               
                 1_16_139_178 
                 95.4 
                 100 
                 94.4 
                 92.9 
                 94.1 
                 92.6 
               
               
                 1_63_173_599 
                 93.9 
                 94.3 
                 93.8 
                 90.8 
                 94.1 
                 90.1 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-2 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 12 
                 65.5 
                 74.3 
                 63.6 
                 56.1 
                 70.6 
                 53.1 
               
               
                 1_12 
                 94.9 
                 94.3 
                 95.1 
                 91.8 
                 94.1 
                 91.4 
               
               
                 1_7_12 
                 98 
                 100 
                 97.5 
                 93.9 
                 94.1 
                 93.8 
               
               
                 12_42_63_609 
                 92.3 
                 97.1 
                 91.3 
                 89.8 
                 100 
                 87.7 
               
               
                 12_16_135_156 
                 98.5 
                 100 
                 98.1 
                 94.9 
                 100 
                 93.8 
               
               
                 12_16_169_178 
                 94.9 
                 100 
                 93.8 
                 88.8 
                 100 
                 86.4 
               
               
                 12_16_139_601 
                 94.9 
                 100 
                 93.8 
                 91.8 
                 100 
                 90.1 
               
               
                 12_16_42_607 
                 97 
                 100 
                 96.3 
                 93.9 
                 100 
                 92.6 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-3 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 16 
                 71.6 
                 97.1 
                 66 
                 74.5 
                 100 
                 69.1 
               
               
                 1_16 
                 95.4 
                 94.3 
                 95.7 
                 93.9 
                 94.1 
                 93.8 
               
               
                 1_16_42 
                 97.5 
                 97.1 
                 97.5 
                 94.9 
                 94.1 
                 95.1 
               
               
                 16_18_139_178 
                 94.4 
                 97.1 
                 93.8 
                 92.9 
                 94.1 
                 92.6 
               
               
                 12_16_37_178 
                 98 
                 100 
                 97.5 
                 88.8 
                 100 
                 86.4 
               
               
                 12_16_37_599 
                 97.5 
                 100 
                 96.9 
                 89.8 
                 100 
                 87.7 
               
               
                 12_16_37_97 
                 96.4 
                 100 
                 95.7 
                 89.8 
                 100 
                 87.7 
               
               
                 12_14_16_599 
                 95.4 
                 100 
                 94.4 
                 87.8 
                 94.1 
                 86.4 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-4 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 37 
                 73.6 
                 77.1 
                 72.8 
                 72.4 
                 82.4 
                 70.4 
               
               
                 1_37 
                 95.9 
                 97.1 
                 95.7 
                 92.9 
                 88.2 
                 93.8 
               
               
                 1_37_135 
                 97 
                 97.1 
                 96.9 
                 92.9 
                 88.2 
                 93.8 
               
               
                 37_63_139_611 
                 93.4 
                 88.6 
                 94.4 
                 88.8 
                 94.1 
                 87.7 
               
               
                 37_42_63_178 
                 91.4 
                 94.3 
                 90.7 
                 90.8 
                 94.1 
                 90.1 
               
               
                 37_42_63_599 
                 91.4 
                 91.4 
                 91.4 
                 91.8 
                 94.1 
                 91.4 
               
               
                 37_42_63_139 
                 91.9 
                 91.4 
                 92 
                 91.8 
                 94.1 
                 91.4 
               
               
                 12_16_37_603 
                 97 
                 100 
                 96.3 
                 89.8 
                 100 
                 87.7 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-5 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 42 
                 57.4 
                 48.6 
                 59.3 
                 59.2 
                 52.9 
                 60.5 
               
               
                 1_42 
                 95.4 
                 94.3 
                 95.7 
                 93.9 
                 94.1 
                 93.8 
               
               
                 1_3_42 
                 97.5 
                 94.3 
                 98.1 
                 95.9 
                 94.1 
                 96.3 
               
               
                 42_63_607_611 
                 90.4 
                 88.6 
                 90.7 
                 90.8 
                 100 
                 88.9 
               
               
                 42_63_609_611 
                 90.8 
                 88.6 
                 91.3 
                 91.8 
                 100 
                 90.1 
               
               
                 42_63_173_599 
                 89.3 
                 91.4 
                 88.9 
                 90.8 
                 100 
                 88.9 
               
               
                 12_16_42_609 
                 96.9 
                 100 
                 96.3 
                 94.9 
                 100 
                 93.8 
               
               
                 42_63_91_609 
                 88.3 
                 91.4 
                 87.6 
                 90.8 
                 100 
                 88.9 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-6 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 63 
                 72.6 
                 88.6 
                 69.1 
                 73.5 
                 88.2 
                 70.4 
               
               
                 1_63 
                 94.9 
                 91.4 
                 95.7 
                 92.9 
                 94.1 
                 92.6 
               
               
                 1_42_63 
                 95.9 
                 94.3 
                 96.3 
                 95.9 
                 94.1 
                 96.3 
               
               
                 10_42_63_599 
                 92.9 
                 97.1 
                 92 
                 91.8 
                 100 
                 90.1 
               
               
                 42_63_599_609 
                 88.8 
                 91.4 
                 88.2 
                 91.8 
                 100 
                 90.1 
               
               
                 42_63_583_609 
                 94.4 
                 91.4 
                 95 
                 89.8 
                 100 
                 87.7 
               
               
                 37_42_63_611 
                 93.9 
                 91.4 
                 94.4 
                 94.9 
                 100 
                 93.8 
               
               
                 12_63_70_599 
                 90.9 
                 100 
                 88.9 
                 89.8 
                 94.1 
                 88.9 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-7 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity  
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 119 
                 46.9 
                 62.9 
                 43.5 
                 48 
                 58.8 
                 45.7 
               
               
                 1_119 
                 94.9 
                 91.4 
                 95.7 
                 91.8 
                 94.1 
                 91.4 
               
               
                 1_16_119 
                 97.4 
                 100 
                 96.9 
                 91.8 
                 88.2 
                 92.6 
               
               
                 12_16_37_119 
                 96.4 
                 100 
                 95.7 
                 89.8 
                 100 
                 87.7 
               
               
                 37_63_119_584 
                 93.4 
                 88.6 
                 94.4 
                 87.8 
                 94.1 
                 86.4 
               
               
                 63_119_173_178 
                 87.2 
                 88.6 
                 87 
                 82.7 
                 94.1 
                 80.2 
               
               
                 63_119_158_173 
                 85.7 
                 88.6 
                 85.1 
                 84.7 
                 88.2 
                 84 
               
               
                 63_119_173_605 
                 87.2 
                 88.6 
                 87 
                 82.7 
                 88.2 
                 81.5 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-8 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 126 
                 66 
                 71.4 
                 64.8 
                 53.1 
                 64.7 
                 50.6 
               
               
                 1_126 
                 94.4 
                 94.3 
                 94.4 
                 91.8 
                 94.1 
                 91.4 
               
               
                 1_126_597 
                 96.4 
                 97.1 
                 96.3 
                 90.8 
                 88.2 
                 91.4 
               
               
                 16_126_597_599 
                 90.9 
                 100 
                 88.9 
                 81.6 
                 88.2 
                 80.2 
               
               
                 16_42_126_599 
                 92.9 
                 94.3 
                 92.6 
                 92.9 
                 100 
                 91.4 
               
               
                 16_126_139_601 
                 93.9 
                 100 
                 92.6 
                 91.8 
                 100 
                 90.1 
               
               
                 16_126_593_599 
                 89.8 
                 97.1 
                 88.3 
                 85.7 
                 94.1 
                 84 
               
               
                 15_16_126_599 
                 91.4 
                 97.1 
                 90.1 
                 81.6 
                 94.1 
                 79 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-9 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 139 
                 43.7 
                 62.9 
                 39.5 
                 40.8 
                 64.7 
                 35.8 
               
               
                 1_139 
                 94.4 
                 91.4 
                 95.1 
                 92.9 
                 94.1 
                 92.6 
               
               
                 1_139_141 
                 96.4 
                 97.1 
                 96.3 
                 94.9 
                 94.1 
                 95.1 
               
               
                 37_63_139_584 
                 92.4 
                 91.4 
                 92.6 
                 90.8 
                 94.1 
                 90.1 
               
               
                 63_139_173_178 
                 85.3 
                 91.4 
                 84 
                 89.8 
                 94.1 
                 88.9 
               
               
                 16_63_139_601 
                 92.4 
                 97.1 
                 91.4 
                 91.8 
                 94.1 
                 91.4 
               
               
                 37_63_139_600 
                 89.8 
                 91.4 
                 89.5 
                 88.8 
                 94.1 
                 87.7 
               
               
                 16_139_178_586 
                 91.4 
                 100 
                 89.5 
                 92.9 
                 100 
                 91.4 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-10 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 173 
                 43.7 
                 51.4 
                 42 
                 55.1 
                 58.8 
                 54.3 
               
               
                 1_173 
                 94.9 
                 94.3 
                 95.1 
                 91.8 
                 94.1 
                 91.4 
               
               
                 1_15_173 
                 97 
                 97.1 
                 96.9 
                 91.8 
                 94.1 
                 91.4 
               
               
                 63_139_173_599 
                 84.8 
                 88.6 
                 84 
                 89.8 
                 94.1 
                 88.9 
               
               
                 63_119_173_581 
                 90.3 
                 91.4 
                 90.1 
                 89.8 
                 94.1 
                 88.9 
               
               
                 63_173_582_599 
                 88.3 
                 91.4 
                 87.7 
                 84.5 
                 88.2 
                 83.8 
               
               
                 63_136_173_599 
                 92.4 
                 94.3 
                 92 
                 95.9 
                 94.1 
                 96.3 
               
               
                 29_63_173_178 
                 87.8 
                 91.4 
                 87 
                 88.8 
                 88.2 
                 88.9 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-11 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 178 
                 68 
                 68.6 
                 67.9 
                 72.4 
                 82.4 
                 70.4 
               
               
                 1_178 
                 94.4 
                 91.4 
                 95.1 
                 91.8 
                 94.1 
                 91.4 
               
               
                 1_15_178 
                 96.4 
                 97.1 
                 96.3 
                 94.9 
                 94.1 
                 95.1 
               
               
                 16_139_178_601 
                 93.4 
                 100 
                 92 
                 90.8 
                 100 
                 88.9 
               
               
                 16_37_139_178 
                 93.4 
                 94.3 
                 93.2 
                 91.8 
                 94.1 
                 91.4 
               
               
                 1_12_16_178 
                 96.4 
                 100 
                 95.7 
                 93.9 
                 100 
                 92.6 
               
               
                 1_63_173_178 
                 94.9 
                 94.3 
                 95.1 
                 91.8 
                 94.1 
                 91.4 
               
               
                 16_139_178_597 
                 93.9 
                 100 
                 92.6 
                 89.8 
                 100 
                 87.7 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-12 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity  
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 599 
                 61.4 
                 74.3 
                 58.6 
                 65.3 
                 82.4 
                 61.7 
               
               
                 1_599 
                 94.4 
                 91.4 
                 95.1 
                 91.8 
                 94.1 
                 91.4 
               
               
                 3_112_599 
                 97.5 
                 97.1 
                 97.5 
                 92.9 
                 94.1 
                 92.6 
               
               
                 12_37_63_599 
                 91.9 
                 97.1 
                 90.7 
                 88.8 
                 94.1 
                 87.7 
               
               
                 42_58_63_599 
                 90.9 
                 94.3 
                 90.1 
                 87.8 
                 94.1 
                 86.4 
               
               
                 1_12_16_599 
                 96.4 
                 100 
                 95.7 
                 94.9 
                 100 
                 93.8 
               
               
                 63_119_173_599 
                 87.2 
                 88.6 
                 87 
                 80.6 
                 88.2 
                 79 
               
               
                 16_18_139_599 
                 94.9 
                 97.1 
                 94.4 
                 92.9 
                 94.1 
                 92.6 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-13 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
               
                 609 
                 59.7 
                 77.1 
                 55.9 
                 65.3 
                 82.4 
                 61.7 
               
               
                 1_609 
                 95.4 
                 94.3 
                 95.7 
                 91.8 
                 94.1 
                 91.4 
               
               
                 1_10_609 
                 96.4 
                 94.3 
                 96.9 
                 91.8 
                 94.1 
                 91.4 
               
               
                 42_63_585_609 
                 89.8 
                 91.4 
                 89.4 
                 91.8 
                 100 
                 90.1 
               
               
                 42_63_592_609 
                 88.8 
                 88.6 
                 88.8 
                 89.8 
                 100 
                 87.7 
               
               
                 18_42_581_609 
                 93.4 
                 94.3 
                 93.2 
                 90.8 
                 94.1 
                 90.1 
               
               
                 12_16_599_609 
                 96.4 
                 100 
                 95.7 
                 88.8 
                 100 
                 86.4 
               
               
                 16_126_599_609 
                 87.2 
                 97.1 
                 85.1 
                 84.7 
                 88.2 
                 84.0 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
             
               
                 TABLE 8-14 
               
             
            
               
                   
               
               
                   
                 Training cohort 
                 Validation cohort 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 Accuracy 
                 Sensitivity 
                 Specificity 
                 Accuracy 
                 Sensitivity 
                 Specificity 
               
               
                 SEQ ID NO: 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 611 
                 55.8 
                 54.3 
                 56.2 
                 62.2 
                 58.8 
                 63 
               
               
                 1_611 
                 94.9 
                 94.3 
                 95.1 
                 91.8 
                 94.1 
                 91.4 
               
               
                 10_15_611 
                 98 
                 100 
                 97.5 
                 90.8 
                 100 
                 88.9 
               
               
                 12_16_37_611 
                 96.4 
                 100 
                 95.7 
                 90.8 
                 100 
                 88.9 
               
               
                 1_63_139_611 
                 94.4 
                 88.6 
                 95.7 
                 91.8 
                 88.2 
                 92.6 
               
               
                 63_158_173_611 
                 87.8 
                 88.6 
                 87.7 
                 83.7 
                 88.2 
                 82.7 
               
               
                 16_37_139_611 
                 93.9 
                 97.1 
                 93.2 
                 90.8 
                 100 
                 88.9 
               
               
                 16_37_595_611 
                 91.9 
                 97.1 
                 90.7 
                 84.7 
                 82.4 
                 85.2 
               
               
                   
               
            
           
         
       
     
     As shown in these Examples, the kit, device and the method of the present invention can detect prostate cancer more sensitively than the existing tumor markers and therefore permit early decision to carry out the surgical resection of the cancer site. As a result, improvement in 5-year survival rate and reduction in the rate of recurrence can be achieved. 
     INDUSTRIAL APPLICABILITY 
     According to the present invention, prostate cancer can be effectively detected by a simple and inexpensive method. This permits early detection, diagnosis and treatment of prostate cancer. The method of the present invention can detect prostate cancer with limited invasiveness using the blood of a patient and therefore allows prostate cancer to be detected conveniently and rapidly. 
     All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.